KIDS Distribution saved on Apr 19, 2013@15:51:44
update process and new NLM valueset release loaded
**KIDS**:KBAIVS*1.0*3^

**INSTALL NAME**
KBAIVS*1.0*3
"BLD",8498,0)
KBAIVS*1.0*3^^0^3130419^n
"BLD",8498,4,0)
^9.64PA^176.804^4
"BLD",8498,4,176.801,0)
176.801
"BLD",8498,4,176.801,222)
y^y^f^^n^^y^o^n
"BLD",8498,4,176.802,0)
176.802
"BLD",8498,4,176.802,222)
y^y^f^^n^^y^o^n
"BLD",8498,4,176.803,0)
176.803
"BLD",8498,4,176.803,222)
y^y^f^^n^^y^o^n
"BLD",8498,4,176.804,0)
176.804
"BLD",8498,4,176.804,222)
y^y^f^^n^^y^o^n
"BLD",8498,4,"B",176.801,176.801)

"BLD",8498,4,"B",176.802,176.802)

"BLD",8498,4,"B",176.803,176.803)

"BLD",8498,4,"B",176.804,176.804)

"BLD",8498,6.3)
5
"BLD",8498,"KRN",0)
^9.67PA^779.2^20
"BLD",8498,"KRN",.4,0)
.4
"BLD",8498,"KRN",.401,0)
.401
"BLD",8498,"KRN",.402,0)
.402
"BLD",8498,"KRN",.403,0)
.403
"BLD",8498,"KRN",.5,0)
.5
"BLD",8498,"KRN",.84,0)
.84
"BLD",8498,"KRN",3.6,0)
3.6
"BLD",8498,"KRN",3.8,0)
3.8
"BLD",8498,"KRN",9.2,0)
9.2
"BLD",8498,"KRN",9.8,0)
9.8
"BLD",8498,"KRN",9.8,"NM",0)
^9.68A^3^3
"BLD",8498,"KRN",9.8,"NM",1,0)
KBAIVS1^^0^B56036030
"BLD",8498,"KRN",9.8,"NM",2,0)
KBAIVS2^^0^B250259233
"BLD",8498,"KRN",9.8,"NM",3,0)
KBAISID^^0^B1057899
"BLD",8498,"KRN",9.8,"NM","B","KBAISID",3)

"BLD",8498,"KRN",9.8,"NM","B","KBAIVS1",1)

"BLD",8498,"KRN",9.8,"NM","B","KBAIVS2",2)

"BLD",8498,"KRN",19,0)
19
"BLD",8498,"KRN",19.1,0)
19.1
"BLD",8498,"KRN",101,0)
101
"BLD",8498,"KRN",409.61,0)
409.61
"BLD",8498,"KRN",771,0)
771
"BLD",8498,"KRN",779.2,0)
779.2
"BLD",8498,"KRN",870,0)
870
"BLD",8498,"KRN",8989.51,0)
8989.51
"BLD",8498,"KRN",8989.52,0)
8989.52
"BLD",8498,"KRN",8994,0)
8994
"BLD",8498,"KRN","B",.4,.4)

"BLD",8498,"KRN","B",.401,.401)

"BLD",8498,"KRN","B",.402,.402)

"BLD",8498,"KRN","B",.403,.403)

"BLD",8498,"KRN","B",.5,.5)

"BLD",8498,"KRN","B",.84,.84)

"BLD",8498,"KRN","B",3.6,3.6)

"BLD",8498,"KRN","B",3.8,3.8)

"BLD",8498,"KRN","B",9.2,9.2)

"BLD",8498,"KRN","B",9.8,9.8)

"BLD",8498,"KRN","B",19,19)

"BLD",8498,"KRN","B",19.1,19.1)

"BLD",8498,"KRN","B",101,101)

"BLD",8498,"KRN","B",409.61,409.61)

"BLD",8498,"KRN","B",771,771)

"BLD",8498,"KRN","B",779.2,779.2)

"BLD",8498,"KRN","B",870,870)

"BLD",8498,"KRN","B",8989.51,8989.51)

"BLD",8498,"KRN","B",8989.52,8989.52)

"BLD",8498,"KRN","B",8994,8994)

"DATA",176.801,1,0)
ACE inhibitor or ARB
"DATA",176.801,1,1)
2.16.840.1.113883.3.526.3.1139
"DATA",176.801,1,4,0)
^176.8012P^2^2
"DATA",176.801,1,4,1,0)
24
"DATA",176.801,1,4,2,0)
34
"DATA",176.801,1,5)
ACEARB39
"DATA",176.801,2,0)
ADHD Medications
"DATA",176.801,2,1)
2.16.840.1.113883.3.464.1003.196.12.1171
"DATA",176.801,2,4,0)
^176.8012P^1^1
"DATA",176.801,2,4,1,0)
33
"DATA",176.801,2,5)
ADHDM71
"DATA",176.801,3,0)
Above Normal Follow-up
"DATA",176.801,3,1)
2.16.840.1.113883.3.600.1.1525
"DATA",176.801,3,4,0)
^176.8012P^1^1
"DATA",176.801,3,4,1,0)
52
"DATA",176.801,3,5)
ANF25
"DATA",176.801,4,0)
Above Normal Medications
"DATA",176.801,4,1)
2.16.840.1.113883.3.600.1.1498
"DATA",176.801,4,4,0)
^176.8012P^1^1
"DATA",176.801,4,4,1,0)
52
"DATA",176.801,4,5)
ANM98
"DATA",176.801,5,0)
Above Normal Referrals
"DATA",176.801,5,1)
2.16.840.1.113883.3.600.1.1527
"DATA",176.801,5,4,0)
^176.8012P^1^1
"DATA",176.801,5,4,1,0)
52
"DATA",176.801,5,5)
ANR27
"DATA",176.801,6,0)
Activation of Emergency Medical System Education
"DATA",176.801,6,1)
2.16.840.1.113883.3.117.1.7.1.377
"DATA",176.801,6,4,0)
^176.8012P^1^1
"DATA",176.801,6,4,1,0)
14
"DATA",176.801,6,5)
AEMSE77
"DATA",176.801,7,0)
Active Labor
"DATA",176.801,7,1)
2.16.840.1.113883.3.117.1.7.1.281
"DATA",176.801,7,4,0)
^176.8012P^1^1
"DATA",176.801,7,4,1,0)
91
"DATA",176.801,7,5)
AL81
"DATA",176.801,8,0)
Acute Myocardial Infarction
"DATA",176.801,8,1)
2.16.840.1.113883.3.464.1003.104.12.1001
"DATA",176.801,8,4,0)
^176.8012P^2^2
"DATA",176.801,8,4,1,0)
25
"DATA",176.801,8,4,2,0)
3
"DATA",176.801,8,5)
AMI01
"DATA",176.801,9,0)
Acute Pharyngitis
"DATA",176.801,9,1)
2.16.840.1.113883.3.464.1003.102.12.1011
"DATA",176.801,9,4,0)
^176.8012P^1^1
"DATA",176.801,9,4,1,0)
74
"DATA",176.801,9,5)
AP11
"DATA",176.801,10,0)
Acute Respiratory Failure
"DATA",176.801,10,1)
2.16.840.1.113883.3.464.1003.102.12.1018
"DATA",176.801,10,4,0)
^176.8012P^1^1
"DATA",176.801,10,4,1,0)
29
"DATA",176.801,10,5)
ARF18
"DATA",176.801,11,0)
Acute Tonsillitis
"DATA",176.801,11,1)
2.16.840.1.113883.3.464.1003.102.12.1012
"DATA",176.801,11,4,0)
^176.8012P^1^1
"DATA",176.801,11,4,1,0)
74
"DATA",176.801,11,5)
AT12
"DATA",176.801,12,0)
Acute and Subacute Iridocyclitis
"DATA",176.801,12,1)
2.16.840.1.113883.3.526.3.1241
"DATA",176.801,12,4,0)
^176.8012P^2^2
"DATA",176.801,12,4,1,0)
19
"DATA",176.801,12,4,2,0)
57
"DATA",176.801,12,5)
ASI41
"DATA",176.801,13,0)
Additional evaluation for depression - adolescent
"DATA",176.801,13,1)
2.16.840.1.113883.3.600.1542
"DATA",176.801,13,4,0)
^176.8012P^1^1
"DATA",176.801,13,4,1,0)
53
"DATA",176.801,13,5)
A42
"DATA",176.801,14,0)
Additional evaluation for depression - adult
"DATA",176.801,14,1)
2.16.840.1.113883.3.600.1545
"DATA",176.801,14,4,0)
^176.8012P^1^1
"DATA",176.801,14,4,1,0)
53
"DATA",176.801,14,5)
A45
"DATA",176.801,15,0)
Adhesions and Disruptions of Iris and Ciliary Body
"DATA",176.801,15,1)
2.16.840.1.113883.3.526.3.1405
"DATA",176.801,15,4,0)
^176.8012P^1^1
"DATA",176.801,15,4,1,0)
57
"DATA",176.801,15,5)
ADICB05
"DATA",176.801,16,0)
Adolescent Depression Screening
"DATA",176.801,16,1)
2.16.840.1.113883.3.600.426
"DATA",176.801,16,4,0)
^176.8012P^1^1
"DATA",176.801,16,4,1,0)
53
"DATA",176.801,16,5)
ADS26
"DATA",176.801,17,0)
Adult Depression Screening
"DATA",176.801,17,1)
2.16.840.1.113883.3.600.431
"DATA",176.801,17,4,0)
^176.8012P^1^1
"DATA",176.801,17,4,1,0)
53
"DATA",176.801,17,5)
ADS31
"DATA",176.801,18,0)
Adverse Drug Reactions Education
"DATA",176.801,18,1)
2.16.840.1.113883.3.117.1.7.1.304
"DATA",176.801,18,4,0)
^176.8012P^1^1
"DATA",176.801,18,4,1,0)
38
"DATA",176.801,18,5)
ADRE04
"DATA",176.801,19,0)
Alcohol and Drug Dependence
"DATA",176.801,19,1)
2.16.840.1.113883.3.464.1003.106.12.1001
"DATA",176.801,19,4,0)
^176.8012P^1^1
"DATA",176.801,19,4,1,0)
76
"DATA",176.801,19,5)
ADD01
"DATA",176.801,20,0)
Alcohol and Drug Dependence Treatment
"DATA",176.801,20,1)
2.16.840.1.113883.3.464.1003.106.12.1005
"DATA",176.801,20,4,0)
^176.8012P^1^1
"DATA",176.801,20,4,1,0)
76
"DATA",176.801,20,5)
ADDT05
"DATA",176.801,21,0)
All Cancer
"DATA",176.801,21,1)
2.16.840.1.113883.3.464.1003.108.12.1011
"DATA",176.801,21,4,0)
^176.8012P^2^2
"DATA",176.801,21,4,1,0)
70
"DATA",176.801,21,4,2,0)
67
"DATA",176.801,21,5)
AC11
"DATA",176.801,22,0)
Allergy to ACE inhibitor or ARB
"DATA",176.801,22,1)
2.16.840.1.113883.3.526.3.1211
"DATA",176.801,22,4,0)
^176.8012P^1^1
"DATA",176.801,22,4,1,0)
24
"DATA",176.801,22,5)
AACEARB11
"DATA",176.801,23,0)
Allergy to Antineoplastic Therapy
"DATA",176.801,23,1)
2.16.840.1.113883.3.526.3.1280
"DATA",176.801,23,4,0)
^176.8012P^1^1
"DATA",176.801,23,4,1,0)
43
"DATA",176.801,23,5)
AAT80
"DATA",176.801,24,0)
Allergy to Beta Blocker Therapy
"DATA",176.801,24,1)
2.16.840.1.113883.3.526.3.1177
"DATA",176.801,24,4,0)
^176.8012P^2^2
"DATA",176.801,24,4,1,0)
41
"DATA",176.801,24,4,2,0)
39
"DATA",176.801,24,5)
ABBT77
"DATA",176.801,25,0)
Allergy to Influenza Vaccine
"DATA",176.801,25,1)
2.16.840.1.113883.3.526.3.1256
"DATA",176.801,25,4,0)
^176.8012P^1^1
"DATA",176.801,25,4,1,0)
59
"DATA",176.801,25,5)
AIV56
"DATA",176.801,26,0)
Allergy to Tamoxifen or Aromatase Inhibitor Therapy
"DATA",176.801,26,1)
2.16.840.1.113883.3.526.3.1317
"DATA",176.801,26,4,0)
^176.8012P^1^1
"DATA",176.801,26,4,1,0)
65
"DATA",176.801,26,5)
ATAIT17
"DATA",176.801,27,0)
Allergy to eggs
"DATA",176.801,27,1)
2.16.840.1.113883.3.526.3.1253
"DATA",176.801,27,4,0)
^176.8012P^1^1
"DATA",176.801,27,4,1,0)
59
"DATA",176.801,27,5)
A53
"DATA",176.801,28,0)
Amblyopia
"DATA",176.801,28,1)
2.16.840.1.113883.3.526.3.1448
"DATA",176.801,28,4,0)
^176.8012P^1^1
"DATA",176.801,28,4,1,0)
19
"DATA",176.801,28,5)
A48
"DATA",176.801,29,0)
Ambulatory
"DATA",176.801,29,1)
2.16.840.1.113883.3.464.1003.122.12.1003
"DATA",176.801,29,4,0)
^176.8012P^1^1
"DATA",176.801,29,4,1,0)
33
"DATA",176.801,29,5)
A03
"DATA",176.801,30,0)
Ambulatory/ED Visit
"DATA",176.801,30,1)
2.16.840.1.113883.3.464.1003.101.12.1061
"DATA",176.801,30,4,0)
^176.8012P^1^1
"DATA",176.801,30,4,1,0)
74
"DATA",176.801,30,5)
AEDV61
"DATA",176.801,31,0)
Anaphylactic Reaction to Common Baker's Yeast
"DATA",176.801,31,1)
2.16.840.1.113883.3.464.1003.199.12.1032
"DATA",176.801,31,4,0)
^176.8012P^1^1
"DATA",176.801,31,4,1,0)
66
"DATA",176.801,31,5)
ARCB'Y32
"DATA",176.801,32,0)
Anaphylactic Reaction to DTaP Vaccine
"DATA",176.801,32,1)
2.16.840.1.113883.3.464.1003.199.12.1031
"DATA",176.801,32,4,0)
^176.8012P^1^1
"DATA",176.801,32,4,1,0)
66
"DATA",176.801,32,5)
ARDTPV31
"DATA",176.801,33,0)
Anaphylactic Reaction to Hemophilus Influenza B (HiB) Vaccine
"DATA",176.801,33,1)
2.16.840.1.113883.3.464.1003.199.12.1030
"DATA",176.801,33,4,0)
^176.8012P^1^1
"DATA",176.801,33,4,1,0)
66
"DATA",176.801,33,5)
ARHIBHBV30
"DATA",176.801,34,0)
Anaphylactic Reaction to Hepatitis A Vaccine
"DATA",176.801,34,1)
2.16.840.1.113883.3.464.1003.199.12.1026
"DATA",176.801,34,4,0)
^176.8012P^1^1
"DATA",176.801,34,4,1,0)
66
"DATA",176.801,34,5)
ARHAV26
"DATA",176.801,35,0)
Anaphylactic Reaction to Hepatitis B Vaccine
"DATA",176.801,35,1)
2.16.840.1.113883.3.464.1003.199.12.1029
"DATA",176.801,35,4,0)
^176.8012P^1^1
"DATA",176.801,35,4,1,0)
66
"DATA",176.801,35,5)
ARHBV29
"DATA",176.801,36,0)
Anaphylactic Reaction to Inactivated Polio Vaccine (IPV)
"DATA",176.801,36,1)
2.16.840.1.113883.3.464.1003.199.12.1023
"DATA",176.801,36,4,0)
^176.8012P^1^1
"DATA",176.801,36,4,1,0)
66
"DATA",176.801,36,5)
ARIPVIPV23
"DATA",176.801,37,0)
Anaphylactic Reaction to Influenza Vaccine
"DATA",176.801,37,1)
2.16.840.1.113883.3.464.1003.199.12.1022
"DATA",176.801,37,4,0)
^176.8012P^1^1
"DATA",176.801,37,4,1,0)
66
"DATA",176.801,37,5)
ARIV22
"DATA",176.801,38,0)
Anaphylactic Reaction to Neomycin
"DATA",176.801,38,1)
2.16.840.1.113883.3.464.1003.199.12.1024
"DATA",176.801,38,4,0)
^176.8012P^1^1
"DATA",176.801,38,4,1,0)
66
"DATA",176.801,38,5)
ARN24
"DATA",176.801,39,0)
Anaphylactic Reaction to Pneumococcal Conjugate Vaccine
"DATA",176.801,39,1)
2.16.840.1.113883.3.464.1003.199.12.1027
"DATA",176.801,39,4,0)
^176.8012P^1^1
"DATA",176.801,39,4,1,0)
66
"DATA",176.801,39,5)
ARPCV27
"DATA",176.801,40,0)
Anaphylactic Reaction to Polymyxin
"DATA",176.801,40,1)
2.16.840.1.113883.3.464.1003.199.12.1025
"DATA",176.801,40,4,0)
^176.8012P^1^1
"DATA",176.801,40,4,1,0)
66
"DATA",176.801,40,5)
ARP25
"DATA",176.801,41,0)
Anaphylactic Reaction to Rotavirus Vaccine
"DATA",176.801,41,1)
2.16.840.1.113883.3.464.1003.199.12.1021
"DATA",176.801,41,4,0)
^176.8012P^1^1
"DATA",176.801,41,4,1,0)
66
"DATA",176.801,41,5)
ARRV21
"DATA",176.801,42,0)
Anaphylactic Reaction to Streptomycin
"DATA",176.801,42,1)
2.16.840.1.113883.3.464.1003.199.12.1028
"DATA",176.801,42,4,0)
^176.8012P^1^1
"DATA",176.801,42,4,1,0)
66
"DATA",176.801,42,5)
ARS28
"DATA",176.801,43,0)
Annual Wellness Visit
"DATA",176.801,43,1)
2.16.840.1.113883.3.526.3.1240
"DATA",176.801,43,4,0)
^176.8012P^16^16
"DATA",176.801,43,4,1,0)
8
"DATA",176.801,43,4,2,0)
80
"DATA",176.801,43,4,3,0)
10
"DATA",176.801,43,4,4,0)
75
"DATA",176.801,43,4,5,0)
63
"DATA",176.801,43,4,6,0)
3
"DATA",176.801,43,4,7,0)
59
"DATA",176.801,43,4,8,0)
25
"DATA",176.801,43,4,9,0)
60
"DATA",176.801,43,4,10,0)
46
"DATA",176.801,43,4,11,0)
87
"DATA",176.801,43,4,12,0)
64
"DATA",176.801,43,4,13,0)
34
"DATA",176.801,43,4,14,0)
71
"DATA",176.801,43,4,15,0)
84
"DATA",176.801,43,4,16,0)
28
"DATA",176.801,43,5)
AWV40
"DATA",176.801,44,0)
Anomalies of Puillary Function
"DATA",176.801,44,1)
2.16.840.1.113883.3.526.3.1406
"DATA",176.801,44,4,0)
^176.8012P^1^1
"DATA",176.801,44,4,1,0)
57
"DATA",176.801,44,5)
APF06
"DATA",176.801,45,0)
Anti-Hypertensive Pharmacologic Therapy
"DATA",176.801,45,1)
2.16.840.1.113883.3.600.1476
"DATA",176.801,45,4,0)
^176.8012P^3^3
"DATA",176.801,45,4,1,0)
5
"DATA",176.801,45,4,2,0)
1
"DATA",176.801,45,4,3,0)
58
"DATA",176.801,45,5)
AHPT76
"DATA",176.801,46,0)
Antibiotic Medications
"DATA",176.801,46,1)
2.16.840.1.113883.3.464.1003.196.12.1001
"DATA",176.801,46,4,0)
^176.8012P^2^2
"DATA",176.801,46,4,1,0)
74
"DATA",176.801,46,4,2,0)
85
"DATA",176.801,46,5)
AM01
"DATA",176.801,47,0)
Anticoagulant Therapy
"DATA",176.801,47,1)
2.16.840.1.113883.3.117.1.7.1.200
"DATA",176.801,47,4,0)
^176.8012P^1^1
"DATA",176.801,47,4,1,0)
2
"DATA",176.801,47,5)
AT00
"DATA",176.801,48,0)
Antidepressant Medication
"DATA",176.801,48,1)
2.16.840.1.113883.3.464.1003.196.12.1213
"DATA",176.801,48,4,0)
^176.8012P^1^1
"DATA",176.801,48,4,1,0)
46
"DATA",176.801,48,5)
AM13
"DATA",176.801,49,0)
Antithrombotic Therapy
"DATA",176.801,49,1)
2.16.840.1.113883.3.117.1.7.1.201
"DATA",176.801,49,4,0)
^176.8012P^2^2
"DATA",176.801,49,4,1,0)
22
"DATA",176.801,49,4,2,0)
49
"DATA",176.801,49,5)
AT01
"DATA",176.801,50,0)
Any Infection SCIP
"DATA",176.801,50,1)
2.16.840.1.113883.3.666.5.2256
"DATA",176.801,50,4,0)
^176.8012P^2^2
"DATA",176.801,50,4,1,0)
78
"DATA",176.801,50,4,2,0)
92
"DATA",176.801,50,5)
AISCIP56
"DATA",176.801,51,0)
Aphakia and other Disorders of Lens
"DATA",176.801,51,1)
2.16.840.1.113883.3.526.3.1407
"DATA",176.801,51,4,0)
^176.8012P^1^1
"DATA",176.801,51,4,1,0)
57
"DATA",176.801,51,5)
ADL07
"DATA",176.801,52,0)
Arrhythmia
"DATA",176.801,52,1)
2.16.840.1.113883.3.526.3.366
"DATA",176.801,52,4,0)
^176.8012P^2^2
"DATA",176.801,52,4,1,0)
39
"DATA",176.801,52,4,2,0)
41
"DATA",176.801,52,5)
A66
"DATA",176.801,53,0)
Arterial or Umbilical Venous Cath Group
"DATA",176.801,53,1)
2.16.840.1.113883.3.666.5.1582
"DATA",176.801,53,4,0)
^176.8012P^1^1
"DATA",176.801,53,4,1,0)
93
"DATA",176.801,53,5)
AUVCG82
"DATA",176.801,54,0)
Aspiration and Injection Procedures
"DATA",176.801,54,1)
2.16.840.1.113883.3.526.3.1408
"DATA",176.801,54,4,0)
^176.8012P^1^1
"DATA",176.801,54,4,1,0)
57
"DATA",176.801,54,5)
AIP08
"DATA",176.801,55,0)
Aspirin Allergen
"DATA",176.801,55,1)
2.16.840.1.113883.3.117.1.7.1.139
"DATA",176.801,55,4,0)
^176.8012P^1^1
"DATA",176.801,55,4,1,0)
69
"DATA",176.801,55,5)
AA39
"DATA",176.801,56,0)
Aspirin and Other Anti-thrombotics
"DATA",176.801,56,1)
2.16.840.1.113883.3.464.1003.196.12.1211
"DATA",176.801,56,4,0)
^176.8012P^1^1
"DATA",176.801,56,4,1,0)
3
"DATA",176.801,56,5)
AOA11
"DATA",176.801,57,0)
Asthma
"DATA",176.801,57,1)
2.16.840.1.113883.3.117.1.7.1.271
"DATA",176.801,57,5)
A71
"DATA",176.801,58,0)
Asthma
"DATA",176.801,58,1)
2.16.840.1.113883.3.526.3.362
"DATA",176.801,58,5)
A62
"DATA",176.801,59,0)
Asthma Management Plan
"DATA",176.801,59,1)
2.16.840.1.113883.3.117.1.7.1.131
"DATA",176.801,59,5)
AMP31
"DATA",176.801,60,0)
Atrial Ablation
"DATA",176.801,60,1)
2.16.840.1.113883.3.117.1.7.1.203
"DATA",176.801,60,4,0)
^176.8012P^1^1
"DATA",176.801,60,4,1,0)
2
"DATA",176.801,60,5)
AA03
"DATA",176.801,61,0)
Atrial Fibrillation/Flutter
"DATA",176.801,61,1)
2.16.840.1.113883.3.117.1.7.1.202
"DATA",176.801,61,4,0)
^176.8012P^3^3
"DATA",176.801,61,4,1,0)
2
"DATA",176.801,61,4,2,0)
90
"DATA",176.801,61,4,3,0)
18
"DATA",176.801,61,5)
AFF02
"DATA",176.801,62,0)
Atrioventricular Block
"DATA",176.801,62,1)
2.16.840.1.113883.3.526.3.367
"DATA",176.801,62,4,0)
^176.8012P^2^2
"DATA",176.801,62,4,1,0)
39
"DATA",176.801,62,4,2,0)
41
"DATA",176.801,62,5)
AB67
"DATA",176.801,63,0)
BH Antidepressant medication
"DATA",176.801,63,1)
2.16.840.1.113883.3.1257.1.972
"DATA",176.801,63,4,0)
^176.8012P^1^1
"DATA",176.801,63,4,1,0)
68
"DATA",176.801,63,5)
BHA72
"DATA",176.801,64,0)
BH Assessment for alcohol or other drugs
"DATA",176.801,64,1)
2.16.840.1.113883.3.1257.1.1604
"DATA",176.801,64,4,0)
^176.8012P^1^1
"DATA",176.801,64,4,1,0)
68
"DATA",176.801,64,5)
BHA04
"DATA",176.801,65,0)
BH Condition involving bipolar disorder
"DATA",176.801,65,1)
2.16.840.1.113883.3.1257.1.1504
"DATA",176.801,65,4,0)
^176.8012P^1^1
"DATA",176.801,65,4,1,0)
68
"DATA",176.801,65,5)
BHC04
"DATA",176.801,66,0)
BH Condition involving unipolar depression
"DATA",176.801,66,1)
2.16.840.1.113883.3.1257.1.1505
"DATA",176.801,66,4,0)
^176.8012P^1^1
"DATA",176.801,66,4,1,0)
68
"DATA",176.801,66,5)
BHC05
"DATA",176.801,67,0)
BH Counseling for depression
"DATA",176.801,67,1)
2.16.840.1.113883.3.1257.1.1616
"DATA",176.801,67,4,0)
^176.8012P^1^1
"DATA",176.801,67,4,1,0)
68
"DATA",176.801,67,5)
BHC16
"DATA",176.801,68,0)
BH Electroconvulsive therapy
"DATA",176.801,68,1)
2.16.840.1.113883.3.1257.1.1533
"DATA",176.801,68,4,0)
^176.8012P^1^1
"DATA",176.801,68,4,1,0)
68
"DATA",176.801,68,5)
BHE33
"DATA",176.801,69,0)
BH Medical or psychiatric consultation
"DATA",176.801,69,1)
2.16.840.1.113883.3.1257.1.1652
"DATA",176.801,69,4,0)
^176.8012P^1^1
"DATA",176.801,69,4,1,0)
47
"DATA",176.801,69,5)
BHM52
"DATA",176.801,70,0)
BH Mood stabilizer medication
"DATA",176.801,70,1)
2.16.840.1.113883.3.1257.1.950
"DATA",176.801,70,4,0)
^176.8012P^1^1
"DATA",176.801,70,4,1,0)
68
"DATA",176.801,70,5)
BHM50
"DATA",176.801,71,0)
BH Outpatient encounter
"DATA",176.801,71,1)
2.16.840.1.113883.3.464.1.49
"DATA",176.801,71,4,0)
^176.8012P^1^1
"DATA",176.801,71,4,1,0)
68
"DATA",176.801,71,5)
BHO49
"DATA",176.801,72,0)
BH Outpatient psychotherapy
"DATA",176.801,72,1)
2.16.840.1.113883.3.1257.1.973
"DATA",176.801,72,4,0)
^176.8012P^1^1
"DATA",176.801,72,4,1,0)
68
"DATA",176.801,72,5)
BHO73
"DATA",176.801,73,0)
BMI Encounter Code Set
"DATA",176.801,73,1)
2.16.840.1.113883.3.600.1.1751
"DATA",176.801,73,4,0)
^176.8012P^1^1
"DATA",176.801,73,4,1,0)
52
"DATA",176.801,73,5)
BMIECS51
"DATA",176.801,74,0)
BMI Finding Code Set
"DATA",176.801,74,1)
2.16.840.1.113883.3.600.1.890
"DATA",176.801,74,4,0)
^176.8012P^1^1
"DATA",176.801,74,4,1,0)
52
"DATA",176.801,74,5)
BMIFCS90
"DATA",176.801,75,0)
BMI LOINC calculation
"DATA",176.801,75,1)
2.16.840.1.113883.3.600.1.2040
"DATA",176.801,75,4,0)
^176.8012P^1^1
"DATA",176.801,75,4,1,0)
52
"DATA",176.801,75,5)
BMILOINC40
"DATA",176.801,76,0)
BMI percentile
"DATA",176.801,76,1)
2.16.840.1.113883.3.464.1003.121.12.1012
"DATA",176.801,76,4,0)
^176.8012P^1^1
"DATA",176.801,76,4,1,0)
6
"DATA",176.801,76,5)
BMI12
"DATA",176.801,77,0)
BP Screening Denominator Encounter Codes Grouped New
"DATA",176.801,77,1)
2.16.840.1.113883.3.600.1920
"DATA",176.801,77,4,0)
^176.8012P^1^1
"DATA",176.801,77,4,1,0)
58
"DATA",176.801,77,5)
BPSDECGN20
"DATA",176.801,78,0)
Baseline State
"DATA",176.801,78,1)
2.16.840.1.113883.3.117.1.7.1.417
"DATA",176.801,78,4,0)
^176.8012P^1^1
"DATA",176.801,78,4,1,0)
15
"DATA",176.801,78,5)
BS17
"DATA",176.801,79,0)
Behavioral Health Follow-up Visit
"DATA",176.801,79,1)
2.16.840.1.113883.3.464.1003.101.12.1054
"DATA",176.801,79,4,0)
^176.8012P^1^1
"DATA",176.801,79,4,1,0)
33
"DATA",176.801,79,5)
BHFV54
"DATA",176.801,80,0)
Behavioral/Neuropsych Assessment
"DATA",176.801,80,1)
2.16.840.1.113883.3.526.3.1023
"DATA",176.801,80,4,0)
^176.8012P^1^1
"DATA",176.801,80,4,1,0)
35
"DATA",176.801,80,5)
BNA23
"DATA",176.801,81,0)
Below Normal Follow up
"DATA",176.801,81,1)
2.16.840.1.113883.3.600.1.1528
"DATA",176.801,81,4,0)
^176.8012P^1^1
"DATA",176.801,81,4,1,0)
52
"DATA",176.801,81,5)
BNF28
"DATA",176.801,82,0)
Below Normal Medications
"DATA",176.801,82,1)
2.16.840.1.113883.3.600.1.1499
"DATA",176.801,82,4,0)
^176.8012P^1^1
"DATA",176.801,82,4,1,0)
52
"DATA",176.801,82,5)
BNM99
"DATA",176.801,83,0)
Below Normal Referrals
"DATA",176.801,83,1)
2.16.840.1.113883.3.600.1.1529
"DATA",176.801,83,4,0)
^176.8012P^1^1
"DATA",176.801,83,4,1,0)
52
"DATA",176.801,83,5)
BNR29
"DATA",176.801,84,0)
Beta Blocker Therapy
"DATA",176.801,84,1)
2.16.840.1.113883.3.526.3.1174
"DATA",176.801,84,4,0)
^176.8012P^2^2
"DATA",176.801,84,4,1,0)
39
"DATA",176.801,84,4,2,0)
41
"DATA",176.801,84,5)
BBT74
"DATA",176.801,85,0)
Beta Blocker Therapy for LVSD
"DATA",176.801,85,1)
2.16.840.1.113883.3.526.3.1184
"DATA",176.801,85,4,0)
^176.8012P^2^2
"DATA",176.801,85,4,1,0)
39
"DATA",176.801,85,4,2,0)
41
"DATA",176.801,85,5)
BBTLVSD84
"DATA",176.801,86,0)
Bilateral Mastectomy
"DATA",176.801,86,1)
2.16.840.1.113883.3.464.1003.198.12.1005
"DATA",176.801,86,4,0)
^176.8012P^1^1
"DATA",176.801,86,4,1,0)
10
"DATA",176.801,86,5)
BM05
"DATA",176.801,87,0)
Bilateral Oophorectomy
"DATA",176.801,87,1)
2.16.840.1.113883.3.526.3.471
"DATA",176.801,87,4,0)
^176.8012P^1^1
"DATA",176.801,87,4,1,0)
65
"DATA",176.801,87,5)
BO71
"DATA",176.801,88,0)
Bipolar Diagnosis
"DATA",176.801,88,1)
2.16.840.1.113883.3.600.450
"DATA",176.801,88,4,0)
^176.8012P^1^1
"DATA",176.801,88,4,1,0)
53
"DATA",176.801,88,5)
BD50
"DATA",176.801,89,0)
Bipolar Disorder
"DATA",176.801,89,1)
2.16.840.1.113883.3.67.1.101.1.128
"DATA",176.801,89,4,0)
^176.8012P^2^2
"DATA",176.801,89,4,1,0)
61
"DATA",176.801,89,4,2,0)
42
"DATA",176.801,89,5)
BD28
"DATA",176.801,90,0)
Birth
"DATA",176.801,90,1)
2.16.840.1.113883.3.117.1.7.1.70
"DATA",176.801,90,4,0)
^176.8012P^3^3
"DATA",176.801,90,4,1,0)
36
"DATA",176.801,90,4,2,0)
93
"DATA",176.801,90,4,3,0)
4
"DATA",176.801,90,5)
B70
"DATA",176.801,91,0)
Birth Trauma or Injuries Group
"DATA",176.801,91,1)
2.16.840.1.113883.3.666.5.1567
"DATA",176.801,91,4,0)
^176.8012P^1^1
"DATA",176.801,91,4,1,0)
93
"DATA",176.801,91,5)
BTIG67
"DATA",176.801,92,0)
Blood Pressure Measured
"DATA",176.801,92,1)
2.16.840.1.113883.3.600.2012
"DATA",176.801,92,4,0)
^176.8012P^1^1
"DATA",176.801,92,4,1,0)
58
"DATA",176.801,92,5)
BPM12
"DATA",176.801,93,0)
Blood Pressure Visit
"DATA",176.801,93,1)
2.16.840.1.113883.3.464.1003.101.12.1056
"DATA",176.801,93,4,0)
^176.8012P^1^1
"DATA",176.801,93,4,1,0)
12
"DATA",176.801,93,5)
BPV56
"DATA",176.801,94,0)
Bone Scan
"DATA",176.801,94,1)
2.16.840.1.113883.3.526.3.320
"DATA",176.801,94,4,0)
^176.8012P^1^1
"DATA",176.801,94,4,1,0)
9
"DATA",176.801,94,5)
BS20
"DATA",176.801,95,0)
Bradycardia
"DATA",176.801,95,1)
2.16.840.1.113883.3.526.3.412
"DATA",176.801,95,4,0)
^176.8012P^2^2
"DATA",176.801,95,4,1,0)
41
"DATA",176.801,95,4,2,0)
39
"DATA",176.801,95,5)
B12
"DATA",176.801,96,0)
Breast Cancer
"DATA",176.801,96,1)
2.16.840.1.113883.3.526.3.389
"DATA",176.801,96,4,0)
^176.8012P^1^1
"DATA",176.801,96,4,1,0)
65
"DATA",176.801,96,5)
BC89
"DATA",176.801,97,0)
Breast Cancer ER or PR Positive
"DATA",176.801,97,1)
2.16.840.1.113883.3.526.3.1303
"DATA",176.801,97,4,0)
^176.8012P^1^1
"DATA",176.801,97,4,1,0)
65
"DATA",176.801,97,5)
BCERPRP03
"DATA",176.801,98,0)
Breast Cancer Primary Tumor Size T0
"DATA",176.801,98,1)
2.16.840.1.113883.3.526.3.1304
"DATA",176.801,98,4,0)
^176.8012P^1^1
"DATA",176.801,98,4,1,0)
65
"DATA",176.801,98,5)
BCPTST004
"DATA",176.801,99,0)
Breast Cancer Primary Tumor Size T1
"DATA",176.801,99,1)
2.16.840.1.113883.3.526.3.1305
"DATA",176.801,99,4,0)
^176.8012P^1^1
"DATA",176.801,99,4,1,0)
65
"DATA",176.801,99,5)
BCPTST105
"DATA",176.801,100,0)
Breast Cancer Primary Tumor Size T1a
"DATA",176.801,100,1)
2.16.840.1.113883.3.526.3.1164
"DATA",176.801,100,4,0)
^176.8012P^1^1
"DATA",176.801,100,4,1,0)
65
"DATA",176.801,100,5)
BCPTST164
"DATA",176.801,101,0)
Breast Cancer Primary Tumor Size T1b
"DATA",176.801,101,1)
2.16.840.1.113883.3.526.3.1270
"DATA",176.801,101,4,0)
^176.8012P^1^1
"DATA",176.801,101,4,1,0)
65
"DATA",176.801,101,5)
BCPTST170
"DATA",176.801,102,0)
Breast Cancer Primary Tumor Size T1c
"DATA",176.801,102,1)
2.16.840.1.113883.3.526.3.1306
"DATA",176.801,102,4,0)
^176.8012P^1^1
"DATA",176.801,102,4,1,0)
65
"DATA",176.801,102,5)
BCPTST106
"DATA",176.801,103,0)
Breast Cancer Primary Tumor Size T1mi
"DATA",176.801,103,1)
2.16.840.1.113883.3.526.3.1197
"DATA",176.801,103,4,0)
^176.8012P^1^1
"DATA",176.801,103,4,1,0)
65
"DATA",176.801,103,5)
BCPTST197
"DATA",176.801,104,0)
Breast Cancer Primary Tumor Size T2
"DATA",176.801,104,1)
2.16.840.1.113883.3.526.3.1307
"DATA",176.801,104,4,0)
^176.8012P^1^1
"DATA",176.801,104,4,1,0)
65
"DATA",176.801,104,5)
BCPTST207
"DATA",176.801,105,0)
Breast Cancer Primary Tumor Size T3
"DATA",176.801,105,1)
2.16.840.1.113883.3.526.3.1308
"DATA",176.801,105,4,0)
^176.8012P^1^1
"DATA",176.801,105,4,1,0)
65
"DATA",176.801,105,5)
BCPTST308
"DATA",176.801,106,0)
Breast Cancer Primary Tumor Size T4
"DATA",176.801,106,1)
2.16.840.1.113883.3.526.3.1309
"DATA",176.801,106,4,0)
^176.8012P^1^1
"DATA",176.801,106,4,1,0)
65
"DATA",176.801,106,5)
BCPTST409
"DATA",176.801,107,0)
Breast Cancer Regional Lymph Node Status N0
"DATA",176.801,107,1)
2.16.840.1.113883.3.526.3.1310
"DATA",176.801,107,4,0)
^176.8012P^1^1
"DATA",176.801,107,4,1,0)
65
"DATA",176.801,107,5)
BCRLNSN010
"DATA",176.801,108,0)
Breast Cancer Regional Lymph Node Status N1
"DATA",176.801,108,1)
2.16.840.1.113883.3.526.3.1329
"DATA",176.801,108,4,0)
^176.8012P^1^1
"DATA",176.801,108,4,1,0)
65
"DATA",176.801,108,5)
BCRLNSN129
"DATA",176.801,109,0)
Breast Cancer Regional Lymph Node Status N2
"DATA",176.801,109,1)
2.16.840.1.113883.3.526.3.1313
"DATA",176.801,109,4,0)
^176.8012P^1^1
"DATA",176.801,109,4,1,0)
65
"DATA",176.801,109,5)
BCRLNSN213
"DATA",176.801,110,0)
Breast Cancer Regional Lymph Node Status N3
"DATA",176.801,110,1)
2.16.840.1.113883.3.526.3.1314
"DATA",176.801,110,4,0)
^176.8012P^1^1
"DATA",176.801,110,4,1,0)
65
"DATA",176.801,110,5)
BCRLNSN314
"DATA",176.801,111,0)
Breast Cancer Regional Lymph Node Status pN1a
"DATA",176.801,111,1)
2.16.840.1.113883.3.526.3.1311
"DATA",176.801,111,4,0)
^176.8012P^1^1
"DATA",176.801,111,4,1,0)
65
"DATA",176.801,111,5)
BCRLNSN111
"DATA",176.801,112,0)
Breast Cancer Regional Lymph Node Status pN1b
"DATA",176.801,112,1)
2.16.840.1.113883.3.526.3.1330
"DATA",176.801,112,4,0)
^176.8012P^1^1
"DATA",176.801,112,4,1,0)
65
"DATA",176.801,112,5)
BCRLNSN130
"DATA",176.801,113,0)
Breast Cancer Regional Lymph Node Status pN1c
"DATA",176.801,113,1)
2.16.840.1.113883.3.526.3.1331
"DATA",176.801,113,4,0)
^176.8012P^1^1
"DATA",176.801,113,4,1,0)
65
"DATA",176.801,113,5)
BCRLNSN131
"DATA",176.801,114,0)
Breast Cancer Regional Lymph Node Status pN1mi
"DATA",176.801,114,1)
2.16.840.1.113883.3.526.3.1312
"DATA",176.801,114,4,0)
^176.8012P^1^1
"DATA",176.801,114,4,1,0)
65
"DATA",176.801,114,5)
BCRLNSN112
"DATA",176.801,115,0)
Breast Distant Metastasis Status M0
"DATA",176.801,115,1)
2.16.840.1.113883.3.526.3.1302
"DATA",176.801,115,4,0)
^176.8012P^1^1
"DATA",176.801,115,4,1,0)
65
"DATA",176.801,115,5)
BDMSM002
"DATA",176.801,116,0)
Breast Milk
"DATA",176.801,116,1)
2.16.840.1.113883.3.117.1.7.1.30
"DATA",176.801,116,4,0)
^176.8012P^1^1
"DATA",176.801,116,4,1,0)
36
"DATA",176.801,116,5)
BM30
"DATA",176.801,117,0)
Burn Confined to Eye and Adnexa
"DATA",176.801,117,1)
2.16.840.1.113883.3.526.3.1409
"DATA",176.801,117,4,0)
^176.8012P^2^2
"DATA",176.801,117,4,1,0)
19
"DATA",176.801,117,4,2,0)
57
"DATA",176.801,117,5)
BCEA09
"DATA",176.801,118,0)
CD4+ Count
"DATA",176.801,118,1)
2.16.840.1.113883.3.464.1003.121.12.1004
"DATA",176.801,118,4,0)
^176.8012P^1^1
"DATA",176.801,118,4,1,0)
11
"DATA",176.801,118,5)
CD4+C04
"DATA",176.801,119,0)
CD4+ Percentage
"DATA",176.801,119,1)
2.16.840.1.113883.3.464.1003.121.12.1005
"DATA",176.801,119,4,0)
^176.8012P^1^1
"DATA",176.801,119,4,1,0)
11
"DATA",176.801,119,5)
CD4+P05
"DATA",176.801,120,0)
CHD or CHD Risk Equivalent
"DATA",176.801,120,1)
2.16.840.1.113883.3.600.863
"DATA",176.801,120,4,0)
^176.8012P^2^2
"DATA",176.801,120,4,1,0)
5
"DATA",176.801,120,4,2,0)
1
"DATA",176.801,120,5)
CHDCHDRE63
"DATA",176.801,121,0)
CT Scan of Lower Spine
"DATA",176.801,121,1)
2.16.840.1.113883.3.464.1003.113.12.1035
"DATA",176.801,121,4,0)
^176.8012P^1^1
"DATA",176.801,121,4,1,0)
67
"DATA",176.801,121,5)
CTSLS35
"DATA",176.801,122,0)
Cancer
"DATA",176.801,122,1)
2.16.840.1.113883.3.526.3.1010
"DATA",176.801,122,4,0)
^176.8012P^1^1
"DATA",176.801,122,4,1,0)
55
"DATA",176.801,122,5)
C10
"DATA",176.801,123,0)
Cardiac Pacer
"DATA",176.801,123,1)
2.16.840.1.113883.3.526.3.1193
"DATA",176.801,123,4,0)
^176.8012P^2^2
"DATA",176.801,123,4,1,0)
41
"DATA",176.801,123,4,2,0)
39
"DATA",176.801,123,5)
CP93
"DATA",176.801,124,0)
Cardiac Pacer in Situ
"DATA",176.801,124,1)
2.16.840.1.113883.3.526.3.368
"DATA",176.801,124,4,0)
^176.8012P^2^2
"DATA",176.801,124,4,1,0)
39
"DATA",176.801,124,4,2,0)
41
"DATA",176.801,124,5)
CPS68
"DATA",176.801,125,0)
Cardiac Surgery
"DATA",176.801,125,1)
2.16.840.1.113883.3.526.3.371
"DATA",176.801,125,4,0)
^176.8012P^1^1
"DATA",176.801,125,4,1,0)
39
"DATA",176.801,125,5)
CS71
"DATA",176.801,126,0)
Cardiopulmonary Resuscitation Group
"DATA",176.801,126,1)
2.16.840.1.113883.3.666.5.1586
"DATA",176.801,126,4,0)
^176.8012P^1^1
"DATA",176.801,126,4,1,0)
93
"DATA",176.801,126,5)
CRG86
"DATA",176.801,127,0)
Care Services in Long-Term Residential Facility
"DATA",176.801,127,1)
2.16.840.1.113883.3.464.1003.101.12.1014
"DATA",176.801,127,4,0)
^176.8012P^9^9
"DATA",176.801,127,4,1,0)
35
"DATA",176.801,127,4,2,0)
81
"DATA",176.801,127,4,3,0)
24
"DATA",176.801,127,4,4,0)
39
"DATA",176.801,127,4,5,0)
59
"DATA",176.801,127,4,6,0)
26
"DATA",176.801,127,4,7,0)
41
"DATA",176.801,127,4,8,0)
27
"DATA",176.801,127,4,9,0)
71
"DATA",176.801,127,5)
CSLTRF14
"DATA",176.801,128,0)
Cataract Secondary to Ocular Disorders
"DATA",176.801,128,1)
2.16.840.1.113883.3.526.3.1410
"DATA",176.801,128,4,0)
^176.8012P^2^2
"DATA",176.801,128,4,1,0)
19
"DATA",176.801,128,4,2,0)
57
"DATA",176.801,128,5)
CSOD10
"DATA",176.801,129,0)
Cataract Surgery
"DATA",176.801,129,1)
2.16.840.1.113883.3.526.3.1411
"DATA",176.801,129,4,0)
^176.8012P^2^2
"DATA",176.801,129,4,1,0)
19
"DATA",176.801,129,4,2,0)
57
"DATA",176.801,129,5)
CS11
"DATA",176.801,130,0)
Cataract, Congenital
"DATA",176.801,130,1)
2.16.840.1.113883.3.526.3.1412
"DATA",176.801,130,4,0)
^176.8012P^1^1
"DATA",176.801,130,4,1,0)
57
"DATA",176.801,130,5)
CC12
"DATA",176.801,131,0)
Cataract, Mature or Hypermature
"DATA",176.801,131,1)
2.16.840.1.113883.3.526.3.1413
"DATA",176.801,131,4,0)
^176.8012P^1^1
"DATA",176.801,131,4,1,0)
57
"DATA",176.801,131,5)
CMH13
"DATA",176.801,132,0)
Cataract, Posterior Polar
"DATA",176.801,132,1)
2.16.840.1.113883.3.526.3.1414
"DATA",176.801,132,4,0)
^176.8012P^1^1
"DATA",176.801,132,4,1,0)
57
"DATA",176.801,132,5)
CPP14
"DATA",176.801,133,0)
Central Corneal Ulcer
"DATA",176.801,133,1)
2.16.840.1.113883.3.526.3.1428
"DATA",176.801,133,4,0)
^176.8012P^2^2
"DATA",176.801,133,4,1,0)
57
"DATA",176.801,133,4,2,0)
19
"DATA",176.801,133,5)
CCU28
"DATA",176.801,134,0)
Certain Types of Iridocyclitis
"DATA",176.801,134,1)
2.16.840.1.113883.3.526.3.1415
"DATA",176.801,134,4,0)
^176.8012P^2^2
"DATA",176.801,134,4,1,0)
19
"DATA",176.801,134,4,2,0)
57
"DATA",176.801,134,5)
CTI15
"DATA",176.801,135,0)
Cesarean Section
"DATA",176.801,135,1)
2.16.840.1.113883.3.117.1.7.1.282
"DATA",176.801,135,4,0)
^176.8012P^1^1
"DATA",176.801,135,4,1,0)
91
"DATA",176.801,135,5)
CS82
"DATA",176.801,136,0)
Chemotherapy
"DATA",176.801,136,1)
2.16.840.1.113883.3.526.3.485
"DATA",176.801,136,4,0)
^176.8012P^1^1
"DATA",176.801,136,4,1,0)
65
"DATA",176.801,136,5)
C85
"DATA",176.801,137,0)
Chemotherapy Administration
"DATA",176.801,137,1)
2.16.840.1.113883.3.526.3.1027
"DATA",176.801,137,4,0)
^176.8012P^1^1
"DATA",176.801,137,4,1,0)
55
"DATA",176.801,137,5)
CA27
"DATA",176.801,138,0)
Chemotherapy for Colon Cancer - capecitabine
"DATA",176.801,138,1)
2.16.840.1.113883.3.526.3.1288
"DATA",176.801,138,4,0)
^176.8012P^1^1
"DATA",176.801,138,4,1,0)
43
"DATA",176.801,138,5)
CCC88
"DATA",176.801,139,0)
Chemotherapy for Colon Cancer - fluorouracil
"DATA",176.801,139,1)
2.16.840.1.113883.3.526.3.1289
"DATA",176.801,139,4,0)
^176.8012P^1^1
"DATA",176.801,139,4,1,0)
43
"DATA",176.801,139,5)
CCC89
"DATA",176.801,140,0)
Chemotherapy for Colon Cancer - leucovorin and levo-leucovorin
"DATA",176.801,140,1)
2.16.840.1.113883.3.526.3.1290
"DATA",176.801,140,4,0)
^176.8012P^1^1
"DATA",176.801,140,4,1,0)
43
"DATA",176.801,140,5)
CCC90
"DATA",176.801,141,0)
Chemotherapy for Colon Cancer - oxaliplatin
"DATA",176.801,141,1)
2.16.840.1.113883.3.526.3.1291
"DATA",176.801,141,4,0)
^176.8012P^1^1
"DATA",176.801,141,4,1,0)
43
"DATA",176.801,141,5)
CCC91
"DATA",176.801,142,0)
Chlamydia
"DATA",176.801,142,1)
2.16.840.1.113883.3.464.1003.112.12.1003
"DATA",176.801,142,4,0)
^176.8012P^1^1
"DATA",176.801,142,4,1,0)
77
"DATA",176.801,142,5)
C03
"DATA",176.801,143,0)
Chlamydia Screening
"DATA",176.801,143,1)
2.16.840.1.113883.3.464.1003.110.12.1052
"DATA",176.801,143,4,0)
^176.8012P^1^1
"DATA",176.801,143,4,1,0)
77
"DATA",176.801,143,5)
CS52
"DATA",176.801,144,0)
Cholesterol Measure Encounter Codes
"DATA",176.801,144,1)
2.16.840.1.113883.3.600.1951
"DATA",176.801,144,4,0)
^176.8012P^2^2
"DATA",176.801,144,4,1,0)
1
"DATA",176.801,144,4,2,0)
5
"DATA",176.801,144,5)
CMEC51
"DATA",176.801,145,0)
Chorioretinal Scars
"DATA",176.801,145,1)
2.16.840.1.113883.3.526.3.1449
"DATA",176.801,145,4,0)
^176.8012P^1^1
"DATA",176.801,145,4,1,0)
19
"DATA",176.801,145,5)
CS49
"DATA",176.801,146,0)
Choroidal Degenerations
"DATA",176.801,146,1)
2.16.840.1.113883.3.526.3.1450
"DATA",176.801,146,4,0)
^176.8012P^1^1
"DATA",176.801,146,4,1,0)
19
"DATA",176.801,146,5)
CD50
"DATA",176.801,147,0)
Choroidal Detachment
"DATA",176.801,147,1)
2.16.840.1.113883.3.526.3.1451
"DATA",176.801,147,4,0)
^176.8012P^1^1
"DATA",176.801,147,4,1,0)
19
"DATA",176.801,147,5)
CD51
"DATA",176.801,148,0)
Choroidal Hemorrhage and Rupture
"DATA",176.801,148,1)
2.16.840.1.113883.3.526.3.1452
"DATA",176.801,148,4,0)
^176.8012P^1^1
"DATA",176.801,148,4,1,0)
19
"DATA",176.801,148,5)
CHR52
"DATA",176.801,149,0)
Chronic Iridocyclitis
"DATA",176.801,149,1)
2.16.840.1.113883.3.526.3.1416
"DATA",176.801,149,4,0)
^176.8012P^2^2
"DATA",176.801,149,4,1,0)
19
"DATA",176.801,149,4,2,0)
57
"DATA",176.801,149,5)
CI16
"DATA",176.801,150,0)
Chronic Kidney Disease, Stage 5
"DATA",176.801,150,1)
2.16.840.1.113883.3.526.3.1002
"DATA",176.801,150,4,0)
^176.8012P^1^1
"DATA",176.801,150,4,1,0)
64
"DATA",176.801,150,5)
CKDS502
"DATA",176.801,151,0)
Chronic Obstructive Pulmonary Disease
"DATA",176.801,151,1)
2.16.840.1.113883.3.464.1003.102.12.1007
"DATA",176.801,151,4,0)
^176.8012P^1^1
"DATA",176.801,151,4,1,0)
29
"DATA",176.801,151,5)
COPD07
"DATA",176.801,152,0)
Classical Cesarean Section
"DATA",176.801,152,1)
2.16.840.1.113883.3.117.1.7.1.421
"DATA",176.801,152,4,0)
^176.8012P^1^1
"DATA",176.801,152,4,1,0)
91
"DATA",176.801,152,5)
CCS21
"DATA",176.801,153,0)
Clinical Oral Evaluation
"DATA",176.801,153,1)
2.16.840.1.113883.3.464.1003.125.12.1003
"DATA",176.801,153,4,0)
^176.8012P^2^2
"DATA",176.801,153,4,1,0)
31
"DATA",176.801,153,4,2,0)
7
"DATA",176.801,153,5)
COE03
"DATA",176.801,154,0)
Clinical Pathway Protocol
"DATA",176.801,154,1)
2.16.840.1.113883.3.117.1.7.1.253
"DATA",176.801,154,4,0)
^176.8012P^1^1
"DATA",176.801,154,4,1,0)
72
"DATA",176.801,154,5)
CPP53
"DATA",176.801,155,0)
Clinical Staging Procedure
"DATA",176.801,155,1)
2.16.840.1.113883.3.526.3.1098
"DATA",176.801,155,4,0)
^176.8012P^3^3
"DATA",176.801,155,4,1,0)
43
"DATA",176.801,155,4,2,0)
65
"DATA",176.801,155,4,3,0)
9
"DATA",176.801,155,5)
CSP98
"DATA",176.801,156,0)
Clinical Trial Participant
"DATA",176.801,156,1)
2.16.840.1.113883.3.526.2.643
"DATA",176.801,156,5)
CTP43
"DATA",176.801,157,0)
Clinical Trial Participant
"DATA",176.801,157,1)
2.16.840.1.113883.3.526.3.1125
"DATA",176.801,157,4,0)
^176.8012P^8^8
"DATA",176.801,157,4,1,0)
69
"DATA",176.801,157,4,2,0)
45
"DATA",176.801,157,4,3,0)
40
"DATA",176.801,157,4,4,0)
79
"DATA",176.801,157,4,5,0)
86
"DATA",176.801,157,4,6,0)
48
"DATA",176.801,157,4,7,0)
78
"DATA",176.801,157,4,8,0)
92
"DATA",176.801,157,5)
CTP25
"DATA",176.801,158,0)
Cloudy Cornea
"DATA",176.801,158,1)
2.16.840.1.113883.3.526.3.1417
"DATA",176.801,158,4,0)
^176.8012P^2^2
"DATA",176.801,158,4,1,0)
19
"DATA",176.801,158,4,2,0)
57
"DATA",176.801,158,5)
CC17
"DATA",176.801,159,0)
Cognitive Assessment
"DATA",176.801,159,1)
2.16.840.1.113883.3.526.3.1332
"DATA",176.801,159,4,0)
^176.8012P^1^1
"DATA",176.801,159,4,1,0)
35
"DATA",176.801,159,5)
CA32
"DATA",176.801,160,0)
Colon Cancer
"DATA",176.801,160,1)
2.16.840.1.113883.3.526.3.391
"DATA",176.801,160,4,0)
^176.8012P^1^1
"DATA",176.801,160,4,1,0)
43
"DATA",176.801,160,5)
CC91
"DATA",176.801,161,0)
Colon Cancer Primary Tumor Size T1
"DATA",176.801,161,1)
2.16.840.1.113883.3.526.3.1292
"DATA",176.801,161,4,0)
^176.8012P^1^1
"DATA",176.801,161,4,1,0)
43
"DATA",176.801,161,5)
CCPTST192
"DATA",176.801,162,0)
Colon Cancer Primary Tumor Size T2
"DATA",176.801,162,1)
2.16.840.1.113883.3.526.3.1293
"DATA",176.801,162,4,0)
^176.8012P^1^1
"DATA",176.801,162,4,1,0)
43
"DATA",176.801,162,5)
CCPTST293
"DATA",176.801,163,0)
Colon Cancer Primary Tumor Size T3
"DATA",176.801,163,1)
2.16.840.1.113883.3.526.3.1294
"DATA",176.801,163,4,0)
^176.8012P^1^1
"DATA",176.801,163,4,1,0)
43
"DATA",176.801,163,5)
CCPTST394
"DATA",176.801,164,0)
Colon Cancer Primary Tumor Size T4a
"DATA",176.801,164,1)
2.16.840.1.113883.3.526.3.1295
"DATA",176.801,164,4,0)
^176.8012P^1^1
"DATA",176.801,164,4,1,0)
43
"DATA",176.801,164,5)
CCPTST495
"DATA",176.801,165,0)
Colon Cancer Primary Tumor Size T4b
"DATA",176.801,165,1)
2.16.840.1.113883.3.526.3.1296
"DATA",176.801,165,4,0)
^176.8012P^1^1
"DATA",176.801,165,4,1,0)
43
"DATA",176.801,165,5)
CCPTST496
"DATA",176.801,166,0)
Colon Cancer Regional Lymph Node Status N1
"DATA",176.801,166,1)
2.16.840.1.113883.3.526.3.1297
"DATA",176.801,166,4,0)
^176.8012P^1^1
"DATA",176.801,166,4,1,0)
43
"DATA",176.801,166,5)
CCRLNSN197
"DATA",176.801,167,0)
Colon Cancer Regional Lymph Node Status N1a
"DATA",176.801,167,1)
2.16.840.1.113883.3.526.3.1327
"DATA",176.801,167,4,0)
^176.8012P^1^1
"DATA",176.801,167,4,1,0)
43
"DATA",176.801,167,5)
CCRLNSN127
"DATA",176.801,168,0)
Colon Cancer Regional Lymph Node Status N1b
"DATA",176.801,168,1)
2.16.840.1.113883.3.526.3.1328
"DATA",176.801,168,4,0)
^176.8012P^1^1
"DATA",176.801,168,4,1,0)
43
"DATA",176.801,168,5)
CCRLNSN128
"DATA",176.801,169,0)
Colon Cancer Regional Lymph Node Status N1c
"DATA",176.801,169,1)
2.16.840.1.113883.3.526.3.1298
"DATA",176.801,169,4,0)
^176.8012P^1^1
"DATA",176.801,169,4,1,0)
43
"DATA",176.801,169,5)
CCRLNSN198
"DATA",176.801,170,0)
Colon Cancer Regional Lymph Node Status N2
"DATA",176.801,170,1)
2.16.840.1.113883.3.526.3.1299
"DATA",176.801,170,4,0)
^176.8012P^1^1
"DATA",176.801,170,4,1,0)
43
"DATA",176.801,170,5)
CCRLNSN299
"DATA",176.801,171,0)
Colon Cancer Regional Lymph Node Status N2a
"DATA",176.801,171,1)
2.16.840.1.113883.3.526.3.1300
"DATA",176.801,171,4,0)
^176.8012P^1^1
"DATA",176.801,171,4,1,0)
43
"DATA",176.801,171,5)
CCRLNSN200
"DATA",176.801,172,0)
Colon Cancer Regional Lymph Node Status N2b
"DATA",176.801,172,1)
2.16.840.1.113883.3.526.3.1301
"DATA",176.801,172,4,0)
^176.8012P^1^1
"DATA",176.801,172,4,1,0)
43
"DATA",176.801,172,5)
CCRLNSN201
"DATA",176.801,173,0)
Colon Distant Metastasis Status M0
"DATA",176.801,173,1)
2.16.840.1.113883.3.526.3.1337
"DATA",176.801,173,4,0)
^176.8012P^1^1
"DATA",176.801,173,4,1,0)
43
"DATA",176.801,173,5)
CDMSM037
"DATA",176.801,174,0)
Colonoscopy
"DATA",176.801,174,1)
2.16.840.1.113883.3.464.1003.108.12.1020
"DATA",176.801,174,4,0)
^176.8012P^1^1
"DATA",176.801,174,4,1,0)
63
"DATA",176.801,174,5)
C20
"DATA",176.801,175,0)
Competing Conditions for Respiratory Conditions
"DATA",176.801,175,1)
2.16.840.1.113883.3.464.1003.102.12.1017
"DATA",176.801,175,4,0)
^176.8012P^1^1
"DATA",176.801,175,4,1,0)
85
"DATA",176.801,175,5)
CCRC17
"DATA",176.801,176,0)
Complete Lipid Panel
"DATA",176.801,176,1)
2.16.840.1.113883.3.464.1003.104.12.1015
"DATA",176.801,176,4,0)
^176.8012P^1^1
"DATA",176.801,176,4,1,0)
25
"DATA",176.801,176,5)
CLP15
"DATA",176.801,177,0)
Complications of Pregnancy, Childbirth and the Puerperium
"DATA",176.801,177,1)
2.16.840.1.113883.3.464.1003.111.12.1012
"DATA",176.801,177,4,0)
^176.8012P^1^1
"DATA",176.801,177,4,1,0)
77
"DATA",176.801,177,5)
CPCP12
"DATA",176.801,178,0)
Computed Value INR percent TTR
"DATA",176.801,178,1)
2.16.840.1.113883.3.464.1003.104.12.1018
"DATA",176.801,178,4,0)
^176.8012P^1^1
"DATA",176.801,178,4,1,0)
62
"DATA",176.801,178,5)
CVINRTTR18
"DATA",176.801,179,0)
Conditions Possibly Justifying Elective Delivery Prior to 39 Weeks Gestation
"DATA",176.801,179,1)
2.16.840.1.113883.3.117.1.7.1.286
"DATA",176.801,179,4,0)
^176.8012P^1^1
"DATA",176.801,179,4,1,0)
91
"DATA",176.801,179,5)
CPJEDP39WG86
"DATA",176.801,180,0)
Congenital Anomalies Group
"DATA",176.801,180,1)
2.16.840.1.113883.3.666.5.1570
"DATA",176.801,180,4,0)
^176.8012P^1^1
"DATA",176.801,180,4,1,0)
93
"DATA",176.801,180,5)
CAG70
"DATA",176.801,181,0)
Congenital or Infantile Cerebral Palsy Group
"DATA",176.801,181,1)
2.16.840.1.113883.3.666.5.1580
"DATA",176.801,181,4,0)
^176.8012P^1^1
"DATA",176.801,181,4,1,0)
93
"DATA",176.801,181,5)
CICPG80
"DATA",176.801,182,0)
Consultant Report
"DATA",176.801,182,1)
2.16.840.1.113883.3.464.1003.121.12.1006
"DATA",176.801,182,4,0)
^176.8012P^1^1
"DATA",176.801,182,4,1,0)
88
"DATA",176.801,182,5)
CR06
"DATA",176.801,183,0)
Contraceptive Medications
"DATA",176.801,183,1)
2.16.840.1.113883.3.464.1003.196.12.1080
"DATA",176.801,183,4,0)
^176.8012P^1^1
"DATA",176.801,183,4,1,0)
77
"DATA",176.801,183,5)
CM80
"DATA",176.801,184,0)
Corneal Edema
"DATA",176.801,184,1)
2.16.840.1.113883.3.526.3.1418
"DATA",176.801,184,4,0)
^176.8012P^2^2
"DATA",176.801,184,4,1,0)
19
"DATA",176.801,184,4,2,0)
57
"DATA",176.801,184,5)
CE18
"DATA",176.801,185,0)
Corneal Opacity and other Disorders of Cornea
"DATA",176.801,185,1)
2.16.840.1.113883.3.526.3.1419
"DATA",176.801,185,4,0)
^176.8012P^2^2
"DATA",176.801,185,4,1,0)
57
"DATA",176.801,185,4,2,0)
19
"DATA",176.801,185,5)
CODC19
"DATA",176.801,186,0)
Coronary Artery Bypass Graft
"DATA",176.801,186,1)
2.16.840.1.113883.3.464.1003.104.12.1002
"DATA",176.801,186,4,0)
^176.8012P^2^2
"DATA",176.801,186,4,1,0)
3
"DATA",176.801,186,4,2,0)
25
"DATA",176.801,186,5)
CABG02
"DATA",176.801,187,0)
Coronary Artery Disease No MI
"DATA",176.801,187,1)
2.16.840.1.113883.3.526.3.369
"DATA",176.801,187,4,0)
^176.8012P^1^1
"DATA",176.801,187,4,1,0)
39
"DATA",176.801,187,5)
CADNMI69
"DATA",176.801,188,0)
Counseling for Nutrition
"DATA",176.801,188,1)
2.16.840.1.113883.3.464.1003.195.12.1003
"DATA",176.801,188,4,0)
^176.8012P^1^1
"DATA",176.801,188,4,1,0)
6
"DATA",176.801,188,5)
CN03
"DATA",176.801,189,0)
Counseling for Physical Activity
"DATA",176.801,189,1)
2.16.840.1.113883.3.464.1003.118.12.1035
"DATA",176.801,189,4,0)
^176.8012P^1^1
"DATA",176.801,189,4,1,0)
6
"DATA",176.801,189,5)
CPA35
"DATA",176.801,190,0)
Cup to Disc Ratio
"DATA",176.801,190,1)
2.16.840.1.113883.3.526.3.1333
"DATA",176.801,190,4,0)
^176.8012P^1^1
"DATA",176.801,190,4,1,0)
81
"DATA",176.801,190,5)
CDR33
"DATA",176.801,191,0)
Current Medications Documented SNMD
"DATA",176.801,191,1)
2.16.840.1.113883.3.600.1.462
"DATA",176.801,191,4,0)
^176.8012P^1^1
"DATA",176.801,191,4,1,0)
54
"DATA",176.801,191,5)
CMDSNMD62
"DATA",176.801,192,0)
Cystic Fibrosis
"DATA",176.801,192,1)
2.16.840.1.113883.3.464.1003.102.12.1002
"DATA",176.801,192,4,0)
^176.8012P^1^1
"DATA",176.801,192,4,1,0)
40
"DATA",176.801,192,5)
CF02
"DATA",176.801,193,0)
Cysts of Iris, Ciliary Body, and Anterior Chamber
"DATA",176.801,193,1)
2.16.840.1.113883.3.526.3.1420
"DATA",176.801,193,4,0)
^176.8012P^1^1
"DATA",176.801,193,4,1,0)
57
"DATA",176.801,193,5)
CICBAC20
"DATA",176.801,194,0)
DTaP Vaccine
"DATA",176.801,194,1)
2.16.840.1.113883.3.464.1003.196.12.1214
"DATA",176.801,194,4,0)
^176.8012P^1^1
"DATA",176.801,194,4,1,0)
66
"DATA",176.801,194,5)
DTPV14
"DATA",176.801,195,0)
DTaP Vaccine Administered
"DATA",176.801,195,1)
2.16.840.1.113883.3.464.1003.110.12.1022
"DATA",176.801,195,4,0)
^176.8012P^1^1
"DATA",176.801,195,4,1,0)
66
"DATA",176.801,195,5)
DTPVA22
"DATA",176.801,196,0)
Dapsone and pyrimethamine
"DATA",176.801,196,1)
2.16.840.1.113883.3.464.1003.196.12.1202
"DATA",176.801,196,4,0)
^176.8012P^1^1
"DATA",176.801,196,4,1,0)
11
"DATA",176.801,196,5)
D02
"DATA",176.801,197,0)
Deceased
"DATA",176.801,197,1)
2.16.840.1.113883.3.67.1.101.11.721
"DATA",176.801,197,4,0)
^176.8012P^2^2
"DATA",176.801,197,4,1,0)
42
"DATA",176.801,197,4,2,0)
61
"DATA",176.801,197,5)
D21
"DATA",176.801,198,0)
Decision to Admit to Hospital Inpatient
"DATA",176.801,198,1)
2.16.840.1.113883.3.117.1.7.1.295
"DATA",176.801,198,4,0)
^176.8012P^1^1
"DATA",176.801,198,4,1,0)
51
"DATA",176.801,198,5)
DAHI95
"DATA",176.801,199,0)
Degeneration of Macula and Posterior Pole
"DATA",176.801,199,1)
2.16.840.1.113883.3.526.3.1453
"DATA",176.801,199,4,0)
^176.8012P^1^1
"DATA",176.801,199,4,1,0)
19
"DATA",176.801,199,5)
DMPP53
"DATA",176.801,200,0)
Degenerative Disorders of Globe
"DATA",176.801,200,1)
2.16.840.1.113883.3.526.3.1454
"DATA",176.801,200,4,0)
^176.8012P^1^1
"DATA",176.801,200,4,1,0)
19
"DATA",176.801,200,5)
DDG54
"DATA",176.801,201,0)
Delivery
"DATA",176.801,201,1)
2.16.840.1.113883.3.67.1.101.1.278
"DATA",176.801,201,4,0)
^176.8012P^1^1
"DATA",176.801,201,4,1,0)
20
"DATA",176.801,201,5)
D78
"DATA",176.801,202,0)
Delivery Live Births
"DATA",176.801,202,1)
2.16.840.1.113883.3.464.1003.111.12.1015
"DATA",176.801,202,4,0)
^176.8012P^1^1
"DATA",176.801,202,4,1,0)
77
"DATA",176.801,202,5)
DLB15
"DATA",176.801,203,0)
Delivery Procedures
"DATA",176.801,203,1)
2.16.840.1.113883.3.117.1.7.1.401
"DATA",176.801,203,4,0)
^176.8012P^1^1
"DATA",176.801,203,4,1,0)
91
"DATA",176.801,203,5)
DP01
"DATA",176.801,204,0)
Delta systolic blood pressure
"DATA",176.801,204,1)
2.16.840.1.113883.3.464.1003.121.12.1013
"DATA",176.801,204,4,0)
^176.8012P^1^1
"DATA",176.801,204,4,1,0)
12
"DATA",176.801,204,5)
D13
"DATA",176.801,205,0)
Dementia & Mental Degenerations
"DATA",176.801,205,1)
2.16.840.1.113883.3.526.3.1005
"DATA",176.801,205,4,0)
^176.8012P^1^1
"DATA",176.801,205,4,1,0)
35
"DATA",176.801,205,5)
D&MD05
"DATA",176.801,206,0)
Dental Caries
"DATA",176.801,206,1)
2.16.840.1.113883.3.464.1003.125.12.1004
"DATA",176.801,206,4,0)
^176.8012P^1^1
"DATA",176.801,206,4,1,0)
31
"DATA",176.801,206,5)
DC04
"DATA",176.801,207,0)
Depression Screening Denominator Encounter Codes New
"DATA",176.801,207,1)
2.16.840.1.113883.3.600.1916
"DATA",176.801,207,4,0)
^176.8012P^1^1
"DATA",176.801,207,4,1,0)
53
"DATA",176.801,207,5)
DSDECN16
"DATA",176.801,208,0)
Depression diagnosis
"DATA",176.801,208,1)
2.16.840.1.113883.3.600.145
"DATA",176.801,208,4,0)
^176.8012P^1^1
"DATA",176.801,208,4,1,0)
53
"DATA",176.801,208,5)
D45
"DATA",176.801,209,0)
Depression medications - adolescent
"DATA",176.801,209,1)
2.16.840.1.113883.3.600.469
"DATA",176.801,209,4,0)
^176.8012P^1^1
"DATA",176.801,209,4,1,0)
53
"DATA",176.801,209,5)
D69
"DATA",176.801,210,0)
Depression medications - adult
"DATA",176.801,210,1)
2.16.840.1.113883.3.600.470
"DATA",176.801,210,4,0)
^176.8012P^1^1
"DATA",176.801,210,4,1,0)
53
"DATA",176.801,210,5)
D70
"DATA",176.801,211,0)
Detoxification Visit
"DATA",176.801,211,1)
2.16.840.1.113883.3.464.1003.101.12.1059
"DATA",176.801,211,4,0)
^176.8012P^1^1
"DATA",176.801,211,4,1,0)
76
"DATA",176.801,211,5)
DV59
"DATA",176.801,212,0)
Diabetes
"DATA",176.801,212,1)
2.16.840.1.113883.3.464.1003.103.12.1001
"DATA",176.801,212,4,0)
^176.8012P^6^6
"DATA",176.801,212,4,1,0)
75
"DATA",176.801,212,4,2,0)
8
"DATA",176.801,212,4,3,0)
87
"DATA",176.801,212,4,4,0)
50
"DATA",176.801,212,4,5,0)
80
"DATA",176.801,212,4,6,0)
34
"DATA",176.801,212,5)
D01
"DATA",176.801,213,0)
Diabetes Visit
"DATA",176.801,213,1)
2.16.840.1.113883.3.464.1003.103.12.1012
"DATA",176.801,213,4,0)
^176.8012P^1^1
"DATA",176.801,213,4,1,0)
50
"DATA",176.801,213,5)
DV12
"DATA",176.801,214,0)
Diabetic Macular Edema
"DATA",176.801,214,1)
2.16.840.1.113883.3.526.3.1455
"DATA",176.801,214,4,0)
^176.8012P^1^1
"DATA",176.801,214,4,1,0)
19
"DATA",176.801,214,5)
DME55
"DATA",176.801,215,0)
Diabetic Nephropathy
"DATA",176.801,215,1)
2.16.840.1.113883.3.464.1003.109.12.1004
"DATA",176.801,215,4,0)
^176.8012P^1^1
"DATA",176.801,215,4,1,0)
34
"DATA",176.801,215,5)
DN04
"DATA",176.801,216,0)
Diabetic Retinopathy
"DATA",176.801,216,1)
2.16.840.1.113883.3.526.3.327
"DATA",176.801,216,4,0)
^176.8012P^3^3
"DATA",176.801,216,4,1,0)
26
"DATA",176.801,216,4,2,0)
19
"DATA",176.801,216,4,3,0)
27
"DATA",176.801,216,5)
DR27
"DATA",176.801,217,0)
Diagnosis of hypertension grouped
"DATA",176.801,217,1)
2.16.840.1.113883.3.600.263
"DATA",176.801,217,4,0)
^176.8012P^3^3
"DATA",176.801,217,4,1,0)
1
"DATA",176.801,217,4,2,0)
5
"DATA",176.801,217,4,3,0)
58
"DATA",176.801,217,5)
D63
"DATA",176.801,218,0)
Diagnostic Studies During Pregnancy
"DATA",176.801,218,1)
2.16.840.1.113883.3.464.1003.111.12.1008
"DATA",176.801,218,4,0)
^176.8012P^1^1
"DATA",176.801,218,4,1,0)
77
"DATA",176.801,218,5)
DSDP08
"DATA",176.801,219,0)
Dialysis Education
"DATA",176.801,219,1)
2.16.840.1.113883.3.464.1003.109.12.1016
"DATA",176.801,219,4,0)
^176.8012P^2^2
"DATA",176.801,219,4,1,0)
34
"DATA",176.801,219,4,2,0)
64
"DATA",176.801,219,5)
DE16
"DATA",176.801,220,0)
Dialysis Services
"DATA",176.801,220,1)
2.16.840.1.113883.3.464.1003.109.12.1013
"DATA",176.801,220,4,0)
^176.8012P^2^2
"DATA",176.801,220,4,1,0)
64
"DATA",176.801,220,4,2,0)
34
"DATA",176.801,220,5)
DS13
"DATA",176.801,221,0)
Diastolic Blood Pressure
"DATA",176.801,221,1)
2.16.840.1.113883.3.526.3.1033
"DATA",176.801,221,4,0)
^176.8012P^2^2
"DATA",176.801,221,4,1,0)
64
"DATA",176.801,221,4,2,0)
58
"DATA",176.801,221,5)
DBP33
"DATA",176.801,222,0)
Dietary Intake Other than Breast Milk
"DATA",176.801,222,1)
2.16.840.1.113883.3.117.1.7.1.27
"DATA",176.801,222,4,0)
^176.8012P^1^1
"DATA",176.801,222,4,1,0)
36
"DATA",176.801,222,5)
DIOBM27
"DATA",176.801,223,0)
Dietary Recommendations
"DATA",176.801,223,1)
2.16.840.1.113883.3.600.1515
"DATA",176.801,223,4,0)
^176.8012P^1^1
"DATA",176.801,223,4,1,0)
58
"DATA",176.801,223,5)
DR15
"DATA",176.801,224,0)
Direct Thrombin Inhibitor
"DATA",176.801,224,1)
2.16.840.1.113883.3.117.1.7.1.205
"DATA",176.801,224,4,0)
^176.8012P^1^1
"DATA",176.801,224,4,1,0)
18
"DATA",176.801,224,5)
DTI05
"DATA",176.801,225,0)
Discharge Services - Hospital Inpatient
"DATA",176.801,225,1)
2.16.840.1.113883.3.464.1003.101.12.1007
"DATA",176.801,225,4,0)
^176.8012P^3^3
"DATA",176.801,225,4,1,0)
24
"DATA",176.801,225,4,2,0)
41
"DATA",176.801,225,4,3,0)
76
"DATA",176.801,225,5)
DSHI07
"DATA",176.801,226,0)
Discharge Services - Hospital Inpatient Same Day Discharge
"DATA",176.801,226,1)
2.16.840.1.113883.3.464.1003.101.12.1006
"DATA",176.801,226,4,0)
^176.8012P^1^1
"DATA",176.801,226,4,1,0)
76
"DATA",176.801,226,5)
DSHISDD06
"DATA",176.801,227,0)
Discharge Services - Nursing Facility
"DATA",176.801,227,1)
2.16.840.1.113883.3.464.1003.101.12.1013
"DATA",176.801,227,4,0)
^176.8012P^1^1
"DATA",176.801,227,4,1,0)
59
"DATA",176.801,227,5)
DSNF13
"DATA",176.801,228,0)
Discharge Services- Observation Care
"DATA",176.801,228,1)
2.16.840.1.113883.3.464.1003.101.12.1039
"DATA",176.801,228,4,0)
^176.8012P^1^1
"DATA",176.801,228,4,1,0)
33
"DATA",176.801,228,5)
DSOC39
"DATA",176.801,229,0)
Discharge To Another Hospital
"DATA",176.801,229,1)
2.16.840.1.113883.3.117.1.7.1.87
"DATA",176.801,229,4,0)
^176.8012P^10^10
"DATA",176.801,229,4,1,0)
2
"DATA",176.801,229,4,2,0)
32
"DATA",176.801,229,4,3,0)
72
"DATA",176.801,229,4,4,0)
36
"DATA",176.801,229,4,5,0)
22
"DATA",176.801,229,4,6,0)
37
"DATA",176.801,229,4,7,0)
93
"DATA",176.801,229,4,8,0)
86
"DATA",176.801,229,4,9,0)
13
"DATA",176.801,229,4,10,0)
69
"DATA",176.801,229,5)
DTAH87
"DATA",176.801,230,0)
Discharge To Home Or Police Custody
"DATA",176.801,230,1)
2.16.840.1.113883.3.117.1.7.1.82
"DATA",176.801,230,4,0)
^176.8012P^2^2
"DATA",176.801,230,4,1,0)
14
"DATA",176.801,230,4,2,0)
38
"DATA",176.801,230,5)
DTHOPC82
"DATA",176.801,231,0)
Discharged to Health Care Facility for Hospice Care
"DATA",176.801,231,1)
2.16.840.1.113883.3.117.1.7.1.207
"DATA",176.801,231,4,0)
^176.8012P^6^6
"DATA",176.801,231,4,1,0)
2
"DATA",176.801,231,4,2,0)
32
"DATA",176.801,231,4,3,0)
22
"DATA",176.801,231,4,4,0)
37
"DATA",176.801,231,4,5,0)
72
"DATA",176.801,231,4,6,0)
13
"DATA",176.801,231,5)
DHCFHC07
"DATA",176.801,232,0)
Discharged to Home for Hospice Care
"DATA",176.801,232,1)
2.16.840.1.113883.3.117.1.7.1.209
"DATA",176.801,232,4,0)
^176.8012P^7^7
"DATA",176.801,232,4,1,0)
2
"DATA",176.801,232,4,2,0)
32
"DATA",176.801,232,4,3,0)
38
"DATA",176.801,232,4,4,0)
72
"DATA",176.801,232,4,5,0)
22
"DATA",176.801,232,4,6,0)
37
"DATA",176.801,232,4,7,0)
13
"DATA",176.801,232,5)
DHHC09
"DATA",176.801,233,0)
Discharged to Rehabilitation Facility
"DATA",176.801,233,1)
2.16.840.1.113883.3.117.1.7.1.132
"DATA",176.801,233,4,0)
^176.8012P^1^1
"DATA",176.801,233,4,1,0)
37
"DATA",176.801,233,5)
DRF32
"DATA",176.801,234,0)
Disorders of Optic Chiasm
"DATA",176.801,234,1)
2.16.840.1.113883.3.526.3.1457
"DATA",176.801,234,4,0)
^176.8012P^1^1
"DATA",176.801,234,4,1,0)
19
"DATA",176.801,234,5)
DOC57
"DATA",176.801,235,0)
Disorders of Visual Cortex
"DATA",176.801,235,1)
2.16.840.1.113883.3.526.3.1458
"DATA",176.801,235,4,0)
^176.8012P^1^1
"DATA",176.801,235,4,1,0)
19
"DATA",176.801,235,5)
DVC58
"DATA",176.801,236,0)
Disorders of the Immune System
"DATA",176.801,236,1)
2.16.840.1.113883.3.464.1003.120.12.1001
"DATA",176.801,236,4,0)
^176.8012P^1^1
"DATA",176.801,236,4,1,0)
66
"DATA",176.801,236,5)
DIS01
"DATA",176.801,237,0)
Disseminated Chorioretinitis and Disseminated Retinochoroiditis
"DATA",176.801,237,1)
2.16.840.1.113883.3.526.3.1459
"DATA",176.801,237,4,0)
^176.8012P^1^1
"DATA",176.801,237,4,1,0)
19
"DATA",176.801,237,5)
DCDR59
"DATA",176.801,238,0)
Drug Interactions Education
"DATA",176.801,238,1)
2.16.840.1.113883.3.117.1.7.1.414
"DATA",176.801,238,4,0)
^176.8012P^1^1
"DATA",176.801,238,4,1,0)
38
"DATA",176.801,238,5)
DIE14
"DATA",176.801,239,0)
Drug Withdrawal Syndrome Group
"DATA",176.801,239,1)
2.16.840.1.113883.3.666.5.1574
"DATA",176.801,239,4,0)
^176.8012P^1^1
"DATA",176.801,239,4,1,0)
93
"DATA",176.801,239,5)
DWSG74
"DATA",176.801,240,0)
Dysthymia
"DATA",176.801,240,1)
2.16.840.1.113883.3.67.1.101.1.254
"DATA",176.801,240,4,0)
^176.8012P^2^2
"DATA",176.801,240,4,1,0)
61
"DATA",176.801,240,4,2,0)
42
"DATA",176.801,240,5)
D54
"DATA",176.801,241,0)
ECOG Performance Status-Poor
"DATA",176.801,241,1)
2.16.840.1.113883.3.526.3.1279
"DATA",176.801,241,4,0)
^176.8012P^1^1
"DATA",176.801,241,4,1,0)
43
"DATA",176.801,241,5)
ECOGPSP79
"DATA",176.801,242,0)
ESRD Monthly Outpatient Services
"DATA",176.801,242,1)
2.16.840.1.113883.3.464.1003.109.12.1014
"DATA",176.801,242,4,0)
^176.8012P^2^2
"DATA",176.801,242,4,1,0)
34
"DATA",176.801,242,4,2,0)
64
"DATA",176.801,242,5)
ESRDMOS14
"DATA",176.801,243,0)
Ejection Fraction
"DATA",176.801,243,1)
2.16.840.1.113883.3.526.3.1134
"DATA",176.801,243,4,0)
^176.8012P^3^3
"DATA",176.801,243,4,1,0)
24
"DATA",176.801,243,4,2,0)
41
"DATA",176.801,243,4,3,0)
39
"DATA",176.801,243,5)
EF34
"DATA",176.801,244,0)
Electrocardiogram (ECG)
"DATA",176.801,244,1)
2.16.840.1.113883.3.600.1483
"DATA",176.801,244,4,0)
^176.8012P^1^1
"DATA",176.801,244,4,1,0)
58
"DATA",176.801,244,5)
EECG83
"DATA",176.801,245,0)
Emergency Department Visit
"DATA",176.801,245,1)
2.16.840.1.113883.3.117.1.7.1.293
"DATA",176.801,245,5)
EDV93
"DATA",176.801,246,0)
Emergency Department Visit
"DATA",176.801,246,1)
2.16.840.1.113883.3.464.1003.101.12.1010
"DATA",176.801,246,4,0)
^176.8012P^6^6
"DATA",176.801,246,4,1,0)
32
"DATA",176.801,246,4,2,0)
72
"DATA",176.801,246,4,3,0)
90
"DATA",176.801,246,4,4,0)
18
"DATA",176.801,246,4,5,0)
38
"DATA",176.801,246,4,6,0)
17
"DATA",176.801,246,5)
EDV10
"DATA",176.801,247,0)
Emphysema
"DATA",176.801,247,1)
2.16.840.1.113883.3.464.1003.102.12.1004
"DATA",176.801,247,4,0)
^176.8012P^1^1
"DATA",176.801,247,4,1,0)
29
"DATA",176.801,247,5)
E04
"DATA",176.801,248,0)
Encephalopathy
"DATA",176.801,248,1)
2.16.840.1.113883.3.464.1003.114.12.1007
"DATA",176.801,248,4,0)
^176.8012P^1^1
"DATA",176.801,248,4,1,0)
66
"DATA",176.801,248,5)
E07
"DATA",176.801,249,0)
Encounter Inpatient
"DATA",176.801,249,1)
2.16.840.1.113883.3.666.5.3001
"DATA",176.801,249,5)
EI01
"DATA",176.801,250,0)
Encounter Inpatient
"DATA",176.801,250,1)
2.16.840.1.113883.3.666.5.307
"DATA",176.801,250,4,0)
^176.8012P^1^1
"DATA",176.801,250,4,1,0)
86
"DATA",176.801,250,5)
EI07
"DATA",176.801,251,0)
Encounter-Influenza
"DATA",176.801,251,1)
2.16.840.1.113883.3.526.3.1252
"DATA",176.801,251,4,0)
^176.8012P^1^1
"DATA",176.801,251,4,1,0)
59
"DATA",176.801,251,5)
EI52
"DATA",176.801,252,0)
End Stage Renal Disease
"DATA",176.801,252,1)
2.16.840.1.113883.3.526.3.353
"DATA",176.801,252,4,0)
^176.8012P^2^2
"DATA",176.801,252,4,1,0)
12
"DATA",176.801,252,4,2,0)
64
"DATA",176.801,252,5)
ESRD53
"DATA",176.801,253,0)
Enophthalmos
"DATA",176.801,253,1)
2.16.840.1.113883.3.526.3.1421
"DATA",176.801,253,4,0)
^176.8012P^1^1
"DATA",176.801,253,4,1,0)
57
"DATA",176.801,253,5)
E21
"DATA",176.801,254,0)
Essential Hypertension
"DATA",176.801,254,1)
2.16.840.1.113883.3.464.1003.104.12.1011
"DATA",176.801,254,4,0)
^176.8012P^1^1
"DATA",176.801,254,4,1,0)
64
"DATA",176.801,254,5)
EH11
"DATA",176.801,255,0)
Ethnicity
"DATA",176.801,255,1)
2.16.840.1.114222.4.11.837
"DATA",176.801,255,4,0)
^176.8012P^93^93
"DATA",176.801,255,4,1,0)
2
"DATA",176.801,255,4,2,0)
74
"DATA",176.801,255,4,3,0)
71
"DATA",176.801,255,4,4,0)
79
"DATA",176.801,255,4,5,0)
23
"DATA",176.801,255,4,6,0)
12
"DATA",176.801,255,4,7,0)
21
"DATA",176.801,255,4,8,0)
1
"DATA",176.801,255,4,9,0)
43
"DATA",176.801,255,4,10,0)
70
"DATA",176.801,255,4,11,0)
32
"DATA",176.801,255,4,12,0)
75
"DATA",176.801,255,4,13,0)
76
"DATA",176.801,255,4,14,0)
27
"DATA",176.801,255,4,15,0)
26
"DATA",176.801,255,4,16,0)
72
"DATA",176.801,255,4,17,0)
87
"DATA",176.801,255,4,18,0)
15
"DATA",176.801,255,4,19,0)
86
"DATA",176.801,255,4,20,0)
64
"DATA",176.801,255,4,21,0)
78
"DATA",176.801,255,4,22,0)
67
"DATA",176.801,255,4,23,0)
9
"DATA",176.801,255,4,24,0)
25
"DATA",176.801,255,4,25,0)
83
"DATA",176.801,255,4,26,0)
16
"DATA",176.801,255,4,27,0)
50
"DATA",176.801,255,4,28,0)
55
"DATA",176.801,255,4,29,0)
11
"DATA",176.801,255,4,30,0)
29
"DATA",176.801,255,4,31,0)
69
"DATA",176.801,255,4,32,0)
45
"DATA",176.801,255,4,33,0)
65
"DATA",176.801,255,4,34,0)
49
"DATA",176.801,255,4,35,0)
8
"DATA",176.801,255,4,36,0)
46
"DATA",176.801,255,4,37,0)
90
"DATA",176.801,255,4,38,0)
63
"DATA",176.801,255,4,39,0)
59
"DATA",176.801,255,4,40,0)
92
"DATA",176.801,255,4,41,0)
88
"DATA",176.801,255,4,42,0)
54
"DATA",176.801,255,4,43,0)
33
"DATA",176.801,255,4,44,0)
53
"DATA",176.801,255,4,45,0)
48
"DATA",176.801,255,4,46,0)
80
"DATA",176.801,255,4,47,0)
82
"DATA",176.801,255,4,48,0)
28
"DATA",176.801,255,4,49,0)
37
"DATA",176.801,255,4,50,0)
51
"DATA",176.801,255,4,51,0)
22
"DATA",176.801,255,4,52,0)
14
"DATA",176.801,255,4,53,0)
47
"DATA",176.801,255,4,54,0)
52
"DATA",176.801,255,4,55,0)
56
"DATA",176.801,255,4,56,0)
3
"DATA",176.801,255,4,57,0)
5
"DATA",176.801,255,4,58,0)
34
"DATA",176.801,255,4,59,0)
91
"DATA",176.801,255,4,60,0)
93
"DATA",176.801,255,4,61,0)
77
"DATA",176.801,255,4,62,0)
7
"DATA",176.801,255,4,63,0)
10
"DATA",176.801,255,4,64,0)
68
"DATA",176.801,255,4,65,0)
6
"DATA",176.801,255,4,66,0)
42
"DATA",176.801,255,4,67,0)
30
"DATA",176.801,255,4,68,0)
40
"DATA",176.801,255,4,69,0)
36
"DATA",176.801,255,4,70,0)
4
"DATA",176.801,255,4,71,0)
18
"DATA",176.801,255,4,72,0)
13
"DATA",176.801,255,4,73,0)
38
"DATA",176.801,255,4,74,0)
17
"DATA",176.801,255,4,75,0)
24
"DATA",176.801,255,4,76,0)
89
"DATA",176.801,255,4,77,0)
35
"DATA",176.801,255,4,78,0)
61
"DATA",176.801,255,4,79,0)
81
"DATA",176.801,255,4,80,0)
44
"DATA",176.801,255,4,81,0)
41
"DATA",176.801,255,4,82,0)
57
"DATA",176.801,255,4,83,0)
66
"DATA",176.801,255,4,84,0)
84
"DATA",176.801,255,4,85,0)
62
"DATA",176.801,255,4,86,0)
60
"DATA",176.801,255,4,87,0)
31
"DATA",176.801,255,4,88,0)
19
"DATA",176.801,255,4,89,0)
20
"DATA",176.801,255,4,90,0)
85
"DATA",176.801,255,4,91,0)
39
"DATA",176.801,255,4,92,0)
73
"DATA",176.801,255,4,93,0)
58
"DATA",176.801,255,5)
E37
"DATA",176.801,256,0)
Excision of Adhesions
"DATA",176.801,256,1)
2.16.840.1.113883.3.526.3.1422
"DATA",176.801,256,4,0)
^176.8012P^1^1
"DATA",176.801,256,4,1,0)
57
"DATA",176.801,256,5)
EA22
"DATA",176.801,257,0)
Expired
"DATA",176.801,257,1)
2.16.840.1.113883.3.666.5.730
"DATA",176.801,257,4,0)
^176.8012P^2^2
"DATA",176.801,257,4,1,0)
79
"DATA",176.801,257,4,2,0)
92
"DATA",176.801,257,5)
E30
"DATA",176.801,258,0)
Face-to-Face Interaction
"DATA",176.801,258,1)
2.16.840.1.113883.3.464.1003.101.12.1048
"DATA",176.801,258,4,0)
^176.8012P^43^43
"DATA",176.801,258,4,1,0)
64
"DATA",176.801,258,4,2,0)
62
"DATA",176.801,258,4,3,0)
66
"DATA",176.801,258,4,4,0)
27
"DATA",176.801,258,4,5,0)
88
"DATA",176.801,258,4,6,0)
43
"DATA",176.801,258,4,7,0)
10
"DATA",176.801,258,4,8,0)
60
"DATA",176.801,258,4,9,0)
47
"DATA",176.801,258,4,10,0)
3
"DATA",176.801,258,4,11,0)
70
"DATA",176.801,258,4,12,0)
33
"DATA",176.801,258,4,13,0)
41
"DATA",176.801,258,4,14,0)
23
"DATA",176.801,258,4,15,0)
30
"DATA",176.801,258,4,16,0)
65
"DATA",176.801,258,4,17,0)
44
"DATA",176.801,258,4,18,0)
6
"DATA",176.801,258,4,19,0)
28
"DATA",176.801,258,4,20,0)
25
"DATA",176.801,258,4,21,0)
7
"DATA",176.801,258,4,22,0)
75
"DATA",176.801,258,4,23,0)
85
"DATA",176.801,258,4,24,0)
31
"DATA",176.801,258,4,25,0)
81
"DATA",176.801,258,4,26,0)
39
"DATA",176.801,258,4,27,0)
71
"DATA",176.801,258,4,28,0)
87
"DATA",176.801,258,4,29,0)
55
"DATA",176.801,258,4,30,0)
73
"DATA",176.801,258,4,31,0)
80
"DATA",176.801,258,4,32,0)
76
"DATA",176.801,258,4,33,0)
24
"DATA",176.801,258,4,34,0)
84
"DATA",176.801,258,4,35,0)
63
"DATA",176.801,258,4,36,0)
8
"DATA",176.801,258,4,37,0)
34
"DATA",176.801,258,4,38,0)
16
"DATA",176.801,258,4,39,0)
29
"DATA",176.801,258,4,40,0)
77
"DATA",176.801,258,4,41,0)
26
"DATA",176.801,258,4,42,0)
46
"DATA",176.801,258,4,43,0)
35
"DATA",176.801,258,5)
FFI48
"DATA",176.801,259,0)
Falls Screening
"DATA",176.801,259,1)
2.16.840.1.113883.3.464.1003.118.12.1028
"DATA",176.801,259,4,0)
^176.8012P^1^1
"DATA",176.801,259,4,1,0)
71
"DATA",176.801,259,5)
FS28
"DATA",176.801,260,0)
Family History CHD
"DATA",176.801,260,1)
2.16.840.1.113883.3.600.1557
"DATA",176.801,260,4,0)
^176.8012P^2^2
"DATA",176.801,260,4,1,0)
5
"DATA",176.801,260,4,2,0)
1
"DATA",176.801,260,5)
FHCHD57
"DATA",176.801,261,0)
Fecal Occult Blood Test (FOBT)
"DATA",176.801,261,1)
2.16.840.1.113883.3.464.1003.198.12.1011
"DATA",176.801,261,4,0)
^176.8012P^1^1
"DATA",176.801,261,4,1,0)
63
"DATA",176.801,261,5)
FOBTFOBT11
"DATA",176.801,262,0)
Female
"DATA",176.801,262,1)
2.16.840.1.113883.3.560.100.2
"DATA",176.801,262,4,0)
^176.8012P^7^7
"DATA",176.801,262,4,1,0)
20
"DATA",176.801,262,4,2,0)
5
"DATA",176.801,262,4,3,0)
1
"DATA",176.801,262,4,4,0)
23
"DATA",176.801,262,4,5,0)
65
"DATA",176.801,262,4,6,0)
10
"DATA",176.801,262,4,7,0)
77
"DATA",176.801,262,5)
F02
"DATA",176.801,263,0)
Flexible Sigmoidoscopy
"DATA",176.801,263,1)
2.16.840.1.113883.3.464.1003.198.12.1010
"DATA",176.801,263,4,0)
^176.8012P^1^1
"DATA",176.801,263,4,1,0)
63
"DATA",176.801,263,5)
FS10
"DATA",176.801,264,0)
Fluoride Varnish Application for Children
"DATA",176.801,264,1)
2.16.840.1.113883.3.464.1003.125.12.1002
"DATA",176.801,264,4,0)
^176.8012P^1^1
"DATA",176.801,264,4,1,0)
7
"DATA",176.801,264,5)
FVAC02
"DATA",176.801,265,0)
Focal Chorioretinitis and Focal Retinochoroiditis
"DATA",176.801,265,1)
2.16.840.1.113883.3.526.3.1460
"DATA",176.801,265,4,0)
^176.8012P^1^1
"DATA",176.801,265,4,1,0)
19
"DATA",176.801,265,5)
FCFR60
"DATA",176.801,266,0)
Follow-up Monitoring
"DATA",176.801,266,1)
2.16.840.1.113883.3.117.1.7.1.303
"DATA",176.801,266,4,0)
^176.8012P^1^1
"DATA",176.801,266,4,1,0)
38
"DATA",176.801,266,5)
FM03
"DATA",176.801,267,0)
Follow-up for depression - adolescent
"DATA",176.801,267,1)
2.16.840.1.113883.3.600.467
"DATA",176.801,267,4,0)
^176.8012P^1^1
"DATA",176.801,267,4,1,0)
53
"DATA",176.801,267,5)
F67
"DATA",176.801,268,0)
Follow-up for depression - adult
"DATA",176.801,268,1)
2.16.840.1.113883.3.600.468
"DATA",176.801,268,4,0)
^176.8012P^1^1
"DATA",176.801,268,4,1,0)
53
"DATA",176.801,268,5)
F68
"DATA",176.801,269,0)
Fracture - Lower Body
"DATA",176.801,269,1)
2.16.840.1.113883.3.464.1003.113.12.1037
"DATA",176.801,269,4,0)
^176.8012P^2^2
"DATA",176.801,269,4,1,0)
16
"DATA",176.801,269,4,2,0)
73
"DATA",176.801,269,5)
FLB37
"DATA",176.801,270,0)
Framingham coronary heart disease 10 year risk
"DATA",176.801,270,1)
2.16.840.1.113883.3.600.1561
"DATA",176.801,270,4,0)
^176.8012P^1^1
"DATA",176.801,270,4,1,0)
1
"DATA",176.801,270,5)
F1061
"DATA",176.801,271,0)
Full Term Delivery
"DATA",176.801,271,1)
2.16.840.1.113883.3.67.1.101.1.273
"DATA",176.801,271,4,0)
^176.8012P^1^1
"DATA",176.801,271,4,1,0)
20
"DATA",176.801,271,5)
FTD73
"DATA",176.801,272,0)
Functional Status Assessment  for Hip Replacement
"DATA",176.801,272,1)
2.16.840.1.113883.3.464.1003.118.12.1029
"DATA",176.801,272,4,0)
^176.8012P^1^1
"DATA",176.801,272,4,1,0)
16
"DATA",176.801,272,5)
FSAHR29
"DATA",176.801,273,0)
Functional Status Assessment for Heart Failure
"DATA",176.801,273,1)
2.16.840.1.113883.3.464.1003.118.12.1031
"DATA",176.801,273,4,0)
^176.8012P^1^1
"DATA",176.801,273,4,1,0)
70
"DATA",176.801,273,5)
FSAHF31
"DATA",176.801,274,0)
Functional Status Assessment for Knee Replacement
"DATA",176.801,274,1)
2.16.840.1.113883.3.464.1003.118.12.1030
"DATA",176.801,274,4,0)
^176.8012P^1^1
"DATA",176.801,274,4,1,0)
73
"DATA",176.801,274,5)
FSAKR30
"DATA",176.801,275,0)
Galactosemia
"DATA",176.801,275,1)
2.16.840.1.113883.3.117.1.7.1.35
"DATA",176.801,275,4,0)
^176.8012P^1^1
"DATA",176.801,275,4,1,0)
36
"DATA",176.801,275,5)
G35
"DATA",176.801,276,0)
Gastrostomy Group
"DATA",176.801,276,1)
2.16.840.1.113883.3.666.5.1584
"DATA",176.801,276,4,0)
^176.8012P^1^1
"DATA",176.801,276,4,1,0)
93
"DATA",176.801,276,5)
GG84
"DATA",176.801,277,0)
Gavage Feeding Group
"DATA",176.801,277,1)
2.16.840.1.113883.3.666.5.1585
"DATA",176.801,277,4,0)
^176.8012P^1^1
"DATA",176.801,277,4,1,0)
93
"DATA",176.801,277,5)
GFG85
"DATA",176.801,278,0)
General Surgery
"DATA",176.801,278,1)
2.16.840.1.113883.3.117.1.7.1.255
"DATA",176.801,278,4,0)
^176.8012P^2^2
"DATA",176.801,278,4,1,0)
90
"DATA",176.801,278,4,2,0)
18
"DATA",176.801,278,5)
GS55
"DATA",176.801,279,0)
General or Neuraxial Anesthesia
"DATA",176.801,279,1)
2.16.840.1.113883.3.117.1.7.1.254
"DATA",176.801,279,4,0)
^176.8012P^3^3
"DATA",176.801,279,4,1,0)
90
"DATA",176.801,279,4,2,0)
18
"DATA",176.801,279,4,3,0)
17
"DATA",176.801,279,5)
GNA54
"DATA",176.801,280,0)
Genital Herpes
"DATA",176.801,280,1)
2.16.840.1.113883.3.464.1003.110.12.1049
"DATA",176.801,280,4,0)
^176.8012P^1^1
"DATA",176.801,280,4,1,0)
77
"DATA",176.801,280,5)
GH49
"DATA",176.801,281,0)
Gestational Age 37-38 weeks
"DATA",176.801,281,1)
2.16.840.1.113883.3.117.1.7.1.287
"DATA",176.801,281,4,0)
^176.8012P^1^1
"DATA",176.801,281,4,1,0)
91
"DATA",176.801,281,5)
GA373887
"DATA",176.801,282,0)
Gestational Age <37 weeks
"DATA",176.801,282,1)
2.16.840.1.113883.3.117.1.7.1.402
"DATA",176.801,282,4,0)
^176.8012P^1^1
"DATA",176.801,282,4,1,0)
91
"DATA",176.801,282,5)
GA3702
"DATA",176.801,283,0)
Gestational Age >38 weeks
"DATA",176.801,283,1)
2.16.840.1.113883.3.117.1.7.1.403
"DATA",176.801,283,4,0)
^176.8012P^1^1
"DATA",176.801,283,4,1,0)
91
"DATA",176.801,283,5)
GA3803
"DATA",176.801,284,0)
Gestational Age Unknown
"DATA",176.801,284,1)
2.16.840.1.113883.3.117.1.7.1.307
"DATA",176.801,284,4,0)
^176.8012P^1^1
"DATA",176.801,284,4,1,0)
91
"DATA",176.801,284,5)
GAU07
"DATA",176.801,285,0)
Gestational Diabetes
"DATA",176.801,285,1)
2.16.840.1.113883.3.464.1003.103.12.1010
"DATA",176.801,285,4,0)
^176.8012P^6^6
"DATA",176.801,285,4,1,0)
34
"DATA",176.801,285,4,2,0)
50
"DATA",176.801,285,4,3,0)
8
"DATA",176.801,285,4,4,0)
75
"DATA",176.801,285,4,5,0)
87
"DATA",176.801,285,4,6,0)
80
"DATA",176.801,285,5)
GD10
"DATA",176.801,286,0)
Gestational age >= 37 weeks
"DATA",176.801,286,1)
2.16.840.1.113883.3.666.5.1596
"DATA",176.801,286,4,0)
^176.8012P^2^2
"DATA",176.801,286,4,1,0)
36
"DATA",176.801,286,4,2,0)
93
"DATA",176.801,286,5)
G=3796
"DATA",176.801,287,0)
Glaucoma
"DATA",176.801,287,1)
2.16.840.1.113883.3.526.3.1423
"DATA",176.801,287,4,0)
^176.8012P^2^2
"DATA",176.801,287,4,1,0)
57
"DATA",176.801,287,4,2,0)
19
"DATA",176.801,287,5)
G23
"DATA",176.801,288,0)
Glaucoma Associated with Congenital Anomalies, Dystrophies, and Systemic Syndromes
"DATA",176.801,288,1)
2.16.840.1.113883.3.526.3.1461
"DATA",176.801,288,4,0)
^176.8012P^1^1
"DATA",176.801,288,4,1,0)
19
"DATA",176.801,288,5)
GACADSS61
"DATA",176.801,289,0)
Gleason Score
"DATA",176.801,289,1)
2.16.840.1.113883.3.526.3.397
"DATA",176.801,289,4,0)
^176.8012P^1^1
"DATA",176.801,289,4,1,0)
9
"DATA",176.801,289,5)
GS97
"DATA",176.801,290,0)
Glomerulonephritis and Nephrotic Syndrome
"DATA",176.801,290,1)
2.16.840.1.113883.3.464.1003.109.12.1018
"DATA",176.801,290,4,0)
^176.8012P^1^1
"DATA",176.801,290,4,1,0)
34
"DATA",176.801,290,5)
GNS18
"DATA",176.801,291,0)
Gonadotropin-releasing hormone analogue medication
"DATA",176.801,291,1)
2.16.840.1.113883.3.526.3.1316
"DATA",176.801,291,4,0)
^176.8012P^1^1
"DATA",176.801,291,4,1,0)
65
"DATA",176.801,291,5)
G16
"DATA",176.801,292,0)
Gonococcal Infections and Venereal Diseases
"DATA",176.801,292,1)
2.16.840.1.113883.3.464.1003.112.12.1001
"DATA",176.801,292,4,0)
^176.8012P^1^1
"DATA",176.801,292,4,1,0)
77
"DATA",176.801,292,5)
GIVD01
"DATA",176.801,293,0)
Graduated compression stockings (GCS)
"DATA",176.801,293,1)
2.16.840.1.113883.3.117.1.7.1.256
"DATA",176.801,293,4,0)
^176.8012P^3^3
"DATA",176.801,293,4,1,0)
90
"DATA",176.801,293,4,2,0)
18
"DATA",176.801,293,4,3,0)
17
"DATA",176.801,293,5)
GGCS56
"DATA",176.801,294,0)
Group A Streptococcus Test
"DATA",176.801,294,1)
2.16.840.1.113883.3.464.1003.198.12.1012
"DATA",176.801,294,4,0)
^176.8012P^1^1
"DATA",176.801,294,4,1,0)
74
"DATA",176.801,294,5)
GAST12
"DATA",176.801,295,0)
Group Psychotherapy
"DATA",176.801,295,1)
2.16.840.1.113883.3.526.3.1187
"DATA",176.801,295,4,0)
^176.8012P^1^1
"DATA",176.801,295,4,1,0)
44
"DATA",176.801,295,5)
GP87
"DATA",176.801,296,0)
Gynecological Surgery
"DATA",176.801,296,1)
2.16.840.1.113883.3.117.1.7.1.257
"DATA",176.801,296,4,0)
^176.8012P^2^2
"DATA",176.801,296,4,1,0)
90
"DATA",176.801,296,4,2,0)
18
"DATA",176.801,296,5)
GS57
"DATA",176.801,297,0)
HBsAg
"DATA",176.801,297,1)
2.16.840.1.113883.3.67.1.101.1.279
"DATA",176.801,297,4,0)
^176.8012P^1^1
"DATA",176.801,297,4,1,0)
20
"DATA",176.801,297,5)
HBA79
"DATA",176.801,298,0)
HDL-C Laboratory Test
"DATA",176.801,298,1)
2.16.840.1.113883.3.464.1003.104.12.1012
"DATA",176.801,298,4,0)
^176.8012P^1^1
"DATA",176.801,298,4,1,0)
25
"DATA",176.801,298,5)
HDLCLT12
"DATA",176.801,299,0)
HIV
"DATA",176.801,299,1)
2.16.840.1.113883.3.464.1003.120.12.1003
"DATA",176.801,299,4,0)
^176.8012P^5^5
"DATA",176.801,299,4,1,0)
89
"DATA",176.801,299,4,2,0)
82
"DATA",176.801,299,4,3,0)
11
"DATA",176.801,299,4,4,0)
77
"DATA",176.801,299,4,5,0)
66
"DATA",176.801,299,5)
HIV03
"DATA",176.801,300,0)
HIV Viral Load
"DATA",176.801,300,1)
2.16.840.1.113883.3.464.1003.120.12.1002
"DATA",176.801,300,4,0)
^176.8012P^1^1
"DATA",176.801,300,4,1,0)
82
"DATA",176.801,300,5)
HIVVL02
"DATA",176.801,301,0)
HIV Visit
"DATA",176.801,301,1)
2.16.840.1.113883.3.464.1003.101.12.1047
"DATA",176.801,301,4,0)
^176.8012P^3^3
"DATA",176.801,301,4,1,0)
82
"DATA",176.801,301,4,2,0)
89
"DATA",176.801,301,4,3,0)
11
"DATA",176.801,301,5)
HIVV47
"DATA",176.801,302,0)
HbA1c Laboratory Test
"DATA",176.801,302,1)
2.16.840.1.113883.3.464.1003.198.12.1013
"DATA",176.801,302,4,0)
^176.8012P^2^2
"DATA",176.801,302,4,1,0)
87
"DATA",176.801,302,4,2,0)
50
"DATA",176.801,302,5)
HA1LT13
"DATA",176.801,303,0)
Health & Behavioral Assessment - Individual
"DATA",176.801,303,1)
2.16.840.1.113883.3.526.3.1020
"DATA",176.801,303,4,0)
^176.8012P^1^1
"DATA",176.801,303,4,1,0)
84
"DATA",176.801,303,5)
H&BAI20
"DATA",176.801,304,0)
Health and Behavioral Assessment - Initial
"DATA",176.801,304,1)
2.16.840.1.113883.3.526.3.1245
"DATA",176.801,304,4,0)
^176.8012P^1^1
"DATA",176.801,304,4,1,0)
84
"DATA",176.801,304,5)
HBAI45
"DATA",176.801,305,0)
Hearing Examination
"DATA",176.801,305,1)
2.16.840.1.114222.4.1.214079.1.1.2
"DATA",176.801,305,4,0)
^176.8012P^1^1
"DATA",176.801,305,4,1,0)
4
"DATA",176.801,305,5)
HE12
"DATA",176.801,306,0)
Heart Failure
"DATA",176.801,306,1)
2.16.840.1.113883.3.526.3.376
"DATA",176.801,306,4,0)
^176.8012P^3^3
"DATA",176.801,306,4,1,0)
24
"DATA",176.801,306,4,2,0)
41
"DATA",176.801,306,4,3,0)
70
"DATA",176.801,306,5)
HF76
"DATA",176.801,307,0)
Heart Rate
"DATA",176.801,307,1)
2.16.840.1.113883.3.526.3.1176
"DATA",176.801,307,4,0)
^176.8012P^2^2
"DATA",176.801,307,4,1,0)
41
"DATA",176.801,307,4,2,0)
39
"DATA",176.801,307,5)
HR76
"DATA",176.801,308,0)
Height
"DATA",176.801,308,1)
2.16.840.1.113883.3.464.1003.121.12.1014
"DATA",176.801,308,4,0)
^176.8012P^1^1
"DATA",176.801,308,4,1,0)
6
"DATA",176.801,308,5)
H14
"DATA",176.801,309,0)
Hemodialysis
"DATA",176.801,309,1)
2.16.840.1.113883.3.526.3.1083
"DATA",176.801,309,4,0)
^176.8012P^2^2
"DATA",176.801,309,4,1,0)
12
"DATA",176.801,309,4,2,0)
59
"DATA",176.801,309,5)
H83
"DATA",176.801,310,0)
Hemolytic Disease Group
"DATA",176.801,310,1)
2.16.840.1.113883.3.666.5.1571
"DATA",176.801,310,4,0)
^176.8012P^1^1
"DATA",176.801,310,4,1,0)
93
"DATA",176.801,310,5)
HDG71
"DATA",176.801,311,0)
Hemophilus Influenze B (HiB) Vaccine
"DATA",176.801,311,1)
2.16.840.1.113883.3.464.1003.196.12.1217
"DATA",176.801,311,4,0)
^176.8012P^1^1
"DATA",176.801,311,4,1,0)
66
"DATA",176.801,311,5)
HIBHBV17
"DATA",176.801,312,0)
Hemophilus Influenze B (HiB) Vaccine Administered
"DATA",176.801,312,1)
2.16.840.1.113883.3.464.1003.110.12.1043
"DATA",176.801,312,4,0)
^176.8012P^1^1
"DATA",176.801,312,4,1,0)
66
"DATA",176.801,312,5)
HIBHBVA43
"DATA",176.801,313,0)
Hemorrhagic Stroke
"DATA",176.801,313,1)
2.16.840.1.113883.3.117.1.7.1.212
"DATA",176.801,313,4,0)
^176.8012P^8^8
"DATA",176.801,313,4,1,0)
2
"DATA",176.801,313,4,2,0)
15
"DATA",176.801,313,4,3,0)
22
"DATA",176.801,313,4,4,0)
37
"DATA",176.801,313,4,5,0)
18
"DATA",176.801,313,4,6,0)
14
"DATA",176.801,313,4,7,0)
13
"DATA",176.801,313,4,8,0)
49
"DATA",176.801,313,5)
HS12
"DATA",176.801,314,0)
Hepatitis A
"DATA",176.801,314,1)
2.16.840.1.113883.3.464.1003.110.12.1024
"DATA",176.801,314,4,0)
^176.8012P^1^1
"DATA",176.801,314,4,1,0)
66
"DATA",176.801,314,5)
HA24
"DATA",176.801,315,0)
Hepatitis A Antigen Test
"DATA",176.801,315,1)
2.16.840.1.113883.3.464.1003.198.12.1033
"DATA",176.801,315,4,0)
^176.8012P^1^1
"DATA",176.801,315,4,1,0)
66
"DATA",176.801,315,5)
HAAT33
"DATA",176.801,316,0)
Hepatitis A Vaccine
"DATA",176.801,316,1)
2.16.840.1.113883.3.464.1003.196.12.1215
"DATA",176.801,316,4,0)
^176.8012P^1^1
"DATA",176.801,316,4,1,0)
66
"DATA",176.801,316,5)
HAV15
"DATA",176.801,317,0)
Hepatitis A Vaccine Administered
"DATA",176.801,317,1)
2.16.840.1.113883.3.464.1003.110.12.1041
"DATA",176.801,317,4,0)
^176.8012P^1^1
"DATA",176.801,317,4,1,0)
66
"DATA",176.801,317,5)
HAVA41
"DATA",176.801,318,0)
Hepatitis B
"DATA",176.801,318,1)
2.16.840.1.113883.3.464.1003.110.12.1025
"DATA",176.801,318,5)
HB25
"DATA",176.801,319,0)
Hepatitis B
"DATA",176.801,319,1)
2.16.840.1.113883.3.67.1.101.1.269
"DATA",176.801,319,4,0)
^176.8012P^1^1
"DATA",176.801,319,4,1,0)
66
"DATA",176.801,319,5)
HB69
"DATA",176.801,320,0)
Hepatitis B Antigen Test
"DATA",176.801,320,1)
2.16.840.1.113883.3.464.1003.198.12.1031
"DATA",176.801,320,4,0)
^176.8012P^1^1
"DATA",176.801,320,4,1,0)
66
"DATA",176.801,320,5)
HBAT31
"DATA",176.801,321,0)
Hepatitis B Vaccine
"DATA",176.801,321,1)
2.16.840.1.113883.3.464.1003.196.12.1216
"DATA",176.801,321,4,0)
^176.8012P^1^1
"DATA",176.801,321,4,1,0)
66
"DATA",176.801,321,5)
HBV16
"DATA",176.801,322,0)
Hepatitis B Vaccine Administered
"DATA",176.801,322,1)
2.16.840.1.113883.3.464.1003.110.12.1042
"DATA",176.801,322,4,0)
^176.8012P^1^1
"DATA",176.801,322,4,1,0)
66
"DATA",176.801,322,5)
HBVA42
"DATA",176.801,323,0)
Hereditary Choroidal Dystrophies
"DATA",176.801,323,1)
2.16.840.1.113883.3.526.3.1462
"DATA",176.801,323,4,0)
^176.8012P^1^1
"DATA",176.801,323,4,1,0)
19
"DATA",176.801,323,5)
HCD62
"DATA",176.801,324,0)
Hereditary Corneal Dystrophies
"DATA",176.801,324,1)
2.16.840.1.113883.3.526.3.1424
"DATA",176.801,324,4,0)
^176.8012P^2^2
"DATA",176.801,324,4,1,0)
19
"DATA",176.801,324,4,2,0)
57
"DATA",176.801,324,5)
HCD24
"DATA",176.801,325,0)
Hereditary Retinal Dystrophies
"DATA",176.801,325,1)
2.16.840.1.113883.3.526.3.1463
"DATA",176.801,325,4,0)
^176.8012P^1^1
"DATA",176.801,325,4,1,0)
19
"DATA",176.801,325,5)
HRD63
"DATA",176.801,326,0)
High Density Lipoprotein (HDL)
"DATA",176.801,326,1)
2.16.840.1.113883.3.600.875
"DATA",176.801,326,4,0)
^176.8012P^2^2
"DATA",176.801,326,4,1,0)
1
"DATA",176.801,326,4,2,0)
5
"DATA",176.801,326,5)
HDLHDL75
"DATA",176.801,327,0)
High Hyperopia
"DATA",176.801,327,1)
2.16.840.1.113883.3.526.3.1425
"DATA",176.801,327,4,0)
^176.8012P^1^1
"DATA",176.801,327,4,1,0)
57
"DATA",176.801,327,5)
HH25
"DATA",176.801,328,0)
High Risk Medications for the Elderly
"DATA",176.801,328,1)
2.16.840.1.113883.3.464.1003.196.12.1253
"DATA",176.801,328,4,0)
^176.8012P^1^1
"DATA",176.801,328,4,1,0)
60
"DATA",176.801,328,5)
HRME53
"DATA",176.801,329,0)
High-Risk Medications With Days Supply Criteria
"DATA",176.801,329,1)
2.16.840.1.113883.3.464.1003.196.12.1254
"DATA",176.801,329,4,0)
^176.8012P^1^1
"DATA",176.801,329,4,1,0)
60
"DATA",176.801,329,5)
HRMWDSC54
"DATA",176.801,330,0)
Hip Fracture Surgery
"DATA",176.801,330,1)
2.16.840.1.113883.3.117.1.7.1.258
"DATA",176.801,330,4,0)
^176.8012P^2^2
"DATA",176.801,330,4,1,0)
90
"DATA",176.801,330,4,2,0)
18
"DATA",176.801,330,5)
HFS58
"DATA",176.801,331,0)
Hip Replacement Surgery
"DATA",176.801,331,1)
2.16.840.1.113883.3.117.1.7.1.259
"DATA",176.801,331,4,0)
^176.8012P^2^2
"DATA",176.801,331,4,1,0)
90
"DATA",176.801,331,4,2,0)
18
"DATA",176.801,331,5)
HRS59
"DATA",176.801,332,0)
History of Pneumococcal Vaccine
"DATA",176.801,332,1)
2.16.840.1.113883.3.464.1003.110.12.1028
"DATA",176.801,332,4,0)
^176.8012P^1^1
"DATA",176.801,332,4,1,0)
28
"DATA",176.801,332,5)
HPV28
"DATA",176.801,333,0)
Home Healthcare Services
"DATA",176.801,333,1)
2.16.840.1.113883.3.464.1003.101.12.1016
"DATA",176.801,333,4,0)
^176.8012P^25^25
"DATA",176.801,333,4,1,0)
35
"DATA",176.801,333,4,2,0)
75
"DATA",176.801,333,4,3,0)
24
"DATA",176.801,333,4,4,0)
46
"DATA",176.801,333,4,5,0)
87
"DATA",176.801,333,4,6,0)
39
"DATA",176.801,333,4,7,0)
25
"DATA",176.801,333,4,8,0)
60
"DATA",176.801,333,4,9,0)
33
"DATA",176.801,333,4,10,0)
64
"DATA",176.801,333,4,11,0)
3
"DATA",176.801,333,4,12,0)
66
"DATA",176.801,333,4,13,0)
41
"DATA",176.801,333,4,14,0)
6
"DATA",176.801,333,4,15,0)
77
"DATA",176.801,333,4,16,0)
23
"DATA",176.801,333,4,17,0)
34
"DATA",176.801,333,4,18,0)
10
"DATA",176.801,333,4,19,0)
71
"DATA",176.801,333,4,20,0)
59
"DATA",176.801,333,4,21,0)
63
"DATA",176.801,333,4,22,0)
80
"DATA",176.801,333,4,23,0)
8
"DATA",176.801,333,4,24,0)
29
"DATA",176.801,333,4,25,0)
28
"DATA",176.801,333,5)
HHS16
"DATA",176.801,334,0)
Home Hospice Care
"DATA",176.801,334,1)
2.16.840.1.113883.3.666.5.648
"DATA",176.801,334,4,0)
^176.8012P^1^1
"DATA",176.801,334,4,1,0)
86
"DATA",176.801,334,5)
HHC48
"DATA",176.801,335,0)
Hospital Inpatient Visit - Initial
"DATA",176.801,335,1)
2.16.840.1.113883.3.464.1003.101.12.1004
"DATA",176.801,335,4,0)
^176.8012P^1^1
"DATA",176.801,335,4,1,0)
76
"DATA",176.801,335,5)
HIVI04
"DATA",176.801,336,0)
Hospital Measures - AMI
"DATA",176.801,336,1)
2.16.840.1.113883.3.666.5.3011
"DATA",176.801,336,4,0)
^176.8012P^4^4
"DATA",176.801,336,4,1,0)
69
"DATA",176.801,336,4,2,0)
45
"DATA",176.801,336,4,3,0)
86
"DATA",176.801,336,4,4,0)
48
"DATA",176.801,336,5)
HMAMI11
"DATA",176.801,337,0)
Hospital Measures - Any infection
"DATA",176.801,337,1)
2.16.840.1.113883.3.666.5.696
"DATA",176.801,337,4,0)
^176.8012P^1^1
"DATA",176.801,337,4,1,0)
40
"DATA",176.801,337,5)
HMA96
"DATA",176.801,338,0)
Hospital Measures - Comfort Measure Only Intervention
"DATA",176.801,338,1)
2.16.840.1.113883.3.666.5.3002
"DATA",176.801,338,4,0)
^176.8012P^1^1
"DATA",176.801,338,4,1,0)
86
"DATA",176.801,338,5)
HMCMOI02
"DATA",176.801,339,0)
Hospital Measures - Encounter ED
"DATA",176.801,339,1)
2.16.840.1.113883.3.666.5.900
"DATA",176.801,339,4,0)
^176.8012P^2^2
"DATA",176.801,339,4,1,0)
45
"DATA",176.801,339,4,2,0)
40
"DATA",176.801,339,5)
HMEED00
"DATA",176.801,340,0)
Hospital Measures - Expired
"DATA",176.801,340,1)
2.16.840.1.113883.3.666.5.1146
"DATA",176.801,340,4,0)
^176.8012P^2^2
"DATA",176.801,340,4,1,0)
69
"DATA",176.801,340,4,2,0)
21
"DATA",176.801,340,5)
HME46
"DATA",176.801,341,0)
Hospital Measures - Hold
"DATA",176.801,341,1)
2.16.840.1.113883.3.666.5.1145
"DATA",176.801,341,4,0)
^176.8012P^1^1
"DATA",176.801,341,4,1,0)
69
"DATA",176.801,341,5)
HMH45
"DATA",176.801,342,0)
Hospital Measures - Home Hospice Care
"DATA",176.801,342,1)
2.16.840.1.113883.3.666.5.3008
"DATA",176.801,342,4,0)
^176.8012P^1^1
"DATA",176.801,342,4,1,0)
69
"DATA",176.801,342,5)
HMHHC08
"DATA",176.801,343,0)
Hospital Measures - Inpatient Hospice Care
"DATA",176.801,343,1)
2.16.840.1.113883.3.666.5.3007
"DATA",176.801,343,4,0)
^176.8012P^1^1
"DATA",176.801,343,4,1,0)
69
"DATA",176.801,343,5)
HMIHC07
"DATA",176.801,344,0)
Hospital Measures - Principal
"DATA",176.801,344,1)
2.16.840.1.113883.3.526.2.8001
"DATA",176.801,344,5)
HMP01
"DATA",176.801,345,0)
Hospital Measures - Principal
"DATA",176.801,345,1)
2.16.840.1.113883.3.666.5.3010
"DATA",176.801,345,4,0)
^176.8012P^3^3
"DATA",176.801,345,4,1,0)
79
"DATA",176.801,345,4,2,0)
92
"DATA",176.801,345,4,3,0)
40
"DATA",176.801,345,5)
HMP10
"DATA",176.801,346,0)
Hospital Measures - Warfarin Anticoagulants
"DATA",176.801,346,1)
2.16.840.1.113883.3.666.5.636
"DATA",176.801,346,4,0)
^176.8012P^1^1
"DATA",176.801,346,4,1,0)
69
"DATA",176.801,346,5)
HMWA36
"DATA",176.801,347,0)
Hospital Measures-Acute care hospital
"DATA",176.801,347,1)
2.16.840.1.113883.3.666.5.3013
"DATA",176.801,347,5)
HMA13
"DATA",176.801,348,0)
Hospital Measures-Acute care hospital
"DATA",176.801,348,1)
2.16.840.1.113883.3.666.5.684
"DATA",176.801,348,4,0)
^176.8012P^3^3
"DATA",176.801,348,4,1,0)
45
"DATA",176.801,348,4,2,0)
48
"DATA",176.801,348,4,3,0)
21
"DATA",176.801,348,5)
HMA84
"DATA",176.801,349,0)
Hospital Measures-Acute or Evolving MI
"DATA",176.801,349,1)
2.16.840.1.113883.3.666.5.3022
"DATA",176.801,349,4,0)
^176.8012P^2^2
"DATA",176.801,349,4,1,0)
45
"DATA",176.801,349,4,2,0)
48
"DATA",176.801,349,5)
HMAEMI22
"DATA",176.801,350,0)
Hospital Measures-Ambulatory surgical center
"DATA",176.801,350,1)
2.16.840.1.113883.3.666.5.687
"DATA",176.801,350,4,0)
^176.8012P^3^3
"DATA",176.801,350,4,1,0)
45
"DATA",176.801,350,4,2,0)
40
"DATA",176.801,350,4,3,0)
48
"DATA",176.801,350,5)
HMA87
"DATA",176.801,351,0)
Hospital Measures-Aortic balloon pump insertion
"DATA",176.801,351,1)
2.16.840.1.113883.3.666.5.1151
"DATA",176.801,351,4,0)
^176.8012P^2^2
"DATA",176.801,351,4,1,0)
45
"DATA",176.801,351,4,2,0)
48
"DATA",176.801,351,5)
HMA51
"DATA",176.801,352,0)
Hospital Measures-Aspirin
"DATA",176.801,352,1)
2.16.840.1.113883.3.666.5.626
"DATA",176.801,352,4,0)
^176.8012P^1^1
"DATA",176.801,352,4,1,0)
69
"DATA",176.801,352,5)
HMA26
"DATA",176.801,353,0)
Hospital Measures-Beta lactams for allergy determination
"DATA",176.801,353,1)
2.16.840.1.113883.3.666.5.1058
"DATA",176.801,353,4,0)
^176.8012P^2^2
"DATA",176.801,353,4,1,0)
92
"DATA",176.801,353,4,2,0)
40
"DATA",176.801,353,5)
HMB58
"DATA",176.801,354,0)
Hospital Measures-Bronchiectasis
"DATA",176.801,354,1)
2.16.840.1.113883.3.666.5.773
"DATA",176.801,354,4,0)
^176.8012P^1^1
"DATA",176.801,354,4,1,0)
40
"DATA",176.801,354,5)
HMB73
"DATA",176.801,355,0)
Hospital Measures-COPD
"DATA",176.801,355,1)
2.16.840.1.113883.3.666.5.776
"DATA",176.801,355,4,0)
^176.8012P^1^1
"DATA",176.801,355,4,1,0)
40
"DATA",176.801,355,5)
HMCOPD76
"DATA",176.801,356,0)
Hospital Measures-CT scan including chest
"DATA",176.801,356,1)
2.16.840.1.113883.3.666.5.680
"DATA",176.801,356,4,0)
^176.8012P^1^1
"DATA",176.801,356,4,1,0)
40
"DATA",176.801,356,5)
HMCT80
"DATA",176.801,357,0)
Hospital Measures-Caesarean Section
"DATA",176.801,357,1)
2.16.840.1.113883.3.666.5.1921
"DATA",176.801,357,4,0)
^176.8012P^1^1
"DATA",176.801,357,4,1,0)
78
"DATA",176.801,357,5)
HMCS21
"DATA",176.801,358,0)
Hospital Measures-Cardiac Valve Surgery
"DATA",176.801,358,1)
2.16.840.1.113883.3.666.5.2275
"DATA",176.801,358,4,0)
^176.8012P^1^1
"DATA",176.801,358,4,1,0)
92
"DATA",176.801,358,5)
HMCVS75
"DATA",176.801,359,0)
Hospital Measures-Cardiopulmonary arrest
"DATA",176.801,359,1)
2.16.840.1.113883.3.666.5.748
"DATA",176.801,359,4,0)
^176.8012P^2^2
"DATA",176.801,359,4,1,0)
45
"DATA",176.801,359,4,2,0)
48
"DATA",176.801,359,5)
HMC48
"DATA",176.801,360,0)
Hospital Measures-Chest xray SM-CT
"DATA",176.801,360,1)
2.16.840.1.113883.3.666.5.678
"DATA",176.801,360,4,0)
^176.8012P^1^1
"DATA",176.801,360,4,1,0)
40
"DATA",176.801,360,5)
HMC78
"DATA",176.801,361,0)
Hospital Measures-Chronic Wound Care
"DATA",176.801,361,1)
2.16.840.1.113883.3.666.5.719
"DATA",176.801,361,4,0)
^176.8012P^1^1
"DATA",176.801,361,4,1,0)
92
"DATA",176.801,361,5)
HMCWC19
"DATA",176.801,362,0)
Hospital Measures-Chronic bronchitis
"DATA",176.801,362,1)
2.16.840.1.113883.3.666.5.775
"DATA",176.801,362,4,0)
^176.8012P^1^1
"DATA",176.801,362,4,1,0)
40
"DATA",176.801,362,5)
HMC75
"DATA",176.801,363,0)
Hospital Measures-Comfort Measures Only Intervention
"DATA",176.801,363,1)
1.3.6.1.4.1.33895.1.3.0.45
"DATA",176.801,363,4,0)
^176.8012P^2^2
"DATA",176.801,363,4,1,0)
69
"DATA",176.801,363,4,2,0)
40
"DATA",176.801,363,5)
HMCMOI45
"DATA",176.801,364,0)
Hospital Measures-Diuretics RxNorm
"DATA",176.801,364,1)
2.16.840.1.113883.3.666.5.829
"DATA",176.801,364,4,0)
^176.8012P^1^1
"DATA",176.801,364,4,1,0)
79
"DATA",176.801,364,5)
HMDRN29
"DATA",176.801,365,0)
Hospital Measures-ECG Impression
"DATA",176.801,365,1)
2.16.840.1.113883.3.666.5.3018
"DATA",176.801,365,4,0)
^176.8012P^2^2
"DATA",176.801,365,4,1,0)
45
"DATA",176.801,365,4,2,0)
48
"DATA",176.801,365,5)
HMECGI18
"DATA",176.801,366,0)
Hospital Measures-ED Locations
"DATA",176.801,366,1)
2.16.840.1.113883.3.666.5.3006
"DATA",176.801,366,4,0)
^176.8012P^2^2
"DATA",176.801,366,4,1,0)
45
"DATA",176.801,366,4,2,0)
48
"DATA",176.801,366,5)
HMEDL06
"DATA",176.801,367,0)
Hospital Measures-Emphysema
"DATA",176.801,367,1)
2.16.840.1.113883.3.666.5.806
"DATA",176.801,367,4,0)
^176.8012P^1^1
"DATA",176.801,367,4,1,0)
40
"DATA",176.801,367,5)
HME06
"DATA",176.801,368,0)
Hospital Measures-Encounter ED
"DATA",176.801,368,1)
2.16.840.1.113883.3.526.2.900
"DATA",176.801,368,4,0)
^176.8012P^1^1
"DATA",176.801,368,4,1,0)
48
"DATA",176.801,368,5)
HMEED00
"DATA",176.801,369,0)
Hospital Measures-Encounter Inpatient
"DATA",176.801,369,1)
2.16.840.1.113883.3.666.5.625
"DATA",176.801,369,4,0)
^176.8012P^4^4
"DATA",176.801,369,4,1,0)
45
"DATA",176.801,369,4,2,0)
48
"DATA",176.801,369,4,3,0)
69
"DATA",176.801,369,4,4,0)
21
"DATA",176.801,369,5)
HMEI25
"DATA",176.801,370,0)
Hospital Measures-Endotrachael intubation
"DATA",176.801,370,1)
2.16.840.1.113883.3.666.5.747
"DATA",176.801,370,4,0)
^176.8012P^2^2
"DATA",176.801,370,4,1,0)
45
"DATA",176.801,370,4,2,0)
48
"DATA",176.801,370,5)
HME47
"DATA",176.801,371,0)
Hospital Measures-Fibrinolytic Therapy
"DATA",176.801,371,1)
2.16.840.1.113883.3.666.5.736
"DATA",176.801,371,4,0)
^176.8012P^2^2
"DATA",176.801,371,4,1,0)
45
"DATA",176.801,371,4,2,0)
48
"DATA",176.801,371,5)
HMFT36
"DATA",176.801,372,0)
Hospital Measures-Francisella Tularensis or Yersinia pestis
"DATA",176.801,372,1)
2.16.840.1.113883.3.666.5.2205
"DATA",176.801,372,4,0)
^176.8012P^1^1
"DATA",176.801,372,4,1,0)
40
"DATA",176.801,372,5)
HMFTY05
"DATA",176.801,373,0)
Hospital Measures-Healthcare associated pneumonia
"DATA",176.801,373,1)
2.16.840.1.113883.3.666.5.783
"DATA",176.801,373,4,0)
^176.8012P^1^1
"DATA",176.801,373,4,1,0)
40
"DATA",176.801,373,5)
HMH83
"DATA",176.801,374,0)
Hospital Measures-Hospital outpatient department
"DATA",176.801,374,1)
2.16.840.1.113883.3.67.1.101.950
"DATA",176.801,374,4,0)
^176.8012P^2^2
"DATA",176.801,374,4,1,0)
45
"DATA",176.801,374,4,2,0)
48
"DATA",176.801,374,5)
HMH50
"DATA",176.801,375,0)
Hospital Measures-ICU Locations
"DATA",176.801,375,1)
2.16.840.1.113883.3.666.5.1083
"DATA",176.801,375,4,0)
^176.8012P^2^2
"DATA",176.801,375,4,1,0)
79
"DATA",176.801,375,4,2,0)
40
"DATA",176.801,375,5)
HMICUL83
"DATA",176.801,376,0)
Hospital Measures-IV Aminoglycosides
"DATA",176.801,376,1)
2.16.840.1.113883.3.666.5.727
"DATA",176.801,376,4,0)
^176.8012P^2^2
"DATA",176.801,376,4,1,0)
92
"DATA",176.801,376,4,2,0)
40
"DATA",176.801,376,5)
HMIVA27
"DATA",176.801,377,0)
Hospital Measures-IV Antipneumococcal/antipseudomonal beta lactams
"DATA",176.801,377,1)
2.16.840.1.113883.3.666.5.759
"DATA",176.801,377,4,0)
^176.8012P^1^1
"DATA",176.801,377,4,1,0)
40
"DATA",176.801,377,5)
HMIVA59
"DATA",176.801,378,0)
Hospital Measures-IV Antipseudomonal quinolones
"DATA",176.801,378,1)
2.16.840.1.113883.3.666.5.896
"DATA",176.801,378,4,0)
^176.8012P^1^1
"DATA",176.801,378,4,1,0)
40
"DATA",176.801,378,5)
HMIVA96
"DATA",176.801,379,0)
Hospital Measures-IV Aztreonam
"DATA",176.801,379,1)
2.16.840.1.113883.3.666.5.728
"DATA",176.801,379,4,0)
^176.8012P^1^1
"DATA",176.801,379,4,1,0)
92
"DATA",176.801,379,5)
HMIVA28
"DATA",176.801,380,0)
Hospital Measures-IV Beta lactams
"DATA",176.801,380,1)
2.16.840.1.113883.3.666.5.770
"DATA",176.801,380,4,0)
^176.8012P^1^1
"DATA",176.801,380,4,1,0)
40
"DATA",176.801,380,5)
HMIVB70
"DATA",176.801,381,0)
Hospital Measures-IV Cardiac or  Vascular Antibiotics
"DATA",176.801,381,1)
2.16.840.1.113883.3.666.5.768
"DATA",176.801,381,4,0)
^176.8012P^1^1
"DATA",176.801,381,4,1,0)
92
"DATA",176.801,381,5)
HMIVCVA68
"DATA",176.801,382,0)
Hospital Measures-IV Clindamycin
"DATA",176.801,382,1)
2.16.840.1.113883.3.666.5.893
"DATA",176.801,382,4,0)
^176.8012P^1^1
"DATA",176.801,382,4,1,0)
92
"DATA",176.801,382,5)
HMIVC93
"DATA",176.801,383,0)
Hospital Measures-IV Colon-Antibiotics
"DATA",176.801,383,1)
2.16.840.1.113883.3.666.5.724
"DATA",176.801,383,4,0)
^176.8012P^1^1
"DATA",176.801,383,4,1,0)
92
"DATA",176.801,383,5)
HMIVCA24
"DATA",176.801,384,0)
Hospital Measures-IV Ertapenem
"DATA",176.801,384,1)
2.16.840.1.113883.3.666.5.725
"DATA",176.801,384,4,0)
^176.8012P^1^1
"DATA",176.801,384,4,1,0)
92
"DATA",176.801,384,5)
HMIVE25
"DATA",176.801,385,0)
Hospital Measures-IV Hysterectomy and Colon Quinolones
"DATA",176.801,385,1)
2.16.840.1.113883.3.666.5.767
"DATA",176.801,385,4,0)
^176.8012P^1^1
"DATA",176.801,385,4,1,0)
92
"DATA",176.801,385,5)
HMIVHCQ67
"DATA",176.801,386,0)
Hospital Measures-IV Macrolides ICU
"DATA",176.801,386,1)
2.16.840.1.113883.3.666.5.758
"DATA",176.801,386,4,0)
^176.8012P^1^1
"DATA",176.801,386,4,1,0)
40
"DATA",176.801,386,5)
HMIVMICU58
"DATA",176.801,387,0)
Hospital Measures-IV Metronidazole
"DATA",176.801,387,1)
2.16.840.1.113883.3.666.5.708
"DATA",176.801,387,4,0)
^176.8012P^1^1
"DATA",176.801,387,4,1,0)
92
"DATA",176.801,387,5)
HMIVM08
"DATA",176.801,388,0)
Hospital Measures-IV PO AntiPseudomonal Quinolones
"DATA",176.801,388,1)
2.16.840.1.113883.3.666.5.804
"DATA",176.801,388,4,0)
^176.8012P^1^1
"DATA",176.801,388,4,1,0)
40
"DATA",176.801,388,5)
HMIVPOAPQ04
"DATA",176.801,389,0)
Hospital Measures-IV PO Quinolone Antipneumococcal
"DATA",176.801,389,1)
2.16.840.1.113883.3.666.5.463
"DATA",176.801,389,4,0)
^176.8012P^1^1
"DATA",176.801,389,4,1,0)
40
"DATA",176.801,389,5)
HMIVPOQA63
"DATA",176.801,390,0)
Hospital Measures-IV Quinolones Antipneumococcal
"DATA",176.801,390,1)
2.16.840.1.113883.3.666.5.465
"DATA",176.801,390,4,0)
^176.8012P^1^1
"DATA",176.801,390,4,1,0)
40
"DATA",176.801,390,5)
HMIVQA65
"DATA",176.801,391,0)
Hospital Measures-IV Tetracycline
"DATA",176.801,391,1)
2.16.840.1.113883.3.666.5.2204
"DATA",176.801,391,4,0)
^176.8012P^1^1
"DATA",176.801,391,4,1,0)
40
"DATA",176.801,391,5)
HMIVT04
"DATA",176.801,392,0)
Hospital Measures-IV Tigecycline
"DATA",176.801,392,1)
2.16.840.1.113883.3.666.5.2203
"DATA",176.801,392,4,0)
^176.8012P^1^1
"DATA",176.801,392,4,1,0)
40
"DATA",176.801,392,5)
HMIVT03
"DATA",176.801,393,0)
Hospital Measures-IV or IM Aztreonam
"DATA",176.801,393,1)
2.16.840.1.113883.3.666.5.779
"DATA",176.801,393,4,0)
^176.8012P^1^1
"DATA",176.801,393,4,1,0)
40
"DATA",176.801,393,5)
HMIVIMA79
"DATA",176.801,394,0)
Hospital Measures-IV or IM Beta lactams
"DATA",176.801,394,1)
2.16.840.1.113883.3.666.5.720
"DATA",176.801,394,4,0)
^176.8012P^1^1
"DATA",176.801,394,4,1,0)
40
"DATA",176.801,394,5)
HMIVIMB20
"DATA",176.801,395,0)
Hospital Measures-IV or PO Levofloxacin
"DATA",176.801,395,1)
2.16.840.1.113883.3.666.5.760
"DATA",176.801,395,4,0)
^176.8012P^1^1
"DATA",176.801,395,4,1,0)
40
"DATA",176.801,395,5)
HMIVL60
"DATA",176.801,396,0)
Hospital Measures-IV or PO Macrolides Non-ICU
"DATA",176.801,396,1)
2.16.840.1.113883.3.666.5.772
"DATA",176.801,396,4,0)
^176.8012P^1^1
"DATA",176.801,396,4,1,0)
40
"DATA",176.801,396,5)
HMIVPOMNICU72
"DATA",176.801,397,0)
Hospital Measures-IV or PO Tetracyclines
"DATA",176.801,397,1)
2.16.840.1.113883.3.666.5.840
"DATA",176.801,397,4,0)
^176.8012P^1^1
"DATA",176.801,397,4,1,0)
40
"DATA",176.801,397,5)
HMIVPOT40
"DATA",176.801,398,0)
Hospital Measures-IV, IM, or PO Antimicrobial Medications
"DATA",176.801,398,1)
2.16.840.1.113883.3.666.5.843
"DATA",176.801,398,4,0)
^176.8012P^1^1
"DATA",176.801,398,4,1,0)
40
"DATA",176.801,398,5)
HMIVPOAM43
"DATA",176.801,399,0)
Hospital Measures-Immunocompromised Conditions
"DATA",176.801,399,1)
2.16.840.1.113883.3.666.5.1940
"DATA",176.801,399,4,0)
^176.8012P^1^1
"DATA",176.801,399,4,1,0)
40
"DATA",176.801,399,5)
HMIC40
"DATA",176.801,400,0)
Hospital Measures-Immunocompromised Therapies
"DATA",176.801,400,1)
2.16.840.1.113883.3.666.5.2348
"DATA",176.801,400,4,0)
^176.8012P^1^1
"DATA",176.801,400,4,1,0)
40
"DATA",176.801,400,5)
HMIT48
"DATA",176.801,401,0)
Hospital Measures-Immunodeficient Conditions
"DATA",176.801,401,1)
2.16.840.1.113883.3.666.5.1726
"DATA",176.801,401,4,0)
^176.8012P^1^1
"DATA",176.801,401,4,1,0)
40
"DATA",176.801,401,5)
HMIC26
"DATA",176.801,402,0)
Hospital Measures-Indwelling urinary catheter
"DATA",176.801,402,1)
2.16.840.1.113883.3.666.5.820
"DATA",176.801,402,4,0)
^176.8012P^1^1
"DATA",176.801,402,4,1,0)
79
"DATA",176.801,402,5)
HMI20
"DATA",176.801,403,0)
Hospital Measures-Infection diagnosis
"DATA",176.801,403,1)
2.16.840.1.113883.3.666.5.695
"DATA",176.801,403,4,0)
^176.8012P^2^2
"DATA",176.801,403,4,1,0)
78
"DATA",176.801,403,4,2,0)
92
"DATA",176.801,403,5)
HMI95
"DATA",176.801,404,0)
Hospital Measures-Intermittent Catheterization
"DATA",176.801,404,1)
2.16.840.1.113883.3.666.5.825
"DATA",176.801,404,4,0)
^176.8012P^1^1
"DATA",176.801,404,4,1,0)
79
"DATA",176.801,404,5)
HMIC25
"DATA",176.801,405,0)
Hospital Measures-Interstital lung disease
"DATA",176.801,405,1)
2.16.840.1.113883.3.666.5.777
"DATA",176.801,405,4,0)
^176.8012P^1^1
"DATA",176.801,405,4,1,0)
40
"DATA",176.801,405,5)
HMI77
"DATA",176.801,406,0)
Hospital Measures-Joint Commission Mental Disorders
"DATA",176.801,406,1)
1.3.6.1.4.1.33895.1.3.0.42
"DATA",176.801,406,4,0)
^176.8012P^1^1
"DATA",176.801,406,4,1,0)
21
"DATA",176.801,406,5)
HMJCMD42
"DATA",176.801,407,0)
Hospital Measures-LBBB
"DATA",176.801,407,1)
2.16.840.1.113883.3.666.5.3021
"DATA",176.801,407,4,0)
^176.8012P^2^2
"DATA",176.801,407,4,1,0)
45
"DATA",176.801,407,4,2,0)
48
"DATA",176.801,407,5)
HMLBBB21
"DATA",176.801,408,0)
Hospital Measures-MRSA Colonization or Infection
"DATA",176.801,408,1)
2.16.840.1.113883.3.666.5.2278
"DATA",176.801,408,4,0)
^176.8012P^1^1
"DATA",176.801,408,4,1,0)
92
"DATA",176.801,408,5)
HMMRSACI78
"DATA",176.801,409,0)
Hospital Measures-Neutrophil count
"DATA",176.801,409,1)
2.16.840.1.113883.3.666.5.787
"DATA",176.801,409,4,0)
^176.8012P^1^1
"DATA",176.801,409,4,1,0)
40
"DATA",176.801,409,5)
HMN87
"DATA",176.801,410,0)
Hospital Measures-Non-ICU Locations
"DATA",176.801,410,1)
2.16.840.1.113883.3.666.5.1084
"DATA",176.801,410,4,0)
^176.8012P^1^1
"DATA",176.801,410,4,1,0)
40
"DATA",176.801,410,5)
HMNICUL84
"DATA",176.801,411,0)
Hospital Measures-Nursing Home or Ext Fac Transfer
"DATA",176.801,411,1)
2.16.840.1.113883.3.666.5.2202
"DATA",176.801,411,4,0)
^176.8012P^1^1
"DATA",176.801,411,4,1,0)
40
"DATA",176.801,411,5)
HMNHEFT02
"DATA",176.801,412,0)
Hospital Measures-Organ transplant
"DATA",176.801,412,1)
2.16.840.1.113883.3.666.5.801
"DATA",176.801,412,4,0)
^176.8012P^1^1
"DATA",176.801,412,4,1,0)
40
"DATA",176.801,412,5)
HMO01
"DATA",176.801,413,0)
Hospital Measures-PCI
"DATA",176.801,413,1)
2.16.840.1.113883.3.666.5.737
"DATA",176.801,413,4,0)
^176.8012P^2^2
"DATA",176.801,413,4,1,0)
45
"DATA",176.801,413,4,2,0)
48
"DATA",176.801,413,5)
HMPCI37
"DATA",176.801,414,0)
Hospital Measures-PO Colon and Hysterectomy Antibiotics-Metronidazole
"DATA",176.801,414,1)
2.16.840.1.113883.3.666.5.1088
"DATA",176.801,414,4,0)
^176.8012P^2^2
"DATA",176.801,414,4,1,0)
78
"DATA",176.801,414,4,2,0)
92
"DATA",176.801,414,5)
HMPOCHAM88
"DATA",176.801,415,0)
Hospital Measures-Pneumonia
"DATA",176.801,415,1)
2.16.840.1.113883.3.666.5.752
"DATA",176.801,415,4,0)
^176.8012P^1^1
"DATA",176.801,415,4,1,0)
40
"DATA",176.801,415,5)
HMP52
"DATA",176.801,416,0)
Hospital Measures-Presumptive Pneumonia
"DATA",176.801,416,1)
2.16.840.1.113883.3.666.5.2323
"DATA",176.801,416,4,0)
^176.8012P^1^1
"DATA",176.801,416,4,1,0)
40
"DATA",176.801,416,5)
HMPP23
"DATA",176.801,417,0)
Hospital Measures-Prolonged QT Interval
"DATA",176.801,417,1)
2.16.840.1.113883.3.666.5.2197
"DATA",176.801,417,4,0)
^176.8012P^1^1
"DATA",176.801,417,4,1,0)
40
"DATA",176.801,417,5)
HMPQTI97
"DATA",176.801,418,0)
Hospital Measures-Radiologic Finding-Normal SM-CT
"DATA",176.801,418,1)
2.16.840.1.113883.3.666.5.2365
"DATA",176.801,418,4,0)
^176.8012P^1^1
"DATA",176.801,418,4,1,0)
40
"DATA",176.801,418,5)
HMRFNSMCT65
"DATA",176.801,419,0)
Hospital Measures-Respiratory failure acute or chronic
"DATA",176.801,419,1)
2.16.840.1.113883.3.666.5.2319
"DATA",176.801,419,4,0)
^176.8012P^1^1
"DATA",176.801,419,4,1,0)
40
"DATA",176.801,419,5)
HMR19
"DATA",176.801,420,0)
Hospital Measures-Respiratory infection
"DATA",176.801,420,1)
2.16.840.1.113883.3.666.5.2162
"DATA",176.801,420,4,0)
^176.8012P^1^1
"DATA",176.801,420,4,1,0)
40
"DATA",176.801,420,5)
HMR62
"DATA",176.801,421,0)
Hospital Measures-Restrictive lung disease
"DATA",176.801,421,1)
2.16.840.1.113883.3.666.5.2160
"DATA",176.801,421,4,0)
^176.8012P^1^1
"DATA",176.801,421,4,1,0)
40
"DATA",176.801,421,5)
HMR60
"DATA",176.801,422,0)
Hospital Measures-Route IV or PO
"DATA",176.801,422,1)
2.16.840.1.113883.3.666.5.1112
"DATA",176.801,422,4,0)
^176.8012P^1^1
"DATA",176.801,422,4,1,0)
40
"DATA",176.801,422,5)
HMRIV12
"DATA",176.801,423,0)
Hospital Measures-Route IV/IM
"DATA",176.801,423,1)
2.16.840.1.113883.3.666.5.1109
"DATA",176.801,423,4,0)
^176.8012P^1^1
"DATA",176.801,423,4,1,0)
40
"DATA",176.801,423,5)
HMRIVIM09
"DATA",176.801,424,0)
Hospital Measures-SCIP Urological/Perineal procedures with potential need of indwelling catheters
"DATA",176.801,424,1)
2.16.840.1.113883.3.666.5.2310
"DATA",176.801,424,4,0)
^176.8012P^1^1
"DATA",176.801,424,4,1,0)
79
"DATA",176.801,424,5)
HMSCIPUP10
"DATA",176.801,425,0)
Hospital Measures-SCIP urinary diversion
"DATA",176.801,425,1)
2.16.840.1.113883.3.666.5.822
"DATA",176.801,425,4,0)
^176.8012P^1^1
"DATA",176.801,425,4,1,0)
79
"DATA",176.801,425,5)
HMSCIP22
"DATA",176.801,426,0)
Hospital Measures-SCIP urinary diversion procedures
"DATA",176.801,426,1)
2.16.840.1.113883.3.666.5.2313
"DATA",176.801,426,4,0)
^176.8012P^1^1
"DATA",176.801,426,4,1,0)
79
"DATA",176.801,426,5)
HMSCIP13
"DATA",176.801,427,0)
Hospital Measures-Septicemia
"DATA",176.801,427,1)
2.16.840.1.113883.3.666.5.672
"DATA",176.801,427,4,0)
^176.8012P^1^1
"DATA",176.801,427,4,1,0)
40
"DATA",176.801,427,5)
HMS72
"DATA",176.801,428,0)
Hospital Measures-Structural lung disease
"DATA",176.801,428,1)
2.16.840.1.113883.3.666.5.774
"DATA",176.801,428,4,0)
^176.8012P^1^1
"DATA",176.801,428,4,1,0)
40
"DATA",176.801,428,5)
HMS74
"DATA",176.801,429,0)
Hospital Measures-Suprapubic catheter
"DATA",176.801,429,1)
2.16.840.1.113883.3.666.5.827
"DATA",176.801,429,4,0)
^176.8012P^1^1
"DATA",176.801,429,4,1,0)
79
"DATA",176.801,429,5)
HMS27
"DATA",176.801,430,0)
Hospital Measures-Systemic corticosteroid/prednisone therapy
"DATA",176.801,430,1)
2.16.840.1.113883.3.666.5.805
"DATA",176.801,430,4,0)
^176.8012P^1^1
"DATA",176.801,430,4,1,0)
40
"DATA",176.801,430,5)
HMS05
"DATA",176.801,431,0)
Hospital Measures-Systemic immunosuppressive therapy
"DATA",176.801,431,1)
2.16.840.1.113883.3.666.5.803
"DATA",176.801,431,4,0)
^176.8012P^1^1
"DATA",176.801,431,4,1,0)
40
"DATA",176.801,431,5)
HMS03
"DATA",176.801,432,0)
Hospital Measures-Tracheostomy care
"DATA",176.801,432,1)
2.16.840.1.113883.3.666.5.781
"DATA",176.801,432,4,0)
^176.8012P^1^1
"DATA",176.801,432,4,1,0)
40
"DATA",176.801,432,5)
HMT81
"DATA",176.801,433,0)
Hospital Measures-Urethra
"DATA",176.801,433,1)
2.16.840.1.113883.3.666.5.1130
"DATA",176.801,433,4,0)
^176.8012P^1^1
"DATA",176.801,433,4,1,0)
79
"DATA",176.801,433,5)
HMU30
"DATA",176.801,434,0)
Hospital Measures-Ventilator care
"DATA",176.801,434,1)
2.16.840.1.113883.3.666.5.782
"DATA",176.801,434,4,0)
^176.8012P^1^1
"DATA",176.801,434,4,1,0)
40
"DATA",176.801,434,5)
HMV82
"DATA",176.801,435,0)
Hospital Measures-Ventricular Assist Device placement
"DATA",176.801,435,1)
2.16.840.1.113883.3.666.5.3015
"DATA",176.801,435,4,0)
^176.8012P^2^2
"DATA",176.801,435,4,1,0)
45
"DATA",176.801,435,4,2,0)
48
"DATA",176.801,435,5)
HMVAD15
"DATA",176.801,436,0)
Hospital Measures-Wound Care
"DATA",176.801,436,1)
2.16.840.1.113883.3.666.5.2192
"DATA",176.801,436,4,0)
^176.8012P^1^1
"DATA",176.801,436,4,1,0)
40
"DATA",176.801,436,5)
HMWC92
"DATA",176.801,437,0)
Hospital Observation Care - Initial
"DATA",176.801,437,1)
2.16.840.1.113883.3.464.1003.101.12.1002
"DATA",176.801,437,4,0)
^176.8012P^3^3
"DATA",176.801,437,4,1,0)
76
"DATA",176.801,437,4,2,0)
85
"DATA",176.801,437,4,3,0)
33
"DATA",176.801,437,5)
HOCI02
"DATA",176.801,438,0)
Hospital measures - Request of physician
"DATA",176.801,438,1)
2.16.840.1.113883.3.666.5.2254
"DATA",176.801,438,4,0)
^176.8012P^1^1
"DATA",176.801,438,4,1,0)
92
"DATA",176.801,438,5)
HR54
"DATA",176.801,439,0)
Hospital measures- Colon surgery
"DATA",176.801,439,1)
2.16.840.1.113883.3.666.5.705
"DATA",176.801,439,4,0)
^176.8012P^2^2
"DATA",176.801,439,4,1,0)
78
"DATA",176.801,439,4,2,0)
92
"DATA",176.801,439,5)
HC05
"DATA",176.801,440,0)
Hospital measures-Abdominal hysterectomy
"DATA",176.801,440,1)
2.16.840.1.113883.3.666.5.710
"DATA",176.801,440,4,0)
^176.8012P^2^2
"DATA",176.801,440,4,1,0)
78
"DATA",176.801,440,4,2,0)
92
"DATA",176.801,440,5)
HA10
"DATA",176.801,441,0)
Hospital measures-Acute care hospital encounter
"DATA",176.801,441,1)
2.16.840.1.113883.3.666.5.2289
"DATA",176.801,441,4,0)
^176.8012P^1^1
"DATA",176.801,441,4,1,0)
92
"DATA",176.801,441,5)
HA89
"DATA",176.801,442,0)
Hospital measures-CABG
"DATA",176.801,442,1)
2.16.840.1.113883.3.666.5.694
"DATA",176.801,442,4,0)
^176.8012P^2^2
"DATA",176.801,442,4,1,0)
78
"DATA",176.801,442,4,2,0)
92
"DATA",176.801,442,5)
HCABG94
"DATA",176.801,443,0)
Hospital measures-Hemodialysis or peritoneal dialysis
"DATA",176.801,443,1)
2.16.840.1.113883.3.666.5.2282
"DATA",176.801,443,4,0)
^176.8012P^2^2
"DATA",176.801,443,4,1,0)
92
"DATA",176.801,443,4,2,0)
40
"DATA",176.801,443,5)
HH82
"DATA",176.801,444,0)
Hospital measures-Hip arthroplasty
"DATA",176.801,444,1)
2.16.840.1.113883.3.666.5.703
"DATA",176.801,444,4,0)
^176.8012P^2^2
"DATA",176.801,444,4,1,0)
78
"DATA",176.801,444,4,2,0)
92
"DATA",176.801,444,5)
HH03
"DATA",176.801,445,0)
Hospital measures-IV Antimicrobial medication
"DATA",176.801,445,1)
2.16.840.1.113883.3.666.5.765
"DATA",176.801,445,4,0)
^176.8012P^1^1
"DATA",176.801,445,4,1,0)
78
"DATA",176.801,445,5)
HIVA65
"DATA",176.801,446,0)
Hospital measures-IV Hysterectomy-Antibiotics
"DATA",176.801,446,1)
2.16.840.1.113883.3.666.5.729
"DATA",176.801,446,4,0)
^176.8012P^1^1
"DATA",176.801,446,4,1,0)
92
"DATA",176.801,446,5)
HIVHA29
"DATA",176.801,447,0)
Hospital measures-IV Vancomycin
"DATA",176.801,447,1)
2.16.840.1.113883.3.666.5.766
"DATA",176.801,447,4,0)
^176.8012P^2^2
"DATA",176.801,447,4,1,0)
78
"DATA",176.801,447,4,2,0)
92
"DATA",176.801,447,5)
HIVV66
"DATA",176.801,448,0)
Hospital measures-IV arthroplasty and colon antibiotics
"DATA",176.801,448,1)
2.16.840.1.113883.3.666.5.732
"DATA",176.801,448,4,0)
^176.8012P^1^1
"DATA",176.801,448,4,1,0)
92
"DATA",176.801,448,5)
HIV32
"DATA",176.801,449,0)
Hospital measures-IV, IM, PO Antimicrobial medications
"DATA",176.801,449,1)
2.16.840.1.113883.3.666.5.693
"DATA",176.801,449,4,0)
^176.8012P^2^2
"DATA",176.801,449,4,1,0)
78
"DATA",176.801,449,4,2,0)
92
"DATA",176.801,449,5)
HIVIMPOA93
"DATA",176.801,450,0)
Hospital measures-Joint Commission evidence of a surgical procedure requiring general or neuraxial anesthesia
"DATA",176.801,450,1)
2.16.840.1.113883.3.666.5.1743
"DATA",176.801,450,4,0)
^176.8012P^3^3
"DATA",176.801,450,4,1,0)
79
"DATA",176.801,450,4,2,0)
78
"DATA",176.801,450,4,3,0)
92
"DATA",176.801,450,5)
HJC43
"DATA",176.801,451,0)
Hospital measures-Knee arthroplasty
"DATA",176.801,451,1)
2.16.840.1.113883.3.666.5.1816
"DATA",176.801,451,4,0)
^176.8012P^2^2
"DATA",176.801,451,4,1,0)
78
"DATA",176.801,451,4,2,0)
92
"DATA",176.801,451,5)
HK16
"DATA",176.801,452,0)
Hospital measures-Other Cardiac Surgery
"DATA",176.801,452,1)
2.16.840.1.113883.3.666.5.701
"DATA",176.801,452,4,0)
^176.8012P^2^2
"DATA",176.801,452,4,1,0)
78
"DATA",176.801,452,4,2,0)
92
"DATA",176.801,452,5)
HOCS01
"DATA",176.801,453,0)
Hospital measures-PO Erythromycin
"DATA",176.801,453,1)
2.16.840.1.113883.3.666.5.1970
"DATA",176.801,453,4,0)
^176.8012P^2^2
"DATA",176.801,453,4,1,0)
78
"DATA",176.801,453,4,2,0)
92
"DATA",176.801,453,5)
HPOE70
"DATA",176.801,454,0)
Hospital measures-PO Neomycin sulfate
"DATA",176.801,454,1)
2.16.840.1.113883.3.666.5.1953
"DATA",176.801,454,4,0)
^176.8012P^2^2
"DATA",176.801,454,4,1,0)
78
"DATA",176.801,454,4,2,0)
92
"DATA",176.801,454,5)
HPON53
"DATA",176.801,455,0)
Hospital measures-Pacemaker or implantable defibrillator device
"DATA",176.801,455,1)
2.16.840.1.113883.3.666.5.1086
"DATA",176.801,455,4,0)
^176.8012P^2^2
"DATA",176.801,455,4,1,0)
78
"DATA",176.801,455,4,2,0)
92
"DATA",176.801,455,5)
HP86
"DATA",176.801,456,0)
Hospital measures-Pacemaker or implantable defibrillator insertion procedure
"DATA",176.801,456,1)
2.16.840.1.113883.3.666.5.1741
"DATA",176.801,456,4,0)
^176.8012P^2^2
"DATA",176.801,456,4,1,0)
78
"DATA",176.801,456,4,2,0)
92
"DATA",176.801,456,5)
HP41
"DATA",176.801,457,0)
Hospital measures-Route IV
"DATA",176.801,457,1)
2.16.840.1.113883.3.666.5.1108
"DATA",176.801,457,4,0)
^176.8012P^3^3
"DATA",176.801,457,4,1,0)
40
"DATA",176.801,457,4,2,0)
78
"DATA",176.801,457,4,3,0)
92
"DATA",176.801,457,5)
HRIV08
"DATA",176.801,458,0)
Hospital measures-Route IV, oral or IM
"DATA",176.801,458,1)
2.16.840.1.113883.3.666.5.1111
"DATA",176.801,458,4,0)
^176.8012P^3^3
"DATA",176.801,458,4,1,0)
78
"DATA",176.801,458,4,2,0)
92
"DATA",176.801,458,4,3,0)
40
"DATA",176.801,458,5)
HRIVIM11
"DATA",176.801,459,0)
Hospital measures-Route oral
"DATA",176.801,459,1)
2.16.840.1.113883.3.666.5.1072
"DATA",176.801,459,4,0)
^176.8012P^2^2
"DATA",176.801,459,4,1,0)
78
"DATA",176.801,459,4,2,0)
92
"DATA",176.801,459,5)
HR72
"DATA",176.801,460,0)
Hospital measures-SCIP IV quinolones
"DATA",176.801,460,1)
2.16.840.1.113883.3.666.5.835
"DATA",176.801,460,4,0)
^176.8012P^1^1
"DATA",176.801,460,4,1,0)
78
"DATA",176.801,460,5)
HSCIPIV35
"DATA",176.801,461,0)
Hospital measures-Vaginal hysterectomy
"DATA",176.801,461,1)
2.16.840.1.113883.3.666.5.712
"DATA",176.801,461,4,0)
^176.8012P^2^2
"DATA",176.801,461,4,1,0)
78
"DATA",176.801,461,4,2,0)
92
"DATA",176.801,461,5)
HV12
"DATA",176.801,462,0)
Hospital measures-Vascular surgery
"DATA",176.801,462,1)
2.16.840.1.113883.3.666.5.713
"DATA",176.801,462,4,0)
^176.8012P^2^2
"DATA",176.801,462,4,1,0)
78
"DATA",176.801,462,4,2,0)
92
"DATA",176.801,462,5)
HV13
"DATA",176.801,463,0)
Hydrops Group
"DATA",176.801,463,1)
2.16.840.1.113883.3.666.5.1573
"DATA",176.801,463,4,0)
^176.8012P^1^1
"DATA",176.801,463,4,1,0)
93
"DATA",176.801,463,5)
HG73
"DATA",176.801,464,0)
Hyperbilirubinemia Group
"DATA",176.801,464,1)
2.16.840.1.113883.3.666.5.1593
"DATA",176.801,464,4,0)
^176.8012P^1^1
"DATA",176.801,464,4,1,0)
93
"DATA",176.801,464,5)
HG93
"DATA",176.801,465,0)
Hypertension
"DATA",176.801,465,1)
2.16.840.1.113883.3.464.1003.104.12.1016
"DATA",176.801,465,4,0)
^176.8012P^1^1
"DATA",176.801,465,4,1,0)
12
"DATA",176.801,465,5)
H16
"DATA",176.801,466,0)
Hypertensive Chronic Kidney Disease
"DATA",176.801,466,1)
2.16.840.1.113883.3.464.1003.109.12.1017
"DATA",176.801,466,4,0)
^176.8012P^1^1
"DATA",176.801,466,4,1,0)
34
"DATA",176.801,466,5)
HCKD17
"DATA",176.801,467,0)
Hypotension
"DATA",176.801,467,1)
2.16.840.1.113883.3.526.3.370
"DATA",176.801,467,4,0)
^176.8012P^2^2
"DATA",176.801,467,4,1,0)
41
"DATA",176.801,467,4,2,0)
39
"DATA",176.801,467,5)
H70
"DATA",176.801,468,0)
Hypotony of Eye
"DATA",176.801,468,1)
2.16.840.1.113883.3.526.3.1426
"DATA",176.801,468,4,0)
^176.8012P^1^1
"DATA",176.801,468,4,1,0)
57
"DATA",176.801,468,5)
HE26
"DATA",176.801,469,0)
Hypoxia or Asphyxia Group
"DATA",176.801,469,1)
2.16.840.1.113883.3.666.5.1577
"DATA",176.801,469,4,0)
^176.8012P^1^1
"DATA",176.801,469,4,1,0)
93
"DATA",176.801,469,5)
HAG77
"DATA",176.801,470,0)
Hysterectomy with No Residual Cervix
"DATA",176.801,470,1)
2.16.840.1.113883.3.464.1003.198.12.1014
"DATA",176.801,470,4,0)
^176.8012P^1^1
"DATA",176.801,470,4,1,0)
23
"DATA",176.801,470,5)
HNRC14
"DATA",176.801,471,0)
ICU Admission or Transfer
"DATA",176.801,471,1)
2.16.840.1.113883.3.117.1.7.1.305
"DATA",176.801,471,4,0)
^176.8012P^2^2
"DATA",176.801,471,4,1,0)
90
"DATA",176.801,471,4,2,0)
18
"DATA",176.801,471,5)
ICUAT05
"DATA",176.801,472,0)
INR
"DATA",176.801,472,1)
2.16.840.1.113883.3.117.1.7.1.213
"DATA",176.801,472,4,0)
^176.8012P^3^3
"DATA",176.801,472,4,1,0)
32
"DATA",176.801,472,4,2,0)
90
"DATA",176.801,472,4,3,0)
18
"DATA",176.801,472,5)
INR13
"DATA",176.801,473,0)
INR Monitoring Education
"DATA",176.801,473,1)
2.16.840.1.113883.3.117.1.7.1.416
"DATA",176.801,473,4,0)
^176.8012P^1^1
"DATA",176.801,473,4,1,0)
38
"DATA",176.801,473,5)
INRME16
"DATA",176.801,474,0)
IV Drug Abuse
"DATA",176.801,474,1)
2.16.840.1.113883.3.464.1003.106.12.1003
"DATA",176.801,474,4,0)
^176.8012P^1^1
"DATA",176.801,474,4,1,0)
67
"DATA",176.801,474,5)
IVDA03
"DATA",176.801,475,0)
IV Positive Inotropic and Vasopressor Agents
"DATA",176.801,475,1)
2.16.840.1.113883.3.666.5.2128
"DATA",176.801,475,4,0)
^176.8012P^1^1
"DATA",176.801,475,4,1,0)
79
"DATA",176.801,475,5)
IVPIVA28
"DATA",176.801,476,0)
Impaired Fetal Growth Group
"DATA",176.801,476,1)
2.16.840.1.113883.3.666.5.1566
"DATA",176.801,476,4,0)
^176.8012P^1^1
"DATA",176.801,476,4,1,0)
93
"DATA",176.801,476,5)
IFGG66
"DATA",176.801,477,0)
Inactivated Polio Vaccine (IPV)
"DATA",176.801,477,1)
2.16.840.1.113883.3.464.1003.196.12.1219
"DATA",176.801,477,4,0)
^176.8012P^1^1
"DATA",176.801,477,4,1,0)
66
"DATA",176.801,477,5)
IPVIPV19
"DATA",176.801,478,0)
Inactivated Polio Vaccine (IPV) Administered
"DATA",176.801,478,1)
2.16.840.1.113883.3.464.1003.110.12.1045
"DATA",176.801,478,4,0)
^176.8012P^1^1
"DATA",176.801,478,4,1,0)
66
"DATA",176.801,478,5)
IPVIPVA45
"DATA",176.801,479,0)
Infection Group
"DATA",176.801,479,1)
2.16.840.1.113883.3.666.5.1590
"DATA",176.801,479,4,0)
^176.8012P^1^1
"DATA",176.801,479,4,1,0)
93
"DATA",176.801,479,5)
IG90
"DATA",176.801,480,0)
Inflammatory Diseases of Female Reproductive Organs
"DATA",176.801,480,1)
2.16.840.1.113883.3.464.1003.112.12.1004
"DATA",176.801,480,4,0)
^176.8012P^1^1
"DATA",176.801,480,4,1,0)
77
"DATA",176.801,480,5)
IDFRO04
"DATA",176.801,481,0)
Influenza Vaccination
"DATA",176.801,481,1)
2.16.840.1.113883.3.526.3.402
"DATA",176.801,481,4,0)
^176.8012P^1^1
"DATA",176.801,481,4,1,0)
59
"DATA",176.801,481,5)
IV02
"DATA",176.801,482,0)
Influenza Vaccination Declined
"DATA",176.801,482,1)
2.16.840.1.113883.3.526.3.1255
"DATA",176.801,482,4,0)
^176.8012P^1^1
"DATA",176.801,482,4,1,0)
59
"DATA",176.801,482,5)
IVD55
"DATA",176.801,483,0)
Influenza Vaccine
"DATA",176.801,483,1)
2.16.840.1.113883.3.464.1003.196.12.1218
"DATA",176.801,483,5)
IV18
"DATA",176.801,484,0)
Influenza Vaccine
"DATA",176.801,484,1)
2.16.840.1.113883.3.526.3.1254
"DATA",176.801,484,4,0)
^176.8012P^1^1
"DATA",176.801,484,4,1,0)
66
"DATA",176.801,484,5)
IV54
"DATA",176.801,485,0)
Influenza Vaccine Administered
"DATA",176.801,485,1)
2.16.840.1.113883.3.464.1003.110.12.1044
"DATA",176.801,485,4,0)
^176.8012P^1^1
"DATA",176.801,485,4,1,0)
66
"DATA",176.801,485,5)
IVA44
"DATA",176.801,486,0)
Injectable Factor Xa Inhibitor
"DATA",176.801,486,1)
2.16.840.1.113883.3.117.1.7.1.211
"DATA",176.801,486,4,0)
^176.8012P^3^3
"DATA",176.801,486,4,1,0)
90
"DATA",176.801,486,4,2,0)
18
"DATA",176.801,486,4,3,0)
17
"DATA",176.801,486,5)
FXI11
"DATA",176.801,487,0)
Injury to Optic Nerve and Pathways
"DATA",176.801,487,1)
2.16.840.1.113883.3.526.3.1427
"DATA",176.801,487,4,0)
^176.8012P^2^2
"DATA",176.801,487,4,1,0)
19
"DATA",176.801,487,4,2,0)
57
"DATA",176.801,487,5)
IONP27
"DATA",176.801,488,0)
Inpatient Encounter
"DATA",176.801,488,1)
2.16.840.1.113883.3.117.1.7.1.23
"DATA",176.801,488,5)
IE23
"DATA",176.801,489,0)
Inpatient Encounter
"DATA",176.801,489,1)
2.16.840.1.113883.3.464.1003.101.12.1060
"DATA",176.801,489,4,0)
^176.8012P^9^9
"DATA",176.801,489,4,1,0)
32
"DATA",176.801,489,4,2,0)
38
"DATA",176.801,489,4,3,0)
72
"DATA",176.801,489,4,4,0)
36
"DATA",176.801,489,4,5,0)
90
"DATA",176.801,489,4,6,0)
4
"DATA",176.801,489,4,7,0)
18
"DATA",176.801,489,4,8,0)
17
"DATA",176.801,489,4,9,0)
91
"DATA",176.801,489,5)
IE60
"DATA",176.801,490,0)
Inpatient Hospice Care
"DATA",176.801,490,1)
2.16.840.1.113883.3.666.5.647
"DATA",176.801,490,4,0)
^176.8012P^1^1
"DATA",176.801,490,4,1,0)
86
"DATA",176.801,490,5)
IHC47
"DATA",176.801,491,0)
Instructions for Follow Up After Discharge
"DATA",176.801,491,1)
2.16.840.1.113883.3.117.1.7.1.378
"DATA",176.801,491,4,0)
^176.8012P^1^1
"DATA",176.801,491,4,1,0)
14
"DATA",176.801,491,5)
IFUAD78
"DATA",176.801,492,0)
Intermittent pneumatic compression devices (IPC)
"DATA",176.801,492,1)
2.16.840.1.113883.3.117.1.7.1.214
"DATA",176.801,492,4,0)
^176.8012P^3^3
"DATA",176.801,492,4,1,0)
90
"DATA",176.801,492,4,2,0)
18
"DATA",176.801,492,4,3,0)
17
"DATA",176.801,492,5)
IIPC14
"DATA",176.801,493,0)
Intolerance to ACE inhibitor or ARB
"DATA",176.801,493,1)
2.16.840.1.113883.3.526.3.1212
"DATA",176.801,493,4,0)
^176.8012P^1^1
"DATA",176.801,493,4,1,0)
24
"DATA",176.801,493,5)
IACEARB12
"DATA",176.801,494,0)
Intolerance to Antineoplastic Therapy
"DATA",176.801,494,1)
2.16.840.1.113883.3.526.3.1287
"DATA",176.801,494,4,0)
^176.8012P^1^1
"DATA",176.801,494,4,1,0)
43
"DATA",176.801,494,5)
IAT87
"DATA",176.801,495,0)
Intolerance to Beta Blocker Therapy
"DATA",176.801,495,1)
2.16.840.1.113883.3.526.3.1178
"DATA",176.801,495,4,0)
^176.8012P^2^2
"DATA",176.801,495,4,1,0)
41
"DATA",176.801,495,4,2,0)
39
"DATA",176.801,495,5)
IBBT78
"DATA",176.801,496,0)
Intolerance to Influenza Vaccine
"DATA",176.801,496,1)
2.16.840.1.113883.3.526.3.1257
"DATA",176.801,496,4,0)
^176.8012P^1^1
"DATA",176.801,496,4,1,0)
59
"DATA",176.801,496,5)
IIV57
"DATA",176.801,497,0)
Intolerance to Tamoxifen or Aromatase Inhibitor Therapy
"DATA",176.801,497,1)
2.16.840.1.113883.3.526.3.1318
"DATA",176.801,497,4,0)
^176.8012P^1^1
"DATA",176.801,497,4,1,0)
65
"DATA",176.801,497,5)
ITAIT18
"DATA",176.801,498,0)
Intracranial Neurosurgery
"DATA",176.801,498,1)
2.16.840.1.113883.3.117.1.7.1.260
"DATA",176.801,498,4,0)
^176.8012P^2^2
"DATA",176.801,498,4,1,0)
90
"DATA",176.801,498,4,2,0)
18
"DATA",176.801,498,5)
IN60
"DATA",176.801,499,0)
Intravenous route
"DATA",176.801,499,1)
2.16.840.1.113883.3.117.1.7.1.222
"DATA",176.801,499,4,0)
^176.8012P^4^4
"DATA",176.801,499,4,1,0)
72
"DATA",176.801,499,4,2,0)
90
"DATA",176.801,499,4,3,0)
18
"DATA",176.801,499,4,4,0)
17
"DATA",176.801,499,5)
I22
"DATA",176.801,500,0)
Ischemic Stroke
"DATA",176.801,500,1)
2.16.840.1.113883.3.117.1.7.1.247
"DATA",176.801,500,4,0)
^176.8012P^8^8
"DATA",176.801,500,4,1,0)
2
"DATA",176.801,500,4,2,0)
15
"DATA",176.801,500,4,3,0)
22
"DATA",176.801,500,4,4,0)
37
"DATA",176.801,500,4,5,0)
18
"DATA",176.801,500,4,6,0)
14
"DATA",176.801,500,4,7,0)
13
"DATA",176.801,500,4,8,0)
49
"DATA",176.801,500,5)
IS47
"DATA",176.801,501,0)
Ischemic Vascular Disease
"DATA",176.801,501,1)
2.16.840.1.113883.3.464.1003.104.12.1003
"DATA",176.801,501,4,0)
^176.8012P^2^2
"DATA",176.801,501,4,1,0)
25
"DATA",176.801,501,4,2,0)
3
"DATA",176.801,501,5)
IVD03
"DATA",176.801,502,0)
Isotretinoin
"DATA",176.801,502,1)
2.16.840.1.113883.3.464.1003.196.12.1143
"DATA",176.801,502,4,0)
^176.8012P^1^1
"DATA",176.801,502,4,1,0)
77
"DATA",176.801,502,5)
I43
"DATA",176.801,503,0)
Kidney Transplant
"DATA",176.801,503,1)
2.16.840.1.113883.3.464.1003.109.12.1012
"DATA",176.801,503,4,0)
^176.8012P^2^2
"DATA",176.801,503,4,1,0)
64
"DATA",176.801,503,4,2,0)
34
"DATA",176.801,503,5)
KT12
"DATA",176.801,504,0)
Knee Replacement Surgery
"DATA",176.801,504,1)
2.16.840.1.113883.3.117.1.7.1.261
"DATA",176.801,504,4,0)
^176.8012P^2^2
"DATA",176.801,504,4,1,0)
90
"DATA",176.801,504,4,2,0)
18
"DATA",176.801,504,5)
KRS61
"DATA",176.801,505,0)
LDL Code
"DATA",176.801,505,1)
2.16.840.1.113883.3.600.872
"DATA",176.801,505,4,0)
^176.8012P^1^1
"DATA",176.801,505,4,1,0)
1
"DATA",176.801,505,5)
LDLC72
"DATA",176.801,506,0)
LDL Test
"DATA",176.801,506,1)
2.16.840.1.113883.3.464.1003.198.12.1016
"DATA",176.801,506,4,0)
^176.8012P^2^2
"DATA",176.801,506,4,1,0)
1
"DATA",176.801,506,4,2,0)
5
"DATA",176.801,506,5)
LDLT16
"DATA",176.801,507,0)
LDL-C Laboratory Test
"DATA",176.801,507,1)
2.16.840.1.113883.3.526.3.1248
"DATA",176.801,507,4,0)
^176.8012P^2^2
"DATA",176.801,507,4,1,0)
8
"DATA",176.801,507,4,2,0)
25
"DATA",176.801,507,5)
LDLCLT48
"DATA",176.801,508,0)
LDL-c
"DATA",176.801,508,1)
2.16.840.1.113883.3.117.1.7.1.215
"DATA",176.801,508,4,0)
^176.8012P^2^2
"DATA",176.801,508,4,1,0)
86
"DATA",176.801,508,4,2,0)
13
"DATA",176.801,508,5)
LDL15
"DATA",176.801,509,0)
Lab Tests During Pregnancy
"DATA",176.801,509,1)
2.16.840.1.113883.3.464.1003.111.12.1007
"DATA",176.801,509,4,0)
^176.8012P^1^1
"DATA",176.801,509,4,1,0)
77
"DATA",176.801,509,5)
LTDP07
"DATA",176.801,510,0)
Lab Tests for Sexually Transmitted Infections
"DATA",176.801,510,1)
2.16.840.1.113883.3.464.1003.110.12.1051
"DATA",176.801,510,4,0)
^176.8012P^1^1
"DATA",176.801,510,4,1,0)
77
"DATA",176.801,510,5)
LTSTI51
"DATA",176.801,511,0)
Laboratory Tests for Hypertension
"DATA",176.801,511,1)
2.16.840.1.113883.3.600.1482
"DATA",176.801,511,4,0)
^176.8012P^1^1
"DATA",176.801,511,4,1,0)
58
"DATA",176.801,511,5)
LTH82
"DATA",176.801,512,0)
Laryngeal Stenosis Group
"DATA",176.801,512,1)
2.16.840.1.113883.3.666.5.1576
"DATA",176.801,512,4,0)
^176.8012P^1^1
"DATA",176.801,512,4,1,0)
93
"DATA",176.801,512,5)
LSG76
"DATA",176.801,513,0)
Left Against Medical Advice
"DATA",176.801,513,1)
2.16.840.1.113883.3.117.1.7.1.308
"DATA",176.801,513,5)
LAMA08
"DATA",176.801,514,0)
Left Against Medical Advice
"DATA",176.801,514,1)
2.16.840.1.113883.3.666.5.1106
"DATA",176.801,514,4,0)
^176.8012P^6^6
"DATA",176.801,514,4,1,0)
2
"DATA",176.801,514,4,2,0)
32
"DATA",176.801,514,4,3,0)
22
"DATA",176.801,514,4,4,0)
37
"DATA",176.801,514,4,5,0)
72
"DATA",176.801,514,4,6,0)
13
"DATA",176.801,514,5)
LAMA06
"DATA",176.801,515,0)
Left ventricular systolic dysfunction
"DATA",176.801,515,1)
2.16.840.1.113883.3.526.3.1091
"DATA",176.801,515,4,0)
^176.8012P^3^3
"DATA",176.801,515,4,1,0)
39
"DATA",176.801,515,4,2,0)
24
"DATA",176.801,515,4,3,0)
41
"DATA",176.801,515,5)
L91
"DATA",176.801,516,0)
Lens Procedure
"DATA",176.801,516,1)
2.16.840.1.113883.3.526.3.1429
"DATA",176.801,516,4,0)
^176.8012P^1^1
"DATA",176.801,516,4,1,0)
57
"DATA",176.801,516,5)
LP29
"DATA",176.801,517,0)
Leucovorin
"DATA",176.801,517,1)
2.16.840.1.113883.3.464.1003.196.12.1205
"DATA",176.801,517,4,0)
^176.8012P^1^1
"DATA",176.801,517,4,1,0)
11
"DATA",176.801,517,5)
L05
"DATA",176.801,518,0)
Level of Severity of Retinopathy Findings
"DATA",176.801,518,1)
2.16.840.1.113883.3.526.3.1283
"DATA",176.801,518,5)
LSRF83
"DATA",176.801,519,0)
Level of Severity of Retinopathy Findings
"DATA",176.801,519,1)
2.16.840.1.113883.3.526.3.1324
"DATA",176.801,519,4,0)
^176.8012P^1^1
"DATA",176.801,519,4,1,0)
26
"DATA",176.801,519,5)
LSRF24
"DATA",176.801,520,0)
Lifestyle Recommendation
"DATA",176.801,520,1)
2.16.840.1.113883.3.600.1508
"DATA",176.801,520,4,0)
^176.8012P^1^1
"DATA",176.801,520,4,1,0)
58
"DATA",176.801,520,5)
LR08
"DATA",176.801,521,0)
Limited Life Expectancy
"DATA",176.801,521,1)
2.16.840.1.113883.3.526.3.1259
"DATA",176.801,521,4,0)
^176.8012P^1^1
"DATA",176.801,521,4,1,0)
84
"DATA",176.801,521,5)
LLE59
"DATA",176.801,522,0)
Lipid-lowering Agent
"DATA",176.801,522,1)
2.16.840.1.113883.3.117.1.7.1.217
"DATA",176.801,522,4,0)
^176.8012P^1^1
"DATA",176.801,522,4,1,0)
13
"DATA",176.801,522,5)
LA17
"DATA",176.801,523,0)
Livebirth
"DATA",176.801,523,1)
2.16.840.1.114222.4.1.214079.1.1.1
"DATA",176.801,523,4,0)
^176.8012P^1^1
"DATA",176.801,523,4,1,0)
4
"DATA",176.801,523,5)
L11
"DATA",176.801,524,0)
Liveborn Born In Hospital
"DATA",176.801,524,1)
2.16.840.1.113883.3.117.1.7.1.29
"DATA",176.801,524,4,0)
^176.8012P^3^3
"DATA",176.801,524,4,1,0)
36
"DATA",176.801,524,4,2,0)
93
"DATA",176.801,524,4,3,0)
4
"DATA",176.801,524,5)
LBIH29
"DATA",176.801,525,0)
Low Back Pain
"DATA",176.801,525,1)
2.16.840.1.113883.3.464.1003.113.12.1001
"DATA",176.801,525,4,0)
^176.8012P^1^1
"DATA",176.801,525,4,1,0)
67
"DATA",176.801,525,5)
LBP01
"DATA",176.801,526,0)
Low Molecular Weight Heparin
"DATA",176.801,526,1)
2.16.840.1.113883.3.117.1.7.1.219
"DATA",176.801,526,4,0)
^176.8012P^3^3
"DATA",176.801,526,4,1,0)
90
"DATA",176.801,526,4,2,0)
18
"DATA",176.801,526,4,3,0)
17
"DATA",176.801,526,5)
LMWH19
"DATA",176.801,527,0)
Low Risk
"DATA",176.801,527,1)
2.16.840.1.113883.3.117.1.7.1.400
"DATA",176.801,527,4,0)
^176.8012P^2^2
"DATA",176.801,527,4,1,0)
90
"DATA",176.801,527,4,2,0)
18
"DATA",176.801,527,5)
LR00
"DATA",176.801,528,0)
MRI of Lower Spine
"DATA",176.801,528,1)
2.16.840.1.113883.3.464.1003.113.12.1034
"DATA",176.801,528,4,0)
^176.8012P^1^1
"DATA",176.801,528,4,1,0)
67
"DATA",176.801,528,5)
MRILS34
"DATA",176.801,529,0)
Macroalbumin Test
"DATA",176.801,529,1)
2.16.840.1.113883.3.464.1003.109.12.1019
"DATA",176.801,529,4,0)
^176.8012P^1^1
"DATA",176.801,529,4,1,0)
34
"DATA",176.801,529,5)
MT19
"DATA",176.801,530,0)
Macular Edema Findings Absent
"DATA",176.801,530,1)
2.16.840.1.113883.3.526.3.1284
"DATA",176.801,530,5)
MEFA84
"DATA",176.801,531,0)
Macular Edema Findings Absent
"DATA",176.801,531,1)
2.16.840.1.113883.3.526.3.1286
"DATA",176.801,531,4,0)
^176.8012P^1^1
"DATA",176.801,531,4,1,0)
26
"DATA",176.801,531,5)
MEFA86
"DATA",176.801,532,0)
Macular Edema Findings Present
"DATA",176.801,532,1)
2.16.840.1.113883.3.526.3.1320
"DATA",176.801,532,5)
MEFP20
"DATA",176.801,533,0)
Macular Edema Findings Present
"DATA",176.801,533,1)
2.16.840.1.113883.3.526.3.1323
"DATA",176.801,533,4,0)
^176.8012P^1^1
"DATA",176.801,533,4,1,0)
26
"DATA",176.801,533,5)
MEFP23
"DATA",176.801,534,0)
Macular Exam
"DATA",176.801,534,1)
2.16.840.1.113883.3.526.3.1251
"DATA",176.801,534,4,0)
^176.8012P^2^2
"DATA",176.801,534,4,1,0)
27
"DATA",176.801,534,4,2,0)
26
"DATA",176.801,534,5)
ME51
"DATA",176.801,535,0)
Major Depression
"DATA",176.801,535,1)
2.16.840.1.113883.3.464.1003.105.12.1007
"DATA",176.801,535,4,0)
^176.8012P^3^3
"DATA",176.801,535,4,1,0)
46
"DATA",176.801,535,4,2,0)
42
"DATA",176.801,535,4,3,0)
61
"DATA",176.801,535,5)
MD07
"DATA",176.801,536,0)
Major Depressive Disorder New or Recurrent
"DATA",176.801,536,1)
2.16.840.1.113883.3.526.3.558
"DATA",176.801,536,4,0)
^176.8012P^2^2
"DATA",176.801,536,4,1,0)
44
"DATA",176.801,536,4,2,0)
30
"DATA",176.801,536,5)
MDDNR58
"DATA",176.801,537,0)
Male
"DATA",176.801,537,1)
2.16.840.1.113883.3.560.100.1
"DATA",176.801,537,4,0)
^176.8012P^3^3
"DATA",176.801,537,4,1,0)
1
"DATA",176.801,537,4,2,0)
5
"DATA",176.801,537,4,3,0)
9
"DATA",176.801,537,5)
M01
"DATA",176.801,538,0)
Malignant Neoplasm of Colon
"DATA",176.801,538,1)
2.16.840.1.113883.3.464.1003.108.12.1001
"DATA",176.801,538,4,0)
^176.8012P^1^1
"DATA",176.801,538,4,1,0)
63
"DATA",176.801,538,5)
MNC01
"DATA",176.801,539,0)
Malignant Neoplasm of Lymphatic Tissue
"DATA",176.801,539,1)
2.16.840.1.113883.3.464.1003.108.12.1021
"DATA",176.801,539,4,0)
^176.8012P^1^1
"DATA",176.801,539,4,1,0)
66
"DATA",176.801,539,5)
MNLT21
"DATA",176.801,540,0)
Mammogram
"DATA",176.801,540,1)
2.16.840.1.113883.3.464.1003.108.12.1018
"DATA",176.801,540,4,0)
^176.8012P^1^1
"DATA",176.801,540,4,1,0)
10
"DATA",176.801,540,5)
M18
"DATA",176.801,541,0)
Maternal Post Partum Depression Care
"DATA",176.801,541,1)
2.16.840.1.113883.3.464.1003.111.12.1013
"DATA",176.801,541,4,0)
^176.8012P^1^1
"DATA",176.801,541,4,1,0)
47
"DATA",176.801,541,5)
MPPDC13
"DATA",176.801,542,0)
Maternal Post Partum Depression Screening
"DATA",176.801,542,1)
2.16.840.1.113883.3.464.1003.111.12.1014
"DATA",176.801,542,4,0)
^176.8012P^1^1
"DATA",176.801,542,4,1,0)
47
"DATA",176.801,542,5)
MPPDS14
"DATA",176.801,543,0)
Maternal Reason
"DATA",176.801,543,1)
2.16.840.1.113883.3.117.1.7.1.84
"DATA",176.801,543,4,0)
^176.8012P^1^1
"DATA",176.801,543,4,1,0)
36
"DATA",176.801,543,5)
MR84
"DATA",176.801,544,0)
Measles
"DATA",176.801,544,1)
2.16.840.1.113883.3.464.1003.110.12.1053
"DATA",176.801,544,4,0)
^176.8012P^1^1
"DATA",176.801,544,4,1,0)
66
"DATA",176.801,544,5)
M53
"DATA",176.801,545,0)
Measles Antigen Test
"DATA",176.801,545,1)
2.16.840.1.113883.3.464.1003.198.12.1029
"DATA",176.801,545,4,0)
^176.8012P^1^1
"DATA",176.801,545,4,1,0)
66
"DATA",176.801,545,5)
MAT29
"DATA",176.801,546,0)
Measles, Mumps and Rubella (MMR) Vaccine
"DATA",176.801,546,1)
2.16.840.1.113883.3.464.1003.196.12.1224
"DATA",176.801,546,4,0)
^176.8012P^1^1
"DATA",176.801,546,4,1,0)
66
"DATA",176.801,546,5)
MMRMMRV24
"DATA",176.801,547,0)
Measles, Mumps and Rubella (MMR) Vaccine Administered
"DATA",176.801,547,1)
2.16.840.1.113883.3.464.1003.110.12.1031
"DATA",176.801,547,4,0)
^176.8012P^1^1
"DATA",176.801,547,4,1,0)
66
"DATA",176.801,547,5)
MMRMMRVA31
"DATA",176.801,548,0)
Medical Contraindication
"DATA",176.801,548,1)
2.16.840.1.113883.3.117.1.7.1.412
"DATA",176.801,548,4,0)
^176.8012P^1^1
"DATA",176.801,548,4,1,0)
17
"DATA",176.801,548,5)
MC12
"DATA",176.801,549,0)
Medical Induction of Labor
"DATA",176.801,549,1)
2.16.840.1.113883.3.117.1.7.1.288
"DATA",176.801,549,4,0)
^176.8012P^1^1
"DATA",176.801,549,4,1,0)
91
"DATA",176.801,549,5)
MIL88
"DATA",176.801,550,0)
Medical Reason
"DATA",176.801,550,1)
2.16.840.1.113883.3.117.1.7.1.473
"DATA",176.801,550,5)
MR73
"DATA",176.801,551,0)
Medical Reason
"DATA",176.801,551,1)
2.16.840.1.113883.3.526.2.313
"DATA",176.801,551,5)
MR13
"DATA",176.801,552,0)
Medical Reason
"DATA",176.801,552,1)
2.16.840.1.113883.3.526.3.1007
"DATA",176.801,552,4,0)
^176.8012P^9^9
"DATA",176.801,552,4,1,0)
2
"DATA",176.801,552,4,2,0)
15
"DATA",176.801,552,4,3,0)
32
"DATA",176.801,552,4,4,0)
22
"DATA",176.801,552,4,5,0)
37
"DATA",176.801,552,4,6,0)
90
"DATA",176.801,552,4,7,0)
18
"DATA",176.801,552,4,8,0)
13
"DATA",176.801,552,4,9,0)
49
"DATA",176.801,552,5)
MR07
"DATA",176.801,553,0)
Medical Reasons
"DATA",176.801,553,1)
2.16.840.1.113883.3.117.1.7.1.18
"DATA",176.801,553,5)
MR18
"DATA",176.801,554,0)
Medical Reasons
"DATA",176.801,554,1)
2.16.840.1.114222.4.1.214079.1.1.7
"DATA",176.801,554,4,0)
^176.8012P^1^1
"DATA",176.801,554,4,1,0)
79
"DATA",176.801,554,5)
MR17
"DATA",176.801,555,0)
Medical Reasons AMI
"DATA",176.801,555,1)
2.16.840.1.113883.3.666.5.3003
"DATA",176.801,555,4,0)
^176.8012P^1^1
"DATA",176.801,555,4,1,0)
86
"DATA",176.801,555,5)
MRAMI03
"DATA",176.801,556,0)
Medical or Other reason not done
"DATA",176.801,556,1)
2.16.840.1.113883.3.600.1.1502
"DATA",176.801,556,4,0)
^176.8012P^2^2
"DATA",176.801,556,4,1,0)
54
"DATA",176.801,556,4,2,0)
52
"DATA",176.801,556,5)
MO02
"DATA",176.801,557,0)
Medical reason
"DATA",176.801,557,1)
2.16.840.1.113883.3.600.1521
"DATA",176.801,557,4,0)
^176.8012P^1^1
"DATA",176.801,557,4,1,0)
58
"DATA",176.801,557,5)
M21
"DATA",176.801,558,0)
Medical reason contraindicated
"DATA",176.801,558,1)
2.16.840.1.113883.3.600.792
"DATA",176.801,558,4,0)
^176.8012P^1^1
"DATA",176.801,558,4,1,0)
53
"DATA",176.801,558,5)
M92
"DATA",176.801,559,0)
Medication Compliance Education
"DATA",176.801,559,1)
2.16.840.1.113883.3.117.1.7.1.301
"DATA",176.801,559,4,0)
^176.8012P^1^1
"DATA",176.801,559,4,1,0)
38
"DATA",176.801,559,5)
MCE01
"DATA",176.801,560,0)
Medications Encounter Code Set
"DATA",176.801,560,1)
2.16.840.1.113883.3.600.1.1834
"DATA",176.801,560,4,0)
^176.8012P^1^1
"DATA",176.801,560,4,1,0)
54
"DATA",176.801,560,5)
MECS34
"DATA",176.801,561,0)
Mental Disorders
"DATA",176.801,561,1)
2.16.840.1.113883.3.117.1.7.1.262
"DATA",176.801,561,4,0)
^176.8012P^1^1
"DATA",176.801,561,4,1,0)
18
"DATA",176.801,561,5)
MD62
"DATA",176.801,562,0)
Mental Health Diagnoses
"DATA",176.801,562,1)
2.16.840.1.113883.3.464.1003.105.12.1004
"DATA",176.801,562,4,0)
^176.8012P^1^1
"DATA",176.801,562,4,1,0)
33
"DATA",176.801,562,5)
MHD04
"DATA",176.801,563,0)
Metastatic Sites Common to Breast Cancer
"DATA",176.801,563,1)
2.16.840.1.113883.3.526.3.447
"DATA",176.801,563,4,0)
^176.8012P^1^1
"DATA",176.801,563,4,1,0)
65
"DATA",176.801,563,5)
MSCBC47
"DATA",176.801,564,0)
Metastatic Sites Common to Colon Cancer
"DATA",176.801,564,1)
2.16.840.1.113883.3.526.3.490
"DATA",176.801,564,4,0)
^176.8012P^1^1
"DATA",176.801,564,4,1,0)
43
"DATA",176.801,564,5)
MSCCC90
"DATA",176.801,565,0)
Microalbumin Test
"DATA",176.801,565,1)
2.16.840.1.113883.3.464.1003.109.12.1005
"DATA",176.801,565,4,0)
^176.8012P^1^1
"DATA",176.801,565,4,1,0)
34
"DATA",176.801,565,5)
MT05
"DATA",176.801,566,0)
Moderate or Severe Impairment, Better Eye, Profound Impairment Lesser Eye
"DATA",176.801,566,1)
2.16.840.1.113883.3.526.3.1464
"DATA",176.801,566,4,0)
^176.8012P^1^1
"DATA",176.801,566,4,1,0)
19
"DATA",176.801,566,5)
MSIBEPILE64
"DATA",176.801,567,0)
Moderate or Severe LVSD
"DATA",176.801,567,1)
2.16.840.1.113883.3.526.3.1090
"DATA",176.801,567,4,0)
^176.8012P^3^3
"DATA",176.801,567,4,1,0)
24
"DATA",176.801,567,4,2,0)
39
"DATA",176.801,567,4,3,0)
41
"DATA",176.801,567,5)
MSLVSD90
"DATA",176.801,568,0)
Moderation of ETOH Consumption Recommendation
"DATA",176.801,568,1)
2.16.840.1.113883.3.600.823
"DATA",176.801,568,4,0)
^176.8012P^1^1
"DATA",176.801,568,4,1,0)
58
"DATA",176.801,568,5)
METOHCR23
"DATA",176.801,569,0)
Mumps
"DATA",176.801,569,1)
2.16.840.1.113883.3.464.1003.110.12.1032
"DATA",176.801,569,4,0)
^176.8012P^1^1
"DATA",176.801,569,4,1,0)
66
"DATA",176.801,569,5)
M32
"DATA",176.801,570,0)
Mumps Antigen Test
"DATA",176.801,570,1)
2.16.840.1.113883.3.464.1003.198.12.1028
"DATA",176.801,570,4,0)
^176.8012P^1^1
"DATA",176.801,570,4,1,0)
66
"DATA",176.801,570,5)
MAT28
"DATA",176.801,571,0)
Myocardial Infarction
"DATA",176.801,571,1)
2.16.840.1.113883.3.526.3.403
"DATA",176.801,571,4,0)
^176.8012P^1^1
"DATA",176.801,571,4,1,0)
39
"DATA",176.801,571,5)
MI03
"DATA",176.801,572,0)
Myomectomy
"DATA",176.801,572,1)
2.16.840.1.113883.3.117.1.7.1.422
"DATA",176.801,572,4,0)
^176.8012P^1^1
"DATA",176.801,572,4,1,0)
91
"DATA",176.801,572,5)
M22
"DATA",176.801,573,0)
Narcolepsy
"DATA",176.801,573,1)
2.16.840.1.113883.3.464.1003.114.12.1011
"DATA",176.801,573,4,0)
^176.8012P^1^1
"DATA",176.801,573,4,1,0)
33
"DATA",176.801,573,5)
N11
"DATA",176.801,574,0)
National Institute of Health Stroke Scale
"DATA",176.801,574,1)
2.16.840.1.113883.3.117.1.7.1.269
"DATA",176.801,574,4,0)
^176.8012P^1^1
"DATA",176.801,574,4,1,0)
15
"DATA",176.801,574,5)
NIHSS69
"DATA",176.801,575,0)
Negative Depression Screening
"DATA",176.801,575,1)
2.16.840.1.113883.3.600.794
"DATA",176.801,575,4,0)
^176.8012P^1^1
"DATA",176.801,575,4,1,0)
53
"DATA",176.801,575,5)
NDS94
"DATA",176.801,576,0)
Negative Finding
"DATA",176.801,576,1)
2.16.840.1.113883.3.464.1003.195.12.1002
"DATA",176.801,576,4,0)
^176.8012P^1^1
"DATA",176.801,576,4,1,0)
80
"DATA",176.801,576,5)
NF02
"DATA",176.801,577,0)
Neonatal Death SM-CT
"DATA",176.801,577,1)
2.16.840.1.113883.3.666.5.1618
"DATA",176.801,577,4,0)
^176.8012P^1^1
"DATA",176.801,577,4,1,0)
93
"DATA",176.801,577,5)
NDSNOMEDCT18
"DATA",176.801,578,0)
Neonatal Intensive Care Unit (NICU)
"DATA",176.801,578,1)
2.16.840.1.113883.3.117.1.7.1.75
"DATA",176.801,578,4,0)
^176.8012P^1^1
"DATA",176.801,578,4,1,0)
36
"DATA",176.801,578,5)
NICUNICU75
"DATA",176.801,579,0)
Neurologic Complications Group
"DATA",176.801,579,1)
2.16.840.1.113883.3.666.5.1591
"DATA",176.801,579,4,0)
^176.8012P^1^1
"DATA",176.801,579,4,1,0)
93
"DATA",176.801,579,5)
NCG91
"DATA",176.801,580,0)
Neurologic Procedure Group
"DATA",176.801,580,1)
2.16.840.1.113883.3.666.5.1592
"DATA",176.801,580,4,0)
^176.8012P^1^1
"DATA",176.801,580,4,1,0)
93
"DATA",176.801,580,5)
NPG92
"DATA",176.801,581,0)
Neurologic Symptoms of Stroke
"DATA",176.801,581,1)
2.16.840.1.113883.3.117.1.7.1.399
"DATA",176.801,581,4,0)
^176.8012P^1^1
"DATA",176.801,581,4,1,0)
15
"DATA",176.801,581,5)
NSS99
"DATA",176.801,582,0)
Neurologic impairment
"DATA",176.801,582,1)
2.16.840.1.113883.3.464.1003.114.12.1012
"DATA",176.801,582,4,0)
^176.8012P^1^1
"DATA",176.801,582,4,1,0)
67
"DATA",176.801,582,5)
N12
"DATA",176.801,583,0)
Newborn Affected by Placenta or Abruption Group
"DATA",176.801,583,1)
2.16.840.1.113883.3.666.5.1568
"DATA",176.801,583,4,0)
^176.8012P^1^1
"DATA",176.801,583,4,1,0)
93
"DATA",176.801,583,5)
NAPAG68
"DATA",176.801,584,0)
Newborn Hearing Screen Left
"DATA",176.801,584,1)
2.16.840.1.114222.4.1.214079.1.1.3
"DATA",176.801,584,4,0)
^176.8012P^1^1
"DATA",176.801,584,4,1,0)
4
"DATA",176.801,584,5)
NHSL13
"DATA",176.801,585,0)
Newborn Hearing Screen Right
"DATA",176.801,585,1)
2.16.840.1.114222.4.1.214079.1.1.4
"DATA",176.801,585,4,0)
^176.8012P^1^1
"DATA",176.801,585,4,1,0)
4
"DATA",176.801,585,5)
NHSR14
"DATA",176.801,586,0)
Non-Elective Inpatient Encounter
"DATA",176.801,586,1)
2.16.840.1.113883.3.117.1.7.1.424
"DATA",176.801,586,4,0)
^176.8012P^7^7
"DATA",176.801,586,4,1,0)
2
"DATA",176.801,586,4,2,0)
15
"DATA",176.801,586,4,3,0)
22
"DATA",176.801,586,4,4,0)
37
"DATA",176.801,586,4,5,0)
14
"DATA",176.801,586,4,6,0)
13
"DATA",176.801,586,4,7,0)
49
"DATA",176.801,586,5)
NEIE24
"DATA",176.801,587,0)
Nursing Facility Visit
"DATA",176.801,587,1)
2.16.840.1.113883.3.464.1003.101.12.1012
"DATA",176.801,587,4,0)
^176.8012P^9^9
"DATA",176.801,587,4,1,0)
35
"DATA",176.801,587,4,2,0)
27
"DATA",176.801,587,4,3,0)
71
"DATA",176.801,587,4,4,0)
24
"DATA",176.801,587,4,5,0)
81
"DATA",176.801,587,4,6,0)
41
"DATA",176.801,587,4,7,0)
26
"DATA",176.801,587,4,8,0)
39
"DATA",176.801,587,4,9,0)
59
"DATA",176.801,587,5)
NFV12
"DATA",176.801,588,0)
Nursing Home
"DATA",176.801,588,1)
2.16.840.1.113883.3.67.1.101.11.722
"DATA",176.801,588,4,0)
^176.8012P^2^2
"DATA",176.801,588,4,1,0)
42
"DATA",176.801,588,4,2,0)
61
"DATA",176.801,588,5)
NH22
"DATA",176.801,589,0)
Nystagmus and other Irregular Eye Movements
"DATA",176.801,589,1)
2.16.840.1.113883.3.526.3.1465
"DATA",176.801,589,4,0)
^176.8012P^1^1
"DATA",176.801,589,4,1,0)
19
"DATA",176.801,589,5)
NIEM65
"DATA",176.801,590,0)
ONC Administrative Sex
"DATA",176.801,590,1)
2.16.840.1.113762.1.4.1
"DATA",176.801,590,4,0)
^176.8012P^93^93
"DATA",176.801,590,4,1,0)
6
"DATA",176.801,590,4,2,0)
16
"DATA",176.801,590,4,3,0)
78
"DATA",176.801,590,4,4,0)
65
"DATA",176.801,590,4,5,0)
50
"DATA",176.801,590,4,6,0)
2
"DATA",176.801,590,4,7,0)
49
"DATA",176.801,590,4,8,0)
18
"DATA",176.801,590,4,9,0)
8
"DATA",176.801,590,4,10,0)
15
"DATA",176.801,590,4,11,0)
93
"DATA",176.801,590,4,12,0)
35
"DATA",176.801,590,4,13,0)
1
"DATA",176.801,590,4,14,0)
84
"DATA",176.801,590,4,15,0)
25
"DATA",176.801,590,4,16,0)
44
"DATA",176.801,590,4,17,0)
13
"DATA",176.801,590,4,18,0)
51
"DATA",176.801,590,4,19,0)
80
"DATA",176.801,590,4,20,0)
86
"DATA",176.801,590,4,21,0)
43
"DATA",176.801,590,4,22,0)
82
"DATA",176.801,590,4,23,0)
23
"DATA",176.801,590,4,24,0)
53
"DATA",176.801,590,4,25,0)
92
"DATA",176.801,590,4,26,0)
33
"DATA",176.801,590,4,27,0)
54
"DATA",176.801,590,4,28,0)
39
"DATA",176.801,590,4,29,0)
66
"DATA",176.801,590,4,30,0)
75
"DATA",176.801,590,4,31,0)
58
"DATA",176.801,590,4,32,0)
45
"DATA",176.801,590,4,33,0)
19
"DATA",176.801,590,4,34,0)
4
"DATA",176.801,590,4,35,0)
48
"DATA",176.801,590,4,36,0)
90
"DATA",176.801,590,4,37,0)
10
"DATA",176.801,590,4,38,0)
77
"DATA",176.801,590,4,39,0)
69
"DATA",176.801,590,4,40,0)
32
"DATA",176.801,590,4,41,0)
38
"DATA",176.801,590,4,42,0)
79
"DATA",176.801,590,4,43,0)
72
"DATA",176.801,590,4,44,0)
87
"DATA",176.801,590,4,45,0)
7
"DATA",176.801,590,4,46,0)
71
"DATA",176.801,590,4,47,0)
74
"DATA",176.801,590,4,48,0)
73
"DATA",176.801,590,4,49,0)
83
"DATA",176.801,590,4,50,0)
63
"DATA",176.801,590,4,51,0)
9
"DATA",176.801,590,4,52,0)
55
"DATA",176.801,590,4,53,0)
26
"DATA",176.801,590,4,54,0)
52
"DATA",176.801,590,4,55,0)
24
"DATA",176.801,590,4,56,0)
5
"DATA",176.801,590,4,57,0)
70
"DATA",176.801,590,4,58,0)
14
"DATA",176.801,590,4,59,0)
61
"DATA",176.801,590,4,60,0)
81
"DATA",176.801,590,4,61,0)
36
"DATA",176.801,590,4,62,0)
59
"DATA",176.801,590,4,63,0)
20
"DATA",176.801,590,4,64,0)
76
"DATA",176.801,590,4,65,0)
56
"DATA",176.801,590,4,66,0)
30
"DATA",176.801,590,4,67,0)
22
"DATA",176.801,590,4,68,0)
42
"DATA",176.801,590,4,69,0)
57
"DATA",176.801,590,4,70,0)
37
"DATA",176.801,590,4,71,0)
67
"DATA",176.801,590,4,72,0)
91
"DATA",176.801,590,4,73,0)
17
"DATA",176.801,590,4,74,0)
21
"DATA",176.801,590,4,75,0)
40
"DATA",176.801,590,4,76,0)
68
"DATA",176.801,590,4,77,0)
88
"DATA",176.801,590,4,78,0)
11
"DATA",176.801,590,4,79,0)
41
"DATA",176.801,590,4,80,0)
64
"DATA",176.801,590,4,81,0)
31
"DATA",176.801,590,4,82,0)
46
"DATA",176.801,590,4,83,0)
60
"DATA",176.801,590,4,84,0)
12
"DATA",176.801,590,4,85,0)
85
"DATA",176.801,590,4,86,0)
3
"DATA",176.801,590,4,87,0)
28
"DATA",176.801,590,4,88,0)
34
"DATA",176.801,590,4,89,0)
62
"DATA",176.801,590,4,90,0)
47
"DATA",176.801,590,4,91,0)
27
"DATA",176.801,590,4,92,0)
89
"DATA",176.801,590,4,93,0)
29
"DATA",176.801,590,5)
ONCAS41
"DATA",176.801,591,0)
Obstetrics
"DATA",176.801,591,1)
2.16.840.1.113883.3.117.1.7.1.263
"DATA",176.801,591,4,0)
^176.8012P^2^2
"DATA",176.801,591,4,1,0)
90
"DATA",176.801,591,4,2,0)
18
"DATA",176.801,591,5)
O63
"DATA",176.801,592,0)
Obstetrics VTE
"DATA",176.801,592,1)
2.16.840.1.113883.3.117.1.7.1.264
"DATA",176.801,592,4,0)
^176.8012P^6^6
"DATA",176.801,592,4,1,0)
32
"DATA",176.801,592,4,2,0)
38
"DATA",176.801,592,4,3,0)
72
"DATA",176.801,592,4,4,0)
90
"DATA",176.801,592,4,5,0)
18
"DATA",176.801,592,4,6,0)
17
"DATA",176.801,592,5)
OVTE64
"DATA",176.801,593,0)
Occupational Therapy Evaluation
"DATA",176.801,593,1)
2.16.840.1.113883.3.526.3.1011
"DATA",176.801,593,4,0)
^176.8012P^2^2
"DATA",176.801,593,4,1,0)
84
"DATA",176.801,593,4,2,0)
35
"DATA",176.801,593,5)
OTE11
"DATA",176.801,594,0)
Office Visit
"DATA",176.801,594,1)
2.16.840.1.113883.3.464.1003.101.12.1001
"DATA",176.801,594,4,0)
^176.8012P^47^47
"DATA",176.801,594,4,1,0)
81
"DATA",176.801,594,4,2,0)
88
"DATA",176.801,594,4,3,0)
70
"DATA",176.801,594,4,4,0)
39
"DATA",176.801,594,4,5,0)
31
"DATA",176.801,594,4,6,0)
43
"DATA",176.801,594,4,7,0)
71
"DATA",176.801,594,4,8,0)
77
"DATA",176.801,594,4,9,0)
85
"DATA",176.801,594,4,10,0)
76
"DATA",176.801,594,4,11,0)
27
"DATA",176.801,594,4,12,0)
59
"DATA",176.801,594,4,13,0)
29
"DATA",176.801,594,4,14,0)
61
"DATA",176.801,594,4,15,0)
33
"DATA",176.801,594,4,16,0)
67
"DATA",176.801,594,4,17,0)
23
"DATA",176.801,594,4,18,0)
44
"DATA",176.801,594,4,19,0)
7
"DATA",176.801,594,4,20,0)
75
"DATA",176.801,594,4,21,0)
8
"DATA",176.801,594,4,22,0)
80
"DATA",176.801,594,4,23,0)
41
"DATA",176.801,594,4,24,0)
64
"DATA",176.801,594,4,25,0)
42
"DATA",176.801,594,4,26,0)
63
"DATA",176.801,594,4,27,0)
10
"DATA",176.801,594,4,28,0)
3
"DATA",176.801,594,4,29,0)
34
"DATA",176.801,594,4,30,0)
84
"DATA",176.801,594,4,31,0)
24
"DATA",176.801,594,4,32,0)
26
"DATA",176.801,594,4,33,0)
16
"DATA",176.801,594,4,34,0)
6
"DATA",176.801,594,4,35,0)
30
"DATA",176.801,594,4,36,0)
35
"DATA",176.801,594,4,37,0)
28
"DATA",176.801,594,4,38,0)
73
"DATA",176.801,594,4,39,0)
65
"DATA",176.801,594,4,40,0)
55
"DATA",176.801,594,4,41,0)
60
"DATA",176.801,594,4,42,0)
62
"DATA",176.801,594,4,43,0)
66
"DATA",176.801,594,4,44,0)
87
"DATA",176.801,594,4,45,0)
46
"DATA",176.801,594,4,46,0)
25
"DATA",176.801,594,4,47,0)
47
"DATA",176.801,594,5)
OV01
"DATA",176.801,595,0)
Open Wound of Eyeball
"DATA",176.801,595,1)
2.16.840.1.113883.3.526.3.1430
"DATA",176.801,595,4,0)
^176.8012P^2^2
"DATA",176.801,595,4,1,0)
57
"DATA",176.801,595,4,2,0)
19
"DATA",176.801,595,5)
OWE30
"DATA",176.801,596,0)
Ophthalmological Services
"DATA",176.801,596,1)
2.16.840.1.113883.3.526.3.1285
"DATA",176.801,596,4,0)
^176.8012P^4^4
"DATA",176.801,596,4,1,0)
27
"DATA",176.801,596,4,2,0)
81
"DATA",176.801,596,4,3,0)
84
"DATA",176.801,596,4,4,0)
26
"DATA",176.801,596,5)
OS85
"DATA",176.801,597,0)
Optic Atrophy
"DATA",176.801,597,1)
2.16.840.1.113883.3.526.3.1466
"DATA",176.801,597,4,0)
^176.8012P^1^1
"DATA",176.801,597,4,1,0)
19
"DATA",176.801,597,5)
OA66
"DATA",176.801,598,0)
Optic Disc Exam for Structural Abnormalities
"DATA",176.801,598,1)
2.16.840.1.113883.3.526.3.1334
"DATA",176.801,598,4,0)
^176.8012P^1^1
"DATA",176.801,598,4,1,0)
81
"DATA",176.801,598,5)
ODESA34
"DATA",176.801,599,0)
Optic Neuritis
"DATA",176.801,599,1)
2.16.840.1.113883.3.526.3.1467
"DATA",176.801,599,4,0)
^176.8012P^1^1
"DATA",176.801,599,4,1,0)
19
"DATA",176.801,599,5)
ON67
"DATA",176.801,600,0)
Oral Factor Xa Inhibitor
"DATA",176.801,600,1)
2.16.840.1.113883.3.117.1.7.1.134
"DATA",176.801,600,4,0)
^176.8012P^4^4
"DATA",176.801,600,4,1,0)
32
"DATA",176.801,600,4,2,0)
90
"DATA",176.801,600,4,3,0)
18
"DATA",176.801,600,4,4,0)
17
"DATA",176.801,600,5)
OFXI34
"DATA",176.801,601,0)
Other Background Retinopathy and Retinal Vascular Changes
"DATA",176.801,601,1)
2.16.840.1.113883.3.526.3.1469
"DATA",176.801,601,4,0)
^176.8012P^1^1
"DATA",176.801,601,4,1,0)
19
"DATA",176.801,601,5)
OBRRVC69
"DATA",176.801,602,0)
Other Corneal Deformities
"DATA",176.801,602,1)
2.16.840.1.113883.3.526.3.1470
"DATA",176.801,602,4,0)
^176.8012P^1^1
"DATA",176.801,602,4,1,0)
19
"DATA",176.801,602,5)
OCD70
"DATA",176.801,603,0)
Other Disorders of Optic Nerve
"DATA",176.801,603,1)
2.16.840.1.113883.3.526.3.1471
"DATA",176.801,603,4,0)
^176.8012P^1^1
"DATA",176.801,603,4,1,0)
19
"DATA",176.801,603,5)
ODON71
"DATA",176.801,604,0)
Other Disorders of Sclera
"DATA",176.801,604,1)
2.16.840.1.113883.3.526.3.1472
"DATA",176.801,604,4,0)
^176.8012P^1^1
"DATA",176.801,604,4,1,0)
19
"DATA",176.801,604,5)
ODS72
"DATA",176.801,605,0)
Other Endophthalmitis
"DATA",176.801,605,1)
2.16.840.1.113883.3.526.3.1473
"DATA",176.801,605,4,0)
^176.8012P^1^1
"DATA",176.801,605,4,1,0)
19
"DATA",176.801,605,5)
OE73
"DATA",176.801,606,0)
Other Female Reproductive Conditions
"DATA",176.801,606,1)
2.16.840.1.113883.3.464.1003.111.12.1006
"DATA",176.801,606,4,0)
^176.8012P^1^1
"DATA",176.801,606,4,1,0)
77
"DATA",176.801,606,5)
OFRC06
"DATA",176.801,607,0)
Other Proliferative Retinopathy
"DATA",176.801,607,1)
2.16.840.1.113883.3.526.3.1480
"DATA",176.801,607,4,0)
^176.8012P^1^1
"DATA",176.801,607,4,1,0)
19
"DATA",176.801,607,5)
OPR80
"DATA",176.801,608,0)
Other Retinal Disorders
"DATA",176.801,608,1)
2.16.840.1.113883.3.526.3.1474
"DATA",176.801,608,4,0)
^176.8012P^1^1
"DATA",176.801,608,4,1,0)
19
"DATA",176.801,608,5)
ORD74
"DATA",176.801,609,0)
Other Services Related to Dialysis
"DATA",176.801,609,1)
2.16.840.1.113883.3.464.1003.109.12.1015
"DATA",176.801,609,4,0)
^176.8012P^2^2
"DATA",176.801,609,4,1,0)
34
"DATA",176.801,609,4,2,0)
64
"DATA",176.801,609,5)
OSRD15
"DATA",176.801,610,0)
Other and Unspecified forms of Chorioretinitis and Retinochoroiditis
"DATA",176.801,610,1)
2.16.840.1.113883.3.526.3.1468
"DATA",176.801,610,4,0)
^176.8012P^1^1
"DATA",176.801,610,4,1,0)
19
"DATA",176.801,610,5)
OUCR68
"DATA",176.801,611,0)
Outpatient Consultation
"DATA",176.801,611,1)
2.16.840.1.113883.3.464.1003.101.12.1008
"DATA",176.801,611,4,0)
^176.8012P^14^14
"DATA",176.801,611,4,1,0)
30
"DATA",176.801,611,4,2,0)
64
"DATA",176.801,611,4,3,0)
16
"DATA",176.801,611,4,4,0)
27
"DATA",176.801,611,4,5,0)
33
"DATA",176.801,611,4,6,0)
41
"DATA",176.801,611,4,7,0)
24
"DATA",176.801,611,4,8,0)
26
"DATA",176.801,611,4,9,0)
44
"DATA",176.801,611,4,10,0)
73
"DATA",176.801,611,4,11,0)
81
"DATA",176.801,611,4,12,0)
39
"DATA",176.801,611,4,13,0)
59
"DATA",176.801,611,4,14,0)
35
"DATA",176.801,611,5)
OC08
"DATA",176.801,612,0)
PHQ-9 Tool
"DATA",176.801,612,1)
2.16.840.1.113883.3.67.1.101.11.723
"DATA",176.801,612,4,0)
^176.8012P^2^2
"DATA",176.801,612,4,1,0)
61
"DATA",176.801,612,4,2,0)
42
"DATA",176.801,612,5)
PHQ9T23
"DATA",176.801,613,0)
Pain Related to Prostate Cancer
"DATA",176.801,613,1)
2.16.840.1.113883.3.526.3.451
"DATA",176.801,613,4,0)
^176.8012P^1^1
"DATA",176.801,613,4,1,0)
9
"DATA",176.801,613,5)
PRPC51
"DATA",176.801,614,0)
Palliative Care
"DATA",176.801,614,1)
2.16.840.1.113883.3.526.2.1076
"DATA",176.801,614,5)
PC76
"DATA",176.801,615,0)
Palliative Care
"DATA",176.801,615,1)
2.16.840.1.113883.3.526.3.1024
"DATA",176.801,615,5)
PC24
"DATA",176.801,616,0)
Palliative Care
"DATA",176.801,616,1)
2.16.840.1.113883.3.600.1.1579
"DATA",176.801,616,4,0)
^176.8012P^11^11
"DATA",176.801,616,4,1,0)
2
"DATA",176.801,616,4,2,0)
32
"DATA",176.801,616,4,3,0)
22
"DATA",176.801,616,4,4,0)
37
"DATA",176.801,616,4,5,0)
72
"DATA",176.801,616,4,6,0)
90
"DATA",176.801,616,4,7,0)
18
"DATA",176.801,616,4,8,0)
14
"DATA",176.801,616,4,9,0)
13
"DATA",176.801,616,4,10,0)
17
"DATA",176.801,616,4,11,0)
49
"DATA",176.801,616,5)
PC79
"DATA",176.801,617,0)
Pap Test
"DATA",176.801,617,1)
2.16.840.1.113883.3.464.1003.108.12.1017
"DATA",176.801,617,4,0)
^176.8012P^2^2
"DATA",176.801,617,4,1,0)
77
"DATA",176.801,617,4,2,0)
23
"DATA",176.801,617,5)
PT17
"DATA",176.801,618,0)
Paracentesis Procedures
"DATA",176.801,618,1)
2.16.840.1.113883.3.526.3.1431
"DATA",176.801,618,4,0)
^176.8012P^1^1
"DATA",176.801,618,4,1,0)
57
"DATA",176.801,618,5)
PP31
"DATA",176.801,619,0)
Paralytic Agents
"DATA",176.801,619,1)
2.16.840.1.113883.3.666.5.2129
"DATA",176.801,619,4,0)
^176.8012P^1^1
"DATA",176.801,619,4,1,0)
79
"DATA",176.801,619,5)
PA29
"DATA",176.801,620,0)
Parental Refusal
"DATA",176.801,620,1)
2.16.840.1.113883.3.117.1.7.1.133
"DATA",176.801,620,4,0)
^176.8012P^1^1
"DATA",176.801,620,4,1,0)
36
"DATA",176.801,620,5)
PR33
"DATA",176.801,621,0)
Parenteral Anticoagulant
"DATA",176.801,621,1)
2.16.840.1.113883.3.117.1.7.1.266
"DATA",176.801,621,4,0)
^176.8012P^1^1
"DATA",176.801,621,4,1,0)
32
"DATA",176.801,621,5)
PA66
"DATA",176.801,622,0)
Parenteral Infusion
"DATA",176.801,622,1)
2.16.840.1.113883.3.117.1.7.1.38
"DATA",176.801,622,4,0)
^176.8012P^1^1
"DATA",176.801,622,4,1,0)
36
"DATA",176.801,622,5)
PI38
"DATA",176.801,623,0)
Pass Or Refer
"DATA",176.801,623,1)
2.16.840.1.114222.4.1.214079.1.1.6
"DATA",176.801,623,4,0)
^176.8012P^1^1
"DATA",176.801,623,4,1,0)
4
"DATA",176.801,623,5)
POR16
"DATA",176.801,624,0)
Pathologic Myopia
"DATA",176.801,624,1)
2.16.840.1.113883.3.526.3.1432
"DATA",176.801,624,4,0)
^176.8012P^2^2
"DATA",176.801,624,4,1,0)
19
"DATA",176.801,624,4,2,0)
57
"DATA",176.801,624,5)
PM32
"DATA",176.801,625,0)
Patient Expired
"DATA",176.801,625,1)
2.16.840.1.113883.3.117.1.7.1.309
"DATA",176.801,625,5)
PE09
"DATA",176.801,626,0)
Patient Expired
"DATA",176.801,626,1)
2.16.840.1.113883.3.117.1.7.1.86
"DATA",176.801,626,5)
PE86
"DATA",176.801,627,0)
Patient Expired
"DATA",176.801,627,1)
2.16.840.1.113883.3.67.1.101.1.78
"DATA",176.801,627,4,0)
^176.8012P^7^7
"DATA",176.801,627,4,1,0)
2
"DATA",176.801,627,4,2,0)
32
"DATA",176.801,627,4,3,0)
72
"DATA",176.801,627,4,4,0)
36
"DATA",176.801,627,4,5,0)
22
"DATA",176.801,627,4,6,0)
37
"DATA",176.801,627,4,7,0)
13
"DATA",176.801,627,5)
PE78
"DATA",176.801,628,0)
Patient Provider Interaction
"DATA",176.801,628,1)
2.16.840.1.113883.3.526.3.1012
"DATA",176.801,628,4,0)
^176.8012P^12^12
"DATA",176.801,628,4,1,0)
43
"DATA",176.801,628,4,2,0)
26
"DATA",176.801,628,4,3,0)
44
"DATA",176.801,628,4,4,0)
81
"DATA",176.801,628,4,5,0)
35
"DATA",176.801,628,4,6,0)
65
"DATA",176.801,628,4,7,0)
24
"DATA",176.801,628,4,8,0)
59
"DATA",176.801,628,4,9,0)
30
"DATA",176.801,628,4,10,0)
27
"DATA",176.801,628,4,11,0)
41
"DATA",176.801,628,4,12,0)
39
"DATA",176.801,628,5)
PPI12
"DATA",176.801,629,0)
Patient Reason
"DATA",176.801,629,1)
2.16.840.1.113883.3.526.2.311
"DATA",176.801,629,5)
PR11
"DATA",176.801,630,0)
Patient Reason
"DATA",176.801,630,1)
2.16.840.1.113883.3.526.3.1008
"DATA",176.801,630,4,0)
^176.8012P^3^3
"DATA",176.801,630,4,1,0)
69
"DATA",176.801,630,4,2,0)
45
"DATA",176.801,630,4,3,0)
48
"DATA",176.801,630,5)
PR08
"DATA",176.801,631,0)
Patient Reason Refused
"DATA",176.801,631,1)
2.16.840.1.113883.3.600.1.1503
"DATA",176.801,631,4,0)
^176.8012P^1^1
"DATA",176.801,631,4,1,0)
52
"DATA",176.801,631,5)
PRR03
"DATA",176.801,632,0)
Patient Reason refused
"DATA",176.801,632,1)
2.16.840.1.113883.3.600.791
"DATA",176.801,632,4,0)
^176.8012P^4^4
"DATA",176.801,632,4,1,0)
1
"DATA",176.801,632,4,2,0)
53
"DATA",176.801,632,4,3,0)
58
"DATA",176.801,632,4,4,0)
5
"DATA",176.801,632,5)
PR91
"DATA",176.801,633,0)
Patient Reasons AMI
"DATA",176.801,633,1)
2.16.840.1.113883.3.666.5.3004
"DATA",176.801,633,4,0)
^176.8012P^1^1
"DATA",176.801,633,4,1,0)
86
"DATA",176.801,633,5)
PRAMI04
"DATA",176.801,634,0)
Patient Refusal
"DATA",176.801,634,1)
2.16.840.1.113883.3.117.1.7.1.93
"DATA",176.801,634,4,0)
^176.8012P^12^12
"DATA",176.801,634,4,1,0)
2
"DATA",176.801,634,4,2,0)
15
"DATA",176.801,634,4,3,0)
32
"DATA",176.801,634,4,4,0)
38
"DATA",176.801,634,4,5,0)
22
"DATA",176.801,634,4,6,0)
37
"DATA",176.801,634,4,7,0)
90
"DATA",176.801,634,4,8,0)
18
"DATA",176.801,634,4,9,0)
14
"DATA",176.801,634,4,10,0)
13
"DATA",176.801,634,4,11,0)
17
"DATA",176.801,634,4,12,0)
49
"DATA",176.801,634,5)
PR93
"DATA",176.801,635,0)
Patient Request
"DATA",176.801,635,1)
2.16.840.1.113883.3.600.1564
"DATA",176.801,635,4,0)
^176.8012P^2^2
"DATA",176.801,635,4,1,0)
5
"DATA",176.801,635,4,2,0)
1
"DATA",176.801,635,5)
PR64
"DATA",176.801,636,0)
Patient not ambulatory
"DATA",176.801,636,1)
2.16.840.1.113883.3.464.1003.118.12.1009
"DATA",176.801,636,4,0)
^176.8012P^1^1
"DATA",176.801,636,4,1,0)
71
"DATA",176.801,636,5)
P09
"DATA",176.801,637,0)
Patient reason for ACE inhibitor or ARB decline
"DATA",176.801,637,1)
2.16.840.1.113883.3.526.3.1140
"DATA",176.801,637,4,0)
^176.8012P^1^1
"DATA",176.801,637,4,1,0)
24
"DATA",176.801,637,5)
PACEARB40
"DATA",176.801,638,0)
Payer
"DATA",176.801,638,1)
2.16.840.1.114222.4.11.3591
"DATA",176.801,638,4,0)
^176.8012P^93^93
"DATA",176.801,638,4,1,0)
72
"DATA",176.801,638,4,2,0)
24
"DATA",176.801,638,4,3,0)
9
"DATA",176.801,638,4,4,0)
34
"DATA",176.801,638,4,5,0)
82
"DATA",176.801,638,4,6,0)
85
"DATA",176.801,638,4,7,0)
11
"DATA",176.801,638,4,8,0)
62
"DATA",176.801,638,4,9,0)
19
"DATA",176.801,638,4,10,0)
2
"DATA",176.801,638,4,11,0)
5
"DATA",176.801,638,4,12,0)
40
"DATA",176.801,638,4,13,0)
55
"DATA",176.801,638,4,14,0)
49
"DATA",176.801,638,4,15,0)
87
"DATA",176.801,638,4,16,0)
81
"DATA",176.801,638,4,17,0)
66
"DATA",176.801,638,4,18,0)
12
"DATA",176.801,638,4,19,0)
7
"DATA",176.801,638,4,20,0)
53
"DATA",176.801,638,4,21,0)
71
"DATA",176.801,638,4,22,0)
15
"DATA",176.801,638,4,23,0)
64
"DATA",176.801,638,4,24,0)
54
"DATA",176.801,638,4,25,0)
41
"DATA",176.801,638,4,26,0)
74
"DATA",176.801,638,4,27,0)
69
"DATA",176.801,638,4,28,0)
6
"DATA",176.801,638,4,29,0)
38
"DATA",176.801,638,4,30,0)
91
"DATA",176.801,638,4,31,0)
42
"DATA",176.801,638,4,32,0)
8
"DATA",176.801,638,4,33,0)
3
"DATA",176.801,638,4,34,0)
65
"DATA",176.801,638,4,35,0)
76
"DATA",176.801,638,4,36,0)
68
"DATA",176.801,638,4,37,0)
45
"DATA",176.801,638,4,38,0)
32
"DATA",176.801,638,4,39,0)
43
"DATA",176.801,638,4,40,0)
25
"DATA",176.801,638,4,41,0)
27
"DATA",176.801,638,4,42,0)
84
"DATA",176.801,638,4,43,0)
50
"DATA",176.801,638,4,44,0)
60
"DATA",176.801,638,4,45,0)
47
"DATA",176.801,638,4,46,0)
28
"DATA",176.801,638,4,47,0)
90
"DATA",176.801,638,4,48,0)
14
"DATA",176.801,638,4,49,0)
92
"DATA",176.801,638,4,50,0)
20
"DATA",176.801,638,4,51,0)
93
"DATA",176.801,638,4,52,0)
17
"DATA",176.801,638,4,53,0)
67
"DATA",176.801,638,4,54,0)
78
"DATA",176.801,638,4,55,0)
35
"DATA",176.801,638,4,56,0)
30
"DATA",176.801,638,4,57,0)
70
"DATA",176.801,638,4,58,0)
46
"DATA",176.801,638,4,59,0)
61
"DATA",176.801,638,4,60,0)
36
"DATA",176.801,638,4,61,0)
39
"DATA",176.801,638,4,62,0)
73
"DATA",176.801,638,4,63,0)
51
"DATA",176.801,638,4,64,0)
48
"DATA",176.801,638,4,65,0)
59
"DATA",176.801,638,4,66,0)
26
"DATA",176.801,638,4,67,0)
86
"DATA",176.801,638,4,68,0)
29
"DATA",176.801,638,4,69,0)
21
"DATA",176.801,638,4,70,0)
23
"DATA",176.801,638,4,71,0)
75
"DATA",176.801,638,4,72,0)
31
"DATA",176.801,638,4,73,0)
56
"DATA",176.801,638,4,74,0)
1
"DATA",176.801,638,4,75,0)
37
"DATA",176.801,638,4,76,0)
63
"DATA",176.801,638,4,77,0)
52
"DATA",176.801,638,4,78,0)
22
"DATA",176.801,638,4,79,0)
33
"DATA",176.801,638,4,80,0)
83
"DATA",176.801,638,4,81,0)
80
"DATA",176.801,638,4,82,0)
79
"DATA",176.801,638,4,83,0)
4
"DATA",176.801,638,4,84,0)
18
"DATA",176.801,638,4,85,0)
13
"DATA",176.801,638,4,86,0)
10
"DATA",176.801,638,4,87,0)
89
"DATA",176.801,638,4,88,0)
57
"DATA",176.801,638,4,89,0)
77
"DATA",176.801,638,4,90,0)
44
"DATA",176.801,638,4,91,0)
16
"DATA",176.801,638,4,92,0)
58
"DATA",176.801,638,4,93,0)
88
"DATA",176.801,638,5)
P91
"DATA",176.801,639,0)
Percutaneous Coronary Interventions
"DATA",176.801,639,1)
2.16.840.1.113883.3.464.1003.104.12.1010
"DATA",176.801,639,4,0)
^176.8012P^2^2
"DATA",176.801,639,4,1,0)
3
"DATA",176.801,639,4,2,0)
25
"DATA",176.801,639,5)
PCI10
"DATA",176.801,640,0)
Perforation of Uterus
"DATA",176.801,640,1)
2.16.840.1.113883.3.117.1.7.1.136
"DATA",176.801,640,4,0)
^176.8012P^1^1
"DATA",176.801,640,4,1,0)
91
"DATA",176.801,640,5)
PU36
"DATA",176.801,641,0)
Peritoneal Dialysis
"DATA",176.801,641,1)
2.16.840.1.113883.3.526.3.1084
"DATA",176.801,641,4,0)
^176.8012P^2^2
"DATA",176.801,641,4,1,0)
12
"DATA",176.801,641,4,2,0)
59
"DATA",176.801,641,5)
PD84
"DATA",176.801,642,0)
Persistent Asthma
"DATA",176.801,642,1)
2.16.840.1.113883.3.464.1003.102.12.1023
"DATA",176.801,642,4,0)
^176.8012P^1^1
"DATA",176.801,642,4,1,0)
29
"DATA",176.801,642,5)
PA23
"DATA",176.801,643,0)
Personality Disorder
"DATA",176.801,643,1)
2.16.840.1.113883.3.67.1.101.1.246
"DATA",176.801,643,4,0)
^176.8012P^2^2
"DATA",176.801,643,4,1,0)
61
"DATA",176.801,643,4,2,0)
42
"DATA",176.801,643,5)
PD46
"DATA",176.801,644,0)
Phototherapy Procedure Group
"DATA",176.801,644,1)
2.16.840.1.113883.3.666.5.1594
"DATA",176.801,644,4,0)
^176.8012P^1^1
"DATA",176.801,644,4,1,0)
93
"DATA",176.801,644,5)
PPG94
"DATA",176.801,645,0)
Physical Activity Recommendation
"DATA",176.801,645,1)
2.16.840.1.113883.3.600.1518
"DATA",176.801,645,4,0)
^176.8012P^1^1
"DATA",176.801,645,4,1,0)
58
"DATA",176.801,645,5)
PAR18
"DATA",176.801,646,0)
Platelet Count
"DATA",176.801,646,1)
2.16.840.1.113883.3.117.1.7.1.267
"DATA",176.801,646,4,0)
^176.8012P^1^1
"DATA",176.801,646,4,1,0)
72
"DATA",176.801,646,5)
PC67
"DATA",176.801,647,0)
Pneumococcal Conjugate Vaccine
"DATA",176.801,647,1)
2.16.840.1.113883.3.464.1003.196.12.1221
"DATA",176.801,647,4,0)
^176.8012P^1^1
"DATA",176.801,647,4,1,0)
66
"DATA",176.801,647,5)
PCV21
"DATA",176.801,648,0)
Pneumococcal Conjugate Vaccine Administered
"DATA",176.801,648,1)
2.16.840.1.113883.3.464.1003.110.12.1046
"DATA",176.801,648,4,0)
^176.8012P^1^1
"DATA",176.801,648,4,1,0)
66
"DATA",176.801,648,5)
PCVA46
"DATA",176.801,649,0)
Pneumococcal Vaccine
"DATA",176.801,649,1)
2.16.840.1.113883.3.464.1003.110.12.1027
"DATA",176.801,649,4,0)
^176.8012P^1^1
"DATA",176.801,649,4,1,0)
28
"DATA",176.801,649,5)
PV27
"DATA",176.801,650,0)
Pneumococcal Vaccine Administered
"DATA",176.801,650,1)
2.16.840.1.113883.3.464.1003.110.12.1034
"DATA",176.801,650,4,0)
^176.8012P^1^1
"DATA",176.801,650,4,1,0)
28
"DATA",176.801,650,5)
PVA34
"DATA",176.801,651,0)
Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis
"DATA",176.801,651,1)
2.16.840.1.113883.3.464.1003.196.12.1076
"DATA",176.801,651,4,0)
^176.8012P^1^1
"DATA",176.801,651,4,1,0)
11
"DATA",176.801,651,5)
PJPPCPP76
"DATA",176.801,652,0)
Positive Depression Screening
"DATA",176.801,652,1)
2.16.840.1.113883.3.600.793
"DATA",176.801,652,4,0)
^176.8012P^1^1
"DATA",176.801,652,4,1,0)
53
"DATA",176.801,652,5)
PDS93
"DATA",176.801,653,0)
Positive Finding
"DATA",176.801,653,1)
2.16.840.1.113883.3.464.1003.121.12.1016
"DATA",176.801,653,4,0)
^176.8012P^1^1
"DATA",176.801,653,4,1,0)
34
"DATA",176.801,653,5)
PF16
"DATA",176.801,654,0)
Posterior Lenticonus
"DATA",176.801,654,1)
2.16.840.1.113883.3.526.3.1433
"DATA",176.801,654,4,0)
^176.8012P^1^1
"DATA",176.801,654,4,1,0)
57
"DATA",176.801,654,5)
PL33
"DATA",176.801,655,0)
Preferred Asthma Therapy
"DATA",176.801,655,1)
2.16.840.1.113883.3.464.1003.196.12.1212
"DATA",176.801,655,4,0)
^176.8012P^1^1
"DATA",176.801,655,4,1,0)
29
"DATA",176.801,655,5)
PAT12
"DATA",176.801,656,0)
Pregnancy
"DATA",176.801,656,1)
2.16.840.1.113883.3.526.3.378
"DATA",176.801,656,5)
P78
"DATA",176.801,657,0)
Pregnancy
"DATA",176.801,657,1)
2.16.840.1.113883.3.600.1622
"DATA",176.801,657,4,0)
^176.8012P^4^4
"DATA",176.801,657,4,1,0)
24
"DATA",176.801,657,4,2,0)
12
"DATA",176.801,657,4,3,0)
6
"DATA",176.801,657,4,4,0)
64
"DATA",176.801,657,5)
P22
"DATA",176.801,658,0)
Pregnancy Dx
"DATA",176.801,658,1)
2.16.840.1.113883.3.600.1.1623
"DATA",176.801,658,4,0)
^176.8012P^1^1
"DATA",176.801,658,4,1,0)
52
"DATA",176.801,658,5)
PD23
"DATA",176.801,659,0)
Pregnancy Test
"DATA",176.801,659,1)
2.16.840.1.113883.3.464.1003.111.12.1011
"DATA",176.801,659,4,0)
^176.8012P^1^1
"DATA",176.801,659,4,1,0)
77
"DATA",176.801,659,5)
PT11
"DATA",176.801,660,0)
Prescribed Medications Education
"DATA",176.801,660,1)
2.16.840.1.113883.3.117.1.7.1.379
"DATA",176.801,660,4,0)
^176.8012P^1^1
"DATA",176.801,660,4,1,0)
14
"DATA",176.801,660,5)
PME79
"DATA",176.801,661,0)
Preventive Care - Established Office Visit, 0 to 17
"DATA",176.801,661,1)
2.16.840.1.113883.3.464.1003.101.12.1024
"DATA",176.801,661,4,0)
^176.8012P^10^10
"DATA",176.801,661,4,1,0)
85
"DATA",176.801,661,4,2,0)
59
"DATA",176.801,661,4,3,0)
66
"DATA",176.801,661,4,4,0)
88
"DATA",176.801,661,4,5,0)
6
"DATA",176.801,661,4,6,0)
33
"DATA",176.801,661,4,7,0)
31
"DATA",176.801,661,4,8,0)
77
"DATA",176.801,661,4,9,0)
7
"DATA",176.801,661,4,10,0)
29
"DATA",176.801,661,5)
PCEOV01724
"DATA",176.801,662,0)
Preventive Care Services - Established Office Visit, 18 and Up
"DATA",176.801,662,1)
2.16.840.1.113883.3.464.1003.101.12.1025
"DATA",176.801,662,4,0)
^176.8012P^22^22
"DATA",176.801,662,4,1,0)
77
"DATA",176.801,662,4,2,0)
29
"DATA",176.801,662,4,3,0)
10
"DATA",176.801,662,4,4,0)
88
"DATA",176.801,662,4,5,0)
7
"DATA",176.801,662,4,6,0)
63
"DATA",176.801,662,4,7,0)
34
"DATA",176.801,662,4,8,0)
84
"DATA",176.801,662,4,9,0)
75
"DATA",176.801,662,4,10,0)
3
"DATA",176.801,662,4,11,0)
46
"DATA",176.801,662,4,12,0)
60
"DATA",176.801,662,4,13,0)
64
"DATA",176.801,662,4,14,0)
87
"DATA",176.801,662,4,15,0)
23
"DATA",176.801,662,4,16,0)
8
"DATA",176.801,662,4,17,0)
31
"DATA",176.801,662,4,18,0)
28
"DATA",176.801,662,4,19,0)
25
"DATA",176.801,662,4,20,0)
59
"DATA",176.801,662,4,21,0)
71
"DATA",176.801,662,4,22,0)
80
"DATA",176.801,662,5)
PCSEOV18U25
"DATA",176.801,663,0)
Preventive Care Services - Group Counseling
"DATA",176.801,663,1)
2.16.840.1.113883.3.464.1003.101.12.1027
"DATA",176.801,663,4,0)
^176.8012P^4^4
"DATA",176.801,663,4,1,0)
84
"DATA",176.801,663,4,2,0)
33
"DATA",176.801,663,4,3,0)
6
"DATA",176.801,663,4,4,0)
59
"DATA",176.801,663,5)
PCSGC27
"DATA",176.801,664,0)
Preventive Care Services - Other
"DATA",176.801,664,1)
2.16.840.1.113883.3.464.1003.101.12.1030
"DATA",176.801,664,4,0)
^176.8012P^2^2
"DATA",176.801,664,4,1,0)
84
"DATA",176.801,664,4,2,0)
59
"DATA",176.801,664,5)
PCSO30
"DATA",176.801,665,0)
Preventive Care Services-Individual Counseling
"DATA",176.801,665,1)
2.16.840.1.113883.3.464.1003.101.12.1026
"DATA",176.801,665,4,0)
^176.8012P^5^5
"DATA",176.801,665,4,1,0)
84
"DATA",176.801,665,4,2,0)
59
"DATA",176.801,665,4,3,0)
33
"DATA",176.801,665,4,4,0)
6
"DATA",176.801,665,4,5,0)
71
"DATA",176.801,665,5)
PCSIC26
"DATA",176.801,666,0)
Preventive Care Services-Initial Office Visit, 18 and Up
"DATA",176.801,666,1)
2.16.840.1.113883.3.464.1003.101.12.1023
"DATA",176.801,666,4,0)
^176.8012P^22^22
"DATA",176.801,666,4,1,0)
8
"DATA",176.801,666,4,2,0)
25
"DATA",176.801,666,4,3,0)
7
"DATA",176.801,666,4,4,0)
34
"DATA",176.801,666,4,5,0)
71
"DATA",176.801,666,4,6,0)
64
"DATA",176.801,666,4,7,0)
59
"DATA",176.801,666,4,8,0)
29
"DATA",176.801,666,4,9,0)
28
"DATA",176.801,666,4,10,0)
23
"DATA",176.801,666,4,11,0)
80
"DATA",176.801,666,4,12,0)
88
"DATA",176.801,666,4,13,0)
3
"DATA",176.801,666,4,14,0)
46
"DATA",176.801,666,4,15,0)
31
"DATA",176.801,666,4,16,0)
87
"DATA",176.801,666,4,17,0)
63
"DATA",176.801,666,4,18,0)
77
"DATA",176.801,666,4,19,0)
84
"DATA",176.801,666,4,20,0)
60
"DATA",176.801,666,4,21,0)
75
"DATA",176.801,666,4,22,0)
10
"DATA",176.801,666,5)
PCSIOV18U23
"DATA",176.801,667,0)
Preventive Care- Initial Office Visit, 0 to 17
"DATA",176.801,667,1)
2.16.840.1.113883.3.464.1003.101.12.1022
"DATA",176.801,667,4,0)
^176.8012P^10^10
"DATA",176.801,667,4,1,0)
59
"DATA",176.801,667,4,2,0)
88
"DATA",176.801,667,4,3,0)
6
"DATA",176.801,667,4,4,0)
7
"DATA",176.801,667,4,5,0)
33
"DATA",176.801,667,4,6,0)
77
"DATA",176.801,667,4,7,0)
85
"DATA",176.801,667,4,8,0)
66
"DATA",176.801,667,4,9,0)
31
"DATA",176.801,667,4,10,0)
29
"DATA",176.801,667,5)
PCIOV01722
"DATA",176.801,668,0)
Previous Receipt of Influenza Vaccine
"DATA",176.801,668,1)
2.16.840.1.113883.3.526.3.1185
"DATA",176.801,668,4,0)
^176.8012P^1^1
"DATA",176.801,668,4,1,0)
59
"DATA",176.801,668,5)
PRIV85
"DATA",176.801,669,0)
Primary Open Angle Glaucoma (POAG)
"DATA",176.801,669,1)
2.16.840.1.113883.3.526.3.326
"DATA",176.801,669,4,0)
^176.8012P^1^1
"DATA",176.801,669,4,1,0)
81
"DATA",176.801,669,5)
POAGPOAG26
"DATA",176.801,670,0)
Primary THA Procedure
"DATA",176.801,670,1)
2.16.840.1.113883.3.464.1003.198.12.1006
"DATA",176.801,670,4,0)
^176.8012P^1^1
"DATA",176.801,670,4,1,0)
16
"DATA",176.801,670,5)
PTHAP06
"DATA",176.801,671,0)
Primary TKA Procedure
"DATA",176.801,671,1)
2.16.840.1.113883.3.464.1003.198.12.1007
"DATA",176.801,671,4,0)
^176.8012P^1^1
"DATA",176.801,671,4,1,0)
73
"DATA",176.801,671,5)
PTKAP07
"DATA",176.801,672,0)
Principal
"DATA",176.801,672,1)
2.16.840.1.113883.3.117.1.7.1.14
"DATA",176.801,672,4,0)
^176.8012P^2^2
"DATA",176.801,672,4,1,0)
90
"DATA",176.801,672,4,2,0)
18
"DATA",176.801,672,5)
P14
"DATA",176.801,673,0)
Principal Diagnosis
"DATA",176.801,673,1)
2.16.840.1.113883.3.117.2.7.1.14
"DATA",176.801,673,4,0)
^176.8012P^12^12
"DATA",176.801,673,4,1,0)
2
"DATA",176.801,673,4,2,0)
15
"DATA",176.801,673,4,3,0)
22
"DATA",176.801,673,4,4,0)
37
"DATA",176.801,673,4,5,0)
86
"DATA",176.801,673,4,6,0)
18
"DATA",176.801,673,4,7,0)
14
"DATA",176.801,673,4,8,0)
13
"DATA",176.801,673,4,9,0)
56
"DATA",176.801,673,4,10,0)
51
"DATA",176.801,673,4,11,0)
17
"DATA",176.801,673,4,12,0)
49
"DATA",176.801,673,5)
PD14
"DATA",176.801,674,0)
Prior Pars Plana Vitrectomy
"DATA",176.801,674,1)
2.16.840.1.113883.3.526.3.1434
"DATA",176.801,674,4,0)
^176.8012P^1^1
"DATA",176.801,674,4,1,0)
57
"DATA",176.801,674,5)
PPPV34
"DATA",176.801,675,0)
Prior Penetrating Keratoplasty
"DATA",176.801,675,1)
2.16.840.1.113883.3.526.3.1475
"DATA",176.801,675,4,0)
^176.8012P^1^1
"DATA",176.801,675,4,1,0)
19
"DATA",176.801,675,5)
PPK75
"DATA",176.801,676,0)
Procedures During Pregnancy
"DATA",176.801,676,1)
2.16.840.1.113883.3.464.1003.111.12.1009
"DATA",176.801,676,4,0)
^176.8012P^1^1
"DATA",176.801,676,4,1,0)
77
"DATA",176.801,676,5)
PDP09
"DATA",176.801,677,0)
Procedures Involving Contraceptive Devices
"DATA",176.801,677,1)
2.16.840.1.113883.3.464.1003.111.12.1010
"DATA",176.801,677,4,0)
^176.8012P^1^1
"DATA",176.801,677,4,1,0)
77
"DATA",176.801,677,5)
PICD10
"DATA",176.801,678,0)
Profound Impairment, Both Eyes
"DATA",176.801,678,1)
2.16.840.1.113883.3.526.3.1476
"DATA",176.801,678,4,0)
^176.8012P^1^1
"DATA",176.801,678,4,1,0)
19
"DATA",176.801,678,5)
PIBE76
"DATA",176.801,679,0)
Prostate Cancer
"DATA",176.801,679,1)
2.16.840.1.113883.3.526.3.319
"DATA",176.801,679,4,0)
^176.8012P^1^1
"DATA",176.801,679,4,1,0)
9
"DATA",176.801,679,5)
PC19
"DATA",176.801,680,0)
Prostate Cancer Primary Tumor Size T1c
"DATA",176.801,680,1)
2.16.840.1.113883.3.526.3.1325
"DATA",176.801,680,4,0)
^176.8012P^1^1
"DATA",176.801,680,4,1,0)
9
"DATA",176.801,680,5)
PCPTST125
"DATA",176.801,681,0)
Prostate Cancer Primary Tumor Size T2a
"DATA",176.801,681,1)
2.16.840.1.113883.3.526.3.1326
"DATA",176.801,681,4,0)
^176.8012P^1^1
"DATA",176.801,681,4,1,0)
9
"DATA",176.801,681,5)
PCPTST226
"DATA",176.801,682,0)
Prostate Cancer Treatment
"DATA",176.801,682,1)
2.16.840.1.113883.3.526.3.398
"DATA",176.801,682,4,0)
^176.8012P^1^1
"DATA",176.801,682,4,1,0)
9
"DATA",176.801,682,5)
PCT98
"DATA",176.801,683,0)
Prostate Specific Antigen Test
"DATA",176.801,683,1)
2.16.840.1.113883.3.526.3.401
"DATA",176.801,683,4,0)
^176.8012P^1^1
"DATA",176.801,683,4,1,0)
9
"DATA",176.801,683,5)
PSAT01
"DATA",176.801,684,0)
Proteinuria
"DATA",176.801,684,1)
2.16.840.1.113883.3.526.3.1003
"DATA",176.801,684,4,0)
^176.8012P^1^1
"DATA",176.801,684,4,1,0)
34
"DATA",176.801,684,5)
P03
"DATA",176.801,685,0)
Pseudoexfoliation Syndrome
"DATA",176.801,685,1)
2.16.840.1.113883.3.526.3.1435
"DATA",176.801,685,4,0)
^176.8012P^1^1
"DATA",176.801,685,4,1,0)
57
"DATA",176.801,685,5)
PS35
"DATA",176.801,686,0)
Psych Visit - Diagnostic or Evaluative Interview
"DATA",176.801,686,1)
2.16.840.1.113883.3.526.3.1013
"DATA",176.801,686,4,0)
^176.8012P^5^5
"DATA",176.801,686,4,1,0)
35
"DATA",176.801,686,4,2,0)
46
"DATA",176.801,686,4,3,0)
44
"DATA",176.801,686,4,4,0)
30
"DATA",176.801,686,4,5,0)
84
"DATA",176.801,686,5)
PVDEI13
"DATA",176.801,687,0)
Psych Visit - Family Psychotherapy
"DATA",176.801,687,1)
2.16.840.1.113883.3.526.3.1018
"DATA",176.801,687,4,0)
^176.8012P^1^1
"DATA",176.801,687,4,1,0)
44
"DATA",176.801,687,5)
PVFP18
"DATA",176.801,688,0)
Psych Visit - Individual Inpatient Interactive Psychotherapy
"DATA",176.801,688,1)
2.16.840.1.113883.3.526.3.1017
"DATA",176.801,688,4,0)
^176.8012P^1^1
"DATA",176.801,688,4,1,0)
35
"DATA",176.801,688,5)
PVIIIP17
"DATA",176.801,689,0)
Psych Visit - Individual Inpatient Psychotherapy
"DATA",176.801,689,1)
2.16.840.1.113883.3.526.3.1016
"DATA",176.801,689,4,0)
^176.8012P^1^1
"DATA",176.801,689,4,1,0)
35
"DATA",176.801,689,5)
PVIIP16
"DATA",176.801,690,0)
Psych Visit - Individual Outpatient Interactive Psychotherapy
"DATA",176.801,690,1)
2.16.840.1.113883.3.526.3.1015
"DATA",176.801,690,4,0)
^176.8012P^6^6
"DATA",176.801,690,4,1,0)
84
"DATA",176.801,690,4,2,0)
76
"DATA",176.801,690,4,3,0)
30
"DATA",176.801,690,4,4,0)
44
"DATA",176.801,690,4,5,0)
46
"DATA",176.801,690,4,6,0)
35
"DATA",176.801,690,5)
PVIOIP15
"DATA",176.801,691,0)
Psych Visit - Individual Outpatient Psychotherapy
"DATA",176.801,691,1)
2.16.840.1.113883.3.526.3.1014
"DATA",176.801,691,4,0)
^176.8012P^8^8
"DATA",176.801,691,4,1,0)
76
"DATA",176.801,691,4,2,0)
35
"DATA",176.801,691,4,3,0)
84
"DATA",176.801,691,4,4,0)
46
"DATA",176.801,691,4,5,0)
30
"DATA",176.801,691,4,6,0)
44
"DATA",176.801,691,4,7,0)
61
"DATA",176.801,691,4,8,0)
42
"DATA",176.801,691,5)
PVIOP14
"DATA",176.801,692,0)
Psych Visit - Medication Management
"DATA",176.801,692,1)
2.16.840.1.113883.3.526.3.1019
"DATA",176.801,692,4,0)
^176.8012P^5^5
"DATA",176.801,692,4,1,0)
84
"DATA",176.801,692,4,2,0)
30
"DATA",176.801,692,4,3,0)
46
"DATA",176.801,692,4,4,0)
35
"DATA",176.801,692,4,5,0)
44
"DATA",176.801,692,5)
PVMM19
"DATA",176.801,693,0)
Psychiatric/Mental Health Patient
"DATA",176.801,693,1)
2.16.840.1.113883.3.117.1.7.1.299
"DATA",176.801,693,4,0)
^176.8012P^2^2
"DATA",176.801,693,4,1,0)
56
"DATA",176.801,693,4,2,0)
51
"DATA",176.801,693,5)
PMHP99
"DATA",176.801,694,0)
Psychoanalysis
"DATA",176.801,694,1)
2.16.840.1.113883.3.526.3.1141
"DATA",176.801,694,4,0)
^176.8012P^3^3
"DATA",176.801,694,4,1,0)
84
"DATA",176.801,694,4,2,0)
44
"DATA",176.801,694,4,3,0)
30
"DATA",176.801,694,5)
P41
"DATA",176.801,695,0)
Psychotherapy and Pharmacologic Management
"DATA",176.801,695,1)
2.16.840.1.113883.3.464.1003.101.12.1055
"DATA",176.801,695,4,0)
^176.8012P^1^1
"DATA",176.801,695,4,1,0)
33
"DATA",176.801,695,5)
PPM55
"DATA",176.801,696,0)
Pulse Exam of Foot
"DATA",176.801,696,1)
2.16.840.1.113883.3.464.1003.103.12.1015
"DATA",176.801,696,4,0)
^176.8012P^1^1
"DATA",176.801,696,4,1,0)
75
"DATA",176.801,696,5)
PEF15
"DATA",176.801,697,0)
Purulent Endophthalmitis
"DATA",176.801,697,1)
2.16.840.1.113883.3.526.3.1477
"DATA",176.801,697,4,0)
^176.8012P^1^1
"DATA",176.801,697,4,1,0)
19
"DATA",176.801,697,5)
PE77
"DATA",176.801,698,0)
Race
"DATA",176.801,698,1)
2.16.840.1.114222.4.11.836
"DATA",176.801,698,4,0)
^176.8012P^93^93
"DATA",176.801,698,4,1,0)
78
"DATA",176.801,698,4,2,0)
82
"DATA",176.801,698,4,3,0)
56
"DATA",176.801,698,4,4,0)
60
"DATA",176.801,698,4,5,0)
21
"DATA",176.801,698,4,6,0)
63
"DATA",176.801,698,4,7,0)
23
"DATA",176.801,698,4,8,0)
81
"DATA",176.801,698,4,9,0)
16
"DATA",176.801,698,4,10,0)
70
"DATA",176.801,698,4,11,0)
79
"DATA",176.801,698,4,12,0)
15
"DATA",176.801,698,4,13,0)
74
"DATA",176.801,698,4,14,0)
2
"DATA",176.801,698,4,15,0)
18
"DATA",176.801,698,4,16,0)
93
"DATA",176.801,698,4,17,0)
43
"DATA",176.801,698,4,18,0)
40
"DATA",176.801,698,4,19,0)
9
"DATA",176.801,698,4,20,0)
65
"DATA",176.801,698,4,21,0)
19
"DATA",176.801,698,4,22,0)
8
"DATA",176.801,698,4,23,0)
7
"DATA",176.801,698,4,24,0)
31
"DATA",176.801,698,4,25,0)
29
"DATA",176.801,698,4,26,0)
69
"DATA",176.801,698,4,27,0)
33
"DATA",176.801,698,4,28,0)
44
"DATA",176.801,698,4,29,0)
92
"DATA",176.801,698,4,30,0)
26
"DATA",176.801,698,4,31,0)
86
"DATA",176.801,698,4,32,0)
12
"DATA",176.801,698,4,33,0)
6
"DATA",176.801,698,4,34,0)
30
"DATA",176.801,698,4,35,0)
57
"DATA",176.801,698,4,36,0)
1
"DATA",176.801,698,4,37,0)
42
"DATA",176.801,698,4,38,0)
45
"DATA",176.801,698,4,39,0)
32
"DATA",176.801,698,4,40,0)
37
"DATA",176.801,698,4,41,0)
54
"DATA",176.801,698,4,42,0)
34
"DATA",176.801,698,4,43,0)
72
"DATA",176.801,698,4,44,0)
62
"DATA",176.801,698,4,45,0)
53
"DATA",176.801,698,4,46,0)
11
"DATA",176.801,698,4,47,0)
24
"DATA",176.801,698,4,48,0)
71
"DATA",176.801,698,4,49,0)
67
"DATA",176.801,698,4,50,0)
50
"DATA",176.801,698,4,51,0)
68
"DATA",176.801,698,4,52,0)
5
"DATA",176.801,698,4,53,0)
51
"DATA",176.801,698,4,54,0)
46
"DATA",176.801,698,4,55,0)
39
"DATA",176.801,698,4,56,0)
64
"DATA",176.801,698,4,57,0)
14
"DATA",176.801,698,4,58,0)
3
"DATA",176.801,698,4,59,0)
87
"DATA",176.801,698,4,60,0)
17
"DATA",176.801,698,4,61,0)
49
"DATA",176.801,698,4,62,0)
75
"DATA",176.801,698,4,63,0)
59
"DATA",176.801,698,4,64,0)
77
"DATA",176.801,698,4,65,0)
85
"DATA",176.801,698,4,66,0)
10
"DATA",176.801,698,4,67,0)
88
"DATA",176.801,698,4,68,0)
66
"DATA",176.801,698,4,69,0)
55
"DATA",176.801,698,4,70,0)
48
"DATA",176.801,698,4,71,0)
27
"DATA",176.801,698,4,72,0)
20
"DATA",176.801,698,4,73,0)
36
"DATA",176.801,698,4,74,0)
22
"DATA",176.801,698,4,75,0)
90
"DATA",176.801,698,4,76,0)
4
"DATA",176.801,698,4,77,0)
13
"DATA",176.801,698,4,78,0)
38
"DATA",176.801,698,4,79,0)
91
"DATA",176.801,698,4,80,0)
58
"DATA",176.801,698,4,81,0)
76
"DATA",176.801,698,4,82,0)
52
"DATA",176.801,698,4,83,0)
41
"DATA",176.801,698,4,84,0)
73
"DATA",176.801,698,4,85,0)
47
"DATA",176.801,698,4,86,0)
83
"DATA",176.801,698,4,87,0)
89
"DATA",176.801,698,4,88,0)
84
"DATA",176.801,698,4,89,0)
35
"DATA",176.801,698,4,90,0)
80
"DATA",176.801,698,4,91,0)
28
"DATA",176.801,698,4,92,0)
61
"DATA",176.801,698,4,93,0)
25
"DATA",176.801,698,5)
R36
"DATA",176.801,699,0)
Radiation Therapy II
"DATA",176.801,699,1)
2.16.840.1.113883.3.526.3.1339
"DATA",176.801,699,4,0)
^176.8012P^1^1
"DATA",176.801,699,4,1,0)
65
"DATA",176.801,699,5)
RTII39
"DATA",176.801,700,0)
Radiation Treatment Management
"DATA",176.801,700,1)
2.16.840.1.113883.3.526.3.1026
"DATA",176.801,700,4,0)
^176.8012P^1^1
"DATA",176.801,700,4,1,0)
55
"DATA",176.801,700,5)
RTM26
"DATA",176.801,701,0)
Reason Documented
"DATA",176.801,701,1)
2.16.840.1.113883.3.526.3.1494
"DATA",176.801,701,4,0)
^176.8012P^1^1
"DATA",176.801,701,4,1,0)
9
"DATA",176.801,701,5)
RD94
"DATA",176.801,702,0)
Recommendation not to change diet
"DATA",176.801,702,1)
2.16.840.1.113883.3.117.1.7.1.413
"DATA",176.801,702,4,0)
^176.8012P^1^1
"DATA",176.801,702,4,1,0)
38
"DATA",176.801,702,5)
R13
"DATA",176.801,703,0)
Referral
"DATA",176.801,703,1)
2.16.840.1.113883.3.464.1003.101.12.1046
"DATA",176.801,703,4,0)
^176.8012P^1^1
"DATA",176.801,703,4,1,0)
88
"DATA",176.801,703,5)
R46
"DATA",176.801,704,0)
Referral for Depression Adolescent
"DATA",176.801,704,1)
2.16.840.1.113883.3.600.537
"DATA",176.801,704,4,0)
^176.8012P^1^1
"DATA",176.801,704,4,1,0)
53
"DATA",176.801,704,5)
RDA37
"DATA",176.801,705,0)
Referral for Depression Adult
"DATA",176.801,705,1)
2.16.840.1.113883.3.600.538
"DATA",176.801,705,4,0)
^176.8012P^1^1
"DATA",176.801,705,4,1,0)
53
"DATA",176.801,705,5)
RDA38
"DATA",176.801,706,0)
Referral to Alternative Provider / Primary Care Provider
"DATA",176.801,706,1)
2.16.840.1.113883.3.600.1475
"DATA",176.801,706,4,0)
^176.8012P^1^1
"DATA",176.801,706,4,1,0)
58
"DATA",176.801,706,5)
RAPPCP75
"DATA",176.801,707,0)
Rehabilitation Services
"DATA",176.801,707,1)
2.16.840.1.113883.3.117.1.7.1.221
"DATA",176.801,707,4,0)
^176.8012P^1^1
"DATA",176.801,707,4,1,0)
37
"DATA",176.801,707,5)
RS21
"DATA",176.801,708,0)
Removal Procedures
"DATA",176.801,708,1)
2.16.840.1.113883.3.526.3.1436
"DATA",176.801,708,4,0)
^176.8012P^1^1
"DATA",176.801,708,4,1,0)
57
"DATA",176.801,708,5)
RP36
"DATA",176.801,709,0)
Renal Failure Due to ACE Inhibitor
"DATA",176.801,709,1)
2.16.840.1.113883.3.526.3.1151
"DATA",176.801,709,4,0)
^176.8012P^1^1
"DATA",176.801,709,4,1,0)
24
"DATA",176.801,709,5)
RFDACEI51
"DATA",176.801,710,0)
Renal Transplant
"DATA",176.801,710,1)
2.16.840.1.113883.3.464.1003.109.12.1002
"DATA",176.801,710,4,0)
^176.8012P^1^1
"DATA",176.801,710,4,1,0)
12
"DATA",176.801,710,5)
RT02
"DATA",176.801,711,0)
Rescreen BP Within 1 Year
"DATA",176.801,711,1)
2.16.840.1.113883.3.600.1474
"DATA",176.801,711,4,0)
^176.8012P^1^1
"DATA",176.801,711,4,1,0)
58
"DATA",176.801,711,5)
RBPW1Y74
"DATA",176.801,712,0)
Rescreen BP within 4 weeks
"DATA",176.801,712,1)
2.16.840.1.113883.3.600.1537
"DATA",176.801,712,4,0)
^176.8012P^1^1
"DATA",176.801,712,4,1,0)
58
"DATA",176.801,712,5)
RBP437
"DATA",176.801,713,0)
Residence
"DATA",176.801,713,1)
2.16.840.1.113883.3.67.1.101.11.725
"DATA",176.801,713,4,0)
^176.8012P^2^2
"DATA",176.801,713,4,1,0)
61
"DATA",176.801,713,4,2,0)
42
"DATA",176.801,713,5)
R25
"DATA",176.801,714,0)
Respiratory Problems Group
"DATA",176.801,714,1)
2.16.840.1.113883.3.666.5.1588
"DATA",176.801,714,4,0)
^176.8012P^1^1
"DATA",176.801,714,4,1,0)
93
"DATA",176.801,714,5)
RPG88
"DATA",176.801,715,0)
Respiratory Procedures Group
"DATA",176.801,715,1)
2.16.840.1.113883.3.666.5.1589
"DATA",176.801,715,4,0)
^176.8012P^1^1
"DATA",176.801,715,4,1,0)
93
"DATA",176.801,715,5)
RPG89
"DATA",176.801,716,0)
Retinal Detachment with Retinal Defect
"DATA",176.801,716,1)
2.16.840.1.113883.3.526.3.1478
"DATA",176.801,716,4,0)
^176.8012P^1^1
"DATA",176.801,716,4,1,0)
19
"DATA",176.801,716,5)
RDRD78
"DATA",176.801,717,0)
Retinal Repair Procedures
"DATA",176.801,717,1)
2.16.840.1.113883.3.526.3.1437
"DATA",176.801,717,4,0)
^176.8012P^1^1
"DATA",176.801,717,4,1,0)
57
"DATA",176.801,717,5)
RRP37
"DATA",176.801,718,0)
Retinal Vascular Occlusion
"DATA",176.801,718,1)
2.16.840.1.113883.3.526.3.1479
"DATA",176.801,718,4,0)
^176.8012P^1^1
"DATA",176.801,718,4,1,0)
19
"DATA",176.801,718,5)
RVO79
"DATA",176.801,719,0)
Retinal or Dilated Eye Exam
"DATA",176.801,719,1)
2.16.840.1.113883.3.464.1003.115.12.1088
"DATA",176.801,719,4,0)
^176.8012P^1^1
"DATA",176.801,719,4,1,0)
80
"DATA",176.801,719,5)
RDEE88
"DATA",176.801,720,0)
Retrolental Fibroplasias
"DATA",176.801,720,1)
2.16.840.1.113883.3.526.3.1438
"DATA",176.801,720,4,0)
^176.8012P^1^1
"DATA",176.801,720,4,1,0)
57
"DATA",176.801,720,5)
RF38
"DATA",176.801,721,0)
Revision Procedures
"DATA",176.801,721,1)
2.16.840.1.113883.3.526.3.1439
"DATA",176.801,721,4,0)
^176.8012P^1^1
"DATA",176.801,721,4,1,0)
57
"DATA",176.801,721,5)
RP39
"DATA",176.801,722,0)
Risk Factors Education
"DATA",176.801,722,1)
2.16.840.1.113883.3.117.1.7.1.380
"DATA",176.801,722,4,0)
^176.8012P^1^1
"DATA",176.801,722,4,1,0)
14
"DATA",176.801,722,5)
RFE80
"DATA",176.801,723,0)
Rotavirus Vaccine (2 dose schedule)
"DATA",176.801,723,1)
2.16.840.1.113883.3.464.1003.196.12.1222
"DATA",176.801,723,4,0)
^176.8012P^1^1
"DATA",176.801,723,4,1,0)
66
"DATA",176.801,723,5)
RV222
"DATA",176.801,724,0)
Rotavirus Vaccine (2 dose schedule) Administered
"DATA",176.801,724,1)
2.16.840.1.113883.3.464.1003.110.12.1048
"DATA",176.801,724,4,0)
^176.8012P^1^1
"DATA",176.801,724,4,1,0)
66
"DATA",176.801,724,5)
RV2A48
"DATA",176.801,725,0)
Rotavirus Vaccine (3 dose schedule)
"DATA",176.801,725,1)
2.16.840.1.113883.3.464.1003.196.12.1223
"DATA",176.801,725,4,0)
^176.8012P^1^1
"DATA",176.801,725,4,1,0)
66
"DATA",176.801,725,5)
RV323
"DATA",176.801,726,0)
Rotavirus Vaccine (3 dose schedule) Administered
"DATA",176.801,726,1)
2.16.840.1.113883.3.464.1003.110.12.1047
"DATA",176.801,726,4,0)
^176.8012P^1^1
"DATA",176.801,726,4,1,0)
66
"DATA",176.801,726,5)
RV3A47
"DATA",176.801,727,0)
Rubella
"DATA",176.801,727,1)
2.16.840.1.113883.3.464.1003.110.12.1037
"DATA",176.801,727,4,0)
^176.8012P^1^1
"DATA",176.801,727,4,1,0)
66
"DATA",176.801,727,5)
R37
"DATA",176.801,728,0)
Rubella Antigen Test
"DATA",176.801,728,1)
2.16.840.1.113883.3.464.1003.198.12.1030
"DATA",176.801,728,4,0)
^176.8012P^1^1
"DATA",176.801,728,4,1,0)
66
"DATA",176.801,728,5)
RAT30
"DATA",176.801,729,0)
SCIP Major Surgical Procedure
"DATA",176.801,729,1)
2.16.840.1.113883.3.117.1.7.1.2
"DATA",176.801,729,4,0)
^176.8012P^1^1
"DATA",176.801,729,4,1,0)
79
"DATA",176.801,729,5)
SCIPMSP12
"DATA",176.801,730,0)
Salvage Therapy
"DATA",176.801,730,1)
2.16.840.1.113883.3.526.3.399
"DATA",176.801,730,4,0)
^176.8012P^1^1
"DATA",176.801,730,4,1,0)
9
"DATA",176.801,730,5)
ST99
"DATA",176.801,731,0)
Scleral Procedures
"DATA",176.801,731,1)
2.16.840.1.113883.3.526.3.1440
"DATA",176.801,731,4,0)
^176.8012P^1^1
"DATA",176.801,731,4,1,0)
57
"DATA",176.801,731,5)
SP40
"DATA",176.801,732,0)
Scleritis and Episcleritis
"DATA",176.801,732,1)
2.16.840.1.113883.3.526.3.1481
"DATA",176.801,732,4,0)
^176.8012P^1^1
"DATA",176.801,732,4,1,0)
19
"DATA",176.801,732,5)
SE81
"DATA",176.801,733,0)
Senile Cataract
"DATA",176.801,733,1)
2.16.840.1.113883.3.526.3.1441
"DATA",176.801,733,4,0)
^176.8012P^1^1
"DATA",176.801,733,4,1,0)
57
"DATA",176.801,733,5)
SC41
"DATA",176.801,734,0)
Sensory Exam of Foot
"DATA",176.801,734,1)
2.16.840.1.113883.3.464.1003.103.12.1014
"DATA",176.801,734,4,0)
^176.8012P^1^1
"DATA",176.801,734,4,1,0)
75
"DATA",176.801,734,5)
SEF14
"DATA",176.801,735,0)
Separation of Retinal Layers
"DATA",176.801,735,1)
2.16.840.1.113883.3.526.3.1482
"DATA",176.801,735,4,0)
^176.8012P^1^1
"DATA",176.801,735,4,1,0)
19
"DATA",176.801,735,5)
SRL82
"DATA",176.801,736,0)
Seropositive
"DATA",176.801,736,1)
2.16.840.1.113883.3.464.1003.110.12.1054
"DATA",176.801,736,4,0)
^176.8012P^1^1
"DATA",176.801,736,4,1,0)
66
"DATA",176.801,736,5)
S54
"DATA",176.801,737,0)
Severe Dementia
"DATA",176.801,737,1)
2.16.840.1.113883.3.526.3.1025
"DATA",176.801,737,4,0)
^176.8012P^4^4
"DATA",176.801,737,4,1,0)
35
"DATA",176.801,737,4,2,0)
16
"DATA",176.801,737,4,3,0)
70
"DATA",176.801,737,4,4,0)
73
"DATA",176.801,737,5)
SD25
"DATA",176.801,738,0)
Shock and Complications Group
"DATA",176.801,738,1)
2.16.840.1.113883.3.666.5.1581
"DATA",176.801,738,4,0)
^176.8012P^1^1
"DATA",176.801,738,4,1,0)
93
"DATA",176.801,738,5)
SCG81
"DATA",176.801,739,0)
Single Live Birth
"DATA",176.801,739,1)
2.16.840.1.113883.3.117.1.7.1.25
"DATA",176.801,739,4,0)
^176.8012P^2^2
"DATA",176.801,739,4,1,0)
36
"DATA",176.801,739,4,2,0)
93
"DATA",176.801,739,5)
SLB25
"DATA",176.801,740,0)
Single Liveborn Newborn Born in Hospital
"DATA",176.801,740,1)
2.16.840.1.113883.3.117.1.7.1.26
"DATA",176.801,740,4,0)
^176.8012P^2^2
"DATA",176.801,740,4,1,0)
36
"DATA",176.801,740,4,2,0)
93
"DATA",176.801,740,5)
SLNBH26
"DATA",176.801,741,0)
Smoking
"DATA",176.801,741,1)
2.16.840.1.113883.3.600.1559
"DATA",176.801,741,4,0)
^176.8012P^2^2
"DATA",176.801,741,4,1,0)
1
"DATA",176.801,741,4,2,0)
5
"DATA",176.801,741,5)
S59
"DATA",176.801,742,0)
Social Reasons Group
"DATA",176.801,742,1)
2.16.840.1.113883.3.666.5.1595
"DATA",176.801,742,4,0)
^176.8012P^1^1
"DATA",176.801,742,4,1,0)
93
"DATA",176.801,742,5)
SRG95
"DATA",176.801,743,0)
Spontaneous Rupture of Membranes
"DATA",176.801,743,1)
2.16.840.1.113883.3.117.1.7.1.300
"DATA",176.801,743,4,0)
^176.8012P^1^1
"DATA",176.801,743,4,1,0)
91
"DATA",176.801,743,5)
SRM00
"DATA",176.801,744,0)
Standardized Pain Assessment Tool
"DATA",176.801,744,1)
2.16.840.1.113883.3.526.3.1028
"DATA",176.801,744,4,0)
^176.8012P^1^1
"DATA",176.801,744,4,1,0)
55
"DATA",176.801,744,5)
SPAT28
"DATA",176.801,745,0)
Standardized Tools for Assessment of Cognition
"DATA",176.801,745,1)
2.16.840.1.113883.3.526.3.1006
"DATA",176.801,745,4,0)
^176.8012P^1^1
"DATA",176.801,745,4,1,0)
35
"DATA",176.801,745,5)
STAC06
"DATA",176.801,746,0)
Statin
"DATA",176.801,746,1)
2.16.840.1.113883.3.117.1.7.1.225
"DATA",176.801,746,4,0)
^176.8012P^1^1
"DATA",176.801,746,4,1,0)
13
"DATA",176.801,746,5)
S25
"DATA",176.801,747,0)
Statin Allergen
"DATA",176.801,747,1)
2.16.840.1.113883.3.117.1.7.1.423
"DATA",176.801,747,4,0)
^176.8012P^1^1
"DATA",176.801,747,4,1,0)
13
"DATA",176.801,747,5)
SA23
"DATA",176.801,748,0)
Statins
"DATA",176.801,748,1)
2.16.840.1.113883.3.117.1.7.1.824
"DATA",176.801,748,4,0)
^176.8012P^1^1
"DATA",176.801,748,4,1,0)
86
"DATA",176.801,748,5)
S24
"DATA",176.801,749,0)
Subcutaneous route
"DATA",176.801,749,1)
2.16.840.1.113883.3.117.1.7.1.223
"DATA",176.801,749,4,0)
^176.8012P^3^3
"DATA",176.801,749,4,1,0)
90
"DATA",176.801,749,4,2,0)
18
"DATA",176.801,749,4,3,0)
17
"DATA",176.801,749,5)
S23
"DATA",176.801,750,0)
Substance Abuse
"DATA",176.801,750,1)
2.16.840.1.113883.3.464.1003.106.12.1004
"DATA",176.801,750,4,0)
^176.8012P^1^1
"DATA",176.801,750,4,1,0)
33
"DATA",176.801,750,5)
SA04
"DATA",176.801,751,0)
Suicide Risk Assessment
"DATA",176.801,751,1)
2.16.840.1.113883.3.526.3.1484
"DATA",176.801,751,5)
SRA84
"DATA",176.801,752,0)
Suicide Risk Assessment
"DATA",176.801,752,1)
2.16.840.1.113883.3.600.559
"DATA",176.801,752,4,0)
^176.8012P^2^2
"DATA",176.801,752,4,1,0)
30
"DATA",176.801,752,4,2,0)
44
"DATA",176.801,752,5)
SRA59
"DATA",176.801,753,0)
Syphilis
"DATA",176.801,753,1)
2.16.840.1.113883.3.464.1003.112.12.1002
"DATA",176.801,753,4,0)
^176.8012P^1^1
"DATA",176.801,753,4,1,0)
77
"DATA",176.801,753,5)
S02
"DATA",176.801,754,0)
System Reason
"DATA",176.801,754,1)
2.16.840.1.113883.3.526.3.1009
"DATA",176.801,754,4,0)
^176.8012P^6^6
"DATA",176.801,754,4,1,0)
24
"DATA",176.801,754,4,2,0)
59
"DATA",176.801,754,4,3,0)
39
"DATA",176.801,754,4,4,0)
43
"DATA",176.801,754,4,5,0)
41
"DATA",176.801,754,4,6,0)
65
"DATA",176.801,754,5)
SR09
"DATA",176.801,755,0)
System Reasons AMI
"DATA",176.801,755,1)
2.16.840.1.113883.3.666.5.3005
"DATA",176.801,755,4,0)
^176.8012P^1^1
"DATA",176.801,755,4,1,0)
86
"DATA",176.801,755,5)
SRAMI05
"DATA",176.801,756,0)
Systolic Blood Pressure
"DATA",176.801,756,1)
2.16.840.1.113883.3.526.3.1032
"DATA",176.801,756,4,0)
^176.8012P^3^3
"DATA",176.801,756,4,1,0)
12
"DATA",176.801,756,4,2,0)
58
"DATA",176.801,756,4,3,0)
64
"DATA",176.801,756,5)
SBP32
"DATA",176.801,757,0)
TPN Procedure Group
"DATA",176.801,757,1)
2.16.840.1.113883.3.666.5.1583
"DATA",176.801,757,4,0)
^176.8012P^1^1
"DATA",176.801,757,4,1,0)
93
"DATA",176.801,757,5)
TPNPG83
"DATA",176.801,758,0)
Tamoxifen or Aromatase Inhibitor Therapy
"DATA",176.801,758,1)
2.16.840.1.113883.3.526.3.1315
"DATA",176.801,758,4,0)
^176.8012P^1^1
"DATA",176.801,758,4,1,0)
65
"DATA",176.801,758,5)
TAIT15
"DATA",176.801,759,0)
Telehealth Services
"DATA",176.801,759,1)
2.16.840.1.113883.3.464.1003.101.12.1031
"DATA",176.801,759,4,0)
^176.8012P^1^1
"DATA",176.801,759,4,1,0)
33
"DATA",176.801,759,5)
TS31
"DATA",176.801,760,0)
Telephone Management
"DATA",176.801,760,1)
2.16.840.1.113883.3.464.1003.101.12.1053
"DATA",176.801,760,4,0)
^176.8012P^1^1
"DATA",176.801,760,4,1,0)
33
"DATA",176.801,760,5)
TM53
"DATA",176.801,761,0)
Thrombolytic (t-PA) Therapy
"DATA",176.801,761,1)
2.16.840.1.113883.3.117.1.7.1.226
"DATA",176.801,761,4,0)
^176.8012P^2^2
"DATA",176.801,761,4,1,0)
15
"DATA",176.801,761,4,2,0)
49
"DATA",176.801,761,5)
TPAT26
"DATA",176.801,762,0)
Tobacco Non-User
"DATA",176.801,762,1)
2.16.840.1.113883.3.526.3.1189
"DATA",176.801,762,4,0)
^176.8012P^1^1
"DATA",176.801,762,4,1,0)
84
"DATA",176.801,762,5)
TNU89
"DATA",176.801,763,0)
Tobacco Use Cessation Counseling
"DATA",176.801,763,1)
2.16.840.1.113883.3.526.3.509
"DATA",176.801,763,4,0)
^176.8012P^1^1
"DATA",176.801,763,4,1,0)
84
"DATA",176.801,763,5)
TUCC09
"DATA",176.801,764,0)
Tobacco Use Cessation Pharmacotherapy
"DATA",176.801,764,1)
2.16.840.1.113883.3.526.3.1190
"DATA",176.801,764,4,0)
^176.8012P^1^1
"DATA",176.801,764,4,1,0)
84
"DATA",176.801,764,5)
TUCP90
"DATA",176.801,765,0)
Tobacco Use Screening
"DATA",176.801,765,1)
2.16.840.1.113883.3.526.3.1278
"DATA",176.801,765,4,0)
^176.8012P^1^1
"DATA",176.801,765,4,1,0)
84
"DATA",176.801,765,5)
TUS78
"DATA",176.801,766,0)
Tobacco User
"DATA",176.801,766,1)
2.16.840.1.113883.3.526.3.1170
"DATA",176.801,766,4,0)
^176.8012P^1^1
"DATA",176.801,766,4,1,0)
84
"DATA",176.801,766,5)
TU70
"DATA",176.801,767,0)
Total Cholesterol
"DATA",176.801,767,1)
2.16.840.1.113883.3.600.879
"DATA",176.801,767,4,0)
^176.8012P^2^2
"DATA",176.801,767,4,1,0)
1
"DATA",176.801,767,4,2,0)
5
"DATA",176.801,767,5)
TC79
"DATA",176.801,768,0)
Total Cholesterol Laboratory Test
"DATA",176.801,768,1)
2.16.840.1.113883.3.464.1003.104.12.1013
"DATA",176.801,768,4,0)
^176.8012P^1^1
"DATA",176.801,768,4,1,0)
25
"DATA",176.801,768,5)
TCLT13
"DATA",176.801,769,0)
Total Colectomy
"DATA",176.801,769,1)
2.16.840.1.113883.3.464.1003.198.12.1019
"DATA",176.801,769,4,0)
^176.8012P^1^1
"DATA",176.801,769,4,1,0)
63
"DATA",176.801,769,5)
TC19
"DATA",176.801,770,0)
Trauma
"DATA",176.801,770,1)
2.16.840.1.113883.3.464.1003.113.12.1036
"DATA",176.801,770,4,0)
^176.8012P^1^1
"DATA",176.801,770,4,1,0)
67
"DATA",176.801,770,5)
T36
"DATA",176.801,771,0)
Traumatic Cataract
"DATA",176.801,771,1)
2.16.840.1.113883.3.526.3.1443
"DATA",176.801,771,4,0)
^176.8012P^1^1
"DATA",176.801,771,4,1,0)
57
"DATA",176.801,771,5)
TC43
"DATA",176.801,772,0)
Treatment Adjusted by Protocol
"DATA",176.801,772,1)
2.16.840.1.113883.3.117.1.7.1.278
"DATA",176.801,772,4,0)
^176.8012P^1^1
"DATA",176.801,772,4,1,0)
72
"DATA",176.801,772,5)
TAP78
"DATA",176.801,773,0)
Triglycerides
"DATA",176.801,773,1)
2.16.840.1.113883.3.600.883
"DATA",176.801,773,4,0)
^176.8012P^2^2
"DATA",176.801,773,4,1,0)
1
"DATA",176.801,773,4,2,0)
5
"DATA",176.801,773,5)
T83
"DATA",176.801,774,0)
Triglycerides Laboratory Test
"DATA",176.801,774,1)
2.16.840.1.113883.3.464.1003.104.12.1014
"DATA",176.801,774,4,0)
^176.8012P^1^1
"DATA",176.801,774,4,1,0)
25
"DATA",176.801,774,5)
TLT14
"DATA",176.801,775,0)
Unfractionated Heparin
"DATA",176.801,775,1)
2.16.840.1.113883.3.117.1.7.1.218
"DATA",176.801,775,4,0)
^176.8012P^4^4
"DATA",176.801,775,4,1,0)
72
"DATA",176.801,775,4,2,0)
90
"DATA",176.801,775,4,3,0)
18
"DATA",176.801,775,4,4,0)
17
"DATA",176.801,775,5)
UH18
"DATA",176.801,776,0)
Unilateral Mastectomy
"DATA",176.801,776,1)
2.16.840.1.113883.3.464.1003.198.12.1020
"DATA",176.801,776,4,0)
^176.8012P^1^1
"DATA",176.801,776,4,1,0)
10
"DATA",176.801,776,5)
UM20
"DATA",176.801,777,0)
Upper Respiratory Infection
"DATA",176.801,777,1)
2.16.840.1.113883.3.464.1003.102.12.1022
"DATA",176.801,777,4,0)
^176.8012P^1^1
"DATA",176.801,777,4,1,0)
85
"DATA",176.801,777,5)
URI22
"DATA",176.801,778,0)
Urological Surgery
"DATA",176.801,778,1)
2.16.840.1.113883.3.117.1.7.1.272
"DATA",176.801,778,4,0)
^176.8012P^2^2
"DATA",176.801,778,4,1,0)
90
"DATA",176.801,778,4,2,0)
18
"DATA",176.801,778,5)
US72
"DATA",176.801,779,0)
Use of Systemic Sympathetic alpha-1a Antagonist Medication for Treatment of Prostatic Hypertrophy
"DATA",176.801,779,1)
2.16.840.1.113883.3.526.3.1442
"DATA",176.801,779,4,0)
^176.8012P^1^1
"DATA",176.801,779,4,1,0)
57
"DATA",176.801,779,5)
USS1AMTPH42
"DATA",176.801,780,0)
Uterine Rupture
"DATA",176.801,780,1)
2.16.840.1.113883.3.117.1.7.1.138
"DATA",176.801,780,4,0)
^176.8012P^1^1
"DATA",176.801,780,4,1,0)
91
"DATA",176.801,780,5)
UR38
"DATA",176.801,781,0)
Uterine Window
"DATA",176.801,781,1)
2.16.840.1.113883.3.117.1.7.1.137
"DATA",176.801,781,4,0)
^176.8012P^1^1
"DATA",176.801,781,4,1,0)
91
"DATA",176.801,781,5)
UW37
"DATA",176.801,782,0)
Uveitis
"DATA",176.801,782,1)
2.16.840.1.113883.3.526.3.1444
"DATA",176.801,782,4,0)
^176.8012P^2^2
"DATA",176.801,782,4,1,0)
19
"DATA",176.801,782,4,2,0)
57
"DATA",176.801,782,5)
U44
"DATA",176.801,783,0)
VTE Confirmed
"DATA",176.801,783,1)
2.16.840.1.113883.3.117.1.7.1.407
"DATA",176.801,783,4,0)
^176.8012P^4^4
"DATA",176.801,783,4,1,0)
32
"DATA",176.801,783,4,2,0)
38
"DATA",176.801,783,4,3,0)
72
"DATA",176.801,783,4,4,0)
17
"DATA",176.801,783,5)
VTEC07
"DATA",176.801,784,0)
VTE Diagnostic Test
"DATA",176.801,784,1)
2.16.840.1.113883.3.117.1.7.1.276
"DATA",176.801,784,4,0)
^176.8012P^4^4
"DATA",176.801,784,4,1,0)
32
"DATA",176.801,784,4,2,0)
72
"DATA",176.801,784,4,3,0)
38
"DATA",176.801,784,4,4,0)
17
"DATA",176.801,784,5)
VTEDT76
"DATA",176.801,785,0)
VTE Risk Assessment
"DATA",176.801,785,1)
2.16.840.1.113883.3.117.1.7.1.357
"DATA",176.801,785,4,0)
^176.8012P^2^2
"DATA",176.801,785,4,1,0)
90
"DATA",176.801,785,4,2,0)
18
"DATA",176.801,785,5)
VTERA57
"DATA",176.801,786,0)
VTE Suspected
"DATA",176.801,786,1)
2.16.840.1.113883.3.117.1.7.1.277
"DATA",176.801,786,4,0)
^176.8012P^1^1
"DATA",176.801,786,4,1,0)
17
"DATA",176.801,786,5)
VTES77
"DATA",176.801,787,0)
Valvular Heart Disease
"DATA",176.801,787,1)
2.16.840.1.113883.3.464.1003.104.12.1017
"DATA",176.801,787,4,0)
^176.8012P^1^1
"DATA",176.801,787,4,1,0)
62
"DATA",176.801,787,5)
VHD17
"DATA",176.801,788,0)
Varicella Zoster
"DATA",176.801,788,1)
2.16.840.1.113883.3.464.1003.110.12.1039
"DATA",176.801,788,4,0)
^176.8012P^1^1
"DATA",176.801,788,4,1,0)
66
"DATA",176.801,788,5)
VZ39
"DATA",176.801,789,0)
Varicella Zoster Antigen Test
"DATA",176.801,789,1)
2.16.840.1.113883.3.464.1003.198.12.1032
"DATA",176.801,789,4,0)
^176.8012P^1^1
"DATA",176.801,789,4,1,0)
66
"DATA",176.801,789,5)
VZAT32
"DATA",176.801,790,0)
Varicella Zoster Vaccine (VZV)
"DATA",176.801,790,1)
2.16.840.1.113883.3.464.1003.196.12.1170
"DATA",176.801,790,4,0)
^176.8012P^1^1
"DATA",176.801,790,4,1,0)
66
"DATA",176.801,790,5)
VZVVZV70
"DATA",176.801,791,0)
Varicella Zoster Vaccine (VZV) Administered
"DATA",176.801,791,1)
2.16.840.1.113883.3.464.1003.110.12.1040
"DATA",176.801,791,4,0)
^176.8012P^1^1
"DATA",176.801,791,4,1,0)
66
"DATA",176.801,791,5)
VZVVZVA40
"DATA",176.801,792,0)
Vascular Access for Dialysis
"DATA",176.801,792,1)
2.16.840.1.113883.3.464.1003.109.12.1011
"DATA",176.801,792,4,0)
^176.8012P^2^2
"DATA",176.801,792,4,1,0)
34
"DATA",176.801,792,4,2,0)
64
"DATA",176.801,792,5)
VAD11
"DATA",176.801,793,0)
Vascular Disorders of Iris and Ciliary Body
"DATA",176.801,793,1)
2.16.840.1.113883.3.526.3.1445
"DATA",176.801,793,4,0)
^176.8012P^1^1
"DATA",176.801,793,4,1,0)
57
"DATA",176.801,793,5)
VDICB45
"DATA",176.801,794,0)
Venous Thromboembolism
"DATA",176.801,794,1)
2.16.840.1.113883.3.117.1.7.1.279
"DATA",176.801,794,4,0)
^176.8012P^6^6
"DATA",176.801,794,4,1,0)
32
"DATA",176.801,794,4,2,0)
72
"DATA",176.801,794,4,3,0)
90
"DATA",176.801,794,4,4,0)
18
"DATA",176.801,794,4,5,0)
38
"DATA",176.801,794,4,6,0)
17
"DATA",176.801,794,5)
VT79
"DATA",176.801,795,0)
Venous foot pumps (VFP)
"DATA",176.801,795,1)
2.16.840.1.113883.3.117.1.7.1.230
"DATA",176.801,795,4,0)
^176.8012P^3^3
"DATA",176.801,795,4,1,0)
90
"DATA",176.801,795,4,2,0)
18
"DATA",176.801,795,4,3,0)
17
"DATA",176.801,795,5)
VVFP30
"DATA",176.801,796,0)
Visual Exam of Foot
"DATA",176.801,796,1)
2.16.840.1.113883.3.464.1003.103.12.1013
"DATA",176.801,796,4,0)
^176.8012P^1^1
"DATA",176.801,796,4,1,0)
75
"DATA",176.801,796,5)
VEF13
"DATA",176.801,797,0)
Visual Field Defects
"DATA",176.801,797,1)
2.16.840.1.113883.3.526.3.1446
"DATA",176.801,797,4,0)
^176.8012P^1^1
"DATA",176.801,797,4,1,0)
19
"DATA",176.801,797,5)
VFD46
"DATA",176.801,798,0)
Visual acuity 20/40 or Better
"DATA",176.801,798,1)
2.16.840.1.113883.3.526.3.1483
"DATA",176.801,798,4,0)
^176.8012P^1^1
"DATA",176.801,798,4,1,0)
19
"DATA",176.801,798,5)
V2040B83
"DATA",176.801,799,0)
Vitamin K Dietary Management
"DATA",176.801,799,1)
2.16.840.1.113883.3.117.1.7.1.302
"DATA",176.801,799,4,0)
^176.8012P^1^1
"DATA",176.801,799,4,1,0)
38
"DATA",176.801,799,5)
VKDM02
"DATA",176.801,800,0)
Vitreous Procedures
"DATA",176.801,800,1)
2.16.840.1.113883.3.526.3.1447
"DATA",176.801,800,4,0)
^176.8012P^1^1
"DATA",176.801,800,4,1,0)
57
"DATA",176.801,800,5)
VP47
"DATA",176.801,801,0)
Warfarin
"DATA",176.801,801,1)
2.16.840.1.113883.3.117.1.7.1.232
"DATA",176.801,801,4,0)
^176.8012P^5^5
"DATA",176.801,801,4,1,0)
32
"DATA",176.801,801,4,2,0)
90
"DATA",176.801,801,4,3,0)
18
"DATA",176.801,801,4,4,0)
38
"DATA",176.801,801,4,5,0)
17
"DATA",176.801,801,5)
W32
"DATA",176.801,802,0)
Warning Signs and Symptoms Education
"DATA",176.801,802,1)
2.16.840.1.113883.3.117.1.7.1.381
"DATA",176.801,802,4,0)
^176.8012P^1^1
"DATA",176.801,802,4,1,0)
14
"DATA",176.801,802,5)
WSSE81
"DATA",176.801,803,0)
Weight
"DATA",176.801,803,1)
2.16.840.1.113883.3.464.1003.121.12.1015
"DATA",176.801,803,4,0)
^176.8012P^1^1
"DATA",176.801,803,4,1,0)
6
"DATA",176.801,803,5)
W15
"DATA",176.801,804,0)
Weight Reduction Recommended
"DATA",176.801,804,1)
2.16.840.1.113883.3.600.1510
"DATA",176.801,804,4,0)
^176.8012P^1^1
"DATA",176.801,804,4,1,0)
58
"DATA",176.801,804,5)
WRR10
"DATA",176.801,805,0)
Written Information Given
"DATA",176.801,805,1)
2.16.840.1.113883.3.117.1.7.1.415
"DATA",176.801,805,4,0)
^176.8012P^2^2
"DATA",176.801,805,4,1,0)
14
"DATA",176.801,805,4,2,0)
38
"DATA",176.801,805,5)
WIG15
"DATA",176.801,806,0)
X-Ray Study (all inclusive)
"DATA",176.801,806,1)
2.16.840.1.113883.3.464.1003.198.12.1034
"DATA",176.801,806,4,0)
^176.8012P^1^1
"DATA",176.801,806,4,1,0)
77
"DATA",176.801,806,5)
XRS34
"DATA",176.801,807,0)
X-Ray of Lower Spine
"DATA",176.801,807,1)
2.16.840.1.113883.3.464.1003.113.12.1033
"DATA",176.801,807,4,0)
^176.8012P^1^1
"DATA",176.801,807,4,1,0)
67
"DATA",176.801,807,5)
XRLS33
"DATA",176.801,808,0)
birth date
"DATA",176.801,808,1)
2.16.840.1.113883.3.560.100.4
"DATA",176.801,808,4,0)
^176.8012P^22^22
"DATA",176.801,808,4,1,0)
69
"DATA",176.801,808,4,2,0)
2
"DATA",176.801,808,4,3,0)
15
"DATA",176.801,808,4,4,0)
45
"DATA",176.801,808,4,5,0)
32
"DATA",176.801,808,4,6,0)
38
"DATA",176.801,808,4,7,0)
72
"DATA",176.801,808,4,8,0)
22
"DATA",176.801,808,4,9,0)
37
"DATA",176.801,808,4,10,0)
79
"DATA",176.801,808,4,11,0)
86
"DATA",176.801,808,4,12,0)
90
"DATA",176.801,808,4,13,0)
48
"DATA",176.801,808,4,14,0)
78
"DATA",176.801,808,4,15,0)
18
"DATA",176.801,808,4,16,0)
14
"DATA",176.801,808,4,17,0)
92
"DATA",176.801,808,4,18,0)
13
"DATA",176.801,808,4,19,0)
17
"DATA",176.801,808,4,20,0)
91
"DATA",176.801,808,4,21,0)
49
"DATA",176.801,808,4,22,0)
40
"DATA",176.801,808,5)
04
"DATA",176.801,809,0)
moderate or severe
"DATA",176.801,809,1)
2.16.840.1.113883.3.526.3.1092
"DATA",176.801,809,4,0)
^176.8012P^3^3
"DATA",176.801,809,4,1,0)
39
"DATA",176.801,809,4,2,0)
24
"DATA",176.801,809,4,3,0)
41
"DATA",176.801,809,5)
92
"DATA",176.801,810,0)
principal
"DATA",176.801,810,1)
2.16.840.1.113883.3.67.1.101.11.724
"DATA",176.801,810,4,0)
^176.8012P^3^3
"DATA",176.801,810,4,1,0)
61
"DATA",176.801,810,4,2,0)
42
"DATA",176.801,810,4,3,0)
33
"DATA",176.801,810,5)
24
"DATA",176.802,1,0)
Preventive Care and Screening: Risk-Stratified Cholesterol  Fasting Low Density Lipoprotein (LDL-C)
"DATA",176.802,1,1)
0336a17b-7c2a-48fc-a657-e9b04269a4cc^Not Applicable
"DATA",176.802,1,2,0)
^^1^1^3130419
"DATA",176.802,1,2,1,0)
Percentage of patients aged 20 through 79 years who had a fasting LDL-C test performed and whose risk-stratified fasting LDL-C is at or below the recommended LDL-C goal.
"DATA",176.802,1,3)
Laboratory Test
"DATA",176.802,1,4)
CMS64v1
"DATA",176.802,1,5)
None^CY 2014 EP
"DATA",176.802,1,6)
Quality Insights of Pennsylvania^Centers for Medicare & Medicaid Services
"DATA",176.802,1,7)
PROCESS
"DATA",176.802,1,8)
Cholesterol Screening B
"DATA",176.802,1,9)
Limited proprietary coding is contained in the measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. Quality Insights of Pennsylvania di
"DATA",176.802,1,10)
64^InProgress
"DATA",176.802,1,11)
1
"DATA",176.802,1,12,0)
^176.8024P^20^20
"DATA",176.802,1,12,1,0)
45
"DATA",176.802,1,12,2,0)
120
"DATA",176.802,1,12,3,0)
144
"DATA",176.802,1,12,4,0)
217
"DATA",176.802,1,12,5,0)
255
"DATA",176.802,1,12,6,0)
260
"DATA",176.802,1,12,7,0)
262
"DATA",176.802,1,12,8,0)
270
"DATA",176.802,1,12,9,0)
326
"DATA",176.802,1,12,10,0)
505
"DATA",176.802,1,12,11,0)
506
"DATA",176.802,1,12,12,0)
537
"DATA",176.802,1,12,13,0)
590
"DATA",176.802,1,12,14,0)
632
"DATA",176.802,1,12,15,0)
635
"DATA",176.802,1,12,16,0)
638
"DATA",176.802,1,12,17,0)
698
"DATA",176.802,1,12,18,0)
741
"DATA",176.802,1,12,19,0)
767
"DATA",176.802,1,12,20,0)
773
"DATA",176.802,1,13)
Percentage of patients aged 20 through 79 years who had a fasting LDL-C test performed and whose risk-stratified fasting LDL-C is at or below the recommended LDL-C goal.
"DATA",176.802,1,14)
PREVENTIVE CARE AND SCREENING: RISK-STRATIFIED CHOLESTEROL  FASTING LOW DENSITY LIPOPROTEIN (LDL-C)^EP
"DATA",176.802,1,15)
^12
"DATA",176.802,2,0)
Anticoagulation Therapy for Atrial Fibrillation/Flutter
"DATA",176.802,2,1)
03876d69-085b-415c-ae9d-9924171040c2^0436
"DATA",176.802,2,2,0)
^^1^1^3130419
"DATA",176.802,2,2,1,0)
Ischemic stroke patients with atrial fibrillation/flutter who are prescribed anticoagulation therapy at hospital discharge.
"DATA",176.802,2,3)
Individual Characteristic
"DATA",176.802,2,4)
CMS71v3
"DATA",176.802,2,5)
National Quality Forum^FY 2014 EH
"DATA",176.802,2,6)
The Joint Commission^The Joint Commission
"DATA",176.802,2,7)
PROCESS
"DATA",176.802,2,8)
STK-3 (Stroke)
"DATA",176.802,2,9)
Measure specifications are in the Public Domain.
"DATA",176.802,2,10)
71^Complete
"DATA",176.802,2,11)
3
"DATA",176.802,2,12,0)
^176.8024P^20^20
"DATA",176.802,2,12,1,0)
47
"DATA",176.802,2,12,2,0)
60
"DATA",176.802,2,12,3,0)
61
"DATA",176.802,2,12,4,0)
229
"DATA",176.802,2,12,5,0)
231
"DATA",176.802,2,12,6,0)
232
"DATA",176.802,2,12,7,0)
255
"DATA",176.802,2,12,8,0)
313
"DATA",176.802,2,12,9,0)
500
"DATA",176.802,2,12,10,0)
514
"DATA",176.802,2,12,11,0)
552
"DATA",176.802,2,12,12,0)
586
"DATA",176.802,2,12,13,0)
590
"DATA",176.802,2,12,14,0)
616
"DATA",176.802,2,12,15,0)
627
"DATA",176.802,2,12,16,0)
634
"DATA",176.802,2,12,17,0)
638
"DATA",176.802,2,12,18,0)
673
"DATA",176.802,2,12,19,0)
698
"DATA",176.802,2,12,20,0)
808
"DATA",176.802,2,13)
Ischemic stroke patients with atrial fibrillation/flutter who are prescribed anticoagulation therapy at hospital discharge.
"DATA",176.802,2,14)
ANTICOAGULATION THERAPY FOR ATRIAL FIBRILLATION/FLUTTER^EH
"DATA",176.802,2,15)
^19
"DATA",176.802,3,0)
Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic
"DATA",176.802,3,1)
0713ea8f-0e5b-4099-8c7c-dd677280398f^0068
"DATA",176.802,3,2,0)
^^1^1^3130419
"DATA",176.802,3,2,1,0)
Percentage of patients 18 years of age and older who were discharged alive for acute myocardial infarction (AMI), coronary artery bypass graft (CABG) or percutaneous coronary interventions (PCI) in the 12 months prior to the measu
"DATA",176.802,3,3)
Individual Characteristic
"DATA",176.802,3,4)
CMS164v1
"DATA",176.802,3,5)
National Quality Forum^CY 2014 EP
"DATA",176.802,3,6)
National Committee for Quality Assurance^National Committee for Quality Assurance
"DATA",176.802,3,7)
PROCESS
"DATA",176.802,3,8)
Supplemental Value Sets
"DATA",176.802,3,9)
Physician Performance Measure (Measures) and related data specifications were developed by the National Committee for Quality Assurance (NCQA).
"DATA",176.802,3,10)
164^Complete
"DATA",176.802,3,11)
1
"DATA",176.802,3,12,0)
^176.8024P^15^15
"DATA",176.802,3,12,1,0)
8
"DATA",176.802,3,12,2,0)
43
"DATA",176.802,3,12,3,0)
56
"DATA",176.802,3,12,4,0)
186
"DATA",176.802,3,12,5,0)
255
"DATA",176.802,3,12,6,0)
258
"DATA",176.802,3,12,7,0)
333
"DATA",176.802,3,12,8,0)
501
"DATA",176.802,3,12,9,0)
590
"DATA",176.802,3,12,10,0)
594
"DATA",176.802,3,12,11,0)
638
"DATA",176.802,3,12,12,0)
639
"DATA",176.802,3,12,13,0)
662
"DATA",176.802,3,12,14,0)
666
"DATA",176.802,3,12,15,0)
698
"DATA",176.802,3,13)
Percentage of patients 18 years of age and older who were discharged alive for acute myocardial infarction (AMI), coronary artery bypass graft (CABG) or percutaneous coronary interventions (PCI) in the 12 months prior to the measu
"DATA",176.802,3,14)
ISCHEMIC VASCULAR DISEASE (IVD): USE OF ASPIRIN OR ANOTHER ANTITHROMBOTIC^EP
"DATA",176.802,3,15)
^15
"DATA",176.802,4,0)
Hearing Screening Prior To Hospital Discharge (EHDI-1a)
"DATA",176.802,4,1)
0924fbae-3fdb-4d0a-aab7-9f354e699fde^1354
"DATA",176.802,4,2,0)
^^1^1^3130419
"DATA",176.802,4,2,1,0)
This measure assesses the proportion of births that have been screened for hearing loss before hospital discharge.
"DATA",176.802,4,3)
Individual Characteristic
"DATA",176.802,4,4)
CMS31v1
"DATA",176.802,4,5)
National Quality Forum^FY 2014 EH
"DATA",176.802,4,6)
CDC Early Hearing Detection and Intervention Program^CDC National Center on Birth Defects and Developmental Disabilities
"DATA",176.802,4,7)
PROCESS
"DATA",176.802,4,8)
Supplemental Value Sets
"DATA",176.802,4,9)
None
"DATA",176.802,4,10)
31^InProgress
"DATA",176.802,4,11)
1
"DATA",176.802,4,12,0)
^176.8024P^12^12
"DATA",176.802,4,12,1,0)
90
"DATA",176.802,4,12,2,0)
255
"DATA",176.802,4,12,3,0)
305
"DATA",176.802,4,12,4,0)
489
"DATA",176.802,4,12,5,0)
523
"DATA",176.802,4,12,6,0)
524
"DATA",176.802,4,12,7,0)
584
"DATA",176.802,4,12,8,0)
585
"DATA",176.802,4,12,9,0)
590
"DATA",176.802,4,12,10,0)
623
"DATA",176.802,4,12,11,0)
638
"DATA",176.802,4,12,12,0)
698
"DATA",176.802,4,13)
This measure assesses the proportion of births that have been screened for hearing loss before hospital discharge.
"DATA",176.802,4,14)
HEARING SCREENING PRIOR TO HOSPITAL DISCHARGE (EHDI-1A)^EH
"DATA",176.802,4,15)
^16
"DATA",176.802,5,0)
Preventive Care and Screening: Cholesterol - Fasting Low Density Lipoprotein (LDL-C) Test Performed
"DATA",176.802,5,1)
0a7f0278-a05c-40aa-94a4-70ec44f5c568^Not Applicable
"DATA",176.802,5,2,0)
^^1^1^3130419
"DATA",176.802,5,2,1,0)
Percentage of patients aged 20 through 79 years whose risk factors have been assessed and a fasting LDL-C test has been performed.
"DATA",176.802,5,3)
Laboratory Test
"DATA",176.802,5,4)
CMS61v1
"DATA",176.802,5,5)
None^CY 2014 EP
"DATA",176.802,5,6)
Quality Insights of Pennsylvania^Centers for Medicare & Medicaid Services
"DATA",176.802,5,7)
PROCESS
"DATA",176.802,5,8)
Cholesterol Screening A
"DATA",176.802,5,9)
Limited proprietary coding is contained in the measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. Quality Insights of Pennsylvania di
"DATA",176.802,5,10)
61^InProgress
"DATA",176.802,5,11)
1
"DATA",176.802,5,12,0)
^176.8024P^18^18
"DATA",176.802,5,12,1,0)
45
"DATA",176.802,5,12,2,0)
120
"DATA",176.802,5,12,3,0)
144
"DATA",176.802,5,12,4,0)
217
"DATA",176.802,5,12,5,0)
255
"DATA",176.802,5,12,6,0)
260
"DATA",176.802,5,12,7,0)
262
"DATA",176.802,5,12,8,0)
326
"DATA",176.802,5,12,9,0)
506
"DATA",176.802,5,12,10,0)
537
"DATA",176.802,5,12,11,0)
590
"DATA",176.802,5,12,12,0)
632
"DATA",176.802,5,12,13,0)
635
"DATA",176.802,5,12,14,0)
638
"DATA",176.802,5,12,15,0)
698
"DATA",176.802,5,12,16,0)
741
"DATA",176.802,5,12,17,0)
767
"DATA",176.802,5,12,18,0)
773
"DATA",176.802,5,13)
Percentage of patients aged 20 through 79 years whose risk factors have been assessed and a fasting LDL-C test has been performed.
"DATA",176.802,5,14)
PREVENTIVE CARE AND SCREENING: CHOLESTEROL - FASTING LOW DENSITY LIPOPROTEIN (LDL-C) TEST PERFORMED^EP
"DATA",176.802,5,15)
^12
"DATA",176.802,6,0)
Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents
"DATA",176.802,6,1)
0b63f730-25d6-4248-b11f-8c09c66a04eb^0024
"DATA",176.802,6,2,0)
^^1^1^3130419
"DATA",176.802,6,2,1,0)
Percentage of patients 3-17 years of age who had an outpatient visit with a Primary Care Physician (PCP) or Obstetrician/Gynecologist (OB/GYN) and who had evidence of the following during the measurement period. Three rates are re
"DATA",176.802,6,3)
Physical Exam
"DATA",176.802,6,4)
CMS155v1
"DATA",176.802,6,5)
National Quality Forum^CY 2014 EP
"DATA",176.802,6,6)
National Committee for Quality Assurance^National Committee for Quality Assurance
"DATA",176.802,6,7)
PROCESS
"DATA",176.802,6,8)
Wght_Assess_Counseling
"DATA",176.802,6,9)
Physician Performance Measure (Measures) and related data specifications were developed by the National Committee for Quality Assurance (NCQA).
"DATA",176.802,6,10)
155^InProgress
"DATA",176.802,6,11)
1
"DATA",176.802,6,12,0)
^176.8024P^17^17
"DATA",176.802,6,12,1,0)
76
"DATA",176.802,6,12,2,0)
188
"DATA",176.802,6,12,3,0)
189
"DATA",176.802,6,12,4,0)
255
"DATA",176.802,6,12,5,0)
258
"DATA",176.802,6,12,6,0)
308
"DATA",176.802,6,12,7,0)
333
"DATA",176.802,6,12,8,0)
590
"DATA",176.802,6,12,9,0)
594
"DATA",176.802,6,12,10,0)
638
"DATA",176.802,6,12,11,0)
657
"DATA",176.802,6,12,12,0)
661
"DATA",176.802,6,12,13,0)
663
"DATA",176.802,6,12,14,0)
665
"DATA",176.802,6,12,15,0)
667
"DATA",176.802,6,12,16,0)
698
"DATA",176.802,6,12,17,0)
803
"DATA",176.802,6,13)
Percentage of patients 3-17 years of age who had an outpatient visit with a Primary Care Physician (PCP) or Obstetrician/Gynecologist (OB/GYN) and who had evidence of the following during the measurement period. Three rates are re
"DATA",176.802,6,14)
WEIGHT ASSESSMENT AND COUNSELING FOR NUTRITION AND PHYSICAL ACTIVITY FOR CHILDREN AND ADOLESCENTS^EP
"DATA",176.802,6,15)
^7
"DATA",176.802,7,0)
Primary Caries Prevention Intervention as Offered by Primary Care Providers, including Dentists
"DATA",176.802,7,1)
0b81b6ba-3b30-41bf-a2f3-95bdc9f558f2^Not Applicable
"DATA",176.802,7,2,0)
^^1^1^3130419
"DATA",176.802,7,2,1,0)
Percentage of children, age 0-20 years, who received a fluoride varnish application during the measurement period.
"DATA",176.802,7,3)
Individual Characteristic
"DATA",176.802,7,4)
CMS74v2
"DATA",176.802,7,5)
None^CY 2014 EP
"DATA",176.802,7,6)
TBD^TBD
"DATA",176.802,7,7)
PROCESS
"DATA",176.802,7,8)
Supplemental Value Sets
"DATA",176.802,7,9)
TBD
"DATA",176.802,7,10)
74^InProgress
"DATA",176.802,7,11)
2
"DATA",176.802,7,12,0)
^176.8024P^12^12
"DATA",176.802,7,12,1,0)
153
"DATA",176.802,7,12,2,0)
255
"DATA",176.802,7,12,3,0)
258
"DATA",176.802,7,12,4,0)
264
"DATA",176.802,7,12,5,0)
590
"DATA",176.802,7,12,6,0)
594
"DATA",176.802,7,12,7,0)
638
"DATA",176.802,7,12,8,0)
661
"DATA",176.802,7,12,9,0)
662
"DATA",176.802,7,12,10,0)
666
"DATA",176.802,7,12,11,0)
667
"DATA",176.802,7,12,12,0)
698
"DATA",176.802,7,13)
Percentage of children, age 0-20 years, who received a fluoride varnish application during the measurement period.
"DATA",176.802,7,14)
PRIMARY CARIES PREVENTION INTERVENTION AS OFFERED BY PRIMARY CARE PROVIDERS, INCLUDING DENTISTS^EP
"DATA",176.802,7,15)
^8
"DATA",176.802,8,0)
Diabetes: Low Density Lipoprotein (LDL) Management
"DATA",176.802,8,1)
0dac1dec-e011-493b-a281-7c28964872dd^0064
"DATA",176.802,8,2,0)
^^1^1^3130419
"DATA",176.802,8,2,1,0)
Percentage of patients 1875 years of age with diabetes whose LDL-C was adequately controlled (<100 mg/dL) during the measurement period.
"DATA",176.802,8,3)
Individual Characteristic
"DATA",176.802,8,4)
CMS163v1
"DATA",176.802,8,5)
National Quality Forum^CY 2014 EP
"DATA",176.802,8,6)
National Committee for Quality Assurance^National Committee for Quality Assurance
"DATA",176.802,8,7)
OUTCOME
"DATA",176.802,8,8)
Supplemental Value Sets
"DATA",176.802,8,9)
Physician Performance Measure (Measures) and related data specifications were developed by the National Committee for Quality Assurance (NCQA).
"DATA",176.802,8,10)
163^Complete
"DATA",176.802,8,11)
1
"DATA",176.802,8,12,0)
^176.8024P^13^13
"DATA",176.802,8,12,1,0)
43
"DATA",176.802,8,12,2,0)
212
"DATA",176.802,8,12,3,0)
255
"DATA",176.802,8,12,4,0)
258
"DATA",176.802,8,12,5,0)
285
"DATA",176.802,8,12,6,0)
333
"DATA",176.802,8,12,7,0)
507
"DATA",176.802,8,12,8,0)
590
"DATA",176.802,8,12,9,0)
594
"DATA",176.802,8,12,10,0)
638
"DATA",176.802,8,12,11,0)
662
"DATA",176.802,8,12,12,0)
666
"DATA",176.802,8,12,13,0)
698
"DATA",176.802,8,13)
Percentage of patients 1875 years of age with diabetes whose LDL-C was adequately controlled (<100 mg/dL) during the measurement period.
"DATA",176.802,8,14)
DIABETES: LOW DENSITY LIPOPROTEIN (LDL) MANAGEMENT^EP
"DATA",176.802,8,15)
^9
"DATA",176.802,9,0)
Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients
"DATA",176.802,9,1)
1635c14d-e612-4fa6-96cd-285361aa7f7b^0389
"DATA",176.802,9,2,0)
^^1^1^3130419
"DATA",176.802,9,2,1,0)
Percentage of patients, regardless of age, with a diagnosis of prostate cancer at low risk of recurrence receiving interstitial prostate brachytherapy, OR external beam radiotherapy to the prostate, OR radical prostatectomy, OR cr
"DATA",176.802,9,3)
Procedure
"DATA",176.802,9,4)
CMS129v1
"DATA",176.802,9,5)
National Quality Forum^CY 2014 EP
"DATA",176.802,9,6)
American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)^American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)
"DATA",176.802,9,7)
PROCESS
"DATA",176.802,9,8)
Prostate_Cancer
"DATA",176.802,9,9)
Copyright 2012 American Medical Association. All Rights Reserved.
"DATA",176.802,9,10)
129^InProgress
"DATA",176.802,9,11)
1
"DATA",176.802,9,12,0)
^176.8024P^16^16
"DATA",176.802,9,12,1,0)
94
"DATA",176.802,9,12,2,0)
155
"DATA",176.802,9,12,3,0)
255
"DATA",176.802,9,12,4,0)
289
"DATA",176.802,9,12,5,0)
537
"DATA",176.802,9,12,6,0)
590
"DATA",176.802,9,12,7,0)
613
"DATA",176.802,9,12,8,0)
638
"DATA",176.802,9,12,9,0)
679
"DATA",176.802,9,12,10,0)
680
"DATA",176.802,9,12,11,0)
681
"DATA",176.802,9,12,12,0)
682
"DATA",176.802,9,12,13,0)
683
"DATA",176.802,9,12,14,0)
698
"DATA",176.802,9,12,15,0)
701
"DATA",176.802,9,12,16,0)
730
"DATA",176.802,9,13)
Percentage of patients, regardless of age, with a diagnosis of prostate cancer at low risk of recurrence receiving interstitial prostate brachytherapy, OR external beam radiotherapy to the prostate, OR radical prostatectomy, OR cr
"DATA",176.802,9,14)
PROSTATE CANCER: AVOIDANCE OF OVERUSE OF BONE SCAN FOR STAGING LOW RISK PROSTATE CANCER PATIENTS^EP
"DATA",176.802,9,15)
^5
"DATA",176.802,10,0)
Breast Cancer Screening
"DATA",176.802,10,1)
19783c1b-4fd1-46c1-8a96-a2f192b97ee0^0031
"DATA",176.802,10,2,0)
^^1^1^3130419
"DATA",176.802,10,2,1,0)
Percentage of women 4069 years of age who had a mammogram to screen for breast cancer.
"DATA",176.802,10,3)
Procedure
"DATA",176.802,10,4)
CMS125v1
"DATA",176.802,10,5)
National Quality Forum^CY 2014 EP
"DATA",176.802,10,6)
National Committee for Quality Assurance^National Committee for Quality Assurance
"DATA",176.802,10,7)
PROCESS
"DATA",176.802,10,8)
Breast_Cancer_Screen
"DATA",176.802,10,9)
Physician Performance Measure (Measures) and related data specifications were developed by the National Committee for Quality Assurance (NCQA).
"DATA",176.802,10,10)
125^InProgress
"DATA",176.802,10,11)
1
"DATA",176.802,10,12,0)
^176.8024P^14^14
"DATA",176.802,10,12,1,0)
43
"DATA",176.802,10,12,2,0)
86
"DATA",176.802,10,12,3,0)
255
"DATA",176.802,10,12,4,0)
258
"DATA",176.802,10,12,5,0)
262
"DATA",176.802,10,12,6,0)
333
"DATA",176.802,10,12,7,0)
540
"DATA",176.802,10,12,8,0)
590
"DATA",176.802,10,12,9,0)
594
"DATA",176.802,10,12,10,0)
638
"DATA",176.802,10,12,11,0)
662
"DATA",176.802,10,12,12,0)
666
"DATA",176.802,10,12,13,0)
698
"DATA",176.802,10,12,14,0)
776
"DATA",176.802,10,13)
Percentage of women 4069 years of age who had a mammogram to screen for breast cancer.
"DATA",176.802,10,14)
BREAST CANCER SCREENING^EP
"DATA",176.802,10,15)
^12
"DATA",176.802,11,0)
HIV/AIDS: Pneumocystis jiroveci pneumonia (PCP) prophylaxis
"DATA",176.802,11,1)
1cdd20de-5de9-4759-8a93-31f1f8baaaa2^0405
"DATA",176.802,11,2,0)
^^1^1^3130419
"DATA",176.802,11,2,1,0)
Percentage of patients aged 6 weeks and older with a diagnosis of HIV/AIDS who were prescribed Pneumocystis jiroveci pneumonia (PCP) prophylaxis
"DATA",176.802,11,3)
Individual Characteristic
"DATA",176.802,11,4)
CMS52v1
"DATA",176.802,11,5)
National Quality Forum^CY 2014 EP
"DATA",176.802,11,6)
National Committee for Quality Assurance (NCQA)/ and American Medical Association - convened Physician Consortium for Performance Improvement (AMA-PCPI)^National Committee for Quality Assurance (NCQA)
"DATA",176.802,11,7)
PROCESS
"DATA",176.802,11,8)
Supplemental Value Sets
"DATA",176.802,11,9)
(c) 2012 American Medical Association and National Committee for Quality Assurance. All Rights Reserved.
"DATA",176.802,11,10)
52^InProgress
"DATA",176.802,11,11)
1
"DATA",176.802,11,12,0)
^176.8024P^11^11
"DATA",176.802,11,12,1,0)
118
"DATA",176.802,11,12,2,0)
119
"DATA",176.802,11,12,3,0)
196
"DATA",176.802,11,12,4,0)
255
"DATA",176.802,11,12,5,0)
299
"DATA",176.802,11,12,6,0)
301
"DATA",176.802,11,12,7,0)
517
"DATA",176.802,11,12,8,0)
590
"DATA",176.802,11,12,9,0)
638
"DATA",176.802,11,12,10,0)
651
"DATA",176.802,11,12,11,0)
698
"DATA",176.802,11,13)
Percentage of patients aged 6 weeks and older with a diagnosis of HIV/AIDS who were prescribed Pneumocystis jiroveci pneumonia (PCP) prophylaxis
"DATA",176.802,11,14)
HIV/AIDS: PNEUMOCYSTIS JIROVECI PNEUMONIA (PCP) PROPHYLAXIS^EP
"DATA",176.802,11,15)
^14
"DATA",176.802,12,0)
Hypertension: Improvement in Blood Pressure
"DATA",176.802,12,1)
1d8363ce-a529-490b-8c98-9b54aa75da06^Not Applicable
"DATA",176.802,12,2,0)
^^1^1^3130419
"DATA",176.802,12,2,1,0)
Percentage of patients aged 18-85 years of age with a diagnosis of hypertension whose blood pressure improved during the measurement period.
"DATA",176.802,12,3)
Physical Exam
"DATA",176.802,12,4)
CMS65v2
"DATA",176.802,12,5)
None^CY 2014 EP
"DATA",176.802,12,6)
National Committee for Quality Assurance (NCQA)^Centers for Medicare & Medicaid Services (CMS)
"DATA",176.802,12,7)
OUTCOME
"DATA",176.802,12,8)
Hypertension  Improvement in BP
"DATA",176.802,12,9)
TBD
"DATA",176.802,12,10)
65^InProgress
"DATA",176.802,12,11)
2
"DATA",176.802,12,12,0)
^176.8024P^13^13
"DATA",176.802,12,12,1,0)
93
"DATA",176.802,12,12,2,0)
204
"DATA",176.802,12,12,3,0)
252
"DATA",176.802,12,12,4,0)
255
"DATA",176.802,12,12,5,0)
309
"DATA",176.802,12,12,6,0)
465
"DATA",176.802,12,12,7,0)
590
"DATA",176.802,12,12,8,0)
638
"DATA",176.802,12,12,9,0)
641
"DATA",176.802,12,12,10,0)
657
"DATA",176.802,12,12,11,0)
698
"DATA",176.802,12,12,12,0)
710
"DATA",176.802,12,12,13,0)
756
"DATA",176.802,12,13)
Percentage of patients aged 18-85 years of age with a diagnosis of hypertension whose blood pressure improved during the measurement period.
"DATA",176.802,12,14)
HYPERTENSION: IMPROVEMENT IN BLOOD PRESSURE^EP
"DATA",176.802,12,15)
^12
"DATA",176.802,13,0)
Discharged on Statin Medication
"DATA",176.802,13,1)
1f503318-bb8d-4b91-af63-223ae0a2328e^0439
"DATA",176.802,13,2,0)
^^1^1^3130419
"DATA",176.802,13,2,1,0)
Ischemic stroke patients with LDL greater than or equal to 100 mg/dL, or LDL not measured, or who were on a lipid-lowering medication prior to hospital arrival are prescribed statin medication at hospital discharge.
"DATA",176.802,13,3)
Individual Characteristic
"DATA",176.802,13,4)
CMS105v2
"DATA",176.802,13,5)
National Quality Forum^FY 2014 EH
"DATA",176.802,13,6)
The Joint Commission^The Joint Commission
"DATA",176.802,13,7)
PROCESS
"DATA",176.802,13,8)
Discharged on Statin Medication
"DATA",176.802,13,9)
Measure specifications are in the Public Domain.
"DATA",176.802,13,10)
105^Complete
"DATA",176.802,13,11)
2
"DATA",176.802,13,12,0)
^176.8024P^21^21
"DATA",176.802,13,12,1,0)
229
"DATA",176.802,13,12,2,0)
231
"DATA",176.802,13,12,3,0)
232
"DATA",176.802,13,12,4,0)
255
"DATA",176.802,13,12,5,0)
313
"DATA",176.802,13,12,6,0)
500
"DATA",176.802,13,12,7,0)
508
"DATA",176.802,13,12,8,0)
514
"DATA",176.802,13,12,9,0)
522
"DATA",176.802,13,12,10,0)
552
"DATA",176.802,13,12,11,0)
586
"DATA",176.802,13,12,12,0)
590
"DATA",176.802,13,12,13,0)
616
"DATA",176.802,13,12,14,0)
627
"DATA",176.802,13,12,15,0)
634
"DATA",176.802,13,12,16,0)
638
"DATA",176.802,13,12,17,0)
673
"DATA",176.802,13,12,18,0)
698
"DATA",176.802,13,12,19,0)
746
"DATA",176.802,13,12,20,0)
747
"DATA",176.802,13,12,21,0)
808
"DATA",176.802,13,13)
Ischemic stroke patients with LDL greater than or equal to 100 mg/dL, or LDL not measured, or who were on a lipid-lowering medication prior to hospital arrival are prescribed statin medication at hospital discharge.
"DATA",176.802,13,14)
DISCHARGED ON STATIN MEDICATION^EH
"DATA",176.802,13,15)
^19
"DATA",176.802,14,0)
Stroke Education
"DATA",176.802,14,1)
217fdf0d-3d64-4720-9116-d5e5afa27f2c^0440
"DATA",176.802,14,2,0)
^^1^1^3130419
"DATA",176.802,14,2,1,0)
Ischemic or hemorrhagic stroke patients or their caregivers who were given educational materials during the hospital stay addressing all of the following: activation of emergency medical system, need for follow-up after discharge,
"DATA",176.802,14,3)
Individual Characteristic
"DATA",176.802,14,4)
CMS107v2
"DATA",176.802,14,5)
National Quality Forum^FY 2014 EH
"DATA",176.802,14,6)
Joint Commission^Joint Commission
"DATA",176.802,14,7)
PROCESS
"DATA",176.802,14,8)
Stroke Education
"DATA",176.802,14,9)
Measure specifications are in the Public Domain
"DATA",176.802,14,10)
107^Complete
"DATA",176.802,14,11)
2
"DATA",176.802,14,12,0)
^176.8024P^18^18
"DATA",176.802,14,12,1,0)
6
"DATA",176.802,14,12,2,0)
230
"DATA",176.802,14,12,3,0)
255
"DATA",176.802,14,12,4,0)
313
"DATA",176.802,14,12,5,0)
491
"DATA",176.802,14,12,6,0)
500
"DATA",176.802,14,12,7,0)
586
"DATA",176.802,14,12,8,0)
590
"DATA",176.802,14,12,9,0)
616
"DATA",176.802,14,12,10,0)
634
"DATA",176.802,14,12,11,0)
638
"DATA",176.802,14,12,12,0)
660
"DATA",176.802,14,12,13,0)
673
"DATA",176.802,14,12,14,0)
698
"DATA",176.802,14,12,15,0)
722
"DATA",176.802,14,12,16,0)
802
"DATA",176.802,14,12,17,0)
805
"DATA",176.802,14,12,18,0)
808
"DATA",176.802,14,13)
Ischemic or hemorrhagic stroke patients or their caregivers who were given educational materials during the hospital stay addressing all of the following: activation of emergency medical system, need for follow-up after discharge,
"DATA",176.802,14,14)
STROKE EDUCATION^EH
"DATA",176.802,14,15)
^19
"DATA",176.802,15,0)
Thrombolytic Therapy
"DATA",176.802,15,1)
2838875a-07b5-4bf0-be04-c3eb99f53975^0437
"DATA",176.802,15,2,0)
^^1^1^3130419
"DATA",176.802,15,2,1,0)
Acute ischemic stroke patients who arrive at this hospital within 2 hours of time last known well and for whom IV t-PA was initiated at this hospital within 3 hours of time last known well.
"DATA",176.802,15,3)
Individual Characteristic
"DATA",176.802,15,4)
CMS91v3
"DATA",176.802,15,5)
National Quality Forum^FY 2014 EH
"DATA",176.802,15,6)
Joint Commission^Joint Commission
"DATA",176.802,15,7)
PROCESS
"DATA",176.802,15,8)
STK-4
"DATA",176.802,15,9)
Measure specifications are in the Public Domain.
"DATA",176.802,15,10)
91^InProgress
"DATA",176.802,15,11)
3
"DATA",176.802,15,12,0)
^176.8024P^15^15
"DATA",176.802,15,12,1,0)
78
"DATA",176.802,15,12,2,0)
255
"DATA",176.802,15,12,3,0)
313
"DATA",176.802,15,12,4,0)
500
"DATA",176.802,15,12,5,0)
552
"DATA",176.802,15,12,6,0)
574
"DATA",176.802,15,12,7,0)
581
"DATA",176.802,15,12,8,0)
586
"DATA",176.802,15,12,9,0)
590
"DATA",176.802,15,12,10,0)
634
"DATA",176.802,15,12,11,0)
638
"DATA",176.802,15,12,12,0)
673
"DATA",176.802,15,12,13,0)
698
"DATA",176.802,15,12,14,0)
761
"DATA",176.802,15,12,15,0)
808
"DATA",176.802,15,13)
Acute ischemic stroke patients who arrive at this hospital within 2 hours of time last known well and for whom IV t-PA was initiated at this hospital within 3 hours of time last known well.
"DATA",176.802,15,14)
THROMBOLYTIC THERAPY^EH
"DATA",176.802,15,15)
^19
"DATA",176.802,16,0)
Functional Status Assessment for Hip Replacement
"DATA",176.802,16,1)
2f291003-3f2f-48af-bef9-e5aacb95ac3e^Not Applicable
"DATA",176.802,16,2,0)
^^1^1^3130419
"DATA",176.802,16,2,1,0)
Percentage of patients aged 18 years and older with primary total hip arthroplasty (THA) who completed baseline and follow-up (patient-reported) functional status assessments
"DATA",176.802,16,3)
Condition/Diagnosis/Problem
"DATA",176.802,16,4)
CMS56v1
"DATA",176.802,16,5)
None^CY 2014 EP
"DATA",176.802,16,6)
National Committee for Quality Assurance (NCQA)^Centers for Medicare & Medicaid Services (CMS)
"DATA",176.802,16,7)
PROCESS
"DATA",176.802,16,8)
Functional Status Assessment Hip
"DATA",176.802,16,9)
TBD
"DATA",176.802,16,10)
56^InProgress
"DATA",176.802,16,11)
1
"DATA",176.802,16,12,0)
^176.8024P^11^11
"DATA",176.802,16,12,1,0)
255
"DATA",176.802,16,12,2,0)
258
"DATA",176.802,16,12,3,0)
269
"DATA",176.802,16,12,4,0)
272
"DATA",176.802,16,12,5,0)
590
"DATA",176.802,16,12,6,0)
594
"DATA",176.802,16,12,7,0)
611
"DATA",176.802,16,12,8,0)
638
"DATA",176.802,16,12,9,0)
670
"DATA",176.802,16,12,10,0)
698
"DATA",176.802,16,12,11,0)
737
"DATA",176.802,16,13)
Percentage of patients aged 18 years and older with primary total hip arthroplasty (THA) who completed baseline and follow-up (patient-reported) functional status assessments
"DATA",176.802,16,14)
FUNCTIONAL STATUS ASSESSMENT FOR HIP REPLACEMENT^EP
"DATA",176.802,16,15)
^17
"DATA",176.802,17,0)
Incidence of Potentially-Preventable Venous Thromboembolism
"DATA",176.802,17,1)
32cfc834-843a-4f45-b359-8e158eac4396^0376
"DATA",176.802,17,2,0)
^^1^1^3130419
"DATA",176.802,17,2,1,0)
This measure assesses the number of patients diagnosed with confirmed VTE during hospitalization (not present at admission) who did not receive VTE prophylaxis between hospital admission and the day before the VTE diagnostic testi
"DATA",176.802,17,3)
Individual Characteristic
"DATA",176.802,17,4)
CMS114v2
"DATA",176.802,17,5)
National Quality Forum^FY 2014 EH
"DATA",176.802,17,6)
Joint Commission^Joint Commission
"DATA",176.802,17,7)
OUTCOME
"DATA",176.802,17,8)
VTE-6
"DATA",176.802,17,9)
Measure specifications are in the Public Domain.
"DATA",176.802,17,10)
114^Complete
"DATA",176.802,17,11)
2
"DATA",176.802,17,12,0)
^176.8024P^27^27
"DATA",176.802,17,12,1,0)
246
"DATA",176.802,17,12,2,0)
255
"DATA",176.802,17,12,3,0)
279
"DATA",176.802,17,12,4,0)
293
"DATA",176.802,17,12,5,0)
486
"DATA",176.802,17,12,6,0)
489
"DATA",176.802,17,12,7,0)
492
"DATA",176.802,17,12,8,0)
499
"DATA",176.802,17,12,9,0)
526
"DATA",176.802,17,12,10,0)
548
"DATA",176.802,17,12,11,0)
590
"DATA",176.802,17,12,12,0)
592
"DATA",176.802,17,12,13,0)
600
"DATA",176.802,17,12,14,0)
616
"DATA",176.802,17,12,15,0)
634
"DATA",176.802,17,12,16,0)
638
"DATA",176.802,17,12,17,0)
673
"DATA",176.802,17,12,18,0)
698
"DATA",176.802,17,12,19,0)
749
"DATA",176.802,17,12,20,0)
775
"DATA",176.802,17,12,21,0)
783
"DATA",176.802,17,12,22,0)
784
"DATA",176.802,17,12,23,0)
786
"DATA",176.802,17,12,24,0)
794
"DATA",176.802,17,12,25,0)
795
"DATA",176.802,17,12,26,0)
801
"DATA",176.802,17,12,27,0)
808
"DATA",176.802,17,13)
This measure assesses the number of patients diagnosed with confirmed VTE during hospitalization (not present at admission) who did not receive VTE prophylaxis between hospital admission and the day before the VTE diagnostic testi
"DATA",176.802,17,14)
INCIDENCE OF POTENTIALLY-PREVENTABLE VENOUS THROMBOEMBOLISM^EH
"DATA",176.802,17,15)
^21
"DATA",176.802,18,0)
Venous Thromboembolism Prophylaxis
"DATA",176.802,18,1)
38b0b5ec-0f63-466f-8fe3-2cd20ddd1622^0371
"DATA",176.802,18,2,0)
^^1^1^3130419
"DATA",176.802,18,2,1,0)
This measure assesses the number of patients who received VTE prophylaxis or have documentation why no VTE prophylaxis was given the day of or the day after hospital admission or surgery end date for surgeries that start the day o
"DATA",176.802,18,3)
Individual Characteristic
"DATA",176.802,18,4)
CMS108v2
"DATA",176.802,18,5)
National Quality Forum^FY 2014 EH
"DATA",176.802,18,6)
Joint Commission^Joint Commission
"DATA",176.802,18,7)
PROCESS
"DATA",176.802,18,8)
Venous Thromboembolism Prophyla
"DATA",176.802,18,9)
Measure specifications are in the Public Domain
"DATA",176.802,18,10)
108^Complete
"DATA",176.802,18,11)
2
"DATA",176.802,18,12,0)
^176.8024P^42^42
"DATA",176.802,18,12,1,0)
61
"DATA",176.802,18,12,2,0)
224
"DATA",176.802,18,12,3,0)
246
"DATA",176.802,18,12,4,0)
255
"DATA",176.802,18,12,5,0)
278
"DATA",176.802,18,12,6,0)
279
"DATA",176.802,18,12,7,0)
293
"DATA",176.802,18,12,8,0)
296
"DATA",176.802,18,12,9,0)
313
"DATA",176.802,18,12,10,0)
330
"DATA",176.802,18,12,11,0)
331
"DATA",176.802,18,12,12,0)
471
"DATA",176.802,18,12,13,0)
472
"DATA",176.802,18,12,14,0)
486
"DATA",176.802,18,12,15,0)
489
"DATA",176.802,18,12,16,0)
492
"DATA",176.802,18,12,17,0)
498
"DATA",176.802,18,12,18,0)
499
"DATA",176.802,18,12,19,0)
500
"DATA",176.802,18,12,20,0)
504
"DATA",176.802,18,12,21,0)
526
"DATA",176.802,18,12,22,0)
527
"DATA",176.802,18,12,23,0)
552
"DATA",176.802,18,12,24,0)
561
"DATA",176.802,18,12,25,0)
590
"DATA",176.802,18,12,26,0)
591
"DATA",176.802,18,12,27,0)
592
"DATA",176.802,18,12,28,0)
600
"DATA",176.802,18,12,29,0)
616
"DATA",176.802,18,12,30,0)
634
"DATA",176.802,18,12,31,0)
638
"DATA",176.802,18,12,32,0)
672
"DATA",176.802,18,12,33,0)
673
"DATA",176.802,18,12,34,0)
698
"DATA",176.802,18,12,35,0)
749
"DATA",176.802,18,12,36,0)
775
"DATA",176.802,18,12,37,0)
778
"DATA",176.802,18,12,38,0)
785
"DATA",176.802,18,12,39,0)
794
"DATA",176.802,18,12,40,0)
795
"DATA",176.802,18,12,41,0)
801
"DATA",176.802,18,12,42,0)
808
"DATA",176.802,18,13)
This measure assesses the number of patients who received VTE prophylaxis or have documentation why no VTE prophylaxis was given the day of or the day after hospital admission or surgery end date for surgeries that start the day o
"DATA",176.802,18,14)
VENOUS THROMBOEMBOLISM PROPHYLAXIS^EH
"DATA",176.802,18,15)
^21
"DATA",176.802,19,0)
Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery
"DATA",176.802,19,1)
39e0424a-1727-4629-89e2-c46c2fbb3f5f^0565
"DATA",176.802,19,2,0)
^^1^1^3130419
"DATA",176.802,19,2,1,0)
Percentage of patients aged 18 years and older with a diagnosis of uncomplicated cataract who had cataract surgery and no significant ocular conditions impacting the visual outcome of surgery and had best-corrected visual acuity o
"DATA",176.802,19,3)
Diagnostic Study
"DATA",176.802,19,4)
CMS133v1
"DATA",176.802,19,5)
National Quality Forum^CY 2014 EP
"DATA",176.802,19,6)
National Committee for Quality Assurance^American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)
"DATA",176.802,19,7)
OUTCOME
"DATA",176.802,19,8)
Cataracts_20-40
"DATA",176.802,19,9)
Copyright 2012 American Medical Association and National Committee for Quality Assurance. All Rights Reserved.
"DATA",176.802,19,10)
133^Complete
"DATA",176.802,19,11)
1
"DATA",176.802,19,12,0)
^176.8024P^57^57
"DATA",176.802,19,12,1,0)
12
"DATA",176.802,19,12,2,0)
28
"DATA",176.802,19,12,3,0)
117
"DATA",176.802,19,12,4,0)
128
"DATA",176.802,19,12,5,0)
129
"DATA",176.802,19,12,6,0)
133
"DATA",176.802,19,12,7,0)
134
"DATA",176.802,19,12,8,0)
145
"DATA",176.802,19,12,9,0)
146
"DATA",176.802,19,12,10,0)
147
"DATA",176.802,19,12,11,0)
148
"DATA",176.802,19,12,12,0)
149
"DATA",176.802,19,12,13,0)
158
"DATA",176.802,19,12,14,0)
184
"DATA",176.802,19,12,15,0)
185
"DATA",176.802,19,12,16,0)
199
"DATA",176.802,19,12,17,0)
200
"DATA",176.802,19,12,18,0)
214
"DATA",176.802,19,12,19,0)
216
"DATA",176.802,19,12,20,0)
234
"DATA",176.802,19,12,21,0)
235
"DATA",176.802,19,12,22,0)
237
"DATA",176.802,19,12,23,0)
255
"DATA",176.802,19,12,24,0)
265
"DATA",176.802,19,12,25,0)
287
"DATA",176.802,19,12,26,0)
288
"DATA",176.802,19,12,27,0)
323
"DATA",176.802,19,12,28,0)
324
"DATA",176.802,19,12,29,0)
325
"DATA",176.802,19,12,30,0)
487
"DATA",176.802,19,12,31,0)
566
"DATA",176.802,19,12,32,0)
589
"DATA",176.802,19,12,33,0)
590
"DATA",176.802,19,12,34,0)
595
"DATA",176.802,19,12,35,0)
597
"DATA",176.802,19,12,36,0)
599
"DATA",176.802,19,12,37,0)
601
"DATA",176.802,19,12,38,0)
602
"DATA",176.802,19,12,39,0)
603
"DATA",176.802,19,12,40,0)
604
"DATA",176.802,19,12,41,0)
605
"DATA",176.802,19,12,42,0)
607
"DATA",176.802,19,12,43,0)
608
"DATA",176.802,19,12,44,0)
610
"DATA",176.802,19,12,45,0)
624
"DATA",176.802,19,12,46,0)
638
"DATA",176.802,19,12,47,0)
675
"DATA",176.802,19,12,48,0)
678
"DATA",176.802,19,12,49,0)
697
"DATA",176.802,19,12,50,0)
698
"DATA",176.802,19,12,51,0)
716
"DATA",176.802,19,12,52,0)
718
"DATA",176.802,19,12,53,0)
732
"DATA",176.802,19,12,54,0)
735
"DATA",176.802,19,12,55,0)
782
"DATA",176.802,19,12,56,0)
797
"DATA",176.802,19,12,57,0)
798
"DATA",176.802,19,13)
Percentage of patients aged 18 years and older with a diagnosis of uncomplicated cataract who had cataract surgery and no significant ocular conditions impacting the visual outcome of surgery and had best-corrected visual acuity o
"DATA",176.802,19,14)
CATARACTS: 20/40 OR BETTER VISUAL ACUITY WITHIN 90 DAYS FOLLOWING CATARACT SURGERY^EP
"DATA",176.802,19,15)
^11
"DATA",176.802,20,0)
Pregnant women that had HBsAg testing
"DATA",176.802,20,1)
3bbfc929-50c8-44b8-8d34-82be75c08a70^0608
"DATA",176.802,20,2,0)
^^1^1^3130419
"DATA",176.802,20,2,1,0)
This measure identifies pregnant women who had a HBsAg (hepatitis B) test during their pregnancy.
"DATA",176.802,20,3)
Individual Characteristic
"DATA",176.802,20,4)
CMS158v1
"DATA",176.802,20,5)
National Quality Forum^CY 2014 EP
"DATA",176.802,20,6)
OptumInsight^OptumInsight
"DATA",176.802,20,7)
PROCESS
"DATA",176.802,20,8)
Supplemental Value Sets
"DATA",176.802,20,9)
None
"DATA",176.802,20,10)
158^InProgress
"DATA",176.802,20,11)
1
"DATA",176.802,20,12,0)
^176.8024P^8^8
"DATA",176.802,20,12,1,0)
201
"DATA",176.802,20,12,2,0)
255
"DATA",176.802,20,12,3,0)
262
"DATA",176.802,20,12,4,0)
271
"DATA",176.802,20,12,5,0)
297
"DATA",176.802,20,12,6,0)
590
"DATA",176.802,20,12,7,0)
638
"DATA",176.802,20,12,8,0)
698
"DATA",176.802,20,13)
This measure identifies pregnant women who had a HBsAg (hepatitis B) test during their pregnancy.
"DATA",176.802,20,14)
PREGNANT WOMEN THAT HAD HBSAG TESTING^EP
"DATA",176.802,20,15)
^18
"DATA",176.802,21,0)
Median Time from ED Arrival to ED Departure for Discharged ED Patients
"DATA",176.802,21,1)
3fd13096-2c8f-40b5-9297-b714e8de9133^0496
"DATA",176.802,21,2,0)
^^1^1^3130419
"DATA",176.802,21,2,1,0)
Median time from emergency department arrival to time of departure from the emergency room for patients discharged from the emergency department.
"DATA",176.802,21,3)
Condition/Diagnosis/Problem
"DATA",176.802,21,4)
CMS32v3
"DATA",176.802,21,5)
National Quality Forum^FY 2014 EH
"DATA",176.802,21,6)
Oklahoma Foundation for Medical Quality^Centers for Medicare & Medicaid Services
"DATA",176.802,21,7)
PROCESS
"DATA",176.802,21,8)
ED-3
"DATA",176.802,21,9)
None
"DATA",176.802,21,10)
32^InProgress
"DATA",176.802,21,11)
3
"DATA",176.802,21,12,0)
^176.8024P^8^8
"DATA",176.802,21,12,1,0)
255
"DATA",176.802,21,12,2,0)
340
"DATA",176.802,21,12,3,0)
348
"DATA",176.802,21,12,4,0)
369
"DATA",176.802,21,12,5,0)
406
"DATA",176.802,21,12,6,0)
590
"DATA",176.802,21,12,7,0)
638
"DATA",176.802,21,12,8,0)
698
"DATA",176.802,21,13)
Median time from emergency department arrival to time of departure from the emergency room for patients discharged from the emergency department.
"DATA",176.802,21,14)
MEDIAN TIME FROM ED ARRIVAL TO ED DEPARTURE FOR DISCHARGED ED PATIENTS^EH
"DATA",176.802,21,15)
^10
"DATA",176.802,22,0)
Discharged on Antithrombotic Therapy
"DATA",176.802,22,1)
42bf391f-38a3-4c0f-9ece-dcd47e9609d9^0435
"DATA",176.802,22,2,0)
^^1^1^3130419
"DATA",176.802,22,2,1,0)
Ischemic stroke patients prescribed antithrombotic therapy at hospital discharge
"DATA",176.802,22,3)
Individual Characteristic
"DATA",176.802,22,4)
CMS104v2
"DATA",176.802,22,5)
National Quality Forum^FY 2014 EH
"DATA",176.802,22,6)
The Joint Commission^The Joint Commission
"DATA",176.802,22,7)
PROCESS
"DATA",176.802,22,8)
Discharged on Antithrombotic The
"DATA",176.802,22,9)
Measure specifications are in the Public Domain
"DATA",176.802,22,10)
104^Complete
"DATA",176.802,22,11)
2
"DATA",176.802,22,12,0)
^176.8024P^18^18
"DATA",176.802,22,12,1,0)
49
"DATA",176.802,22,12,2,0)
229
"DATA",176.802,22,12,3,0)
231
"DATA",176.802,22,12,4,0)
232
"DATA",176.802,22,12,5,0)
255
"DATA",176.802,22,12,6,0)
313
"DATA",176.802,22,12,7,0)
500
"DATA",176.802,22,12,8,0)
514
"DATA",176.802,22,12,9,0)
552
"DATA",176.802,22,12,10,0)
586
"DATA",176.802,22,12,11,0)
590
"DATA",176.802,22,12,12,0)
616
"DATA",176.802,22,12,13,0)
627
"DATA",176.802,22,12,14,0)
634
"DATA",176.802,22,12,15,0)
638
"DATA",176.802,22,12,16,0)
673
"DATA",176.802,22,12,17,0)
698
"DATA",176.802,22,12,18,0)
808
"DATA",176.802,22,13)
Ischemic stroke patients prescribed antithrombotic therapy at hospital discharge
"DATA",176.802,22,14)
DISCHARGED ON ANTITHROMBOTIC THERAPY^EH
"DATA",176.802,22,15)
^19
"DATA",176.802,23,0)
Cervical Cancer Screening
"DATA",176.802,23,1)
42e7e489-790f-427a-a1a6-d6e807f65a6d^0032
"DATA",176.802,23,2,0)
^^1^1^3130419
"DATA",176.802,23,2,1,0)
Percentage of women 21-64 years of age, who received one or more Pap tests to screen for cervical cancer.
"DATA",176.802,23,3)
Individual Characteristic
"DATA",176.802,23,4)
CMS124v1
"DATA",176.802,23,5)
National Quality Forum^CY 2014 EP
"DATA",176.802,23,6)
National Committee for Quality Assurance^National Committee for Quality Assurance
"DATA",176.802,23,7)
PROCESS
"DATA",176.802,23,8)
Supplemental Value Sets
"DATA",176.802,23,9)
Physician Performance Measure (Measures) and related data specifications were developed by the National Committee for Quality Assurance (NCQA).
"DATA",176.802,23,10)
124^InProgress
"DATA",176.802,23,11)
1
"DATA",176.802,23,12,0)
^176.8024P^12^12
"DATA",176.802,23,12,1,0)
255
"DATA",176.802,23,12,2,0)
258
"DATA",176.802,23,12,3,0)
262
"DATA",176.802,23,12,4,0)
333
"DATA",176.802,23,12,5,0)
470
"DATA",176.802,23,12,6,0)
590
"DATA",176.802,23,12,7,0)
594
"DATA",176.802,23,12,8,0)
617
"DATA",176.802,23,12,9,0)
638
"DATA",176.802,23,12,10,0)
662
"DATA",176.802,23,12,11,0)
666
"DATA",176.802,23,12,12,0)
698
"DATA",176.802,23,13)
Percentage of women 21-64 years of age, who received one or more Pap tests to screen for cervical cancer.
"DATA",176.802,23,14)
CERVICAL CANCER SCREENING^EP
"DATA",176.802,23,15)
^12
"DATA",176.802,24,0)
Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)
"DATA",176.802,24,1)
430ffc53-4122-4421-88cc-2edd8117bb3c^0081
"DATA",176.802,24,2,0)
^^1^1^3130419
"DATA",176.802,24,2,1,0)
Percentage of patients aged 18 years and older with a diagnosis of heart failure (HF) with a current or prior left ventricular ejection fraction (LVEF) < 40% who were prescribed ACE inhibitor or ARB therapy either within a 12 m
"DATA",176.802,24,3)
Attribute
"DATA",176.802,24,4)
CMS135v1
"DATA",176.802,24,5)
National Quality Forum^CY 2014 EP
"DATA",176.802,24,6)
American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)^American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)
"DATA",176.802,24,7)
PROCESS
"DATA",176.802,24,8)
HF_ACE_ARB_LVSD
"DATA",176.802,24,9)
Copyright 2012 American College of Cardiology, American Heart Association and American Medical Association. All Rights Reserved.
"DATA",176.802,24,10)
135^Complete
"DATA",176.802,24,11)
1
"DATA",176.802,24,12,0)
^176.8024P^24^24
"DATA",176.802,24,12,1,0)
1
"DATA",176.802,24,12,2,0)
22
"DATA",176.802,24,12,3,0)
127
"DATA",176.802,24,12,4,0)
225
"DATA",176.802,24,12,5,0)
243
"DATA",176.802,24,12,6,0)
255
"DATA",176.802,24,12,7,0)
258
"DATA",176.802,24,12,8,0)
306
"DATA",176.802,24,12,9,0)
333
"DATA",176.802,24,12,10,0)
493
"DATA",176.802,24,12,11,0)
515
"DATA",176.802,24,12,12,0)
567
"DATA",176.802,24,12,13,0)
587
"DATA",176.802,24,12,14,0)
590
"DATA",176.802,24,12,15,0)
594
"DATA",176.802,24,12,16,0)
611
"DATA",176.802,24,12,17,0)
628
"DATA",176.802,24,12,18,0)
637
"DATA",176.802,24,12,19,0)
638
"DATA",176.802,24,12,20,0)
657
"DATA",176.802,24,12,21,0)
698
"DATA",176.802,24,12,22,0)
709
"DATA",176.802,24,12,23,0)
754
"DATA",176.802,24,12,24,0)
809
"DATA",176.802,24,13)
Percentage of patients aged 18 years and older with a diagnosis of heart failure (HF) with a current or prior left ventricular ejection fraction (LVEF) < 40% who were prescribed ACE inhibitor or ARB therapy either within a 12 m
"DATA",176.802,24,14)
HEART FAILURE (HF): ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITOR OR ANGIOTENSIN RECEPTOR BLOCKER (ARB) THERAPY FOR LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (LVSD)^EP
"DATA",176.802,24,15)
^15
"DATA",176.802,25,0)
Ischemic Vascular Disease (IVD): Complete Lipid Panel and LDL Control
"DATA",176.802,25,1)
500e4792-7f94-4e34-8546-ee71c56fe463^0075
"DATA",176.802,25,2,0)
^^1^1^3130419
"DATA",176.802,25,2,1,0)
Percentage of patients 18 years of age and older who were discharged alive for acute myocardial infarction (AMI), coronary artery bypass graft (CABG) or percutaneous coronary interventions (PCI) in the 12 months prior to the measu
"DATA",176.802,25,3)
Laboratory Test
"DATA",176.802,25,4)
CMS182v1
"DATA",176.802,25,5)
National Quality Forum^CY 2014 EP
"DATA",176.802,25,6)
National Committee for Quality Assurance^National Committee for Quality Assurance
"DATA",176.802,25,7)
PROCESS
"DATA",176.802,25,8)
IVD_Lipid_LDL
"DATA",176.802,25,9)
Physician Performance Measure (Measures) and related data specifications were developed by the National Committee for Quality Assurance (NCQA).
"DATA",176.802,25,10)
182^Complete
"DATA",176.802,25,11)
1
"DATA",176.802,25,12,0)
^176.8024P^19^19
"DATA",176.802,25,12,1,0)
8
"DATA",176.802,25,12,2,0)
43
"DATA",176.802,25,12,3,0)
176
"DATA",176.802,25,12,4,0)
186
"DATA",176.802,25,12,5,0)
255
"DATA",176.802,25,12,6,0)
258
"DATA",176.802,25,12,7,0)
298
"DATA",176.802,25,12,8,0)
333
"DATA",176.802,25,12,9,0)
501
"DATA",176.802,25,12,10,0)
507
"DATA",176.802,25,12,11,0)
590
"DATA",176.802,25,12,12,0)
594
"DATA",176.802,25,12,13,0)
638
"DATA",176.802,25,12,14,0)
639
"DATA",176.802,25,12,15,0)
662
"DATA",176.802,25,12,16,0)
666
"DATA",176.802,25,12,17,0)
698
"DATA",176.802,25,12,18,0)
768
"DATA",176.802,25,12,19,0)
774
"DATA",176.802,25,13)
Percentage of patients 18 years of age and older who were discharged alive for acute myocardial infarction (AMI), coronary artery bypass graft (CABG) or percutaneous coronary interventions (PCI) in the 12 months prior to the measu
"DATA",176.802,25,14)
ISCHEMIC VASCULAR DISEASE (IVD): COMPLETE LIPID PANEL AND LDL CONTROL^EP
"DATA",176.802,25,15)
^15
"DATA",176.802,26,0)
Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy
"DATA",176.802,26,1)
50164228-9d64-4efc-af67-da0547ff61f1^0088
"DATA",176.802,26,2,0)
^^1^1^3130419
"DATA",176.802,26,2,1,0)
Percentage of patients aged 18 years and older with a diagnosis of diabetic retinopathy who had a dilated macular or fundus exam performed which included documentation of the level of severity of retinopathy and the presence or ab
"DATA",176.802,26,3)
Individual Characteristic
"DATA",176.802,26,4)
CMS167v1
"DATA",176.802,26,5)
National Quality Forum^CY 2014 EP
"DATA",176.802,26,6)
National Committee for Quality Assurance^American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)
"DATA",176.802,26,7)
PROCESS
"DATA",176.802,26,8)
Supplemental Value Sets
"DATA",176.802,26,9)
Copyright 2012 American Medical Association and National Committee for Quality Assurance. All Rights Reserved.
"DATA",176.802,26,10)
167^Complete
"DATA",176.802,26,11)
1
"DATA",176.802,26,12,0)
^176.8024P^16^16
"DATA",176.802,26,12,1,0)
127
"DATA",176.802,26,12,2,0)
216
"DATA",176.802,26,12,3,0)
255
"DATA",176.802,26,12,4,0)
258
"DATA",176.802,26,12,5,0)
519
"DATA",176.802,26,12,6,0)
531
"DATA",176.802,26,12,7,0)
533
"DATA",176.802,26,12,8,0)
534
"DATA",176.802,26,12,9,0)
587
"DATA",176.802,26,12,10,0)
590
"DATA",176.802,26,12,11,0)
594
"DATA",176.802,26,12,12,0)
596
"DATA",176.802,26,12,13,0)
611
"DATA",176.802,26,12,14,0)
628
"DATA",176.802,26,12,15,0)
638
"DATA",176.802,26,12,16,0)
698
"DATA",176.802,26,13)
Percentage of patients aged 18 years and older with a diagnosis of diabetic retinopathy who had a dilated macular or fundus exam performed which included documentation of the level of severity of retinopathy and the presence or ab
"DATA",176.802,26,14)
DIABETIC RETINOPATHY: DOCUMENTATION OF PRESENCE OR ABSENCE OF MACULAR EDEMA AND LEVEL OF SEVERITY OF RETINOPATHY^EP
"DATA",176.802,26,15)
^9
"DATA",176.802,27,0)
Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care
"DATA",176.802,27,1)
53d6d7c3-43fb-4d24-8099-17e74c022c05^0089
"DATA",176.802,27,2,0)
^^1^1^3130419
"DATA",176.802,27,2,1,0)
Percentage of patients aged 18 years and older with a diagnosis of diabetic retinopathy who had a dilated macular or fundus exam performed with documented communication to the physician who manages the ongoing care of the patient 
"DATA",176.802,27,3)
Individual Characteristic
"DATA",176.802,27,4)
CMS142v1
"DATA",176.802,27,5)
National Quality Forum^CY 2014 EP
"DATA",176.802,27,6)
National Committee for Quality Assurance^American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)
"DATA",176.802,27,7)
PROCESS
"DATA",176.802,27,8)
Supplemental Value Sets
"DATA",176.802,27,9)
Copyright 2012 American Medical Association and National Committee for Quality Assurance. All Rights Reserved.
"DATA",176.802,27,10)
142^Complete
"DATA",176.802,27,11)
1
"DATA",176.802,27,12,0)
^176.8024P^13^13
"DATA",176.802,27,12,1,0)
127
"DATA",176.802,27,12,2,0)
216
"DATA",176.802,27,12,3,0)
255
"DATA",176.802,27,12,4,0)
258
"DATA",176.802,27,12,5,0)
534
"DATA",176.802,27,12,6,0)
587
"DATA",176.802,27,12,7,0)
590
"DATA",176.802,27,12,8,0)
594
"DATA",176.802,27,12,9,0)
596
"DATA",176.802,27,12,10,0)
611
"DATA",176.802,27,12,11,0)
628
"DATA",176.802,27,12,12,0)
638
"DATA",176.802,27,12,13,0)
698
"DATA",176.802,27,13)
Percentage of patients aged 18 years and older with a diagnosis of diabetic retinopathy who had a dilated macular or fundus exam performed with documented communication to the physician who manages the ongoing care of the patient 
"DATA",176.802,27,14)
DIABETIC RETINOPATHY: COMMUNICATION WITH THE PHYSICIAN MANAGING ONGOING DIABETES CARE^EP
"DATA",176.802,27,15)
^9
"DATA",176.802,28,0)
Pneumonia Vaccination Status for Older Adults
"DATA",176.802,28,1)
59657b9b-01bf-4979-a090-8534da1d0516^0043
"DATA",176.802,28,2,0)
^^1^1^3130419
"DATA",176.802,28,2,1,0)
Percentage of patients 65 years of age and older who have ever received a pneumococcal vaccine.
"DATA",176.802,28,3)
Individual Characteristic
"DATA",176.802,28,4)
CMS127v1
"DATA",176.802,28,5)
National Quality Forum^CY 2014 EP
"DATA",176.802,28,6)
National Committee for Quality Assurance^National Committee for Quality Assurance
"DATA",176.802,28,7)
PROCESS
"DATA",176.802,28,8)
Supplemental Value Sets
"DATA",176.802,28,9)
Physician Performance Measure (Measures) and related data specifications were developed by the National Committee for Quality Assurance (NCQA).
"DATA",176.802,28,10)
127^InProgress
"DATA",176.802,28,11)
1
"DATA",176.802,28,12,0)
^176.8024P^13^13
"DATA",176.802,28,12,1,0)
43
"DATA",176.802,28,12,2,0)
255
"DATA",176.802,28,12,3,0)
258
"DATA",176.802,28,12,4,0)
332
"DATA",176.802,28,12,5,0)
333
"DATA",176.802,28,12,6,0)
590
"DATA",176.802,28,12,7,0)
594
"DATA",176.802,28,12,8,0)
638
"DATA",176.802,28,12,9,0)
649
"DATA",176.802,28,12,10,0)
650
"DATA",176.802,28,12,11,0)
662
"DATA",176.802,28,12,12,0)
666
"DATA",176.802,28,12,13,0)
698
"DATA",176.802,28,13)
Percentage of patients 65 years of age and older who have ever received a pneumococcal vaccine.
"DATA",176.802,28,14)
PNEUMONIA VACCINATION STATUS FOR OLDER ADULTS^EP
"DATA",176.802,28,15)
^12
"DATA",176.802,29,0)
Use of Appropriate Medications for Asthma
"DATA",176.802,29,1)
59e84144-6332-4369-aebd-03a7899ca3da^0036
"DATA",176.802,29,2,0)
^^1^1^3130419
"DATA",176.802,29,2,1,0)
Percentage of patients 5-64 years of age who were identified as having persistent asthma and were appropriately prescribed medication during the measurement period.
"DATA",176.802,29,3)
Individual Characteristic
"DATA",176.802,29,4)
CMS126v1
"DATA",176.802,29,5)
National Quality Forum^CY 2014 EP
"DATA",176.802,29,6)
National Committee for Quality Assurance^National Committee for Quality Assurance
"DATA",176.802,29,7)
PROCESS
"DATA",176.802,29,8)
Supplemental Value Sets
"DATA",176.802,29,9)
Physician Performance Measure (Measures) and related data specifications were developed by the National Committee for Quality Assurance (NCQA).
"DATA",176.802,29,10)
126^InProgress
"DATA",176.802,29,11)
1
"DATA",176.802,29,12,0)
^176.8024P^16^16
"DATA",176.802,29,12,1,0)
10
"DATA",176.802,29,12,2,0)
151
"DATA",176.802,29,12,3,0)
247
"DATA",176.802,29,12,4,0)
255
"DATA",176.802,29,12,5,0)
258
"DATA",176.802,29,12,6,0)
333
"DATA",176.802,29,12,7,0)
590
"DATA",176.802,29,12,8,0)
594
"DATA",176.802,29,12,9,0)
638
"DATA",176.802,29,12,10,0)
642
"DATA",176.802,29,12,11,0)
655
"DATA",176.802,29,12,12,0)
661
"DATA",176.802,29,12,13,0)
662
"DATA",176.802,29,12,14,0)
666
"DATA",176.802,29,12,15,0)
667
"DATA",176.802,29,12,16,0)
698
"DATA",176.802,29,13)
Percentage of patients 5-64 years of age who were identified as having persistent asthma and were appropriately prescribed medication during the measurement period.
"DATA",176.802,29,14)
USE OF APPROPRIATE MEDICATIONS FOR ASTHMA^EP
"DATA",176.802,29,15)
^7
"DATA",176.802,30,0)
Major Depressive Disorder (MDD): Suicide Risk Assessment
"DATA",176.802,30,1)
60176fbf-bfdc-4892-9c9e-604f206553c8^0104
"DATA",176.802,30,2,0)
^^1^1^3130419
"DATA",176.802,30,2,1,0)
Percentage of patients aged 18 years and older with a new diagnosis or recurrent episode of MDD who had a suicide risk assessment completed at each visit during the measurement period.
"DATA",176.802,30,3)
Intervention
"DATA",176.802,30,4)
CMS161v1
"DATA",176.802,30,5)
National Quality Forum^CY 2014 EP
"DATA",176.802,30,6)
American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)^American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)
"DATA",176.802,30,7)
PROCESS
"DATA",176.802,30,8)
MDD_Suicide
"DATA",176.802,30,9)
Copyright 2012 American Medical Association. All Rights Reserved.
"DATA",176.802,30,10)
161^Complete
"DATA",176.802,30,11)
1
"DATA",176.802,30,12,0)
^176.8024P^15^15
"DATA",176.802,30,12,1,0)
255
"DATA",176.802,30,12,2,0)
258
"DATA",176.802,30,12,3,0)
536
"DATA",176.802,30,12,4,0)
590
"DATA",176.802,30,12,5,0)
594
"DATA",176.802,30,12,6,0)
611
"DATA",176.802,30,12,7,0)
628
"DATA",176.802,30,12,8,0)
638
"DATA",176.802,30,12,9,0)
686
"DATA",176.802,30,12,10,0)
690
"DATA",176.802,30,12,11,0)
691
"DATA",176.802,30,12,12,0)
692
"DATA",176.802,30,12,13,0)
694
"DATA",176.802,30,12,14,0)
698
"DATA",176.802,30,12,15,0)
752
"DATA",176.802,30,13)
Percentage of patients aged 18 years and older with a new diagnosis or recurrent episode of MDD who had a suicide risk assessment completed at each visit during the measurement period.
"DATA",176.802,30,14)
MAJOR DEPRESSIVE DISORDER (MDD): SUICIDE RISK ASSESSMENT^EP
"DATA",176.802,30,15)
^3
"DATA",176.802,31,0)
Children Who Have Dental Decay or Cavities
"DATA",176.802,31,1)
61947125-4376-4a7b-ab7a-ac2be9bd9138^Not Applicable
"DATA",176.802,31,2,0)
^^1^1^3130419
"DATA",176.802,31,2,1,0)
Percentage of children, age 0-20 years, who have had tooth decay or cavities during the measurement period.
"DATA",176.802,31,3)
Individual Characteristic
"DATA",176.802,31,4)
CMS75v1
"DATA",176.802,31,5)
None^CY 2014 EP
"DATA",176.802,31,6)
TBD^TBD
"DATA",176.802,31,7)
OUTCOME
"DATA",176.802,31,8)
Supplemental Value Sets
"DATA",176.802,31,9)
TBD
"DATA",176.802,31,10)
75^InProgress
"DATA",176.802,31,11)
1
"DATA",176.802,31,12,0)
^176.8024P^12^12
"DATA",176.802,31,12,1,0)
153
"DATA",176.802,31,12,2,0)
206
"DATA",176.802,31,12,3,0)
255
"DATA",176.802,31,12,4,0)
258
"DATA",176.802,31,12,5,0)
590
"DATA",176.802,31,12,6,0)
594
"DATA",176.802,31,12,7,0)
638
"DATA",176.802,31,12,8,0)
661
"DATA",176.802,31,12,9,0)
662
"DATA",176.802,31,12,10,0)
666
"DATA",176.802,31,12,11,0)
667
"DATA",176.802,31,12,12,0)
698
"DATA",176.802,31,13)
Percentage of children, age 0-20 years, who have had tooth decay or cavities during the measurement period.
"DATA",176.802,31,14)
CHILDREN WHO HAVE DENTAL DECAY OR CAVITIES^EP
"DATA",176.802,31,15)
^7
"DATA",176.802,32,0)
Venous Thromboembolism Patients with Anticoagulation Overlap Therapy
"DATA",176.802,32,1)
6f069bb2-b3c4-4bf4-adc5-f6dd424a10b7^0373
"DATA",176.802,32,2,0)
^^1^1^3130419
"DATA",176.802,32,2,1,0)
This measure assesses the number of patients diagnosed with confirmed VTE who received an overlap of parenteral (intravenous [IV] or subcutaneous [subcu]) anticoagulation and warfarin therapy. For patients who received less than f
"DATA",176.802,32,3)
Individual Characteristic
"DATA",176.802,32,4)
CMS73v2
"DATA",176.802,32,5)
National Quality Forum^FY 2014 EH
"DATA",176.802,32,6)
Joint Commission^Joint Commission
"DATA",176.802,32,7)
PROCESS
"DATA",176.802,32,8)
VTE 3
"DATA",176.802,32,9)
Measure specifications are in the Public Domain.
"DATA",176.802,32,10)
73^Complete
"DATA",176.802,32,11)
2
"DATA",176.802,32,12,0)
^176.8024P^23^23
"DATA",176.802,32,12,1,0)
229
"DATA",176.802,32,12,2,0)
231
"DATA",176.802,32,12,3,0)
232
"DATA",176.802,32,12,4,0)
246
"DATA",176.802,32,12,5,0)
255
"DATA",176.802,32,12,6,0)
472
"DATA",176.802,32,12,7,0)
489
"DATA",176.802,32,12,8,0)
514
"DATA",176.802,32,12,9,0)
552
"DATA",176.802,32,12,10,0)
590
"DATA",176.802,32,12,11,0)
592
"DATA",176.802,32,12,12,0)
600
"DATA",176.802,32,12,13,0)
616
"DATA",176.802,32,12,14,0)
621
"DATA",176.802,32,12,15,0)
627
"DATA",176.802,32,12,16,0)
634
"DATA",176.802,32,12,17,0)
638
"DATA",176.802,32,12,18,0)
698
"DATA",176.802,32,12,19,0)
783
"DATA",176.802,32,12,20,0)
784
"DATA",176.802,32,12,21,0)
794
"DATA",176.802,32,12,22,0)
801
"DATA",176.802,32,12,23,0)
808
"DATA",176.802,32,13)
This measure assesses the number of patients diagnosed with confirmed VTE who received an overlap of parenteral (intravenous [IV] or subcutaneous [subcu]) anticoagulation and warfarin therapy. For patients who received less than f
"DATA",176.802,32,14)
VENOUS THROMBOEMBOLISM PATIENTS WITH ANTICOAGULATION OVERLAP THERAPY^EH
"DATA",176.802,32,15)
^21
"DATA",176.802,33,0)
ADHD: Follow-Up Care for Children Prescribed Attention-Deficit/Hyperactivity Disorder (ADHD) Medication
"DATA",176.802,33,1)
703cc49b-b653-4885-80e8-245a057f5ae9^0108
"DATA",176.802,33,2,0)
^^1^1^3130419
"DATA",176.802,33,2,1,0)
Percentage of children 6-12 years of age and newly dispensed a medication for attention-deficit/hyperactivity disorder (ADHD) who had appropriate follow-up care.  Two rates are reported.  
"DATA",176.802,33,3)
Attribute
"DATA",176.802,33,4)
CMS136v1
"DATA",176.802,33,5)
National Quality Forum^CY 2014 EP
"DATA",176.802,33,6)
National Committee for Quality Assurance^National Committee for Quality Assurance
"DATA",176.802,33,7)
PROCESS
"DATA",176.802,33,8)
ADHD_Follow-Up
"DATA",176.802,33,9)
Physician Performance Measure (Measures) and related data specifications were developed by the National Committee for Quality Assurance (NCQA).
"DATA",176.802,33,10)
136^Complete
"DATA",176.802,33,11)
1
"DATA",176.802,33,12,0)
^176.8024P^24^24
"DATA",176.802,33,12,1,0)
2
"DATA",176.802,33,12,2,0)
29
"DATA",176.802,33,12,3,0)
79
"DATA",176.802,33,12,4,0)
228
"DATA",176.802,33,12,5,0)
255
"DATA",176.802,33,12,6,0)
258
"DATA",176.802,33,12,7,0)
333
"DATA",176.802,33,12,8,0)
437
"DATA",176.802,33,12,9,0)
562
"DATA",176.802,33,12,10,0)
573
"DATA",176.802,33,12,11,0)
590
"DATA",176.802,33,12,12,0)
594
"DATA",176.802,33,12,13,0)
611
"DATA",176.802,33,12,14,0)
638
"DATA",176.802,33,12,15,0)
661
"DATA",176.802,33,12,16,0)
663
"DATA",176.802,33,12,17,0)
665
"DATA",176.802,33,12,18,0)
667
"DATA",176.802,33,12,19,0)
695
"DATA",176.802,33,12,20,0)
698
"DATA",176.802,33,12,21,0)
750
"DATA",176.802,33,12,22,0)
759
"DATA",176.802,33,12,23,0)
760
"DATA",176.802,33,12,24,0)
810
"DATA",176.802,33,13)
Percentage of children 6-12 years of age and newly dispensed a medication for attention-deficit/hyperactivity disorder (ADHD) who had appropriate follow-up care.  Two rates are reported.  
"DATA",176.802,33,14)
ADHD: FOLLOW-UP CARE FOR CHILDREN PRESCRIBED ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) MEDICATION^EP
"DATA",176.802,33,15)
^7
"DATA",176.802,34,0)
Diabetes: Urine Protein Screening
"DATA",176.802,34,1)
7b2a9277-43da-4d99-9bee-6ac271a07747^0062
"DATA",176.802,34,2,0)
^^1^1^3130419
"DATA",176.802,34,2,1,0)
The percentage of patients 18-75 years of age with diabetes who had a nephropathy screening test or evidence of nephropathy during the measurement period.
"DATA",176.802,34,3)
Procedure
"DATA",176.802,34,4)
CMS134v1
"DATA",176.802,34,5)
National Quality Forum^CY 2014 EP
"DATA",176.802,34,6)
National Committee for Quality Assurance^National Committee for Quality Assurance
"DATA",176.802,34,7)
PROCESS
"DATA",176.802,34,8)
Diab_Urine
"DATA",176.802,34,9)
Physician Performance Measure (Measures) and related data specifications were developed by the National Committee for Quality Assurance (NCQA).
"DATA",176.802,34,10)
134^Complete
"DATA",176.802,34,11)
1
"DATA",176.802,34,12,0)
^176.8024P^26^26
"DATA",176.802,34,12,1,0)
1
"DATA",176.802,34,12,2,0)
43
"DATA",176.802,34,12,3,0)
212
"DATA",176.802,34,12,4,0)
215
"DATA",176.802,34,12,5,0)
219
"DATA",176.802,34,12,6,0)
220
"DATA",176.802,34,12,7,0)
242
"DATA",176.802,34,12,8,0)
255
"DATA",176.802,34,12,9,0)
258
"DATA",176.802,34,12,10,0)
285
"DATA",176.802,34,12,11,0)
290
"DATA",176.802,34,12,12,0)
333
"DATA",176.802,34,12,13,0)
466
"DATA",176.802,34,12,14,0)
503
"DATA",176.802,34,12,15,0)
529
"DATA",176.802,34,12,16,0)
565
"DATA",176.802,34,12,17,0)
590
"DATA",176.802,34,12,18,0)
594
"DATA",176.802,34,12,19,0)
609
"DATA",176.802,34,12,20,0)
638
"DATA",176.802,34,12,21,0)
653
"DATA",176.802,34,12,22,0)
662
"DATA",176.802,34,12,23,0)
666
"DATA",176.802,34,12,24,0)
684
"DATA",176.802,34,12,25,0)
698
"DATA",176.802,34,12,26,0)
792
"DATA",176.802,34,13)
The percentage of patients 18-75 years of age with diabetes who had a nephropathy screening test or evidence of nephropathy during the measurement period.
"DATA",176.802,34,14)
DIABETES: URINE PROTEIN SCREENING^EP
"DATA",176.802,34,15)
^9
"DATA",176.802,35,0)
Dementia: Cognitive Assessment
"DATA",176.802,35,1)
7c443b9b-1ad1-4467-b527-defc445701ff^Not Applicable
"DATA",176.802,35,2,0)
^^1^1^3130419
"DATA",176.802,35,2,1,0)
Percentage of patients, regardless of age, with a diagnosis of dementia for whom an assessment of cognition is performed and the results reviewed at least once within a 12 month period.
"DATA",176.802,35,3)
Risk Category/Assessment
"DATA",176.802,35,4)
CMS149v1
"DATA",176.802,35,5)
None^CY 2014 EP
"DATA",176.802,35,6)
American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)^American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)
"DATA",176.802,35,7)
PROCESS
"DATA",176.802,35,8)
Dementia_Cognitive
"DATA",176.802,35,9)
Copyright 2012 American Medical Association. All Rights Reserved.
"DATA",176.802,35,10)
149^Complete
"DATA",176.802,35,11)
1
"DATA",176.802,35,12,0)
^176.8024P^23^23
"DATA",176.802,35,12,1,0)
80
"DATA",176.802,35,12,2,0)
127
"DATA",176.802,35,12,3,0)
159
"DATA",176.802,35,12,4,0)
205
"DATA",176.802,35,12,5,0)
255
"DATA",176.802,35,12,6,0)
258
"DATA",176.802,35,12,7,0)
333
"DATA",176.802,35,12,8,0)
587
"DATA",176.802,35,12,9,0)
590
"DATA",176.802,35,12,10,0)
593
"DATA",176.802,35,12,11,0)
594
"DATA",176.802,35,12,12,0)
611
"DATA",176.802,35,12,13,0)
628
"DATA",176.802,35,12,14,0)
638
"DATA",176.802,35,12,15,0)
686
"DATA",176.802,35,12,16,0)
688
"DATA",176.802,35,12,17,0)
689
"DATA",176.802,35,12,18,0)
690
"DATA",176.802,35,12,19,0)
691
"DATA",176.802,35,12,20,0)
692
"DATA",176.802,35,12,21,0)
698
"DATA",176.802,35,12,22,0)
737
"DATA",176.802,35,12,23,0)
745
"DATA",176.802,35,13)
Percentage of patients, regardless of age, with a diagnosis of dementia for whom an assessment of cognition is performed and the results reviewed at least once within a 12 month period.
"DATA",176.802,35,14)
DEMENTIA: COGNITIVE ASSESSMENT^EP
"DATA",176.802,35,15)
^22
"DATA",176.802,36,0)
Exclusive Breast Milk Feeding
"DATA",176.802,36,1)
7d374c6a-3821-4333-a1bc-4531005d77b8^0480
"DATA",176.802,36,2,0)
^^1^1^3130419
"DATA",176.802,36,2,1,0)
PC-05 Exclusive breast milk feeding during the newborn's entire hospitalizationPC-05a Exclusive breast milk feeding during the newborns entire hospitalization considering mothers choice
"DATA",176.802,36,3)
Condition/Diagnosis/Problem
"DATA",176.802,36,4)
CMS9v2
"DATA",176.802,36,5)
National Quality Forum^FY 2014 EH
"DATA",176.802,36,6)
Joint Commission^Joint Commission
"DATA",176.802,36,7)
PROCESS
"DATA",176.802,36,8)
Exclusive Breast Milk Feeding
"DATA",176.802,36,9)
LOINC(R) is a registered trademark of the Regenstrief Institute.
"DATA",176.802,36,10)
9^Complete
"DATA",176.802,36,11)
2
"DATA",176.802,36,12,0)
^176.8024P^19^19
"DATA",176.802,36,12,1,0)
90
"DATA",176.802,36,12,2,0)
116
"DATA",176.802,36,12,3,0)
222
"DATA",176.802,36,12,4,0)
229
"DATA",176.802,36,12,5,0)
255
"DATA",176.802,36,12,6,0)
275
"DATA",176.802,36,12,7,0)
286
"DATA",176.802,36,12,8,0)
489
"DATA",176.802,36,12,9,0)
524
"DATA",176.802,36,12,10,0)
543
"DATA",176.802,36,12,11,0)
578
"DATA",176.802,36,12,12,0)
590
"DATA",176.802,36,12,13,0)
620
"DATA",176.802,36,12,14,0)
622
"DATA",176.802,36,12,15,0)
627
"DATA",176.802,36,12,16,0)
638
"DATA",176.802,36,12,17,0)
698
"DATA",176.802,36,12,18,0)
739
"DATA",176.802,36,12,19,0)
740
"DATA",176.802,36,13)
PC-05 Exclusive breast milk feeding during the newborn's entire hospitalizationPC-05a Exclusive breast milk feeding during the newborns entire hospitalization considering mothers choice
"DATA",176.802,36,14)
EXCLUSIVE BREAST MILK FEEDING^EH
"DATA",176.802,36,15)
^16
"DATA",176.802,37,0)
Assessed for Rehabilitation
"DATA",176.802,37,1)
7dc26160-e615-4cc2-879c-75985189ec1a^0441
"DATA",176.802,37,2,0)
^^1^1^3130419
"DATA",176.802,37,2,1,0)
Ischemic or hemorrhagic stroke patients who were assessed for rehabilitation services.
"DATA",176.802,37,3)
Individual Characteristic
"DATA",176.802,37,4)
CMS102v2
"DATA",176.802,37,5)
National Quality Forum^FY 2014 EH
"DATA",176.802,37,6)
The Joint Commission^The Joint Commission
"DATA",176.802,37,7)
PROCESS
"DATA",176.802,37,8)
Assessed for Rehabilitation
"DATA",176.802,37,9)
Measure specifications are in the Public Domain
"DATA",176.802,37,10)
102^Complete
"DATA",176.802,37,11)
2
"DATA",176.802,37,12,0)
^176.8024P^19^19
"DATA",176.802,37,12,1,0)
229
"DATA",176.802,37,12,2,0)
231
"DATA",176.802,37,12,3,0)
232
"DATA",176.802,37,12,4,0)
233
"DATA",176.802,37,12,5,0)
255
"DATA",176.802,37,12,6,0)
313
"DATA",176.802,37,12,7,0)
500
"DATA",176.802,37,12,8,0)
514
"DATA",176.802,37,12,9,0)
552
"DATA",176.802,37,12,10,0)
586
"DATA",176.802,37,12,11,0)
590
"DATA",176.802,37,12,12,0)
616
"DATA",176.802,37,12,13,0)
627
"DATA",176.802,37,12,14,0)
634
"DATA",176.802,37,12,15,0)
638
"DATA",176.802,37,12,16,0)
673
"DATA",176.802,37,12,17,0)
698
"DATA",176.802,37,12,18,0)
707
"DATA",176.802,37,12,19,0)
808
"DATA",176.802,37,13)
Ischemic or hemorrhagic stroke patients who were assessed for rehabilitation services.
"DATA",176.802,37,14)
ASSESSED FOR REHABILITATION^EH
"DATA",176.802,37,15)
^19
"DATA",176.802,38,0)
Venous Thromboembolism Discharge Instructions
"DATA",176.802,38,1)
7fe69617-fa28-4305-a2b8-ceb6bcd9693d^0375
"DATA",176.802,38,2,0)
^^1^1^3130419
"DATA",176.802,38,2,1,0)
This measure assesses the number of patients diagnosed with confirmed VTE that are discharged to home, home care, court/law enforcement or home on hospice care on warfarin with written discharge instructions that address all four 
"DATA",176.802,38,3)
Individual Characteristic
"DATA",176.802,38,4)
CMS110v2
"DATA",176.802,38,5)
National Quality Forum^FY 2014 EH
"DATA",176.802,38,6)
Joint Commission^Joint Commission
"DATA",176.802,38,7)
PROCESS
"DATA",176.802,38,8)
Venous Thromboembolism Discharge
"DATA",176.802,38,9)
Measure specifications are in the Public Domain
"DATA",176.802,38,10)
110^Complete
"DATA",176.802,38,11)
2
"DATA",176.802,38,12,0)
^176.8024P^23^23
"DATA",176.802,38,12,1,0)
18
"DATA",176.802,38,12,2,0)
230
"DATA",176.802,38,12,3,0)
232
"DATA",176.802,38,12,4,0)
238
"DATA",176.802,38,12,5,0)
246
"DATA",176.802,38,12,6,0)
255
"DATA",176.802,38,12,7,0)
266
"DATA",176.802,38,12,8,0)
473
"DATA",176.802,38,12,9,0)
489
"DATA",176.802,38,12,10,0)
559
"DATA",176.802,38,12,11,0)
590
"DATA",176.802,38,12,12,0)
592
"DATA",176.802,38,12,13,0)
634
"DATA",176.802,38,12,14,0)
638
"DATA",176.802,38,12,15,0)
698
"DATA",176.802,38,12,16,0)
702
"DATA",176.802,38,12,17,0)
783
"DATA",176.802,38,12,18,0)
784
"DATA",176.802,38,12,19,0)
794
"DATA",176.802,38,12,20,0)
799
"DATA",176.802,38,12,21,0)
801
"DATA",176.802,38,12,22,0)
805
"DATA",176.802,38,12,23,0)
808
"DATA",176.802,38,13)
This measure assesses the number of patients diagnosed with confirmed VTE that are discharged to home, home care, court/law enforcement or home on hospice care on warfarin with written discharge instructions that address all four 
"DATA",176.802,38,14)
VENOUS THROMBOEMBOLISM DISCHARGE INSTRUCTIONS^EH
"DATA",176.802,38,15)
^21
"DATA",176.802,39,0)
Coronary Artery Disease (CAD): Beta-Blocker TherapyPrior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%)
"DATA",176.802,39,1)
80744ae2-de81-4b16-a71d-69522eb865c5^0070
"DATA",176.802,39,2,0)
^^1^1^3130419
"DATA",176.802,39,2,1,0)
Percentage of patients aged 18 years and older with a diagnosis of coronary artery disease seen within a 12 month period who also have a prior MI or a current or prior LVEF <40% who were prescribed beta-blocker therapy
"DATA",176.802,39,3)
Attribute
"DATA",176.802,39,4)
CMS145v1
"DATA",176.802,39,5)
National Quality Forum^CY 2014 EP
"DATA",176.802,39,6)
American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)^American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)
"DATA",176.802,39,7)
PROCESS
"DATA",176.802,39,8)
BB_MI_LVEF
"DATA",176.802,39,9)
Copyright 2012 American College of Cardiology, American Heart Association and American Medical Association. All Rights Reserved.
"DATA",176.802,39,10)
145^Complete
"DATA",176.802,39,11)
1
"DATA",176.802,39,12,0)
^176.8024P^30^30
"DATA",176.802,39,12,1,0)
24
"DATA",176.802,39,12,2,0)
52
"DATA",176.802,39,12,3,0)
62
"DATA",176.802,39,12,4,0)
84
"DATA",176.802,39,12,5,0)
85
"DATA",176.802,39,12,6,0)
95
"DATA",176.802,39,12,7,0)
123
"DATA",176.802,39,12,8,0)
124
"DATA",176.802,39,12,9,0)
125
"DATA",176.802,39,12,10,0)
127
"DATA",176.802,39,12,11,0)
187
"DATA",176.802,39,12,12,0)
243
"DATA",176.802,39,12,13,0)
255
"DATA",176.802,39,12,14,0)
258
"DATA",176.802,39,12,15,0)
307
"DATA",176.802,39,12,16,0)
333
"DATA",176.802,39,12,17,0)
467
"DATA",176.802,39,12,18,0)
495
"DATA",176.802,39,12,19,0)
515
"DATA",176.802,39,12,20,0)
567
"DATA",176.802,39,12,21,0)
571
"DATA",176.802,39,12,22,0)
587
"DATA",176.802,39,12,23,0)
590
"DATA",176.802,39,12,24,0)
594
"DATA",176.802,39,12,25,0)
611
"DATA",176.802,39,12,26,0)
628
"DATA",176.802,39,12,27,0)
638
"DATA",176.802,39,12,28,0)
698
"DATA",176.802,39,12,29,0)
754
"DATA",176.802,39,12,30,0)
809
"DATA",176.802,39,13)
Percentage of patients aged 18 years and older with a diagnosis of coronary artery disease seen within a 12 month period who also have a prior MI or a current or prior LVEF <40% who were prescribed beta-blocker therapy
"DATA",176.802,39,14)
CORONARY ARTERY DISEASE (CAD): BETA-BLOCKER THERAPYPRIOR MYOCARDIAL INFARCTION (MI) OR LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (LVEF <40%)^EP
"DATA",176.802,39,15)
^15
"DATA",176.802,40,0)
Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients
"DATA",176.802,40,1)
8243eae0-bbd7-4107-920b-fc3db04b9584^0147
"DATA",176.802,40,2,0)
^^1^1^3130419
"DATA",176.802,40,2,1,0)
(PN-6) Immunocompetent patients with Community-Acquired Pneumonia who receive an initial antibiotic regimen during the first 24 hours that is consistent with current guidelines 
"DATA",176.802,40,3)
Individual Characteristic
"DATA",176.802,40,4)
CMS188v3
"DATA",176.802,40,5)
National Quality Forum^FY 2014 EH
"DATA",176.802,40,6)
Oklahoma Foundation for Medical Quality^Centers for Medicare & Medicaid Services
"DATA",176.802,40,7)
PROCESS
"DATA",176.802,40,8)
PN 6
"DATA",176.802,40,9)
Measure specifications are in the Public Domain
"DATA",176.802,40,10)
188^InProgress
"DATA",176.802,40,11)
3
"DATA",176.802,40,12,0)
^176.8024P^65^65
"DATA",176.802,40,12,1,0)
157
"DATA",176.802,40,12,2,0)
192
"DATA",176.802,40,12,3,0)
255
"DATA",176.802,40,12,4,0)
337
"DATA",176.802,40,12,5,0)
339
"DATA",176.802,40,12,6,0)
345
"DATA",176.802,40,12,7,0)
350
"DATA",176.802,40,12,8,0)
353
"DATA",176.802,40,12,9,0)
354
"DATA",176.802,40,12,10,0)
355
"DATA",176.802,40,12,11,0)
356
"DATA",176.802,40,12,12,0)
360
"DATA",176.802,40,12,13,0)
362
"DATA",176.802,40,12,14,0)
363
"DATA",176.802,40,12,15,0)
367
"DATA",176.802,40,12,16,0)
372
"DATA",176.802,40,12,17,0)
373
"DATA",176.802,40,12,18,0)
375
"DATA",176.802,40,12,19,0)
376
"DATA",176.802,40,12,20,0)
377
"DATA",176.802,40,12,21,0)
378
"DATA",176.802,40,12,22,0)
380
"DATA",176.802,40,12,23,0)
386
"DATA",176.802,40,12,24,0)
388
"DATA",176.802,40,12,25,0)
389
"DATA",176.802,40,12,26,0)
390
"DATA",176.802,40,12,27,0)
391
"DATA",176.802,40,12,28,0)
392
"DATA",176.802,40,12,29,0)
393
"DATA",176.802,40,12,30,0)
394
"DATA",176.802,40,12,31,0)
395
"DATA",176.802,40,12,32,0)
396
"DATA",176.802,40,12,33,0)
397
"DATA",176.802,40,12,34,0)
398
"DATA",176.802,40,12,35,0)
399
"DATA",176.802,40,12,36,0)
400
"DATA",176.802,40,12,37,0)
401
"DATA",176.802,40,12,38,0)
405
"DATA",176.802,40,12,39,0)
409
"DATA",176.802,40,12,40,0)
410
"DATA",176.802,40,12,41,0)
411
"DATA",176.802,40,12,42,0)
412
"DATA",176.802,40,12,43,0)
415
"DATA",176.802,40,12,44,0)
416
"DATA",176.802,40,12,45,0)
417
"DATA",176.802,40,12,46,0)
418
"DATA",176.802,40,12,47,0)
419
"DATA",176.802,40,12,48,0)
420
"DATA",176.802,40,12,49,0)
421
"DATA",176.802,40,12,50,0)
422
"DATA",176.802,40,12,51,0)
423
"DATA",176.802,40,12,52,0)
427
"DATA",176.802,40,12,53,0)
428
"DATA",176.802,40,12,54,0)
430
"DATA",176.802,40,12,55,0)
431
"DATA",176.802,40,12,56,0)
432
"DATA",176.802,40,12,57,0)
434
"DATA",176.802,40,12,58,0)
436
"DATA",176.802,40,12,59,0)
443
"DATA",176.802,40,12,60,0)
457
"DATA",176.802,40,12,61,0)
458
"DATA",176.802,40,12,62,0)
590
"DATA",176.802,40,12,63,0)
638
"DATA",176.802,40,12,64,0)
698
"DATA",176.802,40,12,65,0)
808
"DATA",176.802,40,13)
(PN-6) Immunocompetent patients with Community-Acquired Pneumonia who receive an initial antibiotic regimen during the first 24 hours that is consistent with current guidelines 
"DATA",176.802,40,14)
INITIAL ANTIBIOTIC SELECTION FOR COMMUNITY-ACQUIRED PNEUMONIA (CAP) IN IMMUNOCOMPETENT PATIENTS^EH
"DATA",176.802,40,15)
^6
"DATA",176.802,41,0)
Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)
"DATA",176.802,41,1)
8439f671-2932-4d4c-88ca-ea5faeacc89a^0083
"DATA",176.802,41,2,0)
^^1^1^3130419
"DATA",176.802,41,2,1,0)
Percentage of patients aged 18 years and older with a diagnosis of heart failure (HF) with a current or prior left ventricular ejection fraction (LVEF) < 40% who were prescribed beta-blocker therapy either within a 12 month per
"DATA",176.802,41,3)
Attribute
"DATA",176.802,41,4)
CMS144v1
"DATA",176.802,41,5)
National Quality Forum^CY 2014 EP
"DATA",176.802,41,6)
American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)^American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)
"DATA",176.802,41,7)
PROCESS
"DATA",176.802,41,8)
HF_Beta_LVSD
"DATA",176.802,41,9)
Copyright 2012 American College of Cardiology, American Heart Association and American Medical Association. All Rights Reserved.
"DATA",176.802,41,10)
144^Complete
"DATA",176.802,41,11)
1
"DATA",176.802,41,12,0)
^176.8024P^29^29
"DATA",176.802,41,12,1,0)
24
"DATA",176.802,41,12,2,0)
52
"DATA",176.802,41,12,3,0)
62
"DATA",176.802,41,12,4,0)
84
"DATA",176.802,41,12,5,0)
85
"DATA",176.802,41,12,6,0)
95
"DATA",176.802,41,12,7,0)
123
"DATA",176.802,41,12,8,0)
124
"DATA",176.802,41,12,9,0)
127
"DATA",176.802,41,12,10,0)
225
"DATA",176.802,41,12,11,0)
243
"DATA",176.802,41,12,12,0)
255
"DATA",176.802,41,12,13,0)
258
"DATA",176.802,41,12,14,0)
306
"DATA",176.802,41,12,15,0)
307
"DATA",176.802,41,12,16,0)
333
"DATA",176.802,41,12,17,0)
467
"DATA",176.802,41,12,18,0)
495
"DATA",176.802,41,12,19,0)
515
"DATA",176.802,41,12,20,0)
567
"DATA",176.802,41,12,21,0)
587
"DATA",176.802,41,12,22,0)
590
"DATA",176.802,41,12,23,0)
594
"DATA",176.802,41,12,24,0)
611
"DATA",176.802,41,12,25,0)
628
"DATA",176.802,41,12,26,0)
638
"DATA",176.802,41,12,27,0)
698
"DATA",176.802,41,12,28,0)
754
"DATA",176.802,41,12,29,0)
809
"DATA",176.802,41,13)
Percentage of patients aged 18 years and older with a diagnosis of heart failure (HF) with a current or prior left ventricular ejection fraction (LVEF) < 40% who were prescribed beta-blocker therapy either within a 12 month per
"DATA",176.802,41,14)
HEART FAILURE (HF): BETA-BLOCKER THERAPY FOR LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (LVSD)^EP
"DATA",176.802,41,15)
^15
"DATA",176.802,42,0)
Depression Remission at Twelve Months
"DATA",176.802,42,1)
8455cd3e-dbb9-4e0c-8084-3ece4068fe94^0710
"DATA",176.802,42,2,0)
^^1^1^3130419
"DATA",176.802,42,2,1,0)
Adult patients age 18 and older with major depression or dysthymia and an initial PHQ-9 score > 9 who demonstrate remission at twelve months defined as PHQ-9 score less than 5. This measure applies to both patients with newly d
"DATA",176.802,42,3)
Attribute
"DATA",176.802,42,4)
CMS159v1
"DATA",176.802,42,5)
National Quality Forum^CY 2014 EP
"DATA",176.802,42,6)
Minnesota Community Measurement^Minnesota Community Measurement
"DATA",176.802,42,7)
OUTCOME
"DATA",176.802,42,8)
Dep_Rem_12
"DATA",176.802,42,9)
Copyright MN Community Measurement, 2012. All rights reserved.
"DATA",176.802,42,10)
159^Complete
"DATA",176.802,42,11)
1
"DATA",176.802,42,12,0)
^176.8024P^15^15
"DATA",176.802,42,12,1,0)
89
"DATA",176.802,42,12,2,0)
197
"DATA",176.802,42,12,3,0)
240
"DATA",176.802,42,12,4,0)
255
"DATA",176.802,42,12,5,0)
535
"DATA",176.802,42,12,6,0)
588
"DATA",176.802,42,12,7,0)
590
"DATA",176.802,42,12,8,0)
594
"DATA",176.802,42,12,9,0)
612
"DATA",176.802,42,12,10,0)
638
"DATA",176.802,42,12,11,0)
643
"DATA",176.802,42,12,12,0)
691
"DATA",176.802,42,12,13,0)
698
"DATA",176.802,42,12,14,0)
713
"DATA",176.802,42,12,15,0)
810
"DATA",176.802,42,13)
Adult patients age 18 and older with major depression or dysthymia and an initial PHQ-9 score > 9 who demonstrate remission at twelve months defined as PHQ-9 score less than 5. This measure applies to both patients with newly d
"DATA",176.802,42,14)
DEPRESSION REMISSION AT TWELVE MONTHS^EP
"DATA",176.802,42,15)
^3
"DATA",176.802,43,0)
Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients
"DATA",176.802,43,1)
8479f6d6-4200-4fd0-9438-30048ebe3e29^0385
"DATA",176.802,43,2,0)
^^1^1^3130419
"DATA",176.802,43,2,1,0)
Percentage of patients aged 18 through 80 years with AJCC Stage III colon cancer who are referred for adjuvant chemotherapy, prescribed adjuvant chemotherapy, or have previously received adjuvant chemotherapy within the 12-month r
"DATA",176.802,43,3)
Attribute
"DATA",176.802,43,4)
CMS141v2
"DATA",176.802,43,5)
National Quality Forum^CY 2014 EP
"DATA",176.802,43,6)
American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)^American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)
"DATA",176.802,43,7)
PROCESS
"DATA",176.802,43,8)
Colon_Cancer
"DATA",176.802,43,9)
Copyright 2012 American Medical Association, American Society of Clinical Oncology, and National Comprehensive Cancer Network. All Rights Reserved.
"DATA",176.802,43,10)
141^Complete
"DATA",176.802,43,11)
2
"DATA",176.802,43,12,0)
^176.8024P^31^31
"DATA",176.802,43,12,1,0)
23
"DATA",176.802,43,12,2,0)
138
"DATA",176.802,43,12,3,0)
139
"DATA",176.802,43,12,4,0)
140
"DATA",176.802,43,12,5,0)
141
"DATA",176.802,43,12,6,0)
155
"DATA",176.802,43,12,7,0)
160
"DATA",176.802,43,12,8,0)
161
"DATA",176.802,43,12,9,0)
162
"DATA",176.802,43,12,10,0)
163
"DATA",176.802,43,12,11,0)
164
"DATA",176.802,43,12,12,0)
165
"DATA",176.802,43,12,13,0)
166
"DATA",176.802,43,12,14,0)
167
"DATA",176.802,43,12,15,0)
168
"DATA",176.802,43,12,16,0)
169
"DATA",176.802,43,12,17,0)
170
"DATA",176.802,43,12,18,0)
171
"DATA",176.802,43,12,19,0)
172
"DATA",176.802,43,12,20,0)
173
"DATA",176.802,43,12,21,0)
241
"DATA",176.802,43,12,22,0)
255
"DATA",176.802,43,12,23,0)
258
"DATA",176.802,43,12,24,0)
494
"DATA",176.802,43,12,25,0)
564
"DATA",176.802,43,12,26,0)
590
"DATA",176.802,43,12,27,0)
594
"DATA",176.802,43,12,28,0)
628
"DATA",176.802,43,12,29,0)
638
"DATA",176.802,43,12,30,0)
698
"DATA",176.802,43,12,31,0)
754
"DATA",176.802,43,13)
Percentage of patients aged 18 through 80 years with AJCC Stage III colon cancer who are referred for adjuvant chemotherapy, prescribed adjuvant chemotherapy, or have previously received adjuvant chemotherapy within the 12-month r
"DATA",176.802,43,14)
COLON CANCER: CHEMOTHERAPY FOR AJCC STAGE III COLON CANCER PATIENTS^EP
"DATA",176.802,43,15)
^5
"DATA",176.802,44,0)
Child and Adolescent Major Depressive Disorder (MDD): Suicide Risk Assessment
"DATA",176.802,44,1)
848d09de-7e6b-43c4-bedd-5a2957ccffe3^1365
"DATA",176.802,44,2,0)
^^1^1^3130419
"DATA",176.802,44,2,1,0)
Percentage of patient visits for those patients aged 6 through 17 years with adiagnosis of major depressive disorder with an assessment for suicide risk
"DATA",176.802,44,3)
Intervention
"DATA",176.802,44,4)
CMS177v1
"DATA",176.802,44,5)
National Quality Forum^CY 2014 EP
"DATA",176.802,44,6)
American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)^American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)
"DATA",176.802,44,7)
PROCESS
"DATA",176.802,44,8)
CA MDD SRA
"DATA",176.802,44,9)
Copyright 2012 American Medical Association. All Rights Reserved.
"DATA",176.802,44,10)
177^InProgress
"DATA",176.802,44,11)
1
"DATA",176.802,44,12,0)
^176.8024P^17^17
"DATA",176.802,44,12,1,0)
255
"DATA",176.802,44,12,2,0)
258
"DATA",176.802,44,12,3,0)
295
"DATA",176.802,44,12,4,0)
536
"DATA",176.802,44,12,5,0)
590
"DATA",176.802,44,12,6,0)
594
"DATA",176.802,44,12,7,0)
611
"DATA",176.802,44,12,8,0)
628
"DATA",176.802,44,12,9,0)
638
"DATA",176.802,44,12,10,0)
686
"DATA",176.802,44,12,11,0)
687
"DATA",176.802,44,12,12,0)
690
"DATA",176.802,44,12,13,0)
691
"DATA",176.802,44,12,14,0)
692
"DATA",176.802,44,12,15,0)
694
"DATA",176.802,44,12,16,0)
698
"DATA",176.802,44,12,17,0)
752
"DATA",176.802,44,13)
Percentage of patient visits for those patients aged 6 through 17 years with adiagnosis of major depressive disorder with an assessment for suicide risk
"DATA",176.802,44,14)
CHILD AND ADOLESCENT MAJOR DEPRESSIVE DISORDER (MDD): SUICIDE RISK ASSESSMENT^EP
"DATA",176.802,44,15)
^4
"DATA",176.802,45,0)
Primary PCI Received Within 90 Minutes of Hospital Arrival
"DATA",176.802,45,1)
84b9d0b5-0caf-4e41-b345-3492a23c2e9f^0163
"DATA",176.802,45,2,0)
^^1^1^3130419
"DATA",176.802,45,2,1,0)
Acute myocardial infarction (AMI) patients with ST-segment elevation or LBBB on the ECG closest to arrival time receiving primary PCI during the hospital stay with a time from hospital arrival to PCI of 90 minutes or less.
"DATA",176.802,45,3)
Individual Characteristic
"DATA",176.802,45,4)
CMS53v2
"DATA",176.802,45,5)
National Quality Forum^FY 2014 EH
"DATA",176.802,45,6)
Oklahoma Foundation for Medical Quality^Oklahoma Foundation for Medical Quality
"DATA",176.802,45,7)
PROCESS
"DATA",176.802,45,8)
AMI-8a
"DATA",176.802,45,9)
Measure specifications are in the Public Domain.
"DATA",176.802,45,10)
53^InProgress
"DATA",176.802,45,11)
2
"DATA",176.802,45,12,0)
^176.8024P^23^23
"DATA",176.802,45,12,1,0)
157
"DATA",176.802,45,12,2,0)
255
"DATA",176.802,45,12,3,0)
336
"DATA",176.802,45,12,4,0)
339
"DATA",176.802,45,12,5,0)
348
"DATA",176.802,45,12,6,0)
349
"DATA",176.802,45,12,7,0)
350
"DATA",176.802,45,12,8,0)
351
"DATA",176.802,45,12,9,0)
359
"DATA",176.802,45,12,10,0)
365
"DATA",176.802,45,12,11,0)
366
"DATA",176.802,45,12,12,0)
369
"DATA",176.802,45,12,13,0)
370
"DATA",176.802,45,12,14,0)
371
"DATA",176.802,45,12,15,0)
374
"DATA",176.802,45,12,16,0)
407
"DATA",176.802,45,12,17,0)
413
"DATA",176.802,45,12,18,0)
435
"DATA",176.802,45,12,19,0)
590
"DATA",176.802,45,12,20,0)
630
"DATA",176.802,45,12,21,0)
638
"DATA",176.802,45,12,22,0)
698
"DATA",176.802,45,12,23,0)
808
"DATA",176.802,45,13)
Acute myocardial infarction (AMI) patients with ST-segment elevation or LBBB on the ECG closest to arrival time receiving primary PCI during the hospital stay with a time from hospital arrival to PCI of 90 minutes or less.
"DATA",176.802,45,14)
PRIMARY PCI RECEIVED WITHIN 90 MINUTES OF HOSPITAL ARRIVAL^EH
"DATA",176.802,45,15)
^1
"DATA",176.802,46,0)
Anti-depressant Medication Management
"DATA",176.802,46,1)
8924f2b3-ec06-4650-b634-d70a53dee577^0105
"DATA",176.802,46,2,0)
^^1^1^3130419
"DATA",176.802,46,2,1,0)
Percentage of patients 18 years of age and older who were diagnosed with major depression and treated with antidepressant medication, and who remained on antidepressant medication treatment. Two rates are reported. 
"DATA",176.802,46,3)
Individual Characteristic
"DATA",176.802,46,4)
CMS128v1
"DATA",176.802,46,5)
National Quality Forum^CY 2014 EP
"DATA",176.802,46,6)
National Committee for Quality Assurance^National Committee for Quality Assurance
"DATA",176.802,46,7)
PROCESS
"DATA",176.802,46,8)
Supplemental Value Sets
"DATA",176.802,46,9)
Physician Performance Measure (Measures) and related data specifications were developed by the National Committee for Quality Assurance (NCQA).
"DATA",176.802,46,10)
128^Complete
"DATA",176.802,46,11)
1
"DATA",176.802,46,12,0)
^176.8024P^16^16
"DATA",176.802,46,12,1,0)
43
"DATA",176.802,46,12,2,0)
48
"DATA",176.802,46,12,3,0)
255
"DATA",176.802,46,12,4,0)
258
"DATA",176.802,46,12,5,0)
333
"DATA",176.802,46,12,6,0)
535
"DATA",176.802,46,12,7,0)
590
"DATA",176.802,46,12,8,0)
594
"DATA",176.802,46,12,9,0)
638
"DATA",176.802,46,12,10,0)
662
"DATA",176.802,46,12,11,0)
666
"DATA",176.802,46,12,12,0)
686
"DATA",176.802,46,12,13,0)
690
"DATA",176.802,46,12,14,0)
691
"DATA",176.802,46,12,15,0)
692
"DATA",176.802,46,12,16,0)
698
"DATA",176.802,46,13)
Percentage of patients 18 years of age and older who were diagnosed with major depression and treated with antidepressant medication, and who remained on antidepressant medication treatment. Two rates are reported. 
"DATA",176.802,46,14)
ANTI-DEPRESSANT MEDICATION MANAGEMENT^EP
"DATA",176.802,46,15)
^3
"DATA",176.802,47,0)
Maternal Depression Screening
"DATA",176.802,47,1)
8e6c8479-99fd-4949-b0ad-24fa60fe4201^1401
"DATA",176.802,47,2,0)
^^1^1^3130419
"DATA",176.802,47,2,1,0)
The percentage of children who turned 6 months of age during the measurement year, who had a face-to-face visit between the clinician and the child during childs first 6 months, and who had  a maternal depression screening for 
"DATA",176.802,47,3)
Individual Characteristic
"DATA",176.802,47,4)
CMS82v1
"DATA",176.802,47,5)
National Quality Forum^CY 2014 EP
"DATA",176.802,47,6)
National Committee for Quality Assurance^National Committee for Quality Assurance
"DATA",176.802,47,7)
PROCESS
"DATA",176.802,47,8)
Supplemental Value Sets
"DATA",176.802,47,9)
Physician Performance Measure (Measures) and related data specifications were developed by the National Committee for Quality Assurance (NCQA).
"DATA",176.802,47,10)
82^Complete
"DATA",176.802,47,11)
1
"DATA",176.802,47,12,0)
^176.8024P^9^9
"DATA",176.802,47,12,1,0)
69
"DATA",176.802,47,12,2,0)
255
"DATA",176.802,47,12,3,0)
258
"DATA",176.802,47,12,4,0)
541
"DATA",176.802,47,12,5,0)
542
"DATA",176.802,47,12,6,0)
590
"DATA",176.802,47,12,7,0)
594
"DATA",176.802,47,12,8,0)
638
"DATA",176.802,47,12,9,0)
698
"DATA",176.802,47,13)
The percentage of children who turned 6 months of age during the measurement year, who had a face-to-face visit between the clinician and the child during childs first 6 months, and who had  a maternal depression screening for 
"DATA",176.802,47,14)
MATERNAL DEPRESSION SCREENING^EP
"DATA",176.802,47,15)
^3
"DATA",176.802,48,0)
Fibrinolytic Therapy Received Within 30 Minutes of Hospital Arrival
"DATA",176.802,48,1)
909cf4b4-7a85-4abf-a1c7-cb597ed1c0b6^0164
"DATA",176.802,48,2,0)
^^1^1^3130419
"DATA",176.802,48,2,1,0)
Acute myocardial infarction (AMI) patients with ST-segment elevation or LBBB on the ECG closest to arrival time receiving fibrinolytic therapy during the hospital stay and having a time from hospital arrival to fibrinolysis of 30 
"DATA",176.802,48,3)
Individual Characteristic
"DATA",176.802,48,4)
CMS60v2
"DATA",176.802,48,5)
National Quality Forum^FY 2014 EH
"DATA",176.802,48,6)
Oklahoma Foundation for Medical Quality^Oklahoma Foundation for Medical Quality
"DATA",176.802,48,7)
PROCESS
"DATA",176.802,48,8)
Fibrinolytic Therapy
"DATA",176.802,48,9)
Measure specifications are in the Public Domain.
"DATA",176.802,48,10)
60^Complete
"DATA",176.802,48,11)
2
"DATA",176.802,48,12,0)
^176.8024P^23^23
"DATA",176.802,48,12,1,0)
157
"DATA",176.802,48,12,2,0)
255
"DATA",176.802,48,12,3,0)
336
"DATA",176.802,48,12,4,0)
348
"DATA",176.802,48,12,5,0)
349
"DATA",176.802,48,12,6,0)
350
"DATA",176.802,48,12,7,0)
351
"DATA",176.802,48,12,8,0)
359
"DATA",176.802,48,12,9,0)
365
"DATA",176.802,48,12,10,0)
366
"DATA",176.802,48,12,11,0)
368
"DATA",176.802,48,12,12,0)
369
"DATA",176.802,48,12,13,0)
370
"DATA",176.802,48,12,14,0)
371
"DATA",176.802,48,12,15,0)
374
"DATA",176.802,48,12,16,0)
407
"DATA",176.802,48,12,17,0)
413
"DATA",176.802,48,12,18,0)
435
"DATA",176.802,48,12,19,0)
590
"DATA",176.802,48,12,20,0)
630
"DATA",176.802,48,12,21,0)
638
"DATA",176.802,48,12,22,0)
698
"DATA",176.802,48,12,23,0)
808
"DATA",176.802,48,13)
Acute myocardial infarction (AMI) patients with ST-segment elevation or LBBB on the ECG closest to arrival time receiving fibrinolytic therapy during the hospital stay and having a time from hospital arrival to fibrinolysis of 30 
"DATA",176.802,48,14)
FIBRINOLYTIC THERAPY RECEIVED WITHIN 30 MINUTES OF HOSPITAL ARRIVAL^EH
"DATA",176.802,48,15)
^1
"DATA",176.802,49,0)
Antithrombotic Therapy By End of Hospital Day 2
"DATA",176.802,49,1)
93f3479f-75d8-4731-9a3f-b7749d8bcd37^0438
"DATA",176.802,49,2,0)
^^1^1^3130419
"DATA",176.802,49,2,1,0)
Ischemic stroke patients administered antithrombotic therapy by the end of hospital day 2.
"DATA",176.802,49,3)
Individual Characteristic
"DATA",176.802,49,4)
CMS72v2
"DATA",176.802,49,5)
National Quality Forum^FY 2014 EH
"DATA",176.802,49,6)
The Joint Commission^The Joint Commission
"DATA",176.802,49,7)
PROCESS
"DATA",176.802,49,8)
SKT-5 (Stroke)
"DATA",176.802,49,9)
Measure specifications are in the Public Domain
"DATA",176.802,49,10)
72^Complete
"DATA",176.802,49,11)
2
"DATA",176.802,49,12,0)
^176.8024P^14^14
"DATA",176.802,49,12,1,0)
49
"DATA",176.802,49,12,2,0)
255
"DATA",176.802,49,12,3,0)
313
"DATA",176.802,49,12,4,0)
500
"DATA",176.802,49,12,5,0)
552
"DATA",176.802,49,12,6,0)
586
"DATA",176.802,49,12,7,0)
590
"DATA",176.802,49,12,8,0)
616
"DATA",176.802,49,12,9,0)
634
"DATA",176.802,49,12,10,0)
638
"DATA",176.802,49,12,11,0)
673
"DATA",176.802,49,12,12,0)
698
"DATA",176.802,49,12,13,0)
761
"DATA",176.802,49,12,14,0)
808
"DATA",176.802,49,13)
Ischemic stroke patients administered antithrombotic therapy by the end of hospital day 2.
"DATA",176.802,49,14)
ANTITHROMBOTIC THERAPY BY END OF HOSPITAL DAY 2^EH
"DATA",176.802,49,15)
^19
"DATA",176.802,50,0)
Hemoglobin A1c Test for Pediatric Patients
"DATA",176.802,50,1)
95fb767e-0cb2-4778-b5ff-6ba9a53fa28e^0060
"DATA",176.802,50,2,0)
^^1^1^3130419
"DATA",176.802,50,2,1,0)
Percentage of patients 5-17 years of age with diabetes with an HbA1c test during the measurement period
"DATA",176.802,50,3)
Individual Characteristic
"DATA",176.802,50,4)
CMS148v1
"DATA",176.802,50,5)
National Quality Forum^CY 2014 EP
"DATA",176.802,50,6)
National Committee for Quality Assurance^National Committee for Quality Assurance
"DATA",176.802,50,7)
PROCESS
"DATA",176.802,50,8)
Supplemental Value Sets
"DATA",176.802,50,9)
Physician Performance Measure (Measures) and related data specifications were developed by the National Committee for Quality Assurance (NCQA).
"DATA",176.802,50,10)
148^Complete
"DATA",176.802,50,11)
1
"DATA",176.802,50,12,0)
^176.8024P^8^8
"DATA",176.802,50,12,1,0)
212
"DATA",176.802,50,12,2,0)
213
"DATA",176.802,50,12,3,0)
255
"DATA",176.802,50,12,4,0)
285
"DATA",176.802,50,12,5,0)
302
"DATA",176.802,50,12,6,0)
590
"DATA",176.802,50,12,7,0)
638
"DATA",176.802,50,12,8,0)
698
"DATA",176.802,50,13)
Percentage of patients 5-17 years of age with diabetes with an HbA1c test during the measurement period
"DATA",176.802,50,14)
HEMOGLOBIN A1C TEST FOR PEDIATRIC PATIENTS^EP
"DATA",176.802,50,15)
^9
"DATA",176.802,51,0)
Median Admit Decision Time to ED Departure Time for Admitted Patients
"DATA",176.802,51,1)
979f21bd-3f93-4cdd-8273-b23dfe9c0513^0497
"DATA",176.802,51,2,0)
^^1^1^3130419
"DATA",176.802,51,2,1,0)
Median time (in minutes) from admit decision time to time of departure from the emergency department for emergency department patients admitted to inpatient status.
"DATA",176.802,51,3)
Individual Characteristic
"DATA",176.802,51,4)
CMS111v2
"DATA",176.802,51,5)
National Quality Forum^FY 2014 EH
"DATA",176.802,51,6)
Oklahoma Foundation for Medical Quality^Centers for Medicare & Medicaid Services
"DATA",176.802,51,7)
PROCESS
"DATA",176.802,51,8)
Supplemental Value Sets
"DATA",176.802,51,9)
Measure specifications are in the Public Domain
"DATA",176.802,51,10)
111^Complete
"DATA",176.802,51,11)
2
"DATA",176.802,51,12,0)
^176.8024P^7^7
"DATA",176.802,51,12,1,0)
198
"DATA",176.802,51,12,2,0)
255
"DATA",176.802,51,12,3,0)
590
"DATA",176.802,51,12,4,0)
638
"DATA",176.802,51,12,5,0)
673
"DATA",176.802,51,12,6,0)
693
"DATA",176.802,51,12,7,0)
698
"DATA",176.802,51,13)
Median time (in minutes) from admit decision time to time of departure from the emergency department for emergency department patients admitted to inpatient status.
"DATA",176.802,51,14)
MEDIAN ADMIT DECISION TIME TO ED DEPARTURE TIME FOR ADMITTED PATIENTS^EH
"DATA",176.802,51,15)
^10
"DATA",176.802,52,0)
Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up
"DATA",176.802,52,1)
9a031bb8-3d9b-11e1-8634-00237d5bf174^0421
"DATA",176.802,52,2,0)
^^1^1^3130419
"DATA",176.802,52,2,1,0)
Percentage of patients aged 18 years and older with an encounter during the reporting period with a documented calculated BMI during the encounter or during the previous six months, AND when the BMI is outside of normal parameters
"DATA",176.802,52,3)
Individual Characteristic
"DATA",176.802,52,4)
CMS69v1
"DATA",176.802,52,5)
National Quality Forum^CY 2014 EP
"DATA",176.802,52,6)
Quality Insights of Pennsylvania^Centers for Medicare & Medicaid Services
"DATA",176.802,52,7)
PROCESS
"DATA",176.802,52,8)
Supplemental Value Sets
"DATA",176.802,52,9)
Limited proprietary coding is contained in the measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. Quality Insights of Pennsylvania di
"DATA",176.802,52,10)
69^Complete
"DATA",176.802,52,11)
1
"DATA",176.802,52,12,0)
^176.8024P^16^16
"DATA",176.802,52,12,1,0)
3
"DATA",176.802,52,12,2,0)
4
"DATA",176.802,52,12,3,0)
5
"DATA",176.802,52,12,4,0)
73
"DATA",176.802,52,12,5,0)
74
"DATA",176.802,52,12,6,0)
75
"DATA",176.802,52,12,7,0)
81
"DATA",176.802,52,12,8,0)
82
"DATA",176.802,52,12,9,0)
83
"DATA",176.802,52,12,10,0)
255
"DATA",176.802,52,12,11,0)
556
"DATA",176.802,52,12,12,0)
590
"DATA",176.802,52,12,13,0)
631
"DATA",176.802,52,12,14,0)
638
"DATA",176.802,52,12,15,0)
658
"DATA",176.802,52,12,16,0)
698
"DATA",176.802,52,13)
Percentage of patients aged 18 years and older with an encounter during the reporting period with a documented calculated BMI during the encounter or during the previous six months, AND when the BMI is outside of normal parameters
"DATA",176.802,52,14)
PREVENTIVE CARE AND SCREENING: BODY MASS INDEX (BMI) SCREENING AND FOLLOW-UP^EP
"DATA",176.802,52,15)
^7
"DATA",176.802,53,0)
Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan
"DATA",176.802,53,1)
9a031e24-3d9b-11e1-8634-00237d5bf174^0418
"DATA",176.802,53,2,0)
^^1^1^3130419
"DATA",176.802,53,2,1,0)
Percentage of patients aged 12 years and older screened for clinical depression on the date of the encounter using an age appropriate standardized depression screening tool AND if positive, a follow-up plan is documented on the da
"DATA",176.802,53,3)
Intervention
"DATA",176.802,53,4)
CMS2v1
"DATA",176.802,53,5)
National Quality Forum^CY 2014 EP
"DATA",176.802,53,6)
Quality Insights of Pennsylvania^Centers for Medicare & Medicaid Services
"DATA",176.802,53,7)
PROCESS
"DATA",176.802,53,8)
NQF418
"DATA",176.802,53,9)
Limited proprietary coding is contained in the measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. Quality Insights of Pennsylvania di
"DATA",176.802,53,10)
2^Complete
"DATA",176.802,53,11)
1
"DATA",176.802,53,12,0)
^176.8024P^21^21
"DATA",176.802,53,12,1,0)
13
"DATA",176.802,53,12,2,0)
14
"DATA",176.802,53,12,3,0)
16
"DATA",176.802,53,12,4,0)
17
"DATA",176.802,53,12,5,0)
88
"DATA",176.802,53,12,6,0)
207
"DATA",176.802,53,12,7,0)
208
"DATA",176.802,53,12,8,0)
209
"DATA",176.802,53,12,9,0)
210
"DATA",176.802,53,12,10,0)
255
"DATA",176.802,53,12,11,0)
267
"DATA",176.802,53,12,12,0)
268
"DATA",176.802,53,12,13,0)
558
"DATA",176.802,53,12,14,0)
575
"DATA",176.802,53,12,15,0)
590
"DATA",176.802,53,12,16,0)
632
"DATA",176.802,53,12,17,0)
638
"DATA",176.802,53,12,18,0)
652
"DATA",176.802,53,12,19,0)
698
"DATA",176.802,53,12,20,0)
704
"DATA",176.802,53,12,21,0)
705
"DATA",176.802,53,13)
Percentage of patients aged 12 years and older screened for clinical depression on the date of the encounter using an age appropriate standardized depression screening tool AND if positive, a follow-up plan is documented on the da
"DATA",176.802,53,14)
PREVENTIVE CARE AND SCREENING: SCREENING FOR CLINICAL DEPRESSION AND FOLLOW-UP PLAN^EP
"DATA",176.802,53,15)
^7
"DATA",176.802,54,0)
Documentation of Current Medications in the Medical Record
"DATA",176.802,54,1)
9a032d9c-3d9b-11e1-8634-00237d5bf174^0419
"DATA",176.802,54,2,0)
^^1^1^3130419
"DATA",176.802,54,2,1,0)
Percentage of specified visits for patients aged 18 years and older for which the eligible professional attests to documenting a list of current medications to the best of his/her knowledge and ability.  This list must include ALL
"DATA",176.802,54,3)
Individual Characteristic
"DATA",176.802,54,4)
CMS68v2
"DATA",176.802,54,5)
National Quality Forum^CY 2014 EP
"DATA",176.802,54,6)
Quality Insights of Pennsylvania^Centers for Medicare & Medicaid Services
"DATA",176.802,54,7)
PROCESS
"DATA",176.802,54,8)
Supplemental Value Sets
"DATA",176.802,54,9)
Limited proprietary coding is contained in the measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. Quality Insights of Pennsylvania di
"DATA",176.802,54,10)
68^InProgress
"DATA",176.802,54,11)
2
"DATA",176.802,54,12,0)
^176.8024P^7^7
"DATA",176.802,54,12,1,0)
191
"DATA",176.802,54,12,2,0)
255
"DATA",176.802,54,12,3,0)
556
"DATA",176.802,54,12,4,0)
560
"DATA",176.802,54,12,5,0)
590
"DATA",176.802,54,12,6,0)
638
"DATA",176.802,54,12,7,0)
698
"DATA",176.802,54,13)
Percentage of specified visits for patients aged 18 years and older for which the eligible professional attests to documenting a list of current medications to the best of his/her knowledge and ability.  This list must include ALL
"DATA",176.802,54,14)
DOCUMENTATION OF CURRENT MEDICATIONS IN THE MEDICAL RECORD^EP
"DATA",176.802,54,15)
^7
"DATA",176.802,55,0)
Oncology: Medical and Radiation  Pain Intensity Quantified
"DATA",176.802,55,1)
9a0330d0-3d9b-11e1-8634-00237d5bf174^0384
"DATA",176.802,55,2,0)
^^1^1^3130419
"DATA",176.802,55,2,1,0)
Percentage of patient visits, regardless of patient age, with a diagnosis of cancer currently receiving chemotherapy or radiation therapy in which pain intensity is quantified
"DATA",176.802,55,3)
Risk Category/Assessment
"DATA",176.802,55,4)
CMS157v1
"DATA",176.802,55,5)
National Quality Forum^CY 2014 EP
"DATA",176.802,55,6)
American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)^American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)
"DATA",176.802,55,7)
PROCESS
"DATA",176.802,55,8)
Onc_Pain-Int-Quant
"DATA",176.802,55,9)
Copyright 2012 American Medical Association. All Rights Reserved.
"DATA",176.802,55,10)
157^Complete
"DATA",176.802,55,11)
1
"DATA",176.802,55,12,0)
^176.8024P^10^10
"DATA",176.802,55,12,1,0)
122
"DATA",176.802,55,12,2,0)
137
"DATA",176.802,55,12,3,0)
255
"DATA",176.802,55,12,4,0)
258
"DATA",176.802,55,12,5,0)
590
"DATA",176.802,55,12,6,0)
594
"DATA",176.802,55,12,7,0)
638
"DATA",176.802,55,12,8,0)
698
"DATA",176.802,55,12,9,0)
700
"DATA",176.802,55,12,10,0)
744
"DATA",176.802,55,13)
Percentage of patient visits, regardless of patient age, with a diagnosis of cancer currently receiving chemotherapy or radiation therapy in which pain intensity is quantified
"DATA",176.802,55,14)
ONCOLOGY: MEDICAL AND RADIATION  PAIN INTENSITY QUANTIFIED^EP
"DATA",176.802,55,15)
^5
"DATA",176.802,56,0)
Median Time from ED Arrival to ED Departure for Admitted ED Patients
"DATA",176.802,56,1)
9a033274-3d9b-11e1-8634-00237d5bf174^0495
"DATA",176.802,56,2,0)
^^1^1^3130419
"DATA",176.802,56,2,1,0)
Median time from emergency department arrival to time of departure from the emergency room for patients admitted to the facility from the emergency department.
"DATA",176.802,56,3)
Individual Characteristic
"DATA",176.802,56,4)
CMS55v2
"DATA",176.802,56,5)
National Quality Forum^FY 2014 EH
"DATA",176.802,56,6)
Oklahoma Foundation for Medical Quality^Centers for Medicare & Medicaid Services
"DATA",176.802,56,7)
PROCESS
"DATA",176.802,56,8)
Supplemental Value Sets
"DATA",176.802,56,9)
Measure specifications are in the Public Domain
"DATA",176.802,56,10)
55^Complete
"DATA",176.802,56,11)
2
"DATA",176.802,56,12,0)
^176.8024P^6^6
"DATA",176.802,56,12,1,0)
255
"DATA",176.802,56,12,2,0)
590
"DATA",176.802,56,12,3,0)
638
"DATA",176.802,56,12,4,0)
673
"DATA",176.802,56,12,5,0)
693
"DATA",176.802,56,12,6,0)
698
"DATA",176.802,56,13)
Median time from emergency department arrival to time of departure from the emergency room for patients admitted to the facility from the emergency department.
"DATA",176.802,56,14)
MEDIAN TIME FROM ED ARRIVAL TO ED DEPARTURE FOR ADMITTED ED PATIENTS^EH
"DATA",176.802,56,15)
^10
"DATA",176.802,57,0)
Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures
"DATA",176.802,57,1)
9a0339c2-3d9b-11e1-8634-00237d5bf174^0564
"DATA",176.802,57,2,0)
^^1^1^3130419
"DATA",176.802,57,2,1,0)
Percentage of patients aged 18 years and older with a diagnosis of uncomplicated cataract who had cataract surgery and had any of a specified list of surgical procedures in the 30 days following cataract surgery which would indica
"DATA",176.802,57,3)
Procedure
"DATA",176.802,57,4)
CMS132v1
"DATA",176.802,57,5)
National Quality Forum^CY 2014 EP
"DATA",176.802,57,6)
National Committee for Quality Assurance^American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)
"DATA",176.802,57,7)
OUTCOME
"DATA",176.802,57,8)
Cataracts
"DATA",176.802,57,9)
Copyright 2012 American Medical Association and National Committee for Quality Assurance. All Rights Reserved.
"DATA",176.802,57,10)
132^Complete
"DATA",176.802,57,11)
1
"DATA",176.802,57,12,0)
^176.8024P^47^47
"DATA",176.802,57,12,1,0)
12
"DATA",176.802,57,12,2,0)
15
"DATA",176.802,57,12,3,0)
44
"DATA",176.802,57,12,4,0)
51
"DATA",176.802,57,12,5,0)
54
"DATA",176.802,57,12,6,0)
117
"DATA",176.802,57,12,7,0)
128
"DATA",176.802,57,12,8,0)
129
"DATA",176.802,57,12,9,0)
130
"DATA",176.802,57,12,10,0)
131
"DATA",176.802,57,12,11,0)
132
"DATA",176.802,57,12,12,0)
133
"DATA",176.802,57,12,13,0)
134
"DATA",176.802,57,12,14,0)
149
"DATA",176.802,57,12,15,0)
158
"DATA",176.802,57,12,16,0)
184
"DATA",176.802,57,12,17,0)
185
"DATA",176.802,57,12,18,0)
193
"DATA",176.802,57,12,19,0)
253
"DATA",176.802,57,12,20,0)
255
"DATA",176.802,57,12,21,0)
256
"DATA",176.802,57,12,22,0)
287
"DATA",176.802,57,12,23,0)
324
"DATA",176.802,57,12,24,0)
327
"DATA",176.802,57,12,25,0)
468
"DATA",176.802,57,12,26,0)
487
"DATA",176.802,57,12,27,0)
516
"DATA",176.802,57,12,28,0)
590
"DATA",176.802,57,12,29,0)
595
"DATA",176.802,57,12,30,0)
618
"DATA",176.802,57,12,31,0)
624
"DATA",176.802,57,12,32,0)
638
"DATA",176.802,57,12,33,0)
654
"DATA",176.802,57,12,34,0)
674
"DATA",176.802,57,12,35,0)
685
"DATA",176.802,57,12,36,0)
698
"DATA",176.802,57,12,37,0)
708
"DATA",176.802,57,12,38,0)
717
"DATA",176.802,57,12,39,0)
720
"DATA",176.802,57,12,40,0)
721
"DATA",176.802,57,12,41,0)
731
"DATA",176.802,57,12,42,0)
733
"DATA",176.802,57,12,43,0)
771
"DATA",176.802,57,12,44,0)
779
"DATA",176.802,57,12,45,0)
782
"DATA",176.802,57,12,46,0)
793
"DATA",176.802,57,12,47,0)
800
"DATA",176.802,57,13)
Percentage of patients aged 18 years and older with a diagnosis of uncomplicated cataract who had cataract surgery and had any of a specified list of surgical procedures in the 30 days following cataract surgery which would indica
"DATA",176.802,57,14)
CATARACTS: COMPLICATIONS WITHIN 30 DAYS FOLLOWING CATARACT SURGERY REQUIRING ADDITIONAL SURGICAL PROCEDURES^EP
"DATA",176.802,57,15)
^11
"DATA",176.802,58,0)
Preventive Care and Screening:  Screening for High Blood Pressure and Follow-Up Documented
"DATA",176.802,58,1)
9a033a94-3d9b-11e1-8634-00237d5bf174^Not Applicable
"DATA",176.802,58,2,0)
^^1^1^3130419
"DATA",176.802,58,2,1,0)
Percentage of patients aged 18 years and older seen during the reporting period who were screened for high blood pressure AND a recommended follow-up plan is documented based on the current blood pressure (BP) reading as indicated
"DATA",176.802,58,3)
Intervention
"DATA",176.802,58,4)
CMS22v1
"DATA",176.802,58,5)
None^CY 2014 EP
"DATA",176.802,58,6)
Quality Insights of Pennsylvania^Centers for Medicare & Medicaid Services
"DATA",176.802,58,7)
PROCESS
"DATA",176.802,58,8)
BP Screening
"DATA",176.802,58,9)
Limited proprietary coding is contained in the measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. Quality Insights of Pennsylvania di
"DATA",176.802,58,10)
22^InProgress
"DATA",176.802,58,11)
1
"DATA",176.802,58,12,0)
^176.8024P^22^22
"DATA",176.802,58,12,1,0)
45
"DATA",176.802,58,12,2,0)
77
"DATA",176.802,58,12,3,0)
92
"DATA",176.802,58,12,4,0)
217
"DATA",176.802,58,12,5,0)
221
"DATA",176.802,58,12,6,0)
223
"DATA",176.802,58,12,7,0)
244
"DATA",176.802,58,12,8,0)
255
"DATA",176.802,58,12,9,0)
511
"DATA",176.802,58,12,10,0)
520
"DATA",176.802,58,12,11,0)
557
"DATA",176.802,58,12,12,0)
568
"DATA",176.802,58,12,13,0)
590
"DATA",176.802,58,12,14,0)
632
"DATA",176.802,58,12,15,0)
638
"DATA",176.802,58,12,16,0)
645
"DATA",176.802,58,12,17,0)
698
"DATA",176.802,58,12,18,0)
706
"DATA",176.802,58,12,19,0)
711
"DATA",176.802,58,12,20,0)
712
"DATA",176.802,58,12,21,0)
756
"DATA",176.802,58,12,22,0)
804
"DATA",176.802,58,13)
Percentage of patients aged 18 years and older seen during the reporting period who were screened for high blood pressure AND a recommended follow-up plan is documented based on the current blood pressure (BP) reading as indicated
"DATA",176.802,58,14)
PREVENTIVE CARE AND SCREENING:  SCREENING FOR HIGH BLOOD PRESSURE AND FOLLOW-UP DOCUMENTED^EP
"DATA",176.802,58,15)
^12
"DATA",176.802,59,0)
Preventive Care and Screening: Influenza Immunization
"DATA",176.802,59,1)
a244aa29-7d11-4616-888a-86e376bfcc6f^0041
"DATA",176.802,59,2,0)
^^1^1^3130419
"DATA",176.802,59,2,1,0)
Percentage of patients aged 6 months and older seen for a visit between October 1 and March 31 who received an influenza immunization OR who reported previous receipt of an influenza immunization
"DATA",176.802,59,3)
Attribute
"DATA",176.802,59,4)
CMS147v1
"DATA",176.802,59,5)
National Quality Forum^CY 2014 EP
"DATA",176.802,59,6)
American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)^American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)
"DATA",176.802,59,7)
PROCESS
"DATA",176.802,59,8)
Flu_Imm
"DATA",176.802,59,9)
Copyright 2012 American Medical Association.  All Rights Reserved.
"DATA",176.802,59,10)
147^Complete
"DATA",176.802,59,11)
1
"DATA",176.802,59,12,0)
^176.8024P^29^29
"DATA",176.802,59,12,1,0)
25
"DATA",176.802,59,12,2,0)
27
"DATA",176.802,59,12,3,0)
43
"DATA",176.802,59,12,4,0)
127
"DATA",176.802,59,12,5,0)
227
"DATA",176.802,59,12,6,0)
251
"DATA",176.802,59,12,7,0)
255
"DATA",176.802,59,12,8,0)
309
"DATA",176.802,59,12,9,0)
333
"DATA",176.802,59,12,10,0)
481
"DATA",176.802,59,12,11,0)
482
"DATA",176.802,59,12,12,0)
496
"DATA",176.802,59,12,13,0)
587
"DATA",176.802,59,12,14,0)
590
"DATA",176.802,59,12,15,0)
594
"DATA",176.802,59,12,16,0)
611
"DATA",176.802,59,12,17,0)
628
"DATA",176.802,59,12,18,0)
638
"DATA",176.802,59,12,19,0)
641
"DATA",176.802,59,12,20,0)
661
"DATA",176.802,59,12,21,0)
662
"DATA",176.802,59,12,22,0)
663
"DATA",176.802,59,12,23,0)
664
"DATA",176.802,59,12,24,0)
665
"DATA",176.802,59,12,25,0)
666
"DATA",176.802,59,12,26,0)
667
"DATA",176.802,59,12,27,0)
668
"DATA",176.802,59,12,28,0)
698
"DATA",176.802,59,12,29,0)
754
"DATA",176.802,59,13)
Percentage of patients aged 6 months and older seen for a visit between October 1 and March 31 who received an influenza immunization OR who reported previous receipt of an influenza immunization
"DATA",176.802,59,14)
PREVENTIVE CARE AND SCREENING: INFLUENZA IMMUNIZATION^EP
"DATA",176.802,59,15)
^13
"DATA",176.802,60,0)
Use of High-Risk Medications in the Elderly
"DATA",176.802,60,1)
a3837ff8-1abc-4ba9-800e-fd4e7953adbd^0022
"DATA",176.802,60,2,0)
^^1^1^3130419
"DATA",176.802,60,2,1,0)
Percentage of patients 66 years of age and older who were ordered high-risk medications. Two rates are reported.a. Percentage of patients who were ordered at least one high-risk medication. 
"DATA",176.802,60,3)
Individual Characteristic
"DATA",176.802,60,4)
CMS156v1
"DATA",176.802,60,5)
National Quality Forum^CY 2014 EP
"DATA",176.802,60,6)
National Committee for Quality Assurance^National Committee for Quality Assurance
"DATA",176.802,60,7)
PROCESS
"DATA",176.802,60,8)
Supplemental Value Sets
"DATA",176.802,60,9)
Physician Performance Measure (Measures) and related data specifications were developed by the National Committee for Quality Assurance (NCQA).
"DATA",176.802,60,10)
156^Complete
"DATA",176.802,60,11)
1
"DATA",176.802,60,12,0)
^176.8024P^12^12
"DATA",176.802,60,12,1,0)
43
"DATA",176.802,60,12,2,0)
255
"DATA",176.802,60,12,3,0)
258
"DATA",176.802,60,12,4,0)
328
"DATA",176.802,60,12,5,0)
329
"DATA",176.802,60,12,6,0)
333
"DATA",176.802,60,12,7,0)
590
"DATA",176.802,60,12,8,0)
594
"DATA",176.802,60,12,9,0)
638
"DATA",176.802,60,12,10,0)
662
"DATA",176.802,60,12,11,0)
666
"DATA",176.802,60,12,12,0)
698
"DATA",176.802,60,13)
Percentage of patients 66 years of age and older who were ordered high-risk medications. Two rates are reported.a. Percentage of patients who were ordered at least one high-risk medication. 
"DATA",176.802,60,14)
USE OF HIGH-RISK MEDICATIONS IN THE ELDERLY^EP
"DATA",176.802,60,15)
^7
"DATA",176.802,61,0)
Depression Utilization of the PHQ-9 Tool
"DATA",176.802,61,1)
a4b9763c-847e-4e02-bb7e-acc596e90e2c^0712
"DATA",176.802,61,2,0)
^^1^1^3130419
"DATA",176.802,61,2,1,0)
Adult patients age 18 and older with the diagnosis of major depression or dysthymia who have a PHQ-9 tool administered at least once during a 4 month period in which there was a qualifying visit.
"DATA",176.802,61,3)
Attribute
"DATA",176.802,61,4)
CMS160v1
"DATA",176.802,61,5)
National Quality Forum^CY 2014 EP
"DATA",176.802,61,6)
Minnesota Community Measurement^Minnesota Community Measurement
"DATA",176.802,61,7)
PROCESS
"DATA",176.802,61,8)
Dep_PHQ-9
"DATA",176.802,61,9)
Copyright MN Community Measurement, 2012. All rights reserved
"DATA",176.802,61,10)
160^Complete
"DATA",176.802,61,11)
1
"DATA",176.802,61,12,0)
^176.8024P^15^15
"DATA",176.802,61,12,1,0)
89
"DATA",176.802,61,12,2,0)
197
"DATA",176.802,61,12,3,0)
240
"DATA",176.802,61,12,4,0)
255
"DATA",176.802,61,12,5,0)
535
"DATA",176.802,61,12,6,0)
588
"DATA",176.802,61,12,7,0)
590
"DATA",176.802,61,12,8,0)
594
"DATA",176.802,61,12,9,0)
612
"DATA",176.802,61,12,10,0)
638
"DATA",176.802,61,12,11,0)
643
"DATA",176.802,61,12,12,0)
691
"DATA",176.802,61,12,13,0)
698
"DATA",176.802,61,12,14,0)
713
"DATA",176.802,61,12,15,0)
810
"DATA",176.802,61,13)
Adult patients age 18 and older with the diagnosis of major depression or dysthymia who have a PHQ-9 tool administered at least once during a 4 month period in which there was a qualifying visit.
"DATA",176.802,61,14)
DEPRESSION UTILIZATION OF THE PHQ-9 TOOL^EP
"DATA",176.802,61,15)
^3
"DATA",176.802,62,0)
ADE Prevention and Monitoring: Warfarin Time in Therapeutic Range
"DATA",176.802,62,1)
a5e96a45-8132-4e72-bf4f-e8c81db9e641^NA
"DATA",176.802,62,2,0)
^^1^1^3130419
"DATA",176.802,62,2,1,0)
Average percentage of time in which patients aged 18 and older with atrial fibrillation who are on chronic warfarin therapy have International Normalized Ratio (INR) test results within the therapeutic range (i.e., TTR) during the
"DATA",176.802,62,3)
Condition/Diagnosis/Problem
"DATA",176.802,62,4)
CMS179v1
"DATA",176.802,62,5)
None^CY 2014 EP
"DATA",176.802,62,6)
National Committee for Quality Assurance^National Committee for Quality Assurance
"DATA",176.802,62,7)
OUTCOME
"DATA",176.802,62,8)
ADE TTR CVM
"DATA",176.802,62,9)
Physician Performance Measure (Measures) and related data specifications were developed by the National Committee for Quality Assurance (NCQA).
"DATA",176.802,62,10)
179^Complete
"DATA",176.802,62,11)
1
"DATA",176.802,62,12,0)
^176.8024P^8^8
"DATA",176.802,62,12,1,0)
178
"DATA",176.802,62,12,2,0)
255
"DATA",176.802,62,12,3,0)
258
"DATA",176.802,62,12,4,0)
590
"DATA",176.802,62,12,5,0)
594
"DATA",176.802,62,12,6,0)
638
"DATA",176.802,62,12,7,0)
698
"DATA",176.802,62,12,8,0)
787
"DATA",176.802,62,13)
Average percentage of time in which patients aged 18 and older with atrial fibrillation who are on chronic warfarin therapy have International Normalized Ratio (INR) test results within the therapeutic range (i.e., TTR) during the
"DATA",176.802,62,14)
ADE PREVENTION AND MONITORING: WARFARIN TIME IN THERAPEUTIC RANGE^EP
"DATA",176.802,62,15)
^15
"DATA",176.802,63,0)
Colorectal Cancer Screening
"DATA",176.802,63,1)
aa2a4bbc-864f-45ee-b17a-7ebcc62e6aac^0034
"DATA",176.802,63,2,0)
^^1^1^3130419
"DATA",176.802,63,2,1,0)
Percentage of adults 50-75 years of age who had appropriate screening for colorectal cancer.
"DATA",176.802,63,3)
Procedure
"DATA",176.802,63,4)
CMS130v1
"DATA",176.802,63,5)
National Quality Forum^CY 2014 EP
"DATA",176.802,63,6)
National Committee for Quality Assurance^National Committee for Quality Assurance
"DATA",176.802,63,7)
PROCESS
"DATA",176.802,63,8)
Colorectal_Cancer
"DATA",176.802,63,9)
Physician Performance Measure (Measures) and related data specifications were developed by the National Committee for Quality Assurance (NCQA).
"DATA",176.802,63,10)
130^InProgress
"DATA",176.802,63,11)
1
"DATA",176.802,63,12,0)
^176.8024P^15^15
"DATA",176.802,63,12,1,0)
43
"DATA",176.802,63,12,2,0)
174
"DATA",176.802,63,12,3,0)
255
"DATA",176.802,63,12,4,0)
258
"DATA",176.802,63,12,5,0)
261
"DATA",176.802,63,12,6,0)
263
"DATA",176.802,63,12,7,0)
333
"DATA",176.802,63,12,8,0)
538
"DATA",176.802,63,12,9,0)
590
"DATA",176.802,63,12,10,0)
594
"DATA",176.802,63,12,11,0)
638
"DATA",176.802,63,12,12,0)
662
"DATA",176.802,63,12,13,0)
666
"DATA",176.802,63,12,14,0)
698
"DATA",176.802,63,12,15,0)
769
"DATA",176.802,63,13)
Percentage of adults 50-75 years of age who had appropriate screening for colorectal cancer.
"DATA",176.802,63,14)
COLORECTAL CANCER SCREENING^EP
"DATA",176.802,63,15)
^12
"DATA",176.802,64,0)
Controlling High Blood Pressure
"DATA",176.802,64,1)
abdc37cc-bac6-4156-9b91-d1be2c8b7268^0018
"DATA",176.802,64,2,0)
^^1^1^3130419
"DATA",176.802,64,2,1,0)
Percentage of patients 18-85 years of age who had a diagnosis of hypertension and whose blood pressure was adequately controlled (<140/90mmHg) during the measurement period.
"DATA",176.802,64,3)
Procedure
"DATA",176.802,64,4)
CMS165v1
"DATA",176.802,64,5)
National Quality Forum^CY 2014 EP
"DATA",176.802,64,6)
National Committee for Quality Assurance^National Committee for Quality Assurance
"DATA",176.802,64,7)
PROCESS
"DATA",176.802,64,8)
High_Blood_Press
"DATA",176.802,64,9)
Physician Performance Measure (Measures) and related data specifications were developed by the National Committee for Quality Assurance (NCQA).
"DATA",176.802,64,10)
165^Complete
"DATA",176.802,64,11)
1
"DATA",176.802,64,12,0)
^176.8024P^23^23
"DATA",176.802,64,12,1,0)
43
"DATA",176.802,64,12,2,0)
150
"DATA",176.802,64,12,3,0)
219
"DATA",176.802,64,12,4,0)
220
"DATA",176.802,64,12,5,0)
221
"DATA",176.802,64,12,6,0)
242
"DATA",176.802,64,12,7,0)
252
"DATA",176.802,64,12,8,0)
254
"DATA",176.802,64,12,9,0)
255
"DATA",176.802,64,12,10,0)
258
"DATA",176.802,64,12,11,0)
333
"DATA",176.802,64,12,12,0)
503
"DATA",176.802,64,12,13,0)
590
"DATA",176.802,64,12,14,0)
594
"DATA",176.802,64,12,15,0)
609
"DATA",176.802,64,12,16,0)
611
"DATA",176.802,64,12,17,0)
638
"DATA",176.802,64,12,18,0)
657
"DATA",176.802,64,12,19,0)
662
"DATA",176.802,64,12,20,0)
666
"DATA",176.802,64,12,21,0)
698
"DATA",176.802,64,12,22,0)
756
"DATA",176.802,64,12,23,0)
792
"DATA",176.802,64,13)
Percentage of patients 18-85 years of age who had a diagnosis of hypertension and whose blood pressure was adequately controlled (<140/90mmHg) during the measurement period.
"DATA",176.802,64,14)
CONTROLLING HIGH BLOOD PRESSURE^EP
"DATA",176.802,64,15)
^7
"DATA",176.802,65,0)
Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer
"DATA",176.802,65,1)
ac639794-cb3f-4f4f-8fa6-680300d5ed4e^0387
"DATA",176.802,65,2,0)
^^1^1^3130419
"DATA",176.802,65,2,1,0)
Percentage of female patients aged 18 years and older with Stage IC through IIIC, ER or PR positive breast cancer who were prescribed tamoxifen or aromatase inhibitor (AI) during the 12-month reporting period
"DATA",176.802,65,3)
Medication
"DATA",176.802,65,4)
CMS140v1
"DATA",176.802,65,5)
National Quality Forum^CY 2014 EP
"DATA",176.802,65,6)
American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)^American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)
"DATA",176.802,65,7)
PROCESS
"DATA",176.802,65,8)
Onc_Breast_Cancer
"DATA",176.802,65,9)
Copyright 2012 American Medical Association, American Society of Clinical Oncology, and National Comprehensive Cancer Network. All Rights Reserved.
"DATA",176.802,65,10)
140^Complete
"DATA",176.802,65,11)
1
"DATA",176.802,65,12,0)
^176.8024P^38^38
"DATA",176.802,65,12,1,0)
26
"DATA",176.802,65,12,2,0)
87
"DATA",176.802,65,12,3,0)
96
"DATA",176.802,65,12,4,0)
97
"DATA",176.802,65,12,5,0)
98
"DATA",176.802,65,12,6,0)
99
"DATA",176.802,65,12,7,0)
100
"DATA",176.802,65,12,8,0)
101
"DATA",176.802,65,12,9,0)
102
"DATA",176.802,65,12,10,0)
103
"DATA",176.802,65,12,11,0)
104
"DATA",176.802,65,12,12,0)
105
"DATA",176.802,65,12,13,0)
106
"DATA",176.802,65,12,14,0)
107
"DATA",176.802,65,12,15,0)
108
"DATA",176.802,65,12,16,0)
109
"DATA",176.802,65,12,17,0)
110
"DATA",176.802,65,12,18,0)
111
"DATA",176.802,65,12,19,0)
112
"DATA",176.802,65,12,20,0)
113
"DATA",176.802,65,12,21,0)
114
"DATA",176.802,65,12,22,0)
115
"DATA",176.802,65,12,23,0)
136
"DATA",176.802,65,12,24,0)
155
"DATA",176.802,65,12,25,0)
255
"DATA",176.802,65,12,26,0)
258
"DATA",176.802,65,12,27,0)
262
"DATA",176.802,65,12,28,0)
291
"DATA",176.802,65,12,29,0)
497
"DATA",176.802,65,12,30,0)
563
"DATA",176.802,65,12,31,0)
590
"DATA",176.802,65,12,32,0)
594
"DATA",176.802,65,12,33,0)
628
"DATA",176.802,65,12,34,0)
638
"DATA",176.802,65,12,35,0)
698
"DATA",176.802,65,12,36,0)
699
"DATA",176.802,65,12,37,0)
754
"DATA",176.802,65,12,38,0)
758
"DATA",176.802,65,13)
Percentage of female patients aged 18 years and older with Stage IC through IIIC, ER or PR positive breast cancer who were prescribed tamoxifen or aromatase inhibitor (AI) during the 12-month reporting period
"DATA",176.802,65,14)
BREAST CANCER: HORMONAL THERAPY FOR STAGE IC-IIIC ESTROGEN RECEPTOR/PROGESTERONE RECEPTOR (ER/PR) POSITIVE BREAST CANCER^EP
"DATA",176.802,65,15)
^5
"DATA",176.802,66,0)
Childhood Immunization Status
"DATA",176.802,66,1)
b2802b7a-3580-4be8-9458-921aea62b78c^0038
"DATA",176.802,66,2,0)
^^1^1^3130419
"DATA",176.802,66,2,1,0)
Percentage of children 2 years of age who had four diphtheria, tetanus and acellular pertussis (DTaP); three polio (IPV), one measles, mumps and rubella (MMR); three H influenza type B (HiB); three hepatitis B (Hep B); one chicken
"DATA",176.802,66,3)
Procedure
"DATA",176.802,66,4)
CMS117v1
"DATA",176.802,66,5)
National Quality Forum^CY 2014 EP
"DATA",176.802,66,6)
National Committee for Quality Assurance^National Committee for Quality Assurance
"DATA",176.802,66,7)
PROCESS
"DATA",176.802,66,8)
Child_Imm_Status
"DATA",176.802,66,9)
Physician Performance Measure (Measures) and related data specifications were developed by the National Committee for Quality Assurance (NCQA).
"DATA",176.802,66,10)
117^InProgress
"DATA",176.802,66,11)
1
"DATA",176.802,66,12,0)
^176.8024P^60^60
"DATA",176.802,66,12,1,0)
31
"DATA",176.802,66,12,2,0)
32
"DATA",176.802,66,12,3,0)
33
"DATA",176.802,66,12,4,0)
34
"DATA",176.802,66,12,5,0)
35
"DATA",176.802,66,12,6,0)
36
"DATA",176.802,66,12,7,0)
37
"DATA",176.802,66,12,8,0)
38
"DATA",176.802,66,12,9,0)
39
"DATA",176.802,66,12,10,0)
40
"DATA",176.802,66,12,11,0)
41
"DATA",176.802,66,12,12,0)
42
"DATA",176.802,66,12,13,0)
194
"DATA",176.802,66,12,14,0)
195
"DATA",176.802,66,12,15,0)
236
"DATA",176.802,66,12,16,0)
248
"DATA",176.802,66,12,17,0)
255
"DATA",176.802,66,12,18,0)
258
"DATA",176.802,66,12,19,0)
299
"DATA",176.802,66,12,20,0)
311
"DATA",176.802,66,12,21,0)
312
"DATA",176.802,66,12,22,0)
314
"DATA",176.802,66,12,23,0)
315
"DATA",176.802,66,12,24,0)
316
"DATA",176.802,66,12,25,0)
317
"DATA",176.802,66,12,26,0)
319
"DATA",176.802,66,12,27,0)
320
"DATA",176.802,66,12,28,0)
321
"DATA",176.802,66,12,29,0)
322
"DATA",176.802,66,12,30,0)
333
"DATA",176.802,66,12,31,0)
477
"DATA",176.802,66,12,32,0)
478
"DATA",176.802,66,12,33,0)
484
"DATA",176.802,66,12,34,0)
485
"DATA",176.802,66,12,35,0)
539
"DATA",176.802,66,12,36,0)
544
"DATA",176.802,66,12,37,0)
545
"DATA",176.802,66,12,38,0)
546
"DATA",176.802,66,12,39,0)
547
"DATA",176.802,66,12,40,0)
569
"DATA",176.802,66,12,41,0)
570
"DATA",176.802,66,12,42,0)
590
"DATA",176.802,66,12,43,0)
594
"DATA",176.802,66,12,44,0)
638
"DATA",176.802,66,12,45,0)
647
"DATA",176.802,66,12,46,0)
648
"DATA",176.802,66,12,47,0)
661
"DATA",176.802,66,12,48,0)
667
"DATA",176.802,66,12,49,0)
698
"DATA",176.802,66,12,50,0)
723
"DATA",176.802,66,12,51,0)
724
"DATA",176.802,66,12,52,0)
725
"DATA",176.802,66,12,53,0)
726
"DATA",176.802,66,12,54,0)
727
"DATA",176.802,66,12,55,0)
728
"DATA",176.802,66,12,56,0)
736
"DATA",176.802,66,12,57,0)
788
"DATA",176.802,66,12,58,0)
789
"DATA",176.802,66,12,59,0)
790
"DATA",176.802,66,12,60,0)
791
"DATA",176.802,66,13)
Percentage of children 2 years of age who had four diphtheria, tetanus and acellular pertussis (DTaP); three polio (IPV), one measles, mumps and rubella (MMR); three H influenza type B (HiB); three hepatitis B (Hep B); one chicken
"DATA",176.802,66,14)
CHILDHOOD IMMUNIZATION STATUS^EP
"DATA",176.802,66,15)
^7
"DATA",176.802,67,0)
Use of Imaging Studies for Low Back Pain
"DATA",176.802,67,1)
b6016b47-b65d-4be0-866f-1d397886ca89^0052
"DATA",176.802,67,2,0)
^^1^1^3130419
"DATA",176.802,67,2,1,0)
Percentage of patients 18-50 years of age with a diagnosis of low back pain who did not have an imaging study (plain X-ray, MRI, CT scan) within 28 days of the diagnosis.
"DATA",176.802,67,3)
Diagnostic Study
"DATA",176.802,67,4)
CMS166v1
"DATA",176.802,67,5)
National Quality Forum^CY 2014 EP
"DATA",176.802,67,6)
National Committee for Quality Assurance^National Committee for Quality Assurance
"DATA",176.802,67,7)
PROCESS
"DATA",176.802,67,8)
Low_Back_Pain
"DATA",176.802,67,9)
Physician Performance Measure (Measures) and related data specifications were developed by the National Committee for Quality Assurance (NCQA).
"DATA",176.802,67,10)
166^Complete
"DATA",176.802,67,11)
1
"DATA",176.802,67,12,0)
^176.8024P^13^13
"DATA",176.802,67,12,1,0)
21
"DATA",176.802,67,12,2,0)
121
"DATA",176.802,67,12,3,0)
255
"DATA",176.802,67,12,4,0)
474
"DATA",176.802,67,12,5,0)
525
"DATA",176.802,67,12,6,0)
528
"DATA",176.802,67,12,7,0)
582
"DATA",176.802,67,12,8,0)
590
"DATA",176.802,67,12,9,0)
594
"DATA",176.802,67,12,10,0)
638
"DATA",176.802,67,12,11,0)
698
"DATA",176.802,67,12,12,0)
770
"DATA",176.802,67,12,13,0)
807
"DATA",176.802,67,13)
Percentage of patients 18-50 years of age with a diagnosis of low back pain who did not have an imaging study (plain X-ray, MRI, CT scan) within 28 days of the diagnosis.
"DATA",176.802,67,14)
USE OF IMAGING STUDIES FOR LOW BACK PAIN^EP
"DATA",176.802,67,15)
^7
"DATA",176.802,68,0)
Bipolar Disorder and Major Depression: Appraisal for alcohol or chemical substance use
"DATA",176.802,68,1)
b99aaef6-7889-4aba-85fc-5a2b739dd098^0110
"DATA",176.802,68,2,0)
^^1^1^3130419
"DATA",176.802,68,2,1,0)
Percentage of patients with depression or bipolar disorder with evidence of an initial assessment that includes an appraisal for alcohol or chemical substance use.
"DATA",176.802,68,3)
Individual Characteristic
"DATA",176.802,68,4)
CMS169v1
"DATA",176.802,68,5)
National Quality Forum^CY 2014 EP
"DATA",176.802,68,6)
Center for Quality Assessment & Improvement in Mental Health (CQAIMH)^Center for Quality Assessment & Improvement in Mental Health (CQAIMH)
"DATA",176.802,68,7)
PROCESS
"DATA",176.802,68,8)
Supplemental Value Sets
"DATA",176.802,68,9)
This measure is copyrighted by CQAIMH.  It may be used for research, teaching, and quality measurement / improvement activities  provided the following:
"DATA",176.802,68,10)
169^Complete
"DATA",176.802,68,11)
1
"DATA",176.802,68,12,0)
^176.8024P^13^13
"DATA",176.802,68,12,1,0)
63
"DATA",176.802,68,12,2,0)
64
"DATA",176.802,68,12,3,0)
65
"DATA",176.802,68,12,4,0)
66
"DATA",176.802,68,12,5,0)
67
"DATA",176.802,68,12,6,0)
68
"DATA",176.802,68,12,7,0)
70
"DATA",176.802,68,12,8,0)
71
"DATA",176.802,68,12,9,0)
72
"DATA",176.802,68,12,10,0)
255
"DATA",176.802,68,12,11,0)
590
"DATA",176.802,68,12,12,0)
638
"DATA",176.802,68,12,13,0)
698
"DATA",176.802,68,13)
Percentage of patients with depression or bipolar disorder with evidence of an initial assessment that includes an appraisal for alcohol or chemical substance use.
"DATA",176.802,68,14)
BIPOLAR DISORDER AND MAJOR DEPRESSION: APPRAISAL FOR ALCOHOL OR CHEMICAL SUBSTANCE USE^EP
"DATA",176.802,68,15)
^3
"DATA",176.802,69,0)
Aspirin Prescribed at Discharge
"DATA",176.802,69,1)
bb481284-30dd-4383-928c-82385bbf1b17^0142
"DATA",176.802,69,2,0)
^^1^1^3130419
"DATA",176.802,69,2,1,0)
Acute myocardial infarction (AMI) patients who are prescribed aspirin at hospital discharge
"DATA",176.802,69,3)
Individual Characteristic
"DATA",176.802,69,4)
CMS100v2
"DATA",176.802,69,5)
National Quality Forum^FY 2014 EH
"DATA",176.802,69,6)
Oklahoma Foundation for Medical Quality^Oklahoma Foundation for Medical Quality
"DATA",176.802,69,7)
PROCESS
"DATA",176.802,69,8)
AMI-2
"DATA",176.802,69,9)
Measure specifications are in the Public Domain.
"DATA",176.802,69,10)
100^InProgress
"DATA",176.802,69,11)
2
"DATA",176.802,69,12,0)
^176.8024P^18^18
"DATA",176.802,69,12,1,0)
55
"DATA",176.802,69,12,2,0)
157
"DATA",176.802,69,12,3,0)
229
"DATA",176.802,69,12,4,0)
255
"DATA",176.802,69,12,5,0)
336
"DATA",176.802,69,12,6,0)
340
"DATA",176.802,69,12,7,0)
341
"DATA",176.802,69,12,8,0)
342
"DATA",176.802,69,12,9,0)
343
"DATA",176.802,69,12,10,0)
346
"DATA",176.802,69,12,11,0)
352
"DATA",176.802,69,12,12,0)
363
"DATA",176.802,69,12,13,0)
369
"DATA",176.802,69,12,14,0)
590
"DATA",176.802,69,12,15,0)
630
"DATA",176.802,69,12,16,0)
638
"DATA",176.802,69,12,17,0)
698
"DATA",176.802,69,12,18,0)
808
"DATA",176.802,69,13)
Acute myocardial infarction (AMI) patients who are prescribed aspirin at hospital discharge
"DATA",176.802,69,14)
ASPIRIN PRESCRIBED AT DISCHARGE^EH
"DATA",176.802,69,15)
^1
"DATA",176.802,70,0)
Functional Status Assessment for Complex Chronic Conditions
"DATA",176.802,70,1)
bb9b8ef7-0354-40e0-bec7-d6891b7df519^NA
"DATA",176.802,70,2,0)
^^1^1^3130419
"DATA",176.802,70,2,1,0)
Percentage of patients aged 65 years and older with heart failure who completed initial and follow-up patient-reported functional status assessments
"DATA",176.802,70,3)
Condition/Diagnosis/Problem
"DATA",176.802,70,4)
CMS90v1
"DATA",176.802,70,5)
None^CY 2014 EP
"DATA",176.802,70,6)
National Quality Forum^National Quality Forum
"DATA",176.802,70,7)
PROCESS
"DATA",176.802,70,8)
FSA for complex chronic cond
"DATA",176.802,70,9)
TBD
"DATA",176.802,70,10)
90^InProgress
"DATA",176.802,70,11)
1
"DATA",176.802,70,12,0)
^176.8024P^10^10
"DATA",176.802,70,12,1,0)
21
"DATA",176.802,70,12,2,0)
255
"DATA",176.802,70,12,3,0)
258
"DATA",176.802,70,12,4,0)
273
"DATA",176.802,70,12,5,0)
306
"DATA",176.802,70,12,6,0)
590
"DATA",176.802,70,12,7,0)
594
"DATA",176.802,70,12,8,0)
638
"DATA",176.802,70,12,9,0)
698
"DATA",176.802,70,12,10,0)
737
"DATA",176.802,70,13)
Percentage of patients aged 65 years and older with heart failure who completed initial and follow-up patient-reported functional status assessments
"DATA",176.802,70,14)
FUNCTIONAL STATUS ASSESSMENT FOR COMPLEX CHRONIC CONDITIONS^EP
"DATA",176.802,70,15)
^7
"DATA",176.802,71,0)
Falls: Screening for Future Fall Risk
"DATA",176.802,71,1)
bc5b4a57-b964-4399-9d40-667c896f31ea^0101
"DATA",176.802,71,2,0)
^^1^1^3130419
"DATA",176.802,71,2,1,0)
Percentage of patients 65 years of age and older who were screened for future fall risk during the measurement period.
"DATA",176.802,71,3)
Individual Characteristic
"DATA",176.802,71,4)
CMS139v1
"DATA",176.802,71,5)
National Quality Forum^CY 2014 EP
"DATA",176.802,71,6)
National Committee for Quality Assurance^National Committee for Quality Assurance
"DATA",176.802,71,7)
PROCESS
"DATA",176.802,71,8)
Supplemental Value Sets
"DATA",176.802,71,9)
Copyright 2012 American Medical Association and National Committee for Quality Assurance. All Rights Reserved.
"DATA",176.802,71,10)
139^Complete
"DATA",176.802,71,11)
1
"DATA",176.802,71,12,0)
^176.8024P^15^15
"DATA",176.802,71,12,1,0)
43
"DATA",176.802,71,12,2,0)
127
"DATA",176.802,71,12,3,0)
255
"DATA",176.802,71,12,4,0)
258
"DATA",176.802,71,12,5,0)
259
"DATA",176.802,71,12,6,0)
333
"DATA",176.802,71,12,7,0)
587
"DATA",176.802,71,12,8,0)
590
"DATA",176.802,71,12,9,0)
594
"DATA",176.802,71,12,10,0)
636
"DATA",176.802,71,12,11,0)
638
"DATA",176.802,71,12,12,0)
662
"DATA",176.802,71,12,13,0)
665
"DATA",176.802,71,12,14,0)
666
"DATA",176.802,71,12,15,0)
698
"DATA",176.802,71,13)
Percentage of patients 65 years of age and older who were screened for future fall risk during the measurement period.
"DATA",176.802,71,14)
FALLS: SCREENING FOR FUTURE FALL RISK^EP
"DATA",176.802,71,15)
^12
"DATA",176.802,72,0)
Venous Thromboembolism Patients Receiving Unfractionated Heparin with Dosages/Platelet Count Monitoring by Protocol or Nomogram
"DATA",176.802,72,1)
bcce43dd-08e3-46c3-bfdd-0b1b472690f0^0374
"DATA",176.802,72,2,0)
^^1^1^3130419
"DATA",176.802,72,2,1,0)
This measure assesses the number of patients diagnosed with confirmed VTE who received intravenous (IV) UFH therapy dosages AND had their platelet counts monitored using defined parameters such as a nomogram or protocol.
"DATA",176.802,72,3)
Individual Characteristic
"DATA",176.802,72,4)
CMS109v2
"DATA",176.802,72,5)
National Quality Forum^FY 2014 EH
"DATA",176.802,72,6)
Joint Commission^Joint Commission
"DATA",176.802,72,7)
PROCESS
"DATA",176.802,72,8)
Venous Thromboembolism Patients
"DATA",176.802,72,9)
Measure specifications are in the Public Domain.
"DATA",176.802,72,10)
109^Complete
"DATA",176.802,72,11)
2
"DATA",176.802,72,12,0)
^176.8024P^22^22
"DATA",176.802,72,12,1,0)
154
"DATA",176.802,72,12,2,0)
229
"DATA",176.802,72,12,3,0)
231
"DATA",176.802,72,12,4,0)
232
"DATA",176.802,72,12,5,0)
246
"DATA",176.802,72,12,6,0)
255
"DATA",176.802,72,12,7,0)
489
"DATA",176.802,72,12,8,0)
499
"DATA",176.802,72,12,9,0)
514
"DATA",176.802,72,12,10,0)
590
"DATA",176.802,72,12,11,0)
592
"DATA",176.802,72,12,12,0)
616
"DATA",176.802,72,12,13,0)
627
"DATA",176.802,72,12,14,0)
638
"DATA",176.802,72,12,15,0)
646
"DATA",176.802,72,12,16,0)
698
"DATA",176.802,72,12,17,0)
772
"DATA",176.802,72,12,18,0)
775
"DATA",176.802,72,12,19,0)
783
"DATA",176.802,72,12,20,0)
784
"DATA",176.802,72,12,21,0)
794
"DATA",176.802,72,12,22,0)
808
"DATA",176.802,72,13)
This measure assesses the number of patients diagnosed with confirmed VTE who received intravenous (IV) UFH therapy dosages AND had their platelet counts monitored using defined parameters such as a nomogram or protocol.
"DATA",176.802,72,14)
VENOUS THROMBOEMBOLISM PATIENTS RECEIVING UNFRACTIONATED HEPARIN WITH DOSAGES/PLATELET COUNT MONITORING BY PROTOCOL OR NOMOGRAM^EH
"DATA",176.802,72,15)
^21
"DATA",176.802,73,0)
Functional Status Assessment for Knee Replacement
"DATA",176.802,73,1)
be8d9655-1194-46ef-b43e-4b1d0c36ab71^Not Applicable
"DATA",176.802,73,2,0)
^^1^1^3130419
"DATA",176.802,73,2,1,0)
Percentage of patients aged 18 years and older with primary total knee arthroplasty (TKA) who completed  baseline and follow-up (patient-reported) functional status assessments.
"DATA",176.802,73,3)
Condition/Diagnosis/Problem
"DATA",176.802,73,4)
CMS66v1
"DATA",176.802,73,5)
None^CY 2014 EP
"DATA",176.802,73,6)
National Committee for Quality Assurance (NCQA)^Center for Medicare & Medicaid Services (CMS)
"DATA",176.802,73,7)
PROCESS
"DATA",176.802,73,8)
FSA for Knee Replacement
"DATA",176.802,73,9)
TBD
"DATA",176.802,73,10)
66^InProgress
"DATA",176.802,73,11)
1
"DATA",176.802,73,12,0)
^176.8024P^11^11
"DATA",176.802,73,12,1,0)
255
"DATA",176.802,73,12,2,0)
258
"DATA",176.802,73,12,3,0)
269
"DATA",176.802,73,12,4,0)
274
"DATA",176.802,73,12,5,0)
590
"DATA",176.802,73,12,6,0)
594
"DATA",176.802,73,12,7,0)
611
"DATA",176.802,73,12,8,0)
638
"DATA",176.802,73,12,9,0)
671
"DATA",176.802,73,12,10,0)
698
"DATA",176.802,73,12,11,0)
737
"DATA",176.802,73,13)
Percentage of patients aged 18 years and older with primary total knee arthroplasty (TKA) who completed  baseline and follow-up (patient-reported) functional status assessments.
"DATA",176.802,73,14)
FUNCTIONAL STATUS ASSESSMENT FOR KNEE REPLACEMENT^EP
"DATA",176.802,73,15)
^17
"DATA",176.802,74,0)
Appropriate Testing for Children with Pharyngitis
"DATA",176.802,74,1)
beb1c33c-2549-4e7f-9567-05ed38448464^0002
"DATA",176.802,74,2,0)
^^1^1^3130419
"DATA",176.802,74,2,1,0)
Percentage of children 2-18 years of age who were diagnosed with pharyngitis, ordered an antibiotic and received a group A streptococcus (strep) test for the episode.
"DATA",176.802,74,3)
Individual Characteristic
"DATA",176.802,74,4)
CMS146v1
"DATA",176.802,74,5)
National Quality Forum^CY 2014 EP
"DATA",176.802,74,6)
National Committee for Quality Assurance^National Committee for Quality Assurance
"DATA",176.802,74,7)
PROCESS
"DATA",176.802,74,8)
Supplemental Value Sets
"DATA",176.802,74,9)
Physician Performance Measure (Measures) and related data specifications were developed by the National Committee for Quality Assurance (NCQA).
"DATA",176.802,74,10)
146^Complete
"DATA",176.802,74,11)
1
"DATA",176.802,74,12,0)
^176.8024P^9^9
"DATA",176.802,74,12,1,0)
9
"DATA",176.802,74,12,2,0)
11
"DATA",176.802,74,12,3,0)
30
"DATA",176.802,74,12,4,0)
46
"DATA",176.802,74,12,5,0)
255
"DATA",176.802,74,12,6,0)
294
"DATA",176.802,74,12,7,0)
590
"DATA",176.802,74,12,8,0)
638
"DATA",176.802,74,12,9,0)
698
"DATA",176.802,74,13)
Percentage of children 2-18 years of age who were diagnosed with pharyngitis, ordered an antibiotic and received a group A streptococcus (strep) test for the episode.
"DATA",176.802,74,14)
APPROPRIATE TESTING FOR CHILDREN WITH PHARYNGITIS^EP
"DATA",176.802,74,15)
^7
"DATA",176.802,75,0)
Diabetes: Foot Exam
"DATA",176.802,75,1)
c0d72444-7c26-4863-9b51-8080f8928a85^0056
"DATA",176.802,75,2,0)
^^1^1^3130419
"DATA",176.802,75,2,1,0)
Percentage of patients aged 18-75 years of age with diabetes who had a foot exam during the measurement period.
"DATA",176.802,75,3)
Physical Exam
"DATA",176.802,75,4)
CMS123v1
"DATA",176.802,75,5)
National Quality Forum^CY 2014 EP
"DATA",176.802,75,6)
National Committee for Quality Assurance^National Committee for Quality Assurance
"DATA",176.802,75,7)
PROCESS
"DATA",176.802,75,8)
Diab_Foot
"DATA",176.802,75,9)
Physician Performance Measure (Measures) and related data specifications were developed by the National Committee for Quality Assurance (NCQA).
"DATA",176.802,75,10)
123^Complete
"DATA",176.802,75,11)
1
"DATA",176.802,75,12,0)
^176.8024P^15^15
"DATA",176.802,75,12,1,0)
43
"DATA",176.802,75,12,2,0)
212
"DATA",176.802,75,12,3,0)
255
"DATA",176.802,75,12,4,0)
258
"DATA",176.802,75,12,5,0)
285
"DATA",176.802,75,12,6,0)
333
"DATA",176.802,75,12,7,0)
590
"DATA",176.802,75,12,8,0)
594
"DATA",176.802,75,12,9,0)
638
"DATA",176.802,75,12,10,0)
662
"DATA",176.802,75,12,11,0)
666
"DATA",176.802,75,12,12,0)
696
"DATA",176.802,75,12,13,0)
698
"DATA",176.802,75,12,14,0)
734
"DATA",176.802,75,12,15,0)
796
"DATA",176.802,75,13)
Percentage of patients aged 18-75 years of age with diabetes who had a foot exam during the measurement period.
"DATA",176.802,75,14)
DIABETES: FOOT EXAM^EP
"DATA",176.802,75,15)
^9
"DATA",176.802,76,0)
Initiation and Engagement of Alcohol and Other Drug Dependence Treatment
"DATA",176.802,76,1)
c3657d72-21b4-4675-820a-86c7fe293bf5^0004
"DATA",176.802,76,2,0)
^^1^1^3130419
"DATA",176.802,76,2,1,0)
Percentage of patients 13 years of age and older with a new episode of alcohol and other drug (AOD) dependence who received the following. Two rates are reported.
"DATA",176.802,76,3)
Individual Characteristic
"DATA",176.802,76,4)
CMS137v1
"DATA",176.802,76,5)
National Quality Forum^CY 2014 EP
"DATA",176.802,76,6)
National Committee for Quality Assurance^National Committee for Quality Assurance
"DATA",176.802,76,7)
PROCESS
"DATA",176.802,76,8)
Supplemental Value Sets
"DATA",176.802,76,9)
Physician Performance Measure (Measures) and related data specifications were developed by the National Committee for Quality Assurance (NCQA).
"DATA",176.802,76,10)
137^Complete
"DATA",176.802,76,11)
1
"DATA",176.802,76,12,0)
^176.8024P^15^15
"DATA",176.802,76,12,1,0)
19
"DATA",176.802,76,12,2,0)
20
"DATA",176.802,76,12,3,0)
211
"DATA",176.802,76,12,4,0)
225
"DATA",176.802,76,12,5,0)
226
"DATA",176.802,76,12,6,0)
255
"DATA",176.802,76,12,7,0)
258
"DATA",176.802,76,12,8,0)
335
"DATA",176.802,76,12,9,0)
437
"DATA",176.802,76,12,10,0)
590
"DATA",176.802,76,12,11,0)
594
"DATA",176.802,76,12,12,0)
638
"DATA",176.802,76,12,13,0)
690
"DATA",176.802,76,12,14,0)
691
"DATA",176.802,76,12,15,0)
698
"DATA",176.802,76,13)
Percentage of patients 13 years of age and older with a new episode of alcohol and other drug (AOD) dependence who received the following. Two rates are reported.
"DATA",176.802,76,14)
INITIATION AND ENGAGEMENT OF ALCOHOL AND OTHER DRUG DEPENDENCE TREATMENT^EP
"DATA",176.802,76,15)
^3
"DATA",176.802,77,0)
Chlamydia Screening for Women
"DATA",176.802,77,1)
c9930664-be3d-4ffe-ae4a-5cf4933ecb89^0033
"DATA",176.802,77,2,0)
^^1^1^3130419
"DATA",176.802,77,2,1,0)
Percentage of women 16-24 years of age who were identified as sexually active and who had at least one test for chlamydia during the measurement period.
"DATA",176.802,77,3)
Diagnostic Study
"DATA",176.802,77,4)
CMS153v1
"DATA",176.802,77,5)
National Quality Forum^CY 2014 EP
"DATA",176.802,77,6)
National Committee for Quality Assurance^National Committee for Quality Assurance
"DATA",176.802,77,7)
PROCESS
"DATA",176.802,77,8)
Chlamydia
"DATA",176.802,77,9)
Physician Performance Measure (Measures) and related data specifications were developed by the National Committee for Quality Assurance (NCQA).
"DATA",176.802,77,10)
153^InProgress
"DATA",176.802,77,11)
1
"DATA",176.802,77,12,0)
^176.8024P^32^32
"DATA",176.802,77,12,1,0)
142
"DATA",176.802,77,12,2,0)
143
"DATA",176.802,77,12,3,0)
177
"DATA",176.802,77,12,4,0)
183
"DATA",176.802,77,12,5,0)
202
"DATA",176.802,77,12,6,0)
218
"DATA",176.802,77,12,7,0)
255
"DATA",176.802,77,12,8,0)
258
"DATA",176.802,77,12,9,0)
262
"DATA",176.802,77,12,10,0)
280
"DATA",176.802,77,12,11,0)
292
"DATA",176.802,77,12,12,0)
299
"DATA",176.802,77,12,13,0)
333
"DATA",176.802,77,12,14,0)
480
"DATA",176.802,77,12,15,0)
502
"DATA",176.802,77,12,16,0)
509
"DATA",176.802,77,12,17,0)
510
"DATA",176.802,77,12,18,0)
590
"DATA",176.802,77,12,19,0)
594
"DATA",176.802,77,12,20,0)
606
"DATA",176.802,77,12,21,0)
617
"DATA",176.802,77,12,22,0)
638
"DATA",176.802,77,12,23,0)
659
"DATA",176.802,77,12,24,0)
661
"DATA",176.802,77,12,25,0)
662
"DATA",176.802,77,12,26,0)
666
"DATA",176.802,77,12,27,0)
667
"DATA",176.802,77,12,28,0)
676
"DATA",176.802,77,12,29,0)
677
"DATA",176.802,77,12,30,0)
698
"DATA",176.802,77,12,31,0)
753
"DATA",176.802,77,12,32,0)
806
"DATA",176.802,77,13)
Percentage of women 16-24 years of age who were identified as sexually active and who had at least one test for chlamydia during the measurement period.
"DATA",176.802,77,14)
CHLAMYDIA SCREENING FOR WOMEN^EP
"DATA",176.802,77,15)
^7
"DATA",176.802,78,0)
Prophylactic Antibiotic Received Within One Hour Prior to Surgical Incision
"DATA",176.802,78,1)
d09add1d-30f5-462d-b677-3d17d9ccd664^0527
"DATA",176.802,78,2,0)
^^1^1^3130419
"DATA",176.802,78,2,1,0)
Surgical patients with prophylactic antibiotics initiated within one hour prior to surgical incision. Patients who received vancomycin or a fluoroquinolone for prophylactic antibiotics should have the antibiotics initiated within 
"DATA",176.802,78,3)
Individual Characteristic
"DATA",176.802,78,4)
CMS171v3
"DATA",176.802,78,5)
National Quality Forum^FY 2014 EH
"DATA",176.802,78,6)
Oklahoma Foundation for Medical Quality^Centers for Medicare & Medicaid Services
"DATA",176.802,78,7)
PROCESS
"DATA",176.802,78,8)
SCIP Prophylactic Antibiotic 1 H
"DATA",176.802,78,9)
Measure specifications are in the Public Domain.
"DATA",176.802,78,10)
171^InProgress
"DATA",176.802,78,11)
3
"DATA",176.802,78,12,0)
^176.8024P^30^30
"DATA",176.802,78,12,1,0)
50
"DATA",176.802,78,12,2,0)
157
"DATA",176.802,78,12,3,0)
255
"DATA",176.802,78,12,4,0)
357
"DATA",176.802,78,12,5,0)
403
"DATA",176.802,78,12,6,0)
414
"DATA",176.802,78,12,7,0)
439
"DATA",176.802,78,12,8,0)
440
"DATA",176.802,78,12,9,0)
442
"DATA",176.802,78,12,10,0)
444
"DATA",176.802,78,12,11,0)
445
"DATA",176.802,78,12,12,0)
447
"DATA",176.802,78,12,13,0)
449
"DATA",176.802,78,12,14,0)
450
"DATA",176.802,78,12,15,0)
451
"DATA",176.802,78,12,16,0)
452
"DATA",176.802,78,12,17,0)
453
"DATA",176.802,78,12,18,0)
454
"DATA",176.802,78,12,19,0)
455
"DATA",176.802,78,12,20,0)
456
"DATA",176.802,78,12,21,0)
457
"DATA",176.802,78,12,22,0)
458
"DATA",176.802,78,12,23,0)
459
"DATA",176.802,78,12,24,0)
460
"DATA",176.802,78,12,25,0)
461
"DATA",176.802,78,12,26,0)
462
"DATA",176.802,78,12,27,0)
590
"DATA",176.802,78,12,28,0)
638
"DATA",176.802,78,12,29,0)
698
"DATA",176.802,78,12,30,0)
808
"DATA",176.802,78,13)
Surgical patients with prophylactic antibiotics initiated within one hour prior to surgical incision. Patients who received vancomycin or a fluoroquinolone for prophylactic antibiotics should have the antibiotics initiated within 
"DATA",176.802,78,14)
PROPHYLACTIC ANTIBIOTIC RECEIVED WITHIN ONE HOUR PRIOR TO SURGICAL INCISION^EH
"DATA",176.802,78,15)
^20
"DATA",176.802,79,0)
Urinary catheter removed on Postoperative Day 1 (POD 1) or Postoperative Day 2 (POD 2) with day of surgery being day zero
"DATA",176.802,79,1)
d78ce034-8288-4012-a31e-7f485a74f2a9^0453
"DATA",176.802,79,2,0)
^^1^1^3130419
"DATA",176.802,79,2,1,0)
Surgical patients with urinary catheter removed on Postoperative Day 1 or Postoperative Day 2 with day of surgery being day zero.
"DATA",176.802,79,3)
Individual Characteristic
"DATA",176.802,79,4)
CMS178v3
"DATA",176.802,79,5)
National Quality Forum^FY 2014 EH
"DATA",176.802,79,6)
Oklahoma Foundation for Medical Quality^Centers for Medicare & Medicaid Services
"DATA",176.802,79,7)
PROCESS
"DATA",176.802,79,8)
Urinary catheter removed postop
"DATA",176.802,79,9)
Measure specifications are in the Public Domain
"DATA",176.802,79,10)
178^InProgress
"DATA",176.802,79,11)
3
"DATA",176.802,79,12,0)
^176.8024P^22^22
"DATA",176.802,79,12,1,0)
157
"DATA",176.802,79,12,2,0)
255
"DATA",176.802,79,12,3,0)
257
"DATA",176.802,79,12,4,0)
345
"DATA",176.802,79,12,5,0)
364
"DATA",176.802,79,12,6,0)
375
"DATA",176.802,79,12,7,0)
402
"DATA",176.802,79,12,8,0)
404
"DATA",176.802,79,12,9,0)
424
"DATA",176.802,79,12,10,0)
425
"DATA",176.802,79,12,11,0)
426
"DATA",176.802,79,12,12,0)
429
"DATA",176.802,79,12,13,0)
433
"DATA",176.802,79,12,14,0)
450
"DATA",176.802,79,12,15,0)
475
"DATA",176.802,79,12,16,0)
554
"DATA",176.802,79,12,17,0)
590
"DATA",176.802,79,12,18,0)
619
"DATA",176.802,79,12,19,0)
638
"DATA",176.802,79,12,20,0)
698
"DATA",176.802,79,12,21,0)
729
"DATA",176.802,79,12,22,0)
808
"DATA",176.802,79,13)
Surgical patients with urinary catheter removed on Postoperative Day 1 or Postoperative Day 2 with day of surgery being day zero.
"DATA",176.802,79,14)
URINARY CATHETER REMOVED ON POSTOPERATIVE DAY 1 (POD 1) OR POSTOPERATIVE DAY 2 (POD 2) WITH DAY OF SURGERY BEING DAY ZERO^EH
"DATA",176.802,79,15)
^20
"DATA",176.802,80,0)
Diabetes: Eye Exam
"DATA",176.802,80,1)
d90bdab4-b9d2-4329-9993-5c34e2c0dc66^0055
"DATA",176.802,80,2,0)
^^1^1^3130419
"DATA",176.802,80,2,1,0)
Percentage of patients 18-75 years of age with diabetes who had a retinal or dilated eye exam by an eye care professional during the measurement period or a negative retinal exam (no evidence of retinopathy) in the 12 months prior
"DATA",176.802,80,3)
Physical Exam
"DATA",176.802,80,4)
CMS131v1
"DATA",176.802,80,5)
National Quality Forum^CY 2014 EP
"DATA",176.802,80,6)
National Committee for Quality Assurance^National Committee for Quality Assurance
"DATA",176.802,80,7)
PROCESS
"DATA",176.802,80,8)
Diab_Eye
"DATA",176.802,80,9)
Physician Performance Measure (Measures) and related data specifications were developed by the National Committee for Quality Assurance (NCQA).
"DATA",176.802,80,10)
131^Complete
"DATA",176.802,80,11)
1
"DATA",176.802,80,12,0)
^176.8024P^14^14
"DATA",176.802,80,12,1,0)
43
"DATA",176.802,80,12,2,0)
212
"DATA",176.802,80,12,3,0)
255
"DATA",176.802,80,12,4,0)
258
"DATA",176.802,80,12,5,0)
285
"DATA",176.802,80,12,6,0)
333
"DATA",176.802,80,12,7,0)
576
"DATA",176.802,80,12,8,0)
590
"DATA",176.802,80,12,9,0)
594
"DATA",176.802,80,12,10,0)
638
"DATA",176.802,80,12,11,0)
662
"DATA",176.802,80,12,12,0)
666
"DATA",176.802,80,12,13,0)
698
"DATA",176.802,80,12,14,0)
719
"DATA",176.802,80,13)
Percentage of patients 18-75 years of age with diabetes who had a retinal or dilated eye exam by an eye care professional during the measurement period or a negative retinal exam (no evidence of retinopathy) in the 12 months prior
"DATA",176.802,80,14)
DIABETES: EYE EXAM^EP
"DATA",176.802,80,15)
^11
"DATA",176.802,81,0)
Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation
"DATA",176.802,81,1)
db9d9f09-6b6a-4749-a8b2-8c1fdb018823^0086
"DATA",176.802,81,2,0)
^^1^1^3130419
"DATA",176.802,81,2,1,0)
Percentage of patients aged 18 years and older with a diagnosis of POAG who have an optic nerve head evaluation during one or more office visits within 12 months
"DATA",176.802,81,3)
Individual Characteristic
"DATA",176.802,81,4)
CMS143v1
"DATA",176.802,81,5)
National Quality Forum^CY 2014 EP
"DATA",176.802,81,6)
National Committee for Quality Assurance^American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)
"DATA",176.802,81,7)
PROCESS
"DATA",176.802,81,8)
Supplemental Value Sets
"DATA",176.802,81,9)
Copyright 2012 American Medical Association and National Committee for Quality Assurance. All Rights Reserved
"DATA",176.802,81,10)
143^InProgress
"DATA",176.802,81,11)
1
"DATA",176.802,81,12,0)
^176.8024P^14^14
"DATA",176.802,81,12,1,0)
127
"DATA",176.802,81,12,2,0)
190
"DATA",176.802,81,12,3,0)
255
"DATA",176.802,81,12,4,0)
258
"DATA",176.802,81,12,5,0)
587
"DATA",176.802,81,12,6,0)
590
"DATA",176.802,81,12,7,0)
594
"DATA",176.802,81,12,8,0)
596
"DATA",176.802,81,12,9,0)
598
"DATA",176.802,81,12,10,0)
611
"DATA",176.802,81,12,11,0)
628
"DATA",176.802,81,12,12,0)
638
"DATA",176.802,81,12,13,0)
669
"DATA",176.802,81,12,14,0)
698
"DATA",176.802,81,13)
Percentage of patients aged 18 years and older with a diagnosis of POAG who have an optic nerve head evaluation during one or more office visits within 12 months
"DATA",176.802,81,14)
PRIMARY OPEN ANGLE GLAUCOMA (POAG): OPTIC NERVE EVALUATION^EP
"DATA",176.802,81,15)
^11
"DATA",176.802,82,0)
HIV/AIDS: RNA Control for Patients with HIV
"DATA",176.802,82,1)
e0a07809-7b74-473f-bcc4-1891be506aaa^Not Applicable
"DATA",176.802,82,2,0)
^^1^1^3130419
"DATA",176.802,82,2,1,0)
Percentage of patients aged 13 years and older with a diagnosis of HIV/AIDS, with at least two visits during the measurement year, with at least 90 days between each visit, whose most recent HIV RNA level is <200 copies/mL.
"DATA",176.802,82,3)
Individual Characteristic
"DATA",176.802,82,4)
CMS77v1
"DATA",176.802,82,5)
None^CY 2014 EP
"DATA",176.802,82,6)
TBD^TBD
"DATA",176.802,82,7)
OUTCOME
"DATA",176.802,82,8)
Supplemental Value Sets
"DATA",176.802,82,9)
TBD
"DATA",176.802,82,10)
77^InProgress
"DATA",176.802,82,11)
1
"DATA",176.802,82,12,0)
^176.8024P^7^7
"DATA",176.802,82,12,1,0)
255
"DATA",176.802,82,12,2,0)
299
"DATA",176.802,82,12,3,0)
300
"DATA",176.802,82,12,4,0)
301
"DATA",176.802,82,12,5,0)
590
"DATA",176.802,82,12,6,0)
638
"DATA",176.802,82,12,7,0)
698
"DATA",176.802,82,13)
Percentage of patients aged 13 years and older with a diagnosis of HIV/AIDS, with at least two visits during the measurement year, with at least 90 days between each visit, whose most recent HIV RNA level is <200 copies/mL.
"DATA",176.802,82,14)
HIV/AIDS: RNA CONTROL FOR PATIENTS WITH HIV^EP
"DATA",176.802,82,15)
^14
"DATA",176.802,83,0)
Home Management Plan of Care (HMPC) Document Given to Patient/Caregiver
"DATA",176.802,83,1)
e1cb05e0-97d5-40fc-b456-15c5dbf44309^0338
"DATA",176.802,83,2,0)
^^1^1^3130419
"DATA",176.802,83,2,1,0)
An assessment that there is documentation in the medical record that a Home Management Plan of Care (HMPC) document was given to the pediatric asthma patient/caregiver.
"DATA",176.802,83,3)
Individual Characteristic
"DATA",176.802,83,4)
CMS26v1
"DATA",176.802,83,5)
National Quality Forum^FY 2014 EH
"DATA",176.802,83,6)
Joint Commission^Joint Commission
"DATA",176.802,83,7)
PROCESS
"DATA",176.802,83,8)
Supplemental Value Sets
"DATA",176.802,83,9)
LOINC(R) is a registered trademark of the Regenstrief Institute.
"DATA",176.802,83,10)
26^InProgress
"DATA",176.802,83,11)
1
"DATA",176.802,83,12,0)
^176.8024P^4^4
"DATA",176.802,83,12,1,0)
255
"DATA",176.802,83,12,2,0)
590
"DATA",176.802,83,12,3,0)
638
"DATA",176.802,83,12,4,0)
698
"DATA",176.802,83,13)
An assessment that there is documentation in the medical record that a Home Management Plan of Care (HMPC) document was given to the pediatric asthma patient/caregiver.
"DATA",176.802,83,14)
HOME MANAGEMENT PLAN OF CARE (HMPC) DOCUMENT GIVEN TO PATIENT/CAREGIVER^EH
"DATA",176.802,83,15)
^2
"DATA",176.802,84,0)
Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
"DATA",176.802,84,1)
e35791df-5b25-41bb-b260-673337bc44a8^0028
"DATA",176.802,84,2,0)
^^1^1^3130419
"DATA",176.802,84,2,1,0)
Percentage of patients aged 18 years and older who were screened for tobacco use one or more times within 24 months AND who received cessation counseling intervention if identified as a tobacco user
"DATA",176.802,84,3)
Individual Characteristic
"DATA",176.802,84,4)
CMS138v1
"DATA",176.802,84,5)
National Quality Forum^CY 2014 EP
"DATA",176.802,84,6)
American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)^American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)
"DATA",176.802,84,7)
PROCESS
"DATA",176.802,84,8)
Tobacco
"DATA",176.802,84,9)
Copyright 2012 American Medical Association. All Rights Reserved.
"DATA",176.802,84,10)
138^InProgress
"DATA",176.802,84,11)
1
"DATA",176.802,84,12,0)
^176.8024P^27^27
"DATA",176.802,84,12,1,0)
43
"DATA",176.802,84,12,2,0)
255
"DATA",176.802,84,12,3,0)
258
"DATA",176.802,84,12,4,0)
303
"DATA",176.802,84,12,5,0)
304
"DATA",176.802,84,12,6,0)
521
"DATA",176.802,84,12,7,0)
590
"DATA",176.802,84,12,8,0)
593
"DATA",176.802,84,12,9,0)
594
"DATA",176.802,84,12,10,0)
596
"DATA",176.802,84,12,11,0)
638
"DATA",176.802,84,12,12,0)
662
"DATA",176.802,84,12,13,0)
663
"DATA",176.802,84,12,14,0)
664
"DATA",176.802,84,12,15,0)
665
"DATA",176.802,84,12,16,0)
666
"DATA",176.802,84,12,17,0)
686
"DATA",176.802,84,12,18,0)
690
"DATA",176.802,84,12,19,0)
691
"DATA",176.802,84,12,20,0)
692
"DATA",176.802,84,12,21,0)
694
"DATA",176.802,84,12,22,0)
698
"DATA",176.802,84,12,23,0)
762
"DATA",176.802,84,12,24,0)
763
"DATA",176.802,84,12,25,0)
764
"DATA",176.802,84,12,26,0)
765
"DATA",176.802,84,12,27,0)
766
"DATA",176.802,84,13)
Percentage of patients aged 18 years and older who were screened for tobacco use one or more times within 24 months AND who received cessation counseling intervention if identified as a tobacco user
"DATA",176.802,84,14)
PREVENTIVE CARE AND SCREENING: TOBACCO USE: SCREENING AND CESSATION INTERVENTION^EP
"DATA",176.802,84,15)
^7
"DATA",176.802,85,0)
Appropriate Treatment for Children with Upper Respiratory Infection (URI)
"DATA",176.802,85,1)
e455fac0-f2cb-4074-a351-1e68a90fb7cf^0069
"DATA",176.802,85,2,0)
^^1^1^3130419
"DATA",176.802,85,2,1,0)
Percentage of children 3 months-18 years of age who were diagnosed with upper respiratory infection (URI) and were not dispensed an antibiotic prescription on or three days after the episode.
"DATA",176.802,85,3)
Condition/Diagnosis/Problem
"DATA",176.802,85,4)
CMS154v1
"DATA",176.802,85,5)
National Quality Forum^CY 2014 EP
"DATA",176.802,85,6)
National Committee for Quality Assurance^National Committee for Quality Assurance
"DATA",176.802,85,7)
PROCESS
"DATA",176.802,85,8)
URI
"DATA",176.802,85,9)
Physician Performance Measure (Measures) and related data specifications were developed by the National Committee for Quality Assurance (NCQA).
"DATA",176.802,85,10)
154^Complete
"DATA",176.802,85,11)
1
"DATA",176.802,85,12,0)
^176.8024P^12^12
"DATA",176.802,85,12,1,0)
46
"DATA",176.802,85,12,2,0)
175
"DATA",176.802,85,12,3,0)
255
"DATA",176.802,85,12,4,0)
258
"DATA",176.802,85,12,5,0)
437
"DATA",176.802,85,12,6,0)
590
"DATA",176.802,85,12,7,0)
594
"DATA",176.802,85,12,8,0)
638
"DATA",176.802,85,12,9,0)
661
"DATA",176.802,85,12,10,0)
667
"DATA",176.802,85,12,11,0)
698
"DATA",176.802,85,12,12,0)
777
"DATA",176.802,85,13)
Percentage of children 3 months-18 years of age who were diagnosed with upper respiratory infection (URI) and were not dispensed an antibiotic prescription on or three days after the episode.
"DATA",176.802,85,14)
APPROPRIATE TREATMENT FOR CHILDREN WITH UPPER RESPIRATORY INFECTION (URI)^EP
"DATA",176.802,85,15)
^7
"DATA",176.802,86,0)
Statin Prescribed at Discharge
"DATA",176.802,86,1)
ebfa203e-acc1-4228-906c-855c4bf11310^0639
"DATA",176.802,86,2,0)
^^1^1^3130419
"DATA",176.802,86,2,1,0)
Acute myocardial infarction (AMI) patients who are prescribed a statin at hospital discharge.
"DATA",176.802,86,3)
Individual Characteristic
"DATA",176.802,86,4)
CMS30v3
"DATA",176.802,86,5)
National Quality Forum^FY 2014 EH
"DATA",176.802,86,6)
Oklahoma Foundation for Medical Quality^Centers for Medicare & Medicaid Services
"DATA",176.802,86,7)
PROCESS
"DATA",176.802,86,8)
AMI-10
"DATA",176.802,86,9)
Measure specifications are in the Public Domain
"DATA",176.802,86,10)
30^InProgress
"DATA",176.802,86,11)
3
"DATA",176.802,86,12,0)
^176.8024P^18^18
"DATA",176.802,86,12,1,0)
157
"DATA",176.802,86,12,2,0)
229
"DATA",176.802,86,12,3,0)
250
"DATA",176.802,86,12,4,0)
255
"DATA",176.802,86,12,5,0)
334
"DATA",176.802,86,12,6,0)
336
"DATA",176.802,86,12,7,0)
338
"DATA",176.802,86,12,8,0)
490
"DATA",176.802,86,12,9,0)
508
"DATA",176.802,86,12,10,0)
555
"DATA",176.802,86,12,11,0)
590
"DATA",176.802,86,12,12,0)
633
"DATA",176.802,86,12,13,0)
638
"DATA",176.802,86,12,14,0)
673
"DATA",176.802,86,12,15,0)
698
"DATA",176.802,86,12,16,0)
748
"DATA",176.802,86,12,17,0)
755
"DATA",176.802,86,12,18,0)
808
"DATA",176.802,86,13)
Acute myocardial infarction (AMI) patients who are prescribed a statin at hospital discharge.
"DATA",176.802,86,14)
STATIN PRESCRIBED AT DISCHARGE^EH
"DATA",176.802,86,15)
^1
"DATA",176.802,87,0)
Diabetes: Hemoglobin A1c Poor Control
"DATA",176.802,87,1)
f2986519-5a4e-4149-a8f2-af0a1dc7f6bc^0059
"DATA",176.802,87,2,0)
^^1^1^3130419
"DATA",176.802,87,2,1,0)
Percentage of patients 18-75 years of age with diabetes who had hemoglobin A1c > 9.0% during the measurement period.
"DATA",176.802,87,3)
Individual Characteristic
"DATA",176.802,87,4)
CMS122v1
"DATA",176.802,87,5)
National Quality Forum^CY 2014 EP
"DATA",176.802,87,6)
National Committee for Quality Assurance^National Committee for Quality Assurance
"DATA",176.802,87,7)
OUTCOME
"DATA",176.802,87,8)
Supplemental Value Sets
"DATA",176.802,87,9)
Physician Performance Measure (Measures) and related data specifications were developed by the National Committee for Quality Assurance (NCQA).
"DATA",176.802,87,10)
122^Complete
"DATA",176.802,87,11)
1
"DATA",176.802,87,12,0)
^176.8024P^13^13
"DATA",176.802,87,12,1,0)
43
"DATA",176.802,87,12,2,0)
212
"DATA",176.802,87,12,3,0)
255
"DATA",176.802,87,12,4,0)
258
"DATA",176.802,87,12,5,0)
285
"DATA",176.802,87,12,6,0)
302
"DATA",176.802,87,12,7,0)
333
"DATA",176.802,87,12,8,0)
590
"DATA",176.802,87,12,9,0)
594
"DATA",176.802,87,12,10,0)
638
"DATA",176.802,87,12,11,0)
662
"DATA",176.802,87,12,12,0)
666
"DATA",176.802,87,12,13,0)
698
"DATA",176.802,87,13)
Percentage of patients 18-75 years of age with diabetes who had hemoglobin A1c > 9.0% during the measurement period.
"DATA",176.802,87,14)
DIABETES: HEMOGLOBIN A1C POOR CONTROL^EP
"DATA",176.802,87,15)
^9
"DATA",176.802,88,0)
Closing the referral loop: receipt of specialist report
"DATA",176.802,88,1)
f58fc0d6-edf5-416a-8d29-79afbfd24dea^Not Applicable
"DATA",176.802,88,2,0)
^^1^1^3130419
"DATA",176.802,88,2,1,0)
Percentage of patients with referrals, regardless of age, for which the referring provider receives a report from the provider to whom the patient was referred.
"DATA",176.802,88,3)
Intervention
"DATA",176.802,88,4)
CMS50v1
"DATA",176.802,88,5)
None^CY 2014 EP
"DATA",176.802,88,6)
National Committee for Quality Assurance (NCQA)^Centers for Medicare & Medicaid Services (CMS)
"DATA",176.802,88,7)
PROCESS
"DATA",176.802,88,8)
Closing the referral loop
"DATA",176.802,88,9)
TBD
"DATA",176.802,88,10)
50^InProgress
"DATA",176.802,88,11)
1
"DATA",176.802,88,12,0)
^176.8024P^12^12
"DATA",176.802,88,12,1,0)
182
"DATA",176.802,88,12,2,0)
255
"DATA",176.802,88,12,3,0)
258
"DATA",176.802,88,12,4,0)
590
"DATA",176.802,88,12,5,0)
594
"DATA",176.802,88,12,6,0)
638
"DATA",176.802,88,12,7,0)
661
"DATA",176.802,88,12,8,0)
662
"DATA",176.802,88,12,9,0)
666
"DATA",176.802,88,12,10,0)
667
"DATA",176.802,88,12,11,0)
698
"DATA",176.802,88,12,12,0)
703
"DATA",176.802,88,13)
Percentage of patients with referrals, regardless of age, for which the referring provider receives a report from the provider to whom the patient was referred.
"DATA",176.802,88,14)
CLOSING THE REFERRAL LOOP: RECEIPT OF SPECIALIST REPORT^EP
"DATA",176.802,88,15)
^7
"DATA",176.802,89,0)
HIV/AIDS: Medical Visit
"DATA",176.802,89,1)
f70b2984-af4a-4072-ae0d-cec677a7ff8f^0403
"DATA",176.802,89,2,0)
^^1^1^3130419
"DATA",176.802,89,2,1,0)
Percentage of patients, regardless of age, with a diagnosis of HIV/AIDS with at least two medical visits during the measurement year with a minimum of 90 days between each visit
"DATA",176.802,89,3)
Individual Characteristic
"DATA",176.802,89,4)
CMS62v1
"DATA",176.802,89,5)
National Quality Forum^CY 2014 EP
"DATA",176.802,89,6)
National Committee for Quality Assurance (NCQA)/American Medical Association-convened Physician Consortium for Performance Improvement (R) (AMA-PCPI)^National Committee for Quality Assurance (NCQA)
"DATA",176.802,89,7)
PROCESS
"DATA",176.802,89,8)
Supplemental Value Sets
"DATA",176.802,89,9)
(c) 2012 American Medical Association and National Committee for Quality Assurance. All Rights Reserved
"DATA",176.802,89,10)
62^InProgress
"DATA",176.802,89,11)
1
"DATA",176.802,89,12,0)
^176.8024P^6^6
"DATA",176.802,89,12,1,0)
255
"DATA",176.802,89,12,2,0)
299
"DATA",176.802,89,12,3,0)
301
"DATA",176.802,89,12,4,0)
590
"DATA",176.802,89,12,5,0)
638
"DATA",176.802,89,12,6,0)
698
"DATA",176.802,89,13)
Percentage of patients, regardless of age, with a diagnosis of HIV/AIDS with at least two medical visits during the measurement year with a minimum of 90 days between each visit
"DATA",176.802,89,14)
HIV/AIDS: MEDICAL VISIT^EP
"DATA",176.802,89,15)
^14
"DATA",176.802,90,0)
Intensive Care Unit Venous Thromboembolism Prophylaxis
"DATA",176.802,90,1)
fa91ba68-1e66-4a23-8eb2-baa8e6df2f2f^0372
"DATA",176.802,90,2,0)
^^1^1^3130419
"DATA",176.802,90,2,1,0)
This measure assesses the number of patients who received VTE prophylaxis or have documentation why no VTE prophylaxis was given the day of or the day after the initial admission (or transfer) to the Intensive Care Unit (ICU) or s
"DATA",176.802,90,3)
Individual Characteristic
"DATA",176.802,90,4)
CMS190v2
"DATA",176.802,90,5)
National Quality Forum^FY 2014 EH
"DATA",176.802,90,6)
Joint Commission^Joint Commission
"DATA",176.802,90,7)
PROCESS
"DATA",176.802,90,8)
VTE-2
"DATA",176.802,90,9)
Measure specifications are in the Public Domain
"DATA",176.802,90,10)
190^InProgress
"DATA",176.802,90,11)
2
"DATA",176.802,90,12,0)
^176.8024P^37^37
"DATA",176.802,90,12,1,0)
61
"DATA",176.802,90,12,2,0)
246
"DATA",176.802,90,12,3,0)
255
"DATA",176.802,90,12,4,0)
278
"DATA",176.802,90,12,5,0)
279
"DATA",176.802,90,12,6,0)
293
"DATA",176.802,90,12,7,0)
296
"DATA",176.802,90,12,8,0)
330
"DATA",176.802,90,12,9,0)
331
"DATA",176.802,90,12,10,0)
471
"DATA",176.802,90,12,11,0)
472
"DATA",176.802,90,12,12,0)
486
"DATA",176.802,90,12,13,0)
489
"DATA",176.802,90,12,14,0)
492
"DATA",176.802,90,12,15,0)
498
"DATA",176.802,90,12,16,0)
499
"DATA",176.802,90,12,17,0)
504
"DATA",176.802,90,12,18,0)
526
"DATA",176.802,90,12,19,0)
527
"DATA",176.802,90,12,20,0)
552
"DATA",176.802,90,12,21,0)
590
"DATA",176.802,90,12,22,0)
591
"DATA",176.802,90,12,23,0)
592
"DATA",176.802,90,12,24,0)
600
"DATA",176.802,90,12,25,0)
616
"DATA",176.802,90,12,26,0)
634
"DATA",176.802,90,12,27,0)
638
"DATA",176.802,90,12,28,0)
672
"DATA",176.802,90,12,29,0)
698
"DATA",176.802,90,12,30,0)
749
"DATA",176.802,90,12,31,0)
775
"DATA",176.802,90,12,32,0)
778
"DATA",176.802,90,12,33,0)
785
"DATA",176.802,90,12,34,0)
794
"DATA",176.802,90,12,35,0)
795
"DATA",176.802,90,12,36,0)
801
"DATA",176.802,90,12,37,0)
808
"DATA",176.802,90,13)
This measure assesses the number of patients who received VTE prophylaxis or have documentation why no VTE prophylaxis was given the day of or the day after the initial admission (or transfer) to the Intensive Care Unit (ICU) or s
"DATA",176.802,90,14)
INTENSIVE CARE UNIT VENOUS THROMBOEMBOLISM PROPHYLAXIS^EH
"DATA",176.802,90,15)
^21
"DATA",176.802,91,0)
Elective Delivery
"DATA",176.802,91,1)
fd7ca18d-b56d-4bca-af35-71ce36b15246^0469
"DATA",176.802,91,2,0)
^^1^1^3130419
"DATA",176.802,91,2,1,0)
Patients with elective vaginal deliveries or elective cesarean sections at >= 37 and < 39 weeks of gestation completed
"DATA",176.802,91,3)
Individual Characteristic
"DATA",176.802,91,4)
CMS113v2
"DATA",176.802,91,5)
National Quality Forum^FY 2014 EH
"DATA",176.802,91,6)
Joint Commission^Joint Commission
"DATA",176.802,91,7)
PROCESS
"DATA",176.802,91,8)
Elective Delivery
"DATA",176.802,91,9)
Measure specifications are in the Public Domain
"DATA",176.802,91,10)
113^Complete
"DATA",176.802,91,11)
2
"DATA",176.802,91,12,0)
^176.8024P^21^21
"DATA",176.802,91,12,1,0)
7
"DATA",176.802,91,12,2,0)
135
"DATA",176.802,91,12,3,0)
152
"DATA",176.802,91,12,4,0)
179
"DATA",176.802,91,12,5,0)
203
"DATA",176.802,91,12,6,0)
255
"DATA",176.802,91,12,7,0)
281
"DATA",176.802,91,12,8,0)
282
"DATA",176.802,91,12,9,0)
283
"DATA",176.802,91,12,10,0)
284
"DATA",176.802,91,12,11,0)
489
"DATA",176.802,91,12,12,0)
549
"DATA",176.802,91,12,13,0)
572
"DATA",176.802,91,12,14,0)
590
"DATA",176.802,91,12,15,0)
638
"DATA",176.802,91,12,16,0)
640
"DATA",176.802,91,12,17,0)
698
"DATA",176.802,91,12,18,0)
743
"DATA",176.802,91,12,19,0)
780
"DATA",176.802,91,12,20,0)
781
"DATA",176.802,91,12,21,0)
808
"DATA",176.802,91,13)
Patients with elective vaginal deliveries or elective cesarean sections at >= 37 and < 39 weeks of gestation completed
"DATA",176.802,91,14)
ELECTIVE DELIVERY^EH
"DATA",176.802,91,15)
^18
"DATA",176.802,92,0)
Prophylactic Antibiotic Selection for Surgical Patients
"DATA",176.802,92,1)
feea3922-f61f-4b05-98f9-b72a11815f12^0528
"DATA",176.802,92,2,0)
^^1^1^3130419
"DATA",176.802,92,2,1,0)
Surgical patients who received prophylactic antibiotics consistent with current guidelines (specific to each type of surgical procedure).
"DATA",176.802,92,3)
Individual Characteristic
"DATA",176.802,92,4)
CMS172v3
"DATA",176.802,92,5)
National Quality Forum^FY 2014 EH
"DATA",176.802,92,6)
Oklahoma Foundation for Medical Quality^Centers for Medicare & Medicaid Services
"DATA",176.802,92,7)
PROCESS
"DATA",176.802,92,8)
SCIP Antibiotic Selection
"DATA",176.802,92,9)
Measure specifications are in the Public Domain
"DATA",176.802,92,10)
172^InProgress
"DATA",176.802,92,11)
3
"DATA",176.802,92,12,0)
^176.8024P^46^46
"DATA",176.802,92,12,1,0)
50
"DATA",176.802,92,12,2,0)
157
"DATA",176.802,92,12,3,0)
255
"DATA",176.802,92,12,4,0)
257
"DATA",176.802,92,12,5,0)
345
"DATA",176.802,92,12,6,0)
353
"DATA",176.802,92,12,7,0)
358
"DATA",176.802,92,12,8,0)
361
"DATA",176.802,92,12,9,0)
376
"DATA",176.802,92,12,10,0)
379
"DATA",176.802,92,12,11,0)
381
"DATA",176.802,92,12,12,0)
382
"DATA",176.802,92,12,13,0)
383
"DATA",176.802,92,12,14,0)
384
"DATA",176.802,92,12,15,0)
385
"DATA",176.802,92,12,16,0)
387
"DATA",176.802,92,12,17,0)
403
"DATA",176.802,92,12,18,0)
408
"DATA",176.802,92,12,19,0)
414
"DATA",176.802,92,12,20,0)
438
"DATA",176.802,92,12,21,0)
439
"DATA",176.802,92,12,22,0)
440
"DATA",176.802,92,12,23,0)
441
"DATA",176.802,92,12,24,0)
442
"DATA",176.802,92,12,25,0)
443
"DATA",176.802,92,12,26,0)
444
"DATA",176.802,92,12,27,0)
446
"DATA",176.802,92,12,28,0)
447
"DATA",176.802,92,12,29,0)
448
"DATA",176.802,92,12,30,0)
449
"DATA",176.802,92,12,31,0)
450
"DATA",176.802,92,12,32,0)
451
"DATA",176.802,92,12,33,0)
452
"DATA",176.802,92,12,34,0)
453
"DATA",176.802,92,12,35,0)
454
"DATA",176.802,92,12,36,0)
455
"DATA",176.802,92,12,37,0)
456
"DATA",176.802,92,12,38,0)
457
"DATA",176.802,92,12,39,0)
458
"DATA",176.802,92,12,40,0)
459
"DATA",176.802,92,12,41,0)
461
"DATA",176.802,92,12,42,0)
462
"DATA",176.802,92,12,43,0)
590
"DATA",176.802,92,12,44,0)
638
"DATA",176.802,92,12,45,0)
698
"DATA",176.802,92,12,46,0)
808
"DATA",176.802,92,13)
Surgical patients who received prophylactic antibiotics consistent with current guidelines (specific to each type of surgical procedure).
"DATA",176.802,92,14)
PROPHYLACTIC ANTIBIOTIC SELECTION FOR SURGICAL PATIENTS^EH
"DATA",176.802,92,15)
^20
"DATA",176.802,93,0)
Healthy Term Newborn
"DATA",176.802,93,1)
ff796fd9-f99d-41fd-b8c2-57d0a59a5d8d^0716
"DATA",176.802,93,2,0)
^^1^1^3130419
"DATA",176.802,93,2,1,0)
Percent of term singleton live births (excluding those with diagnoses originating in the fetal period) who DO NOT have significant complications during birth or the nursery care.
"DATA",176.802,93,3)
Procedure
"DATA",176.802,93,4)
CMS185v2
"DATA",176.802,93,5)
National Quality Forum^FY 2014 EH
"DATA",176.802,93,6)
California Maternal Quality Care Collaborative (CMQCC)^California Maternal Quality Care Collaborative (CMQCC)
"DATA",176.802,93,7)
PROCESS
"DATA",176.802,93,8)
Healthy Term Newborn
"DATA",176.802,93,9)
Measure specifications are in the Public Domain
"DATA",176.802,93,10)
185^InProgress
"DATA",176.802,93,11)
2
"DATA",176.802,93,12,0)
^176.8024P^35^35
"DATA",176.802,93,12,1,0)
53
"DATA",176.802,93,12,2,0)
90
"DATA",176.802,93,12,3,0)
91
"DATA",176.802,93,12,4,0)
126
"DATA",176.802,93,12,5,0)
180
"DATA",176.802,93,12,6,0)
181
"DATA",176.802,93,12,7,0)
229
"DATA",176.802,93,12,8,0)
239
"DATA",176.802,93,12,9,0)
255
"DATA",176.802,93,12,10,0)
276
"DATA",176.802,93,12,11,0)
277
"DATA",176.802,93,12,12,0)
286
"DATA",176.802,93,12,13,0)
310
"DATA",176.802,93,12,14,0)
463
"DATA",176.802,93,12,15,0)
464
"DATA",176.802,93,12,16,0)
469
"DATA",176.802,93,12,17,0)
476
"DATA",176.802,93,12,18,0)
479
"DATA",176.802,93,12,19,0)
512
"DATA",176.802,93,12,20,0)
524
"DATA",176.802,93,12,21,0)
577
"DATA",176.802,93,12,22,0)
579
"DATA",176.802,93,12,23,0)
580
"DATA",176.802,93,12,24,0)
583
"DATA",176.802,93,12,25,0)
590
"DATA",176.802,93,12,26,0)
638
"DATA",176.802,93,12,27,0)
644
"DATA",176.802,93,12,28,0)
698
"DATA",176.802,93,12,29,0)
714
"DATA",176.802,93,12,30,0)
715
"DATA",176.802,93,12,31,0)
738
"DATA",176.802,93,12,32,0)
739
"DATA",176.802,93,12,33,0)
740
"DATA",176.802,93,12,34,0)
742
"DATA",176.802,93,12,35,0)
757
"DATA",176.802,93,13)
Percent of term singleton live births (excluding those with diagnoses originating in the fetal period) who DO NOT have significant complications during birth or the nursery care.
"DATA",176.802,93,14)
HEALTHY TERM NEWBORN^EH
"DATA",176.802,93,15)
^16
"DATA",176.804,1,0)
Acute Myocardial Infarction^AMI
"DATA",176.804,2,0)
Asthma^ASMA
"DATA",176.804,3,0)
Behavioral Health Adult^BHA
"DATA",176.804,4,0)
Behavioral Health Pediatric^BHP
"DATA",176.804,5,0)
Cancer^CANC
"DATA",176.804,6,0)
Community Acquired Pneumonia^CAP
"DATA",176.804,7,0)
Core^CORE
"DATA",176.804,8,0)
Dental^DENT
"DATA",176.804,9,0)
Diabetes^DIAB
"DATA",176.804,10,0)
Emergency Department^ED
"DATA",176.804,11,0)
Eye^EYE
"DATA",176.804,12,0)
General Practice Adult^GPA
"DATA",176.804,13,0)
General Practice Pediatric^GPP
"DATA",176.804,14,0)
HIV^HIV
"DATA",176.804,15,0)
Heart^CARD
"DATA",176.804,16,0)
Newborn^NEWB
"DATA",176.804,17,0)
Orthopedics^ORTH
"DATA",176.804,18,0)
Pregnancy^PREG
"DATA",176.804,19,0)
Stroke^STK
"DATA",176.804,20,0)
Surgical Care Improvement Project^SURG
"DATA",176.804,21,0)
Venous Thromboembolism^VTE
"DATA",176.804,22,0)
Behavioral Health General^BHG
"FIA",176.801)
C0Q VALUE SET CODES
"FIA",176.801,0)
^C0QVS(176.801,
"FIA",176.801,0,0)
176.801I
"FIA",176.801,0,1)
y^y^f^^n^^y^o^n
"FIA",176.801,0,10)

"FIA",176.801,0,11)

"FIA",176.801,0,"RLRO")

"FIA",176.801,176.801)
0
"FIA",176.801,176.8011)
0
"FIA",176.801,176.8012)
0
"FIA",176.802)
C0Q NLM QUALITY MEASURE GROUPS
"FIA",176.802,0)
^C0QVS(176.802,
"FIA",176.802,0,0)
176.802I
"FIA",176.802,0,1)
y^y^f^^n^^y^o^n
"FIA",176.802,0,10)

"FIA",176.802,0,11)

"FIA",176.802,0,"RLRO")

"FIA",176.802,176.802)
0
"FIA",176.802,176.8021)
0
"FIA",176.802,176.8024)
0
"FIA",176.803)
C0Q CODE SYSTEMS
"FIA",176.803,0)
^C0QVS(176.803,
"FIA",176.803,0,0)
176.803
"FIA",176.803,0,1)
y^y^f^^n^^y^o^n
"FIA",176.803,0,10)

"FIA",176.803,0,11)

"FIA",176.803,0,"RLRO")

"FIA",176.803,176.803)
0
"FIA",176.804)
C0Q CYPRESS CLINICAL CATETORIES
"FIA",176.804,0)
^C0QVS(176.804,
"FIA",176.804,0,0)
176.804I
"FIA",176.804,0,1)
y^y^f^^n^^y^o^n
"FIA",176.804,0,10)

"FIA",176.804,0,11)

"FIA",176.804,0,"RLRO")

"FIA",176.804,176.804)
0
"IX",176.801,176.801,"B",0)
176.801^B^Uniqueness Index for Value Set Name key (A)^R^^F^IR^I^176.801^^^^^LS
"IX",176.801,176.801,"B",1)
S ^C0QVS(176.801,"B",X,DA)=""
"IX",176.801,176.801,"B",2)
K ^C0QVS(176.801,"B",X,DA)
"IX",176.801,176.801,"B",2.5)
K ^C0QVS(176.801,"B")
"IX",176.801,176.801,"B",11.1,0)
^.114IA^1^1
"IX",176.801,176.801,"B",11.1,1,0)
1^F^176.801^.01^^1^F
"IX",176.801,176.801,"B",11.1,1,3)

"IX",176.801,176.801,"CODE",0)
176.801^CODE^Whole-file lookup index of value sets by code^R^^F^IR^W^176.8011^^^^^LS
"IX",176.801,176.801,"CODE",1)
S ^C0QVS(176.801,"CODE",X,DA(1),DA)=""
"IX",176.801,176.801,"CODE",2)
K ^C0QVS(176.801,"CODE",X,DA(1),DA)
"IX",176.801,176.801,"CODE",2.5)
K ^C0QVS(176.801,"CODE")
"IX",176.801,176.801,"CODE",11.1,0)
^.114IA^1^1
"IX",176.801,176.801,"CODE",11.1,1,0)
1^F^176.8011^.01^^1^F
"IX",176.801,176.801,"CODE",11.1,1,3)

"IX",176.801,176.801,"ID",0)
176.801^ID^Uniqueness index on the Value Set ID (key B)^R^^F^IR^I^176.801^^^^^LS
"IX",176.801,176.801,"ID",1)
S ^C0QVS(176.801,"ID",X,DA)=""
"IX",176.801,176.801,"ID",2)
K ^C0QVS(176.801,"ID",X,DA)
"IX",176.801,176.801,"ID",2.5)
K ^C0QVS(176.801,"ID")
"IX",176.801,176.801,"ID",11.1,0)
^.114IA^1^1
"IX",176.801,176.801,"ID",11.1,1,0)
1^F^176.801^.02^^1^F
"IX",176.801,176.801,"ID",11.1,1,3)

"IX",176.801,176.801,"MEASURE",0)
176.801^MEASURE^Whole-file lookup index of value sets by measure^R^^F^IR^W^176.8012^^^^^LS
"IX",176.801,176.801,"MEASURE",1)
S ^C0QVS(176.801,"MEASURE",X,DA(1),DA)=""
"IX",176.801,176.801,"MEASURE",2)
K ^C0QVS(176.801,"MEASURE",X,DA(1),DA)
"IX",176.801,176.801,"MEASURE",2.5)
K ^C0QVS(176.801,"MEASURE")
"IX",176.801,176.801,"MEASURE",11.1,0)
^.114IA^1^1
"IX",176.801,176.801,"MEASURE",11.1,1,0)
1^F^176.8012^.01^^1^F
"IX",176.801,176.801,"SID",0)
176.801^SID^REGULAR INDEX ON THE SID FIELD^R^^F^IR^I^176.801^^^^^LS
"IX",176.801,176.801,"SID",1)
S ^C0QVS(176.801,"SID",$E(X,1,30),DA)=""
"IX",176.801,176.801,"SID",2)
K ^C0QVS(176.801,"SID",$E(X,1,30),DA)
"IX",176.801,176.801,"SID",2.5)
K ^C0QVS(176.801,"SID")
"IX",176.801,176.801,"SID",11.1,0)
^.114IA^1^1
"IX",176.801,176.801,"SID",11.1,1,0)
1^F^176.801^.03^30^1^F
"IX",176.802,176.802,"B",0)
176.802^B^Uniqueness index for measure group title (key A)^R^^F^IR^I^176.802^^^^^LS
"IX",176.802,176.802,"B",1)
S ^C0QVS(176.802,"B",X,DA)=""
"IX",176.802,176.802,"B",2)
K ^C0QVS(176.802,"B",X,DA)
"IX",176.802,176.802,"B",2.5)
K ^C0QVS(176.802,"B")
"IX",176.802,176.802,"B",11.1,0)
^.114IA^1^1
"IX",176.802,176.802,"B",11.1,1,0)
1^F^176.802^.01^^1^F
"IX",176.802,176.802,"CABBR",0)
176.802^CABBR^Regular Index on the Category Abbreviation^R^^F^IR^I^176.802^^^^^LS
"IX",176.802,176.802,"CABBR",1)
S ^C0QVS(176.802,"CABBR",X(2),DA)=""
"IX",176.802,176.802,"CABBR",2)
K ^C0QVS(176.802,"CABBR",X(2),DA)
"IX",176.802,176.802,"CABBR",2.5)
K ^C0QVS(176.802,"CABBR")
"IX",176.802,176.802,"CABBR",11.1,0)
^.114IA^2^2
"IX",176.802,176.802,"CABBR",11.1,1,0)
1^F^176.802^5.1^^^F
"IX",176.802,176.802,"CABBR",11.1,2,0)
2^C^^^^1
"IX",176.802,176.802,"CABBR",11.1,2,1.5)
S X=$$GET1^DIQ(176.804,X(1)_",",.02)
"IX",176.802,176.802,"CAT",0)
176.802^CAT^Regular index of Cypress Clinical Category Abbreviation^R^^F^IR^I^176.802^^^^^LS
"IX",176.802,176.802,"CAT",1)
S ^C0QVS(176.802,"CAT",X,DA)=""
"IX",176.802,176.802,"CAT",2)
K ^C0QVS(176.802,"CAT",X,DA)
"IX",176.802,176.802,"CAT",2.5)
K ^C0QVS(176.802,"CAT")
"IX",176.802,176.802,"CAT",11.1,0)
^.114IA^1^1
"IX",176.802,176.802,"CAT",11.1,1,0)
1^F^176.802^5.1^^1^F
"IX",176.802,176.802,"CQM",0)
176.802^CQM^Regular index on the EP/EH field as CQMEP and CQMEH^R^^F^IR^I^176.802^^^^^LS
"IX",176.802,176.802,"CQM",1)
S ^C0QVS(176.802,"CQM",X,DA)=""
"IX",176.802,176.802,"CQM",2)
K ^C0QVS(176.802,"CQM",X,DA)
"IX",176.802,176.802,"CQM",2.5)
K ^C0QVS(176.802,"CQM")
"IX",176.802,176.802,"CQM",11.1,0)
^.114IA^1^1
"IX",176.802,176.802,"CQM",11.1,1,0)
1^F^176.802^5^^1^F
"IX",176.802,176.802,"GUID",0)
176.802^GUID^Uniqueness index on GUID (key B)^R^^F^IR^I^176.802^^^^^LS
"IX",176.802,176.802,"GUID",1)
S ^C0QVS(176.802,"GUID",X,DA)=""
"IX",176.802,176.802,"GUID",2)
K ^C0QVS(176.802,"GUID",X,DA)
"IX",176.802,176.802,"GUID",2.5)
K ^C0QVS(176.802,"GUID")
"IX",176.802,176.802,"GUID",11.1,0)
^.114IA^1^1
"IX",176.802,176.802,"GUID",11.1,1,0)
1^F^176.802^.02^^1^F
"IX",176.802,176.802,"ID",0)
176.802^ID^Lookup index on CMS eMeasure ID field^R^^F^IR^I^176.802^^^^^LS
"IX",176.802,176.802,"ID",1)
S ^C0QVS(176.802,"ID",X,DA)=""
"IX",176.802,176.802,"ID",2)
K ^C0QVS(176.802,"ID",X,DA)
"IX",176.802,176.802,"ID",2.5)
K ^C0QVS(176.802,"ID")
"IX",176.802,176.802,"ID",11.1,0)
^.114IA^1^1
"IX",176.802,176.802,"ID",11.1,1,0)
1^F^176.802^2.2^^1^F
"IX",176.802,176.802,"ID",11.1,1,3)

"IX",176.802,176.802,"NQF",0)
176.802^NQF^Uniqueness index for partial key on NQF Number field^R^^F^IR^I^176.802^^^^^LS
"IX",176.802,176.802,"NQF",1)
S ^C0QVS(176.802,"NQF",X,DA)=""
"IX",176.802,176.802,"NQF",2)
K ^C0QVS(176.802,"NQF",X,DA)
"IX",176.802,176.802,"NQF",2.5)
K ^C0QVS(176.802,"NQF")
"IX",176.802,176.802,"NQF",11.1,0)
^.114IA^1^1
"IX",176.802,176.802,"NQF",11.1,1,0)
1^F^176.802^.03^^1^F
"IX",176.803,176.803,"B",0)
176.803^B^Lookup index onCode System Name field^R^^F^IR^I^176.803^^^^^LS
"IX",176.803,176.803,"B",1)
S ^C0QVS(176.803,"B",X,DA)=""
"IX",176.803,176.803,"B",2)
K ^C0QVS(176.803,"B",X,DA)
"IX",176.803,176.803,"B",2.5)
K ^C0QVS(176.803,"B")
"IX",176.803,176.803,"B",11.1,0)
^.114IA^1^1
"IX",176.803,176.803,"B",11.1,1,0)
1^F^176.803^.01^^1^F
"IX",176.803,176.803,"NV",0)
176.803^NV^Uniqueness index on Code System Name and Version (key A)^R^^R^IR^I^176.803^^^^^LS
"IX",176.803,176.803,"NV",1)
S ^C0QVS(176.803,"NV",X(1),X(2),DA)=""
"IX",176.803,176.803,"NV",2)
K ^C0QVS(176.803,"NV",X(1),X(2),DA)
"IX",176.803,176.803,"NV",2.5)
K ^C0QVS(176.803,"NV")
"IX",176.803,176.803,"NV",11.1,0)
^.114IA^2^2
"IX",176.803,176.803,"NV",11.1,1,0)
1^F^176.803^.01^^1^F
"IX",176.803,176.803,"NV",11.1,1,3)

"IX",176.803,176.803,"NV",11.1,2,0)
2^F^176.803^.03^^2^F
"IX",176.803,176.803,"NV",11.1,2,3)

"IX",176.803,176.803,"OID",0)
176.803^OID^Lookup index on the Code System OID field^R^^F^IR^I^176.803^^^^^LS
"IX",176.803,176.803,"OID",1)
S ^C0QVS(176.803,"OID",X,DA)=""
"IX",176.803,176.803,"OID",2)
K ^C0QVS(176.803,"OID",X,DA)
"IX",176.803,176.803,"OID",2.5)
K ^C0QVS(176.803,"OID")
"IX",176.803,176.803,"OID",11.1,0)
^.114IA^1^1
"IX",176.803,176.803,"OID",11.1,1,0)
1^F^176.803^.02^^1^F
"IX",176.803,176.803,"OV",0)
176.803^OV^Uniqueness index on Code System OID and Version (key B)^R^^R^IR^I^176.803^^^^^LS
"IX",176.803,176.803,"OV",1)
S ^C0QVS(176.803,"OV",X(1),X(2),DA)=""
"IX",176.803,176.803,"OV",2)
K ^C0QVS(176.803,"OV",X(1),X(2),DA)
"IX",176.803,176.803,"OV",2.5)
K ^C0QVS(176.803,"OV")
"IX",176.803,176.803,"OV",11.1,0)
^.114IA^2^2
"IX",176.803,176.803,"OV",11.1,1,0)
1^F^176.803^.02^^1^F
"IX",176.803,176.803,"OV",11.1,1,3)

"IX",176.803,176.803,"OV",11.1,2,0)
2^F^176.803^.03^^2^F
"IX",176.803,176.803,"OV",11.1,2,3)

"KEY",176.801,176.801,"A",0)
176.801^A^P^884
"KEY",176.801,176.801,"A",2,0)
^.312IA^1^1
"KEY",176.801,176.801,"A",2,1,0)
.02^176.801^1
"KEY",176.802,176.802,"A",0)
176.802^A^P^887
"KEY",176.802,176.802,"A",2,0)
^.312IA^1^1
"KEY",176.802,176.802,"A",2,1,0)
.01^176.802^1
"KEY",176.802,176.802,"B",0)
176.802^B^S^889
"KEY",176.802,176.802,"B",2,0)
^.312IA^1^1
"KEY",176.802,176.802,"B",2,1,0)
.02^176.802^1
"KEY",176.803,176.803,"A",0)
176.803^A^P^894
"KEY",176.803,176.803,"A",2,0)
^.312IA^2^2
"KEY",176.803,176.803,"A",2,1,0)
.01^176.803^1
"KEY",176.803,176.803,"A",2,2,0)
.03^176.803^2
"KEY",176.803,176.803,"B",0)
176.803^B^S^895
"KEY",176.803,176.803,"B",2,0)
^.312IA^2^2
"KEY",176.803,176.803,"B",2,1,0)
.02^176.803^1
"KEY",176.803,176.803,"B",2,2,0)
.03^176.803^2
"KEYPTR",176.801,176.801,"A")
176.801^ID
"KEYPTR",176.802,176.802,"A")
176.802^B
"KEYPTR",176.802,176.802,"B")
176.802^GUID
"KEYPTR",176.803,176.803,"A")
176.803^NV
"KEYPTR",176.803,176.803,"B")
176.803^OV
"MBREQ")
0
"QUES","XPF1",0)
Y
"QUES","XPF1","??")
^D REP^XPDH
"QUES","XPF1","A")
Shall I write over your |FLAG| File
"QUES","XPF1","B")
YES
"QUES","XPF1","M")
D XPF1^XPDIQ
"QUES","XPF2",0)
Y
"QUES","XPF2","??")
^D DTA^XPDH
"QUES","XPF2","A")
Want my data |FLAG| yours
"QUES","XPF2","B")
YES
"QUES","XPF2","M")
D XPF2^XPDIQ
"QUES","XPI1",0)
YO
"QUES","XPI1","??")
^D INHIBIT^XPDH
"QUES","XPI1","A")
Want KIDS to INHIBIT LOGONs during the install
"QUES","XPI1","B")
NO
"QUES","XPI1","M")
D XPI1^XPDIQ
"QUES","XPM1",0)
PO^VA(200,:EM
"QUES","XPM1","??")
^D MG^XPDH
"QUES","XPM1","A")
Enter the Coordinator for Mail Group '|FLAG|'
"QUES","XPM1","B")

"QUES","XPM1","M")
D XPM1^XPDIQ
"QUES","XPO1",0)
Y
"QUES","XPO1","??")
^D MENU^XPDH
"QUES","XPO1","A")
Want KIDS to Rebuild Menu Trees Upon Completion of Install
"QUES","XPO1","B")
NO
"QUES","XPO1","M")
D XPO1^XPDIQ
"QUES","XPZ1",0)
Y
"QUES","XPZ1","??")
^D OPT^XPDH
"QUES","XPZ1","A")
Want to DISABLE Scheduled Options, Menu Options, and Protocols
"QUES","XPZ1","B")
NO
"QUES","XPZ1","M")
D XPZ1^XPDIQ
"QUES","XPZ2",0)
Y
"QUES","XPZ2","??")
^D RTN^XPDH
"QUES","XPZ2","A")
Want to MOVE routines to other CPUs
"QUES","XPZ2","B")
NO
"QUES","XPZ2","M")
D XPZ2^XPDIQ
"RTN")
3
"RTN","KBAISID")
0^3^B1057899
"RTN","KBAISID",1,0)
KBAISID ; GPL - NLM Valueset Short ID generator  ; 4/6/13 4:51pm
"RTN","KBAISID",2,0)
 ;;0.1;C0Q;nopatch;noreleasedate;Build 5
"RTN","KBAISID",3,0)
 ;Copyright 2013 George Lilly.  Licensed Apache 2
"RTN","KBAISID",4,0)
 ;
"RTN","KBAISID",5,0)
 Q
"RTN","KBAISID",6,0)
 ;
"RTN","KBAISID",7,0)
SID(ZNAME,ZOID,WHERE) ; extrinsic returns the short ID which is a compressed name with 
"RTN","KBAISID",8,0)
 ; 2 digits from the end of the OID
"RTN","KBAISID",9,0)
 ; ZNAME and ZOID are passed by value
"RTN","KBAISID",10,0)
 ;
"RTN","KBAISID",11,0)
 I '$D(WHERE) D  ;
"RTN","KBAISID",12,0)
 . S WHERE=$NA(^TMP("KBAIVS","SID"))
"RTN","KBAISID",13,0)
 . S @WHERE@(0)=""
"RTN","KBAISID",14,0)
 S ZSID=$O(@WHERE@(ZOID,""))
"RTN","KBAISID",15,0)
 I ZSID'="" Q ZSID  ; already found
"RTN","KBAISID",16,0)
 N ZAP
"RTN","KBAISID",17,0)
 S ZAP="abcdefghijklmnopqrstuvwxyz ,/><-()" ; characters to zap
"RTN","KBAISID",18,0)
 N ZEXT S ZEXT=$TR(ZOID,".")
"RTN","KBAISID",19,0)
 S ZEXT=$E(ZEXT,$L(ZEXT)-1,$L(ZEXT))
"RTN","KBAISID",20,0)
 N ZSID
"RTN","KBAISID",21,0)
 S ZSID=$TR(ZNAME,ZAP)_ZEXT
"RTN","KBAISID",22,0)
 I $D(@WHERE@(ZOID,ZSID)) D  ;
"RTN","KBAISID",23,0)
 . W !,"FIXING DUP: ",ZSID
"RTN","KBAISID",24,0)
 . S ZSID=ZSID_$R(10)
"RTN","KBAISID",25,0)
 . W " WITH: ",ZSID
"RTN","KBAISID",26,0)
 S @WHERE@(ZOID,ZSID)=""
"RTN","KBAISID",27,0)
 Q ZSID
"RTN","KBAISID",28,0)
 ;
"RTN","KBAIVS1")
0^1^B56036030
"RTN","KBAIVS1",1,0)
KBAIVS1 ; GPL - NLM Valueset import routines  ;2/20/13  17:05
"RTN","KBAIVS1",2,0)
 ;;0.1;C0X;nopatch;noreleasedate;Build 5
"RTN","KBAIVS1",3,0)
 ;Copyright 2013 George Lilly.  Licensed Apache 2
"RTN","KBAIVS1",4,0)
 ;
"RTN","KBAIVS1",5,0)
 Q
"RTN","KBAIVS1",6,0)
 ;
"RTN","KBAIVS1",7,0)
tree(where,prefix) ; show a tree starting at a node in MXML. node is passed by name
"RTN","KBAIVS1",8,0)
 ; 
"RTN","KBAIVS1",9,0)
 i $g(prefix)="" s prefix="|--" ; starting prefix
"RTN","KBAIVS1",10,0)
 ;i '$d(C0XJOB) s C0XJOB=$J
"RTN","KBAIVS1",11,0)
 n node s node=$na(^KBAI("KBAIVS","DOM",where))
"RTN","KBAIVS1",12,0)
 n txt s txt=$$CLEAN($$ALLTXT(node))
"RTN","KBAIVS1",13,0)
 w !,prefix_@node_" "_txt
"RTN","KBAIVS1",14,0)
 n zi s zi=""
"RTN","KBAIVS1",15,0)
 f  s zi=$o(@node@("A",zi)) q:zi=""  d  ;
"RTN","KBAIVS1",16,0)
 . w !,prefix_"  : "_zi_"^"_$g(@node@("A",zi))
"RTN","KBAIVS1",17,0)
 f  s zi=$o(@node@("C",zi)) q:zi=""  d  ;
"RTN","KBAIVS1",18,0)
 . d tree(zi,"|  "_prefix)
"RTN","KBAIVS1",19,0)
 q
"RTN","KBAIVS1",20,0)
 ;
"RTN","KBAIVS1",21,0)
show(what) ;
"RTN","KBAIVS1",22,0)
 ;S C0XJOB=26295
"RTN","KBAIVS1",23,0)
 I '$D(C0XJOB) S C0XJOB=$J
"RTN","KBAIVS1",24,0)
 d tree(what)
"RTN","KBAIVS1",25,0)
 q
"RTN","KBAIVS1",26,0)
 ; 
"RTN","KBAIVS1",27,0)
tree2(where,prefix) ; show a tree starting at a node in MXML. node is passed by name
"RTN","KBAIVS1",28,0)
 ; tree2 handles ConceptLists as tables
"RTN","KBAIVS1",29,0)
 i $g(prefix)="" s prefix="|--" ; starting prefix
"RTN","KBAIVS1",30,0)
 i '$d(C0XJOB) s C0XJOB=$J
"RTN","KBAIVS1",31,0)
 n node s node=$na(^KBAI("KBAIVS","DOM",where))
"RTN","KBAIVS1",32,0)
 ;n txt s txt=$$CLEAN($$ALLTXT(node))
"RTN","KBAIVS1",33,0)
 n txt d alltxt(.txt,node)
"RTN","KBAIVS1",34,0)
 ;w !,prefix_@node_" "_txt
"RTN","KBAIVS1",35,0)
 n zk s zk=""
"RTN","KBAIVS1",36,0)
 f  s zk=$o(txt(zk)) q:zk=""  d  ;
"RTN","KBAIVS1",37,0)
 . i zk=1 d out(prefix_@node_" "_txt(zk))  q  ;
"RTN","KBAIVS1",38,0)
 . d out(prefix_txt(zk))
"RTN","KBAIVS1",39,0)
 i @node["ns0:ConceptList" d  q  ;
"RTN","KBAIVS1",40,0)
 . d clist(where,prefix)
"RTN","KBAIVS1",41,0)
 n zi s zi=""
"RTN","KBAIVS1",42,0)
 f  s zi=$o(@node@("A",zi)) q:zi=""  d  ;
"RTN","KBAIVS1",43,0)
 . ;w !,prefix_"  : "_zi_"^"_$g(@node@("A",zi))
"RTN","KBAIVS1",44,0)
 . d out(prefix_"  : "_zi_"^"_$g(@node@("A",zi)))
"RTN","KBAIVS1",45,0)
 n grpstart s grpstart=0
"RTN","KBAIVS1",46,0)
 f  s zi=$o(@node@("C",zi)) q:zi=""  d  ;
"RTN","KBAIVS1",47,0)
 . i @node@("C",zi)="ns0:RevisionDate" d newgrp
"RTN","KBAIVS1",48,0)
 . i @node@("C",zi)="ns0:Group" d group(zi)  q  ;
"RTN","KBAIVS1",49,0)
 . d tree2(zi,"|  "_prefix)
"RTN","KBAIVS1",50,0)
 d:grpstart grpout
"RTN","KBAIVS1",51,0)
 q
"RTN","KBAIVS1",52,0)
 ;
"RTN","KBAIVS1",53,0)
newgrp ; kill the group array for a new group
"RTN","KBAIVS1",54,0)
 ;W !,"NEW GROUP"
"RTN","KBAIVS1",55,0)
 k ^KBAI("KBAIVS","GROUP")
"RTN","KBAIVS1",56,0)
 q
"RTN","KBAIVS1",57,0)
 ;
"RTN","KBAIVS1",58,0)
group(where) ; add a group node to the group array
"RTN","KBAIVS1",59,0)
 s grpstart=1
"RTN","KBAIVS1",60,0)
 n gn s gn=$na(^KBAI("KBAIVS","GROUP"))
"RTN","KBAIVS1",61,0)
 n node s node=$na(^KBAI("KBAIVS","DOM"))
"RTN","KBAIVS1",62,0)
 n gnum s gnum=$g(@node@(where,"A","ID"))
"RTN","KBAIVS1",63,0)
 i gnum="" d  q  ;
"RTN","KBAIVS1",64,0)
 . w !,"error finding group number ",where
"RTN","KBAIVS1",65,0)
 n var s var=@node@(where,"A","displayName")
"RTN","KBAIVS1",66,0)
 n valref s valref=$o(@node@(where,"C",""))
"RTN","KBAIVS1",67,0)
 i valref="" d  q  ;
"RTN","KBAIVS1",68,0)
 . w !,"error finding value reference ",where
"RTN","KBAIVS1",69,0)
 n val s val=@node@(valref,"T",1)
"RTN","KBAIVS1",70,0)
 s @gn@(gnum,var)=val
"RTN","KBAIVS1",71,0)
 q
"RTN","KBAIVS1",72,0)
 ;
"RTN","KBAIVS1",73,0)
grpout ; output the group array
"RTN","KBAIVS1",74,0)
 n gn s gn=$na(^KBAI("KBAIVS","GROUP"))
"RTN","KBAIVS1",75,0)
 n grp s grp=""
"RTN","KBAIVS1",76,0)
 f  s grp=$o(@gn@(grp)) q:grp=""  d  ;
"RTN","KBAIVS1",77,0)
 . d out("--------------------------------------------------------------")
"RTN","KBAIVS1",78,0)
 . n attr s attr=""
"RTN","KBAIVS1",79,0)
 . f  s attr=$o(@gn@(grp,attr)) q:attr=""  d  ;
"RTN","KBAIVS1",80,0)
 . . d out(attr_": "_@gn@(grp,attr))
"RTN","KBAIVS1",81,0)
 q
"RTN","KBAIVS1",82,0)
 ;
"RTN","KBAIVS1",83,0)
out(txt) ; add line to output array
"RTN","KBAIVS1",84,0)
 s c0xout=$na(^KBAI("KBAIOUT",$J))
"RTN","KBAIVS1",85,0)
 n cnt
"RTN","KBAIVS1",86,0)
 s cnt=$o(@c0xout@(""),-1)
"RTN","KBAIVS1",87,0)
 i cnt="" s cnt=0
"RTN","KBAIVS1",88,0)
 s @c0xout@(cnt+1)=txt
"RTN","KBAIVS1",89,0)
 q
"RTN","KBAIVS1",90,0)
 ;
"RTN","KBAIVS1",91,0)
clist(where,prefix,nohead) 
"RTN","KBAIVS1",92,0)
 n nd s nd=$na(^KBAI("KBAIVS","DOM"))
"RTN","KBAIVS1",93,0)
 ;i '$d(nohead) s nohead=0
"RTN","KBAIVS1",94,0)
 ;i 'nohead d  ;
"RTN","KBAIVS1",95,0)
 d out($j("Code",20)_$j("System",10)_$j("Description",20))
"RTN","KBAIVS1",96,0)
 n zzi s zzi=""
"RTN","KBAIVS1",97,0)
 f  s zzi=$o(@nd@(where,"C",zzi)) q:zzi=""  d  ;
"RTN","KBAIVS1",98,0)
 . n code,system,desc
"RTN","KBAIVS1",99,0)
 . s code=$g(@nd@(zzi,"A","code"))
"RTN","KBAIVS1",100,0)
 . s system=$g(@nd@(zzi,"A","codeSystemName"))
"RTN","KBAIVS1",101,0)
 . s desc=$g(@nd@(zzi,"A","displayName"))
"RTN","KBAIVS1",102,0)
 . d out($j(code,20)_$j(system,10)_"  "_desc)
"RTN","KBAIVS1",103,0)
 ;w @nd,":",@nd@("T",1)  
"RTN","KBAIVS1",104,0)
 q
"RTN","KBAIVS1",105,0)
 ;
"RTN","KBAIVS1",106,0)
alltxt(rtn,node) ; handle arrays of text
"RTN","KBAIVS1",107,0)
 m rtn=@node@("T")
"RTN","KBAIVS1",108,0)
 n zj s zj=""
"RTN","KBAIVS1",109,0)
 f  s zj=$o(rtn(zj)) q:zj=""  d  ;
"RTN","KBAIVS1",110,0)
 . s rtn(zj)=$$CLEAN(rtn(zj))
"RTN","KBAIVS1",111,0)
 . s rtn(zj)=$$LDBLNKS(rtn(zj))
"RTN","KBAIVS1",112,0)
 . i rtn(zj)="" k rtn(zj)
"RTN","KBAIVS1",113,0)
 . i (rtn(zj)=" ")&(zj>1) k rtn(zj)
"RTN","KBAIVS1",114,0)
 q
"RTN","KBAIVS1",115,0)
 ;
"RTN","KBAIVS1",116,0)
ALLTXT(where) ; extrinsic which returns all text lines from the node .. concatinated 
"RTN","KBAIVS1",117,0)
 ; together
"RTN","KBAIVS1",118,0)
 n zti s zti=""
"RTN","KBAIVS1",119,0)
 n ztr s ztr=""
"RTN","KBAIVS1",120,0)
 f  s zti=$o(@where@("T",zti)) q:zti=""  d  ;
"RTN","KBAIVS1",121,0)
 . s ztr=ztr_$g(@where@("T",zti))
"RTN","KBAIVS1",122,0)
 q ztr
"RTN","KBAIVS1",123,0)
 ;
"RTN","KBAIVS1",124,0)
CLEAN(STR) ; extrinsic function; returns string - gpl borrowed from the CCR package
"RTN","KBAIVS1",125,0)
 ;; Removes all non printable characters from a string.
"RTN","KBAIVS1",126,0)
 ;; STR by Value
"RTN","KBAIVS1",127,0)
 N TR,I
"RTN","KBAIVS1",128,0)
 F I=0:1:31 S TR=$G(TR)_$C(I)
"RTN","KBAIVS1",129,0)
 S TR=TR_$C(127)
"RTN","KBAIVS1",130,0)
 N ZR S ZR=$TR(STR,TR)
"RTN","KBAIVS1",131,0)
 S ZR=$$LDBLNKS(ZR) ; get rid of leading blanks
"RTN","KBAIVS1",132,0)
 QUIT ZR
"RTN","KBAIVS1",133,0)
 ;
"RTN","KBAIVS1",134,0)
LDBLNKS(st) ; extrinsic which removes leading blanks from a string
"RTN","KBAIVS1",135,0)
 n pos f pos=1:1:$l(st)  q:$e(st,pos)'=" "
"RTN","KBAIVS1",136,0)
 q $e(st,pos,$l(st))
"RTN","KBAIVS1",137,0)
 ;
"RTN","KBAIVS1",138,0)
VACCD ; set C0XJOB to the VA CCD
"RTN","KBAIVS1",139,0)
 s C0XJOB=14921
"RTN","KBAIVS1",140,0)
 q
"RTN","KBAIVS1",141,0)
 ;
"RTN","KBAIVS1",142,0)
NLMVS ; set C0XJOB to the NLM Values Set xml
"RTN","KBAIVS1",143,0)
 s C0XJOB=26295
"RTN","KBAIVS1",144,0)
 Q
"RTN","KBAIVS1",145,0)
 ;
"RTN","KBAIVS1",146,0)
contents(zrtn,ids) ; produce an agenda for the docId 1 in the MXML dom
"RTN","KBAIVS1",147,0)
 ; generally, a first level index to the document
"RTN","KBAIVS1",148,0)
 ; set C0XJOB if you want to use a different $J to locate the dom
"RTN","KBAIVS1",149,0)
 ; zrtn passed by name
"RTN","KBAIVS1",150,0)
 ; ids=1 names them by number ids=0 or null names them by displayname
"RTN","KBAIVS1",151,0)
 n zi s zi=""
"RTN","KBAIVS1",152,0)
 n dom s dom=$na(^KBAI("KBAIVS","DOM"))
"RTN","KBAIVS1",153,0)
 f  s zi=$o(@dom@(1,"C",zi)) q:zi=""  d  ;
"RTN","KBAIVS1",154,0)
 . n zn ;
"RTN","KBAIVS1",155,0)
 . d:$g(ids)  ;
"RTN","KBAIVS1",156,0)
 . . s zn=$tr($g(@dom@(zi,"A","ID")),".","-")_".txt"
"RTN","KBAIVS1",157,0)
 . . s @zrtn@(zn,zi)=""
"RTN","KBAIVS1",158,0)
 . d:'$g(ids)  ;
"RTN","KBAIVS1",159,0)
 . . s zn=$tr($g(@dom@(zi,"A","displayName"))," ","_")_".txt"
"RTN","KBAIVS1",160,0)
 . . s zn=$tr(zn,"()","") ; get rid of parens for valid filename
"RTN","KBAIVS1",161,0)
 . . s zn=$tr(zn,"/","-") ; get rid of slash for valid filename
"RTN","KBAIVS1",162,0)
 . . s @zrtn@(zn,zi)=""
"RTN","KBAIVS1",163,0)
 q
"RTN","KBAIVS1",164,0)
 ;
"RTN","KBAIVS1",165,0)
export ; exports separate files for each value set
"RTN","KBAIVS1",166,0)
 ; one copy in a file with a text name based on the displayName
"RTN","KBAIVS1",167,0)
 n g,zi,fname,where,dirname,gn
"RTN","KBAIVS1",168,0)
 s gn=$na(^KBAI("KBAIOUT",$J))
"RTN","KBAIVS1",169,0)
 w !,"Please enter directory name for valueset files by name"
"RTN","KBAIVS1",170,0)
 q:'$$GETDIR(.dirname,"/home/vista/valuesets/by-name/")
"RTN","KBAIVS1",171,0)
 s zi=""
"RTN","KBAIVS1",172,0)
 d contents("g") ; first with text names
"RTN","KBAIVS1",173,0)
 f  s zi=$o(g(zi)) q:zi=""  d  ;
"RTN","KBAIVS1",174,0)
 . s fname=zi
"RTN","KBAIVS1",175,0)
 . s where=$o(g(zi,""))
"RTN","KBAIVS1",176,0)
 . k @gn
"RTN","KBAIVS1",177,0)
 . d tree2(where,"| ")
"RTN","KBAIVS1",178,0)
 . n gn2 s gn2=$na(@gn@(1)) ; name for gtf
"RTN","KBAIVS1",179,0)
 . s ok=$$GTF^%ZISH(gn2,3,dirname,fname)
"RTN","KBAIVS1",180,0)
 q
"RTN","KBAIVS1",181,0)
 ;
"RTN","KBAIVS1",182,0)
export2 ; exports separate files for each value set
"RTN","KBAIVS1",183,0)
 ; one copy in a file with a numeric file name based on ID
"RTN","KBAIVS1",184,0)
 n g,zi,fname,where,dirname,gn
"RTN","KBAIVS1",185,0)
 s gn=$na(^KBAI("KBAIOUT",$J))
"RTN","KBAIVS1",186,0)
 w !,"Please enter directory name for valueset files by id"
"RTN","KBAIVS1",187,0)
 q:'$$GETDIR(.dirname,"/home/vista/valuesets/by-id/")
"RTN","KBAIVS1",188,0)
 ;s dirname="/home/wvehr2/valuesets/by-id/"
"RTN","KBAIVS1",189,0)
 s zi=""
"RTN","KBAIVS1",190,0)
 d contents("g",1) ; with id names
"RTN","KBAIVS1",191,0)
 f  s zi=$o(g(zi)) q:zi=""  d  ;
"RTN","KBAIVS1",192,0)
 . s fname=zi
"RTN","KBAIVS1",193,0)
 . s where=$o(g(zi,""))
"RTN","KBAIVS1",194,0)
 . k @gn
"RTN","KBAIVS1",195,0)
 . d tree2(where,"| ")
"RTN","KBAIVS1",196,0)
 . n gn2 s gn2=$na(@gn@(1)) ; name for gtf
"RTN","KBAIVS1",197,0)
 . s ok=$$GTF^%ZISH(gn2,3,dirname,fname)
"RTN","KBAIVS1",198,0)
 q
"RTN","KBAIVS1",199,0)
 ;
"RTN","KBAIVS1",200,0)
FILEIN ; import the valueset xml file, parse with MXML, and put the dom in ^TMP
"RTN","KBAIVS1",201,0)
 ;
"RTN","KBAIVS1",202,0)
 N FNAME,DIRNAME
"RTN","KBAIVS1",203,0)
 W !,"Please enter the directory and file name for the NLM Valueset XML file"
"RTN","KBAIVS1",204,0)
 Q:'$$GETDIR(.DIRNAME,"/home/glilly/nlm-vs") ; prompt the user for the directory
"RTN","KBAIVS1",205,0)
 Q:'$$GETFN(.FNAME,"valuesets.xml") ; prompt user for filename
"RTN","KBAIVS1",206,0)
 N GN S GN=$NA(^KBAI("KBAIVS")) ; root to store xml and dom
"RTN","KBAIVS1",207,0)
 K @GN ; clear the area
"RTN","KBAIVS1",208,0)
 N GN1 S GN1=$NA(@GN@("XML",1)) ; place to put the xml file
"RTN","KBAIVS1",209,0)
 W !,"Reading in file ",FNAME," from directory ",DIRNAME
"RTN","KBAIVS1",210,0)
 Q:$$FTG^%ZISH(DIRNAME,FNAME,GN1,3)=""
"RTN","KBAIVS1",211,0)
 N KBAIDID
"RTN","KBAIVS1",212,0)
 W !,"Parsing file ",FNAME
"RTN","KBAIVS1",213,0)
 S KBAIDID=$$EN^MXMLDOM($NA(@GN@("XML")),"W")
"RTN","KBAIVS1",214,0)
 I KBAIDID=0 D  Q  ;
"RTN","KBAIVS1",215,0)
 . ZWRITE ^TMP("MXMLERR",$J,*)
"RTN","KBAIVS1",216,0)
 W !,"Merging MXMLDOM to TMP"
"RTN","KBAIVS1",217,0)
 M @GN@("DOM")=^TMP("MXMLDOM",$J,KBAIDID)
"RTN","KBAIVS1",218,0)
 K ^TMP("MXMLDOM",$J)
"RTN","KBAIVS1",219,0)
 Q
"RTN","KBAIVS1",220,0)
 ;
"RTN","KBAIVS1",221,0)
GETDIR(KBAIDIR,KBAIDEF) ; extrinsic which prompts for directory
"RTN","KBAIVS1",222,0)
 ; returns true if the user gave values
"RTN","KBAIVS1",223,0)
 S DIR(0)="F^3:240"
"RTN","KBAIVS1",224,0)
 S DIR("A")="File Directory"
"RTN","KBAIVS1",225,0)
 I '$D(KBAIDEF) S KBAIDEF="/home/glilly/nlm-vs"
"RTN","KBAIVS1",226,0)
 S DIR("B")=KBAIDEF
"RTN","KBAIVS1",227,0)
 D ^DIR
"RTN","KBAIVS1",228,0)
 I Y="^" Q 0 ;
"RTN","KBAIVS1",229,0)
 S KBAIDIR=Y
"RTN","KBAIVS1",230,0)
 Q 1
"RTN","KBAIVS1",231,0)
 ;
"RTN","KBAIVS1",232,0)
GETFN(KBAIFN,KBAIDEF) ; extrinsic which prompts for filename
"RTN","KBAIVS1",233,0)
 ; returns true if the user gave values
"RTN","KBAIVS1",234,0)
 S DIR(0)="F^3:240"
"RTN","KBAIVS1",235,0)
 S DIR("A")="File Name"
"RTN","KBAIVS1",236,0)
 I '$D(KBAIDEF) S KBAIDEF="valuesets.xml"
"RTN","KBAIVS1",237,0)
 S DIR("B")=KBAIDEF
"RTN","KBAIVS1",238,0)
 D ^DIR
"RTN","KBAIVS1",239,0)
 I Y="" Q 0 ;
"RTN","KBAIVS1",240,0)
 I Y="^" Q 0 ;
"RTN","KBAIVS1",241,0)
 S KBAIFN=Y
"RTN","KBAIVS1",242,0)
 Q 1
"RTN","KBAIVS1",243,0)
 ;
"RTN","KBAIVS2")
0^2^B250259233
"RTN","KBAIVS2",1,0)
KBAIVS2 ; GPL - NLM Valueset import routines fileman version ; 4/11/13 5:49pm
"RTN","KBAIVS2",2,0)
 ;;0.1;C0Q;nopatch;noreleasedate;Build 5
"RTN","KBAIVS2",3,0)
 ;Copyright 2013 George Lilly.  Licensed Apache 2
"RTN","KBAIVS2",4,0)
 ;
"RTN","KBAIVS2",5,0)
 Q
"RTN","KBAIVS2",6,0)
 ;
"RTN","KBAIVS2",7,0)
 ; This version of the NLM Valueset importer imports the ValueSets to three
"RTN","KBAIVS2",8,0)
 ;   fileman files:
"RTN","KBAIVS2",9,0)
 ;
"RTN","KBAIVS2",10,0)
 ; ^DIC(176.801,0)="C0Q VALUE SET CODES^176.801"
"RTN","KBAIVS2",11,0)
 ; ^DIC(176.802,0)="C0Q NLM QUALITY MEASURE GROUPS^176.802"
"RTN","KBAIVS2",12,0)
 ; ^DIC(176.803,0)="C0Q CODE SYSTEMS^176.803"
"RTN","KBAIVS2",13,0)
 ;
"RTN","KBAIVS2",14,0)
 ;
"RTN","KBAIVS2",15,0)
 Q
"RTN","KBAIVS2",16,0)
 ;
"RTN","KBAIVS2",17,0)
C0QVSFN() Q 176.801  ; file number of C0Q VALUE SET CODES file
"RTN","KBAIVS2",18,0)
C0QVSCFN() Q 176.8011  ; subfile number of value set codes multiple
"RTN","KBAIVS2",19,0)
C0QVSGFN() Q 176.8012  ; subfile number of value set measure group multiple
"RTN","KBAIVS2",20,0)
 ;
"RTN","KBAIVS2",21,0)
C0QGRFN() Q 176.802  ; file number of the C0Q NLM MEASURE GROUP file
"RTN","KBAIVS2",22,0)
C0QGRCD() Q 176.8024  ; subfile number of the CODE SET subfile
"RTN","KBAIVS2",23,0)
 ;
"RTN","KBAIVS2",24,0)
C0QBKFN() Q 176.888 ; mapping backup file
"RTN","KBAIVS2",25,0)
C0QBKID() Q 176.8881 ; mapping backup identifier subfile
"RTN","KBAIVS2",26,0)
C0QBKFLD() Q 176.88811 ; field subfile of identifier subfile of mapping backup file
"RTN","KBAIVS2",27,0)
 ;
"RTN","KBAIVS2",28,0)
 ; field identifiers for adding to the measure group file
"RTN","KBAIVS2",29,0)
GRPFLDS ; format = identifier^field number
"RTN","KBAIVS2",30,0)
 ;;CATEGORY^2.1
"RTN","KBAIVS2",31,0)
 ;;CMS eMeasure ID^2.2
"RTN","KBAIVS2",32,0)
 ;;Endorsed By^2.3
"RTN","KBAIVS2",33,0)
 ;;GUID^.02
"RTN","KBAIVS2",34,0)
 ;;Meaningful Use Measures^2.4
"RTN","KBAIVS2",35,0)
 ;;Measure Developer^2.5
"RTN","KBAIVS2",36,0)
 ;;Measure Steward^2.6
"RTN","KBAIVS2",37,0)
 ;;Measure Type^2.7
"RTN","KBAIVS2",38,0)
 ;;NQF Number^.03
"RTN","KBAIVS2",39,0)
 ;;SHEETNAME^2.8
"RTN","KBAIVS2",40,0)
 ;;eMeasure Copyright^2.9
"RTN","KBAIVS2",41,0)
 ;;eMeasure Description^1.1
"RTN","KBAIVS2",42,0)
 ;;eMeasure Identifier^3
"RTN","KBAIVS2",43,0)
 ;;eMeasure Status^3.1
"RTN","KBAIVS2",44,0)
 ;;eMeasure Title^.01
"RTN","KBAIVS2",45,0)
 ;;eMeasure Version number^.04
"RTN","KBAIVS2",46,0)
 Q
"RTN","KBAIVS2",47,0)
 ;
"RTN","KBAIVS2",48,0)
ADDGRPS ; adds groups to 176.802. 
"RTN","KBAIVS2",49,0)
 ;
"RTN","KBAIVS2",50,0)
 n gn s gn=$na(^KBAI("KBAIVS","ALLGROUPS"))
"RTN","KBAIVS2",51,0)
 n guid s guid=""
"RTN","KBAIVS2",52,0)
 f  s guid=$o(@gn@(guid)) q:guid=""  d  ;
"RTN","KBAIVS2",53,0)
 . k KBAIFDA
"RTN","KBAIVS2",54,0)
 . n seq,map,tag,field
"RTN","KBAIVS2",55,0)
 . f seq=1:1 s map=$p($t(GRPFLDS+seq),";;",2) q:map=""  d  ;
"RTN","KBAIVS2",56,0)
 . . s tag=$p(map,"^",1)
"RTN","KBAIVS2",57,0)
 . . s field=$p(map,"^",2)
"RTN","KBAIVS2",58,0)
 . . s KBAIFDA($$C0QGRFN,"?+1,",field)=$$CLEAN($g(@gn@(guid,tag)))
"RTN","KBAIVS2",59,0)
 . n KBAIEN
"RTN","KBAIVS2",60,0)
 . d UPDIE(.KBAIFDA,.KBAIEN)
"RTN","KBAIVS2",61,0)
 . ;
"RTN","KBAIVS2",62,0)
 . n KBAIMSG
"RTN","KBAIVS2",63,0)
 . n KBAIWPR s KBAIWPR(1,0)=$g(@gn@(guid,"eMeasure Description"))
"RTN","KBAIVS2",64,0)
 . d WP^DIE($$C0QGRFN,KBAIEN(1)_",",1,"K","KBAIWPR","KBAIMSG")
"RTN","KBAIVS2",65,0)
 . i $G(DIERR) break
"RTN","KBAIVS2",66,0)
 q
"RTN","KBAIVS2",67,0)
 ;
"RTN","KBAIVS2",68,0)
tree(where,prefix) ; show a tree starting at a node in MXML. where is passed by value
"RTN","KBAIVS2",69,0)
 ; 
"RTN","KBAIVS2",70,0)
 i $g(prefix)="" s prefix="|--" ; starting prefix
"RTN","KBAIVS2",71,0)
 ;i '$d(C0XJOB) s C0XJOB=$J
"RTN","KBAIVS2",72,0)
 n node s node=$na(^KBAI("KBAIVS","DOM",where))
"RTN","KBAIVS2",73,0)
 n txt s txt=$$CLEAN($$ALLTXT(node))
"RTN","KBAIVS2",74,0)
 w !,prefix_@node_" "_txt
"RTN","KBAIVS2",75,0)
 n zi s zi=""
"RTN","KBAIVS2",76,0)
 f  s zi=$o(@node@("A",zi)) q:zi=""  d  ;
"RTN","KBAIVS2",77,0)
 . w !,prefix_"  : "_zi_"^"_$g(@node@("A",zi))
"RTN","KBAIVS2",78,0)
 f  s zi=$o(@node@("C",zi)) q:zi=""  d  ;
"RTN","KBAIVS2",79,0)
 . d tree(zi,"|  "_prefix)
"RTN","KBAIVS2",80,0)
 q
"RTN","KBAIVS2",81,0)
 ;
"RTN","KBAIVS2",82,0)
show(what) ;
"RTN","KBAIVS2",83,0)
 ;S C0XJOB=26295
"RTN","KBAIVS2",84,0)
 I '$D(C0XJOB) S C0XJOB=$J
"RTN","KBAIVS2",85,0)
 d tree(what)
"RTN","KBAIVS2",86,0)
 q
"RTN","KBAIVS2",87,0)
 ; 
"RTN","KBAIVS2",88,0)
tree2(where,prefix) ; show a tree starting at a node in MXML. where is passed by value
"RTN","KBAIVS2",89,0)
 ; tree2 handles ConceptLists as tables
"RTN","KBAIVS2",90,0)
 i $g(prefix)="" s prefix="|--" ; starting prefix
"RTN","KBAIVS2",91,0)
 i '$d(C0XJOB) s C0XJOB=$J
"RTN","KBAIVS2",92,0)
 n node s node=$na(^KBAI("KBAIVS","DOM",where))
"RTN","KBAIVS2",93,0)
 ;n txt s txt=$$CLEAN($$ALLTXT(node))
"RTN","KBAIVS2",94,0)
 n txt d alltxt(.txt,node)
"RTN","KBAIVS2",95,0)
 ;w !,prefix_@node_" "_txt
"RTN","KBAIVS2",96,0)
 n zk s zk=""
"RTN","KBAIVS2",97,0)
 f  s zk=$o(txt(zk)) q:zk=""  d  ;
"RTN","KBAIVS2",98,0)
 . i zk=1 d out(prefix_@node_" "_txt(zk))  q  ;
"RTN","KBAIVS2",99,0)
 . d out(prefix_txt(zk))
"RTN","KBAIVS2",100,0)
 i @node["ns0:ConceptList" d  q  ;
"RTN","KBAIVS2",101,0)
 . d clist(where,prefix)
"RTN","KBAIVS2",102,0)
 n zi s zi=""
"RTN","KBAIVS2",103,0)
 f  s zi=$o(@node@("A",zi)) q:zi=""  d  ;
"RTN","KBAIVS2",104,0)
 . ;w !,prefix_"  : "_zi_"^"_$g(@node@("A",zi))
"RTN","KBAIVS2",105,0)
 . d out(prefix_"  : "_zi_"^"_$g(@node@("A",zi)))
"RTN","KBAIVS2",106,0)
 n grpstart s grpstart=0
"RTN","KBAIVS2",107,0)
 f  s zi=$o(@node@("C",zi)) q:zi=""  d  ;
"RTN","KBAIVS2",108,0)
 . i @node@("C",zi)="ns0:RevisionDate" d newgrp
"RTN","KBAIVS2",109,0)
 . i @node@("C",zi)="ns0:Group" d group(zi)  q  ;
"RTN","KBAIVS2",110,0)
 . d tree2(zi,"|  "_prefix)
"RTN","KBAIVS2",111,0)
 d:grpstart grpout2
"RTN","KBAIVS2",112,0)
 q
"RTN","KBAIVS2",113,0)
 ;
"RTN","KBAIVS2",114,0)
newgrp ; kill the group array for a new group
"RTN","KBAIVS2",115,0)
 ;W !,"NEW GROUP"
"RTN","KBAIVS2",116,0)
 k ^KBAI("KBAIVS","GROUP")
"RTN","KBAIVS2",117,0)
 q
"RTN","KBAIVS2",118,0)
 ;
"RTN","KBAIVS2",119,0)
group(where) ; add a group node to the group array
"RTN","KBAIVS2",120,0)
 s grpstart=1
"RTN","KBAIVS2",121,0)
 n gn s gn=$na(^KBAI("KBAIVS","GROUP"))
"RTN","KBAIVS2",122,0)
 n node s node=$na(^KBAI("KBAIVS","DOM"))
"RTN","KBAIVS2",123,0)
 n gnum s gnum=$g(@node@(where,"A","ID"))
"RTN","KBAIVS2",124,0)
 i gnum="" d  q  ;
"RTN","KBAIVS2",125,0)
 . w !,"error finding group number ",where
"RTN","KBAIVS2",126,0)
 n var s var=@node@(where,"A","displayName")
"RTN","KBAIVS2",127,0)
 n valref s valref=$o(@node@(where,"C",""))
"RTN","KBAIVS2",128,0)
 i valref="" d  q  ;
"RTN","KBAIVS2",129,0)
 . w !,"error finding value reference ",where
"RTN","KBAIVS2",130,0)
 n val s val=@node@(valref,"T",1)
"RTN","KBAIVS2",131,0)
 s @gn@(gnum,var)=val
"RTN","KBAIVS2",132,0)
 q
"RTN","KBAIVS2",133,0)
 ;
"RTN","KBAIVS2",134,0)
grpout ; output the group array
"RTN","KBAIVS2",135,0)
 n gn s gn=$na(^KBAI("KBAIVS","GROUP"))
"RTN","KBAIVS2",136,0)
 n grp s grp=""
"RTN","KBAIVS2",137,0)
 f  s grp=$o(@gn@(grp)) q:grp=""  d  ;
"RTN","KBAIVS2",138,0)
 . d out("--------------------------------------------------------------")
"RTN","KBAIVS2",139,0)
 . n attr s attr=""
"RTN","KBAIVS2",140,0)
 . f  s attr=$o(@gn@(grp,attr)) q:attr=""  d  ;
"RTN","KBAIVS2",141,0)
 . . d out(attr_": "_@gn@(grp,attr))
"RTN","KBAIVS2",142,0)
 q
"RTN","KBAIVS2",143,0)
 ;
"RTN","KBAIVS2",144,0)
grpout2 ; merge the group array with all groups
"RTN","KBAIVS2",145,0)
 n gn s gn=$na(^KBAI("KBAIVS","GROUP"))
"RTN","KBAIVS2",146,0)
 n gnall s gnall=$na(^KBAI("KBAIVS","ALLGROUPS"))
"RTN","KBAIVS2",147,0)
 n grp s grp=""
"RTN","KBAIVS2",148,0)
 f  s grp=$o(@gn@(grp)) q:grp=""  d  ;
"RTN","KBAIVS2",149,0)
 . n guid s guid=$g(@gn@(grp,"GUID"))
"RTN","KBAIVS2",150,0)
 . i guid="" d  q  ;
"RTN","KBAIVS2",151,0)
 . . w !,"no guid for ",$o(@gn@(grp,""))
"RTN","KBAIVS2",152,0)
 . m @gnall@(guid)=@gn@(grp)
"RTN","KBAIVS2",153,0)
 . n mien s mien=$o(^C0QVS(176.802,"GUID",guid,""))
"RTN","KBAIVS2",154,0)
 . i mien="" d  q  ;
"RTN","KBAIVS2",155,0)
 . . w !,"measure file not built yet... run ADDGRPS then rerun import"
"RTN","KBAIVS2",156,0)
 . k KBAIFDA
"RTN","KBAIVS2",157,0)
 . i KBAIREC="" d  q  ;
"RTN","KBAIVS2",158,0)
 . . w !,"KBAIREC not defined, skipping ",guid
"RTN","KBAIVS2",159,0)
 . s KBAIFDA($$C0QVSGFN,"?+1,"_KBAIREC_",",.01)=mien
"RTN","KBAIVS2",160,0)
 . n KBAIIEN
"RTN","KBAIVS2",161,0)
 . d UPDIE(.KBAIFDA,.KBAIIEN)
"RTN","KBAIVS2",162,0)
 . k KBAIFDA,KBAIIEN
"RTN","KBAIVS2",163,0)
 . s KBAIFDA($$C0QGRCD,"?+1,"_mien_",",.01)=KBAIREC
"RTN","KBAIVS2",164,0)
 . d UPDIE(.KBAIFDA,.KBAIIEN)
"RTN","KBAIVS2",165,0)
 q
"RTN","KBAIVS2",166,0)
 ;
"RTN","KBAIVS2",167,0)
out(txt) ; add line to output array
"RTN","KBAIVS2",168,0)
 q  ; do nothing
"RTN","KBAIVS2",169,0)
 s c0xout=$na(^KBAI("KBAIOUT",$J))
"RTN","KBAIVS2",170,0)
 n cnt
"RTN","KBAIVS2",171,0)
 s cnt=$o(@c0xout@(""),-1)
"RTN","KBAIVS2",172,0)
 i cnt="" s cnt=0
"RTN","KBAIVS2",173,0)
 s @c0xout@(cnt+1)=txt
"RTN","KBAIVS2",174,0)
 q
"RTN","KBAIVS2",175,0)
 ;
"RTN","KBAIVS2",176,0)
clist(where,prefix,nohead) 
"RTN","KBAIVS2",177,0)
 n nd s nd=$na(^KBAI("KBAIVS","DOM"))
"RTN","KBAIVS2",178,0)
 ;i '$d(nohead) s nohead=0
"RTN","KBAIVS2",179,0)
 ;i 'nohead d  ;
"RTN","KBAIVS2",180,0)
 d out($j("Code",20)_$j("System",10)_$j("Description",20))
"RTN","KBAIVS2",181,0)
 n zzi s zzi=""
"RTN","KBAIVS2",182,0)
 f  s zzi=$o(@nd@(where,"C",zzi)) q:zzi=""  d  ;
"RTN","KBAIVS2",183,0)
 . n code,system,desc
"RTN","KBAIVS2",184,0)
 . s code=$g(@nd@(zzi,"A","code"))
"RTN","KBAIVS2",185,0)
 . s system=$g(@nd@(zzi,"A","codeSystemName"))
"RTN","KBAIVS2",186,0)
 . s desc=$g(@nd@(zzi,"A","displayName"))
"RTN","KBAIVS2",187,0)
 . d out($j(code,20)_$j(system,10)_"  "_desc)
"RTN","KBAIVS2",188,0)
 ;w @nd,":",@nd@("T",1)  
"RTN","KBAIVS2",189,0)
 q
"RTN","KBAIVS2",190,0)
 ;
"RTN","KBAIVS2",191,0)
alltxt(rtn,node) ; handle arrays of text
"RTN","KBAIVS2",192,0)
 m rtn=@node@("T")
"RTN","KBAIVS2",193,0)
 n zj s zj=""
"RTN","KBAIVS2",194,0)
 f  s zj=$o(rtn(zj)) q:zj=""  d  ;
"RTN","KBAIVS2",195,0)
 . s rtn(zj)=$$CLEAN(rtn(zj))
"RTN","KBAIVS2",196,0)
 . s rtn(zj)=$$LDBLNKS(rtn(zj))
"RTN","KBAIVS2",197,0)
 . i rtn(zj)="" k rtn(zj)
"RTN","KBAIVS2",198,0)
 . i (rtn(zj)=" ")&(zj>1) k rtn(zj)
"RTN","KBAIVS2",199,0)
 q
"RTN","KBAIVS2",200,0)
 ;
"RTN","KBAIVS2",201,0)
ALLTXT(where) ; extrinsic which returns all text lines from the node .. concatinated 
"RTN","KBAIVS2",202,0)
 ; together
"RTN","KBAIVS2",203,0)
 n zti s zti=""
"RTN","KBAIVS2",204,0)
 n ztr s ztr=""
"RTN","KBAIVS2",205,0)
 f  s zti=$o(@where@("T",zti)) q:zti=""  d  ;
"RTN","KBAIVS2",206,0)
 . s ztr=ztr_$g(@where@("T",zti))
"RTN","KBAIVS2",207,0)
 q ztr
"RTN","KBAIVS2",208,0)
 ;
"RTN","KBAIVS2",209,0)
CLEAN(STR) ; extrinsic function; returns string - gpl borrowed from the CCR package
"RTN","KBAIVS2",210,0)
 ;; Removes all non printable characters from a string.
"RTN","KBAIVS2",211,0)
 ;; STR by Value
"RTN","KBAIVS2",212,0)
 N TR,I
"RTN","KBAIVS2",213,0)
 F I=0:1:31,128:1:256 S TR=$G(TR)_$C(I)
"RTN","KBAIVS2",214,0)
 S TR=TR_$C(127)
"RTN","KBAIVS2",215,0)
 N ZR S ZR=$TR(STR,TR)
"RTN","KBAIVS2",216,0)
 S ZR=$$LDBLNKS(ZR) ; get rid of leading blanks
"RTN","KBAIVS2",217,0)
 QUIT ZR
"RTN","KBAIVS2",218,0)
 ;
"RTN","KBAIVS2",219,0)
LDBLNKS(st) ; extrinsic which removes leading blanks from a string
"RTN","KBAIVS2",220,0)
 n pos f pos=1:1:$l(st)  q:$e(st,pos)'=" "
"RTN","KBAIVS2",221,0)
 q $e(st,pos,$l(st))
"RTN","KBAIVS2",222,0)
 ;
"RTN","KBAIVS2",223,0)
VACCD ; set C0XJOB to the VA CCD
"RTN","KBAIVS2",224,0)
 s C0XJOB=14921
"RTN","KBAIVS2",225,0)
 q
"RTN","KBAIVS2",226,0)
 ;
"RTN","KBAIVS2",227,0)
NLMVS ; set C0XJOB to the NLM Values Set xml
"RTN","KBAIVS2",228,0)
 s C0XJOB=26295
"RTN","KBAIVS2",229,0)
 Q
"RTN","KBAIVS2",230,0)
 ;
"RTN","KBAIVS2",231,0)
contents(zrtn,ids) ; produce an agenda for the docId 1 in the MXML dom
"RTN","KBAIVS2",232,0)
 ; generally, a first level index to the document
"RTN","KBAIVS2",233,0)
 ; set C0XJOB if you want to use a different $J to locate the dom
"RTN","KBAIVS2",234,0)
 ; zrtn passed by name
"RTN","KBAIVS2",235,0)
 ; ids=1 names them by number ids=0 or null names them by displayname
"RTN","KBAIVS2",236,0)
 n zi s zi=""
"RTN","KBAIVS2",237,0)
 n dom s dom=$na(^KBAI("KBAIVS","DOM"))
"RTN","KBAIVS2",238,0)
 f  s zi=$o(@dom@(1,"C",zi)) q:zi=""  d  ;
"RTN","KBAIVS2",239,0)
 . n zn ;
"RTN","KBAIVS2",240,0)
 . d:$g(ids)  ;
"RTN","KBAIVS2",241,0)
 . . s zn=$tr($g(@dom@(zi,"A","ID")),".","-")_".txt"
"RTN","KBAIVS2",242,0)
 . . s @zrtn@(zn,zi)=""
"RTN","KBAIVS2",243,0)
 . d:'$g(ids)  ;
"RTN","KBAIVS2",244,0)
 . . s zn=$tr($g(@dom@(zi,"A","displayName"))," ","_")_".txt"
"RTN","KBAIVS2",245,0)
 . . s zn=$tr(zn,"()","") ; get rid of parens for valid filename
"RTN","KBAIVS2",246,0)
 . . s zn=$tr(zn,"/","-") ; get rid of slash for valid filename
"RTN","KBAIVS2",247,0)
 . . s @zrtn@(zn,zi)=""
"RTN","KBAIVS2",248,0)
 q
"RTN","KBAIVS2",249,0)
 ;
"RTN","KBAIVS2",250,0)
contents2(zrtn) ; produce an agenda for the docId 1 in the MXML dom
"RTN","KBAIVS2",251,0)
 ; generally, a first level index to the document
"RTN","KBAIVS2",252,0)
 ; set C0XJOB if you want to use a different $J to locate the dom
"RTN","KBAIVS2",253,0)
 ; zrtn passed by name
"RTN","KBAIVS2",254,0)
 n zi s zi=""
"RTN","KBAIVS2",255,0)
 n dom s dom=$na(^KBAI("KBAIVS","DOM"))
"RTN","KBAIVS2",256,0)
 f  s zi=$o(@dom@(1,"C",zi)) q:zi=""  d  ;
"RTN","KBAIVS2",257,0)
 . n zn,zid,zidfile,zfile ;
"RTN","KBAIVS2",258,0)
 . s zid=$g(@dom@(zi,"A","ID"))
"RTN","KBAIVS2",259,0)
 . s @zrtn@("ID",zid,zi)=""
"RTN","KBAIVS2",260,0)
 . s @zrtn@(zi,"ID")=zid
"RTN","KBAIVS2",261,0)
 . s zidfile=$tr($g(@dom@(zi,"A","ID")),".","-")_".txt"
"RTN","KBAIVS2",262,0)
 . s @zrtn@("IDFILE",zidfile,zi)=""
"RTN","KBAIVS2",263,0)
 . s @zrtn@(zi,"IDFILE")=zidfile
"RTN","KBAIVS2",264,0)
 . s zfile=$tr($g(@dom@(zi,"A","displayName"))," ","_")_".txt"
"RTN","KBAIVS2",265,0)
 . s zfile=$tr(zfile,"()","") ; get rid of parens for valid filename
"RTN","KBAIVS2",266,0)
 . s zfile=$tr(zfile,"/","-") ; get rid of slash for valid filename
"RTN","KBAIVS2",267,0)
 . s @zrtn@("FILE",zfile,zi)=""
"RTN","KBAIVS2",268,0)
 . s @zrtn@(zi,"FILE")=zfile
"RTN","KBAIVS2",269,0)
 . s zn=$g(@dom@(zi,"A","displayName"))
"RTN","KBAIVS2",270,0)
 . s @zrtn@("NAME",zn,zi)=""
"RTN","KBAIVS2",271,0)
 . s @zrtn@(zi,"NAME")=zn
"RTN","KBAIVS2",272,0)
 s zi=""
"RTN","KBAIVS2",273,0)
 f  s zi=$o(@zrtn@("ID",zi)) q:zi=""  d  ;
"RTN","KBAIVS2",274,0)
 . n zien s zien=$o(@zrtn@("ID",zi,""))
"RTN","KBAIVS2",275,0)
 . n sid s sid=$$SID^KBAISID(@zrtn@(zien,"NAME"),zi)
"RTN","KBAIVS2",276,0)
 . s @zrtn@(zien,"SID")=sid
"RTN","KBAIVS2",277,0)
 . s @zrtn@("SID",sid,zien)=""
"RTN","KBAIVS2",278,0)
 q
"RTN","KBAIVS2",279,0)
 ;
"RTN","KBAIVS2",280,0)
import ; imports value sets into fileman files
"RTN","KBAIVS2",281,0)
 ; 
"RTN","KBAIVS2",282,0)
 n g,zi,zname,where,dirname,gn,zid
"RTN","KBAIVS2",283,0)
 ;s gn=$na(^KBAI("KBAIOUT",$J))
"RTN","KBAIVS2",284,0)
 ;w !,"Please enter directory name for valueset files by name"
"RTN","KBAIVS2",285,0)
 ;q:'$$GETDIR(.dirname,"/home/vista/valuesets/by-name/")
"RTN","KBAIVS2",286,0)
 s zi=""
"RTN","KBAIVS2",287,0)
 d contents2("g") ; new contents format includes both name and id
"RTN","KBAIVS2",288,0)
 f  s zi=$o(g("NAME",zi)) q:zi=""  d  ;
"RTN","KBAIVS2",289,0)
 . n znum s znum=""
"RTN","KBAIVS2",290,0)
 . f  s znum=$o(g("NAME",zi,znum)) q:znum=""  d  ;
"RTN","KBAIVS2",291,0)
 . . s zid=g(znum,"ID")
"RTN","KBAIVS2",292,0)
 . . s KBAIREC=$$laygo(zi,zid) ; add the record if it's not already there
"RTN","KBAIVS2",293,0)
 . . ;k KBAIFDA
"RTN","KBAIVS2",294,0)
 . . ;s KBAIFDA($$C0QVSFN,"?+1,",.01)=zi
"RTN","KBAIVS2",295,0)
 . . ;s KBAIFDA($$C0QVSFN,"?+1,",.02)=zid
"RTN","KBAIVS2",296,0)
 . . ;n KBAIIEN
"RTN","KBAIVS2",297,0)
 . . ;d UPDIE(.KBAIFDA,.KBAIIEN) ; KBAIIEN is ien of the current valueset (see groupout2)
"RTN","KBAIVS2",298,0)
 . . ;s KBAIREC=$G(KBAIIEN)
"RTN","KBAIVS2",299,0)
 . . ;i KBAIREC="" D  ;
"RTN","KBAIVS2",300,0)
 . . ;. s KBAIREC=$O(^C0QVS(176.801,"ID",zid,""))
"RTN","KBAIVS2",301,0)
 . . ;. i KBAIREC="" B  ;
"RTN","KBAIVS2",302,0)
 . s where=$o(g("NAME",zi,""))
"RTN","KBAIVS2",303,0)
 . s KBAIROOT=where ; node of current Value Set 
"RTN","KBAIVS2",304,0)
 . ;k @gn
"RTN","KBAIVS2",305,0)
 . d tree2(where,"| ")
"RTN","KBAIVS2",306,0)
 . ;n gn2 s gn2=$na(@gn@(1)) ; name for gtf
"RTN","KBAIVS2",307,0)
 . ;s ok=$$GTF^%ZISH(gn2,3,dirname,fname)
"RTN","KBAIVS2",308,0)
 q
"RTN","KBAIVS2",309,0)
 ;
"RTN","KBAIVS2",310,0)
laygo(zname,zoid) ; extrinsic that returns the ien, adds the record if it's new
"RTN","KBAIVS2",311,0)
 ;
"RTN","KBAIVS2",312,0)
 n gn s gn=$na(^C0QVS(176.801,"ID"))
"RTN","KBAIVS2",313,0)
 n zien
"RTN","KBAIVS2",314,0)
 s zien=$o(@gn@(zoid,""))
"RTN","KBAIVS2",315,0)
 i zien'="" q zien
"RTN","KBAIVS2",316,0)
 k KBAIFDA
"RTN","KBAIVS2",317,0)
 s KBAIFDA($$C0QVSFN,"+1,",.01)=zname
"RTN","KBAIVS2",318,0)
 s KBAIFDA($$C0QVSFN,"+1,",.02)=zoid
"RTN","KBAIVS2",319,0)
 w !,"will add: ",zname," ",zoid
"RTN","KBAIVS2",320,0)
 d UPDIE(.KBAIFDA,.zien) ; zien is ien of the current valueset (see groupout2)
"RTN","KBAIVS2",321,0)
 q zien
"RTN","KBAIVS2",322,0)
 ;
"RTN","KBAIVS2",323,0)
impsid ; import all the sids
"RTN","KBAIVS2",324,0)
 ;
"RTN","KBAIVS2",325,0)
 n g
"RTN","KBAIVS2",326,0)
 d contents2("g")
"RTN","KBAIVS2",327,0)
 n gn s gn=$NA(^C0QVS(176.801))
"RTN","KBAIVS2",328,0)
 K KBAIFDA
"RTN","KBAIVS2",329,0)
 n zoid s zoid=""
"RTN","KBAIVS2",330,0)
 f  s zoid=$o(g("ID",zoid)) q:zoid=""  d  ;
"RTN","KBAIVS2",331,0)
 . n zien
"RTN","KBAIVS2",332,0)
 . s zien=$o(@gn@("ID",zoid,""))
"RTN","KBAIVS2",333,0)
 . n zsid
"RTN","KBAIVS2",334,0)
 . n grec s grec=$o(g("ID",zoid,""))
"RTN","KBAIVS2",335,0)
 . s zsid=g(grec,"SID")
"RTN","KBAIVS2",336,0)
 . s KBAIFDA($$C0QVSFN,zien_",",.03)=zsid
"RTN","KBAIVS2",337,0)
 N ZIEN
"RTN","KBAIVS2",338,0)
 ;B
"RTN","KBAIVS2",339,0)
 d UPDIE(.KBAIFDA,.ZIEN)
"RTN","KBAIVS2",340,0)
 q
"RTN","KBAIVS2",341,0)
 ;
"RTN","KBAIVS2",342,0)
export ; exports separate files for each value set
"RTN","KBAIVS2",343,0)
 ; one copy in a file with a text name based on the displayName
"RTN","KBAIVS2",344,0)
 n g,zi,fname,where,dirname,gn
"RTN","KBAIVS2",345,0)
 s gn=$na(^KBAI("KBAIOUT",$J))
"RTN","KBAIVS2",346,0)
 w !,"Please enter directory name for valueset files by name"
"RTN","KBAIVS2",347,0)
 q:'$$GETDIR(.dirname,"/home/vista/valuesets/by-name/")
"RTN","KBAIVS2",348,0)
 s zi=""
"RTN","KBAIVS2",349,0)
 d contents("g") ; first with text names
"RTN","KBAIVS2",350,0)
 f  s zi=$o(g(zi)) q:zi=""  d  ;
"RTN","KBAIVS2",351,0)
 . s fname=zi
"RTN","KBAIVS2",352,0)
 . s where=$o(g(zi,""))
"RTN","KBAIVS2",353,0)
 . k @gn
"RTN","KBAIVS2",354,0)
 . d tree2(where,"| ")
"RTN","KBAIVS2",355,0)
 . n gn2 s gn2=$na(@gn@(1)) ; name for gtf
"RTN","KBAIVS2",356,0)
 . s ok=$$GTF^%ZISH(gn2,3,dirname,fname)
"RTN","KBAIVS2",357,0)
 q
"RTN","KBAIVS2",358,0)
 ;
"RTN","KBAIVS2",359,0)
export2 ; exports separate files for each value set
"RTN","KBAIVS2",360,0)
 ; one copy in a file with a numeric file name based on ID
"RTN","KBAIVS2",361,0)
 n g,zi,fname,where,dirname,gn
"RTN","KBAIVS2",362,0)
 s gn=$na(^KBAI("KBAIOUT",$J))
"RTN","KBAIVS2",363,0)
 w !,"Please enter directory name for valueset files by id"
"RTN","KBAIVS2",364,0)
 q:'$$GETDIR(.dirname,"/home/vista/valuesets/by-id/")
"RTN","KBAIVS2",365,0)
 ;s dirname="/home/wvehr2/valuesets/by-id/"
"RTN","KBAIVS2",366,0)
 s zi=""
"RTN","KBAIVS2",367,0)
 d contents("g",1) ; with id names
"RTN","KBAIVS2",368,0)
 f  s zi=$o(g(zi)) q:zi=""  d  ;
"RTN","KBAIVS2",369,0)
 . s fname=zi
"RTN","KBAIVS2",370,0)
 . s where=$o(g(zi,""))
"RTN","KBAIVS2",371,0)
 . k @gn
"RTN","KBAIVS2",372,0)
 . d tree2(where,"| ")
"RTN","KBAIVS2",373,0)
 . n gn2 s gn2=$na(@gn@(1)) ; name for gtf
"RTN","KBAIVS2",374,0)
 . ;s ok=$$GTF^%ZISH(gn2,3,dirname,fname)
"RTN","KBAIVS2",375,0)
 q
"RTN","KBAIVS2",376,0)
 ;
"RTN","KBAIVS2",377,0)
FILEIN ; import the valueset xml file, parse with MXML, and put the dom in ^TMP
"RTN","KBAIVS2",378,0)
 ;
"RTN","KBAIVS2",379,0)
 N FNAME,DIRNAME
"RTN","KBAIVS2",380,0)
 W !,"Please enter the directory and file name for the NLM Valueset XML file"
"RTN","KBAIVS2",381,0)
 Q:'$$GETDIR(.DIRNAME,"/home/glilly/nlm-vs") ; prompt the user for the directory
"RTN","KBAIVS2",382,0)
 Q:'$$GETFN(.FNAME,"valuesets.xml") ; prompt user for filename
"RTN","KBAIVS2",383,0)
 N GN S GN=$NA(^KBAI("KBAIVS")) ; root to store xml and dom
"RTN","KBAIVS2",384,0)
 K @GN ; clear the area
"RTN","KBAIVS2",385,0)
 N GN1 S GN1=$NA(@GN@("XML",1)) ; place to put the xml file
"RTN","KBAIVS2",386,0)
 W !,"Reading in file ",FNAME," from directory ",DIRNAME
"RTN","KBAIVS2",387,0)
 Q:$$FTG^%ZISH(DIRNAME,FNAME,GN1,3)=""
"RTN","KBAIVS2",388,0)
 N KBAIDID
"RTN","KBAIVS2",389,0)
 W !,"Parsing file ",FNAME
"RTN","KBAIVS2",390,0)
 S KBAIDID=$$EN^MXMLDOM($NA(@GN@("XML")),"W")
"RTN","KBAIVS2",391,0)
 I KBAIDID=0 D  Q  ;
"RTN","KBAIVS2",392,0)
 . ZWRITE ^TMP("MXMLERR",$J,*)
"RTN","KBAIVS2",393,0)
 W !,"Merging MXMLDOM to TMP"
"RTN","KBAIVS2",394,0)
 M @GN@("DOM")=^TMP("MXMLDOM",$J,KBAIDID)
"RTN","KBAIVS2",395,0)
 K ^TMP("MXMLDOM",$J)
"RTN","KBAIVS2",396,0)
 Q
"RTN","KBAIVS2",397,0)
 ;
"RTN","KBAIVS2",398,0)
GETDIR(KBAIDIR,KBAIDEF) ; extrinsic which prompts for directory
"RTN","KBAIVS2",399,0)
 ; returns true if the user gave values
"RTN","KBAIVS2",400,0)
 S DIR(0)="F^3:240"
"RTN","KBAIVS2",401,0)
 S DIR("A")="File Directory"
"RTN","KBAIVS2",402,0)
 I '$D(KBAIDEF) S KBAIDEF="/home/glilly/nlm-vs"
"RTN","KBAIVS2",403,0)
 S DIR("B")=KBAIDEF
"RTN","KBAIVS2",404,0)
 D ^DIR
"RTN","KBAIVS2",405,0)
 I Y="^" Q 0 ;
"RTN","KBAIVS2",406,0)
 S KBAIDIR=Y
"RTN","KBAIVS2",407,0)
 Q 1
"RTN","KBAIVS2",408,0)
 ;
"RTN","KBAIVS2",409,0)
GETFN(KBAIFN,KBAIDEF) ; extrinsic which prompts for filename
"RTN","KBAIVS2",410,0)
 ; returns true if the user gave values
"RTN","KBAIVS2",411,0)
 S DIR(0)="F^3:240"
"RTN","KBAIVS2",412,0)
 S DIR("A")="File Name"
"RTN","KBAIVS2",413,0)
 I '$D(KBAIDEF) S KBAIDEF="valuesets.xml"
"RTN","KBAIVS2",414,0)
 S DIR("B")=KBAIDEF
"RTN","KBAIVS2",415,0)
 D ^DIR
"RTN","KBAIVS2",416,0)
 I Y="" Q 0 ;
"RTN","KBAIVS2",417,0)
 I Y="^" Q 0 ;
"RTN","KBAIVS2",418,0)
 S KBAIFN=Y
"RTN","KBAIVS2",419,0)
 Q 1
"RTN","KBAIVS2",420,0)
 ;
"RTN","KBAIVS2",421,0)
UPDIE(ZFDA,ZIEN) ; INTERNAL ROUTINE TO CALL UPDATE^DIE AND CHECK FOR ERRORS
"RTN","KBAIVS2",422,0)
 ; ZFDA IS PASSED BY REFERENCE
"RTN","KBAIVS2",423,0)
 ; ZIEN IS PASSED BY REFERENCE
"RTN","KBAIVS2",424,0)
 D:$G(DEBUG)
"RTN","KBAIVS2",425,0)
 . ZWRITE ZFDA
"RTN","KBAIVS2",426,0)
 . B
"RTN","KBAIVS2",427,0)
 K ZERR
"RTN","KBAIVS2",428,0)
 D CLEAN^DILF
"RTN","KBAIVS2",429,0)
 D UPDATE^DIE("K","ZFDA","ZIEN","ZERR")
"RTN","KBAIVS2",430,0)
 I $D(ZERR) S ZZERR=ZZERR ; ZZERR DOESN'T EXIST, 
"RTN","KBAIVS2",431,0)
 ; INVOKE THE ERROR TRAP IF TASKED
"RTN","KBAIVS2",432,0)
 ;. W "ERROR",!
"RTN","KBAIVS2",433,0)
 ;. ZWR ZERR
"RTN","KBAIVS2",434,0)
 ;. B
"RTN","KBAIVS2",435,0)
 K ZFDA
"RTN","KBAIVS2",436,0)
 Q
"RTN","KBAIVS2",437,0)
 ;
"RTN","KBAIVS2",438,0)
O2BKMAPS ; backup mapping values in preparation for loading a new value set xml file
"RTN","KBAIVS2",439,0)
 N GN S GN=$NA(^KBAI("VSBAK"))
"RTN","KBAIVS2",440,0)
 K @GN ; clear the old backup if any
"RTN","KBAIVS2",441,0)
 D SLSII^KBAIII(GN,$NA(^C0QVS(176.802))) ; invert all simple indexes
"RTN","KBAIVS2",442,0)
 Q
"RTN","KBAIVS2",443,0)
 ;
"RTN","KBAIVS2",444,0)
BKMAPS ; third time's a charm ... brute force
"RTN","KBAIVS2",445,0)
 N GN S GN=$NA(^KBAI("VSBAK"))
"RTN","KBAIVS2",446,0)
 K @GN
"RTN","KBAIVS2",447,0)
 N GV S GV=$NA(^C0QVS(176.802))
"RTN","KBAIVS2",448,0)
 M @GN@("CQM")=@GV@("CQM")
"RTN","KBAIVS2",449,0)
 M @GN@("GUID")=@GV@("GUID")
"RTN","KBAIVS2",450,0)
 M @GN@("CAT")=@GV@("CAT")
"RTN","KBAIVS2",451,0)
 M @GN@("ID")=@GV@("ID")
"RTN","KBAIVS2",452,0)
 N ZI S ZI=""
"RTN","KBAIVS2",453,0)
 F  S ZI=$O(@GN@(ZI)) Q:ZI=""  D  ;
"RTN","KBAIVS2",454,0)
 . I ZI="ROOT" Q  ;
"RTN","KBAIVS2",455,0)
 . N VAL S VAL=""
"RTN","KBAIVS2",456,0)
 . F  S VAL=$O(@GN@(ZI,VAL)) Q:VAL=""  D  ;
"RTN","KBAIVS2",457,0)
 . . N REC S REC=""
"RTN","KBAIVS2",458,0)
 . . F  S REC=$O(@GN@(ZI,VAL,REC)) Q:REC=""  D  ;
"RTN","KBAIVS2",459,0)
 . . . S @GN@("ROOT",REC,ZI,VAL)=""
"RTN","KBAIVS2",460,0)
 Q
"RTN","KBAIVS2",461,0)
 ;
"RTN","KBAIVS2",462,0)
RESTORE ; restores mapping fields to 176.802 from backup
"RTN","KBAIVS2",463,0)
 ; this is used after loading a new SVS xml file
"RTN","KBAIVS2",464,0)
 N ZI S ZI=""
"RTN","KBAIVS2",465,0)
 S GN=$NA(^KBAI("VSBAK","ROOT")) ; Location of the backup (see BKMAPS above)
"RTN","KBAIVS2",466,0)
 F  S ZI=$O(@GN@(ZI)) Q:ZI=""  D  ;
"RTN","KBAIVS2",467,0)
 . N ZID S ZID=$O(@GN@(ZI,"GUID","")) ; measure guid
"RTN","KBAIVS2",468,0)
 . Q:ZID=""
"RTN","KBAIVS2",469,0)
 . W !,ZID
"RTN","KBAIVS2",470,0)
 . N ZIEN S ZIEN=$O(^C0QVS(176.802,"GUID",ZID,"")) ; record to update
"RTN","KBAIVS2",471,0)
 . Q:ZIEN=""
"RTN","KBAIVS2",472,0)
 . W " ",ZIEN
"RTN","KBAIVS2",473,0)
 . K KBAIFDA
"RTN","KBAIVS2",474,0)
 . S KBAIFDA($$C0QGRFN(),ZIEN_",",5)=$O(@GN@(ZI,"CQM",""))
"RTN","KBAIVS2",475,0)
 . S KBAIFDA($$C0QGRFN(),ZIEN_",",5.1)=$O(@GN@(ZI,"CAT",""))
"RTN","KBAIVS2",476,0)
 . N OK
"RTN","KBAIVS2",477,0)
 . W ! ZWR KBAIFDA
"RTN","KBAIVS2",478,0)
 . ZWR @GN@(ZI,*)
"RTN","KBAIVS2",479,0)
 . D UPDIE(.KBAIFDA,.OK)
"RTN","KBAIVS2",480,0)
 Q
"RTN","KBAIVS2",481,0)
 ;
"RTN","KBAIVS2",482,0)
RELOAD ; deletes the 176.801 and 176.802 files and reloads from xml, then
"RTN","KBAIVS2",483,0)
 ; restores the mappings
"RTN","KBAIVS2",484,0)
 ;D BKMAPS ; make sure the mappings are backed up
"RTN","KBAIVS2",485,0)
 K ^C0QVS(176.801)
"RTN","KBAIVS2",486,0)
 K ^C0QVS(176.802)
"RTN","KBAIVS2",487,0)
 W !,"REBUILDING MEASURE GROUPS"
"RTN","KBAIVS2",488,0)
 D ADDGRPS ; import group definitions
"RTN","KBAIVS2",489,0)
 W !,"REBUILDING VALUE SETS"
"RTN","KBAIVS2",490,0)
 D import ; import valueset definitions
"RTN","KBAIVS2",491,0)
 D impsid ; import short identifiers
"RTN","KBAIVS2",492,0)
 D RESTORE
"RTN","KBAIVS2",493,0)
 Q
"RTN","KBAIVS2",494,0)
 ;
"RTN","KBAIVS2",495,0)
 ;C0QBKFN() Q 176.888 ; mapping backup file
"RTN","KBAIVS2",496,0)
 ;;C0QBKID() Q 176.8881 ; mapping backup identifier subfile
"RTN","KBAIVS2",497,0)
 ;;;C0QBKFLD() Q 176.88811 ; field subfile of identifier subfile of mapping backup file
"RTN","KBAIVS2",498,0)
OLDBKMAPS ; backup mapping fields -- THIS DOESN'T WORK -- PLEASE IGNORE (DEBUGGING)
"RTN","KBAIVS2",499,0)
 N GN S GN=$NA(^C0QVS(176.802,"ID")) ; CMS index to the measures file
"RTN","KBAIVS2",500,0)
 N FIIEN S FIIEN=$O(^C0QBAK(176.888,"B",176.802,""))
"RTN","KBAIVS2",501,0)
 I FIIEN="" D  ;
"RTN","KBAIVS2",502,0)
 . K KBAIFDA
"RTN","KBAIVS2",503,0)
 . S KBAIFDA($$C0QBKFN,"?+1,",.01)=176.802
"RTN","KBAIVS2",504,0)
 . D UPDIE(.KBAIFDA,.FIIEN)
"RTN","KBAIVS2",505,0)
 . S FIIEN=$O(^C0QBAK(176.888,"B",176.802,""))
"RTN","KBAIVS2",506,0)
 W !,"FIIEN= ",FIIEN
"RTN","KBAIVS2",507,0)
 I FIIEN="" B
"RTN","KBAIVS2",508,0)
 N ZCMSID S ZCMSID=""
"RTN","KBAIVS2",509,0)
 F  S ZCMSID=$O(@GN@(ZCMSID)) Q:ZCMSID=""  D  ; for each measure
"RTN","KBAIVS2",510,0)
 . N ZZIEN
"RTN","KBAIVS2",511,0)
 . S ZZIEN=$O(@GN@(ZCMSID,""))
"RTN","KBAIVS2",512,0)
 . B
"RTN","KBAIVS2",513,0)
 . W !,"ZIIEN= ",ZIIEN
"RTN","KBAIVS2",514,0)
 . K KBAIFDA
"RTN","KBAIVS2",515,0)
 . S KBAIFDA($$C0QBKID(),"?+1,"_FIIEN_",",.01)=ZCMSID
"RTN","KBAIVS2",516,0)
 . N IDIEN
"RTN","KBAIVS2",517,0)
 . D UPDIE(.KBAIFDA,.IDIEN)
"RTN","KBAIVS2",518,0)
 . ;B
"RTN","KBAIVS2",519,0)
 . S IDIEN=$O(^C0QBAK(176.888,FIIEN,"B",ZCMSID,""))
"RTN","KBAIVS2",520,0)
 . W !,"IDIEN= ",IDIEN
"RTN","KBAIVS2",521,0)
 . I '$D(IDIEN) B
"RTN","KBAIVS2",522,0)
 . K KBAIFDA
"RTN","KBAIVS2",523,0)
 . S KBAIFDA($$C0QBKID(),IDIEN_","_FIIEN_",",5)=$$GET1^DIQ($$C0QGRFN(),ZZIEN_",",5,"E")
"RTN","KBAIVS2",524,0)
 . S KBAIFDA($$C0QBKID(),IDIEN_","_FIIEN_",",5.1)=$$GET1^DIQ($$C0QGRFN(),ZZIEN_",",5.1,"E")
"RTN","KBAIVS2",525,0)
 . S KBAIFDA($$C0QBKID(),IDIEN_","_FIIEN_",",5.2)=$$GET1^DIQ($$C0QGRFN(),ZZIEN_",",5.2,"E")
"RTN","KBAIVS2",526,0)
 . D UPDIE(.KBAIFDA,.ZFIDIEN)
"RTN","KBAIVS2",527,0)
 Q
"RTN","KBAIVS2",528,0)
 ;
"SEC","^DD",176.801,176.8012,.02,9)

"SEC","^DD",176.801,176.8012,.03,9)

"SEC","^DD",176.802,176.802,5.2,9)

"SEC","^DIC",176.801,176.801,0,"AUDIT")
@
"SEC","^DIC",176.801,176.801,0,"DD")
@
"SEC","^DIC",176.801,176.801,0,"DEL")
@
"SEC","^DIC",176.801,176.801,0,"LAYGO")
@
"SEC","^DIC",176.801,176.801,0,"RD")
@
"SEC","^DIC",176.801,176.801,0,"WR")
@
"SEC","^DIC",176.802,176.802,0,"AUDIT")
@
"SEC","^DIC",176.802,176.802,0,"DD")
@
"SEC","^DIC",176.802,176.802,0,"DEL")
@
"SEC","^DIC",176.802,176.802,0,"LAYGO")
@
"SEC","^DIC",176.802,176.802,0,"RD")
@
"SEC","^DIC",176.802,176.802,0,"WR")
@
"SEC","^DIC",176.803,176.803,0,"AUDIT")
@
"SEC","^DIC",176.803,176.803,0,"DD")
@
"SEC","^DIC",176.803,176.803,0,"DEL")
@
"SEC","^DIC",176.803,176.803,0,"LAYGO")
@
"SEC","^DIC",176.803,176.803,0,"RD")
@
"SEC","^DIC",176.803,176.803,0,"WR")
@
"SEC","^DIC",176.804,176.804,0,"AUDIT")
@
"SEC","^DIC",176.804,176.804,0,"DD")
@
"SEC","^DIC",176.804,176.804,0,"DEL")
@
"SEC","^DIC",176.804,176.804,0,"LAYGO")
@
"SEC","^DIC",176.804,176.804,0,"RD")
@
"SEC","^DIC",176.804,176.804,0,"WR")
@
"VER")
8.0^22.0
"^DD",176.801,176.801,0)
FIELD^^.03^6
"^DD",176.801,176.801,0,"DDA")
N
"^DD",176.801,176.801,0,"DT")
3130412
"^DD",176.801,176.801,0,"ID",.03)
W:$D(^(5)) "   ",$P(^(5),U,1)
"^DD",176.801,176.801,0,"NM","C0Q VALUE SET CODES")

"^DD",176.801,176.801,0,"PT",176.8024,.01)

"^DD",176.801,176.801,.01,0)
VALUE SET^RF^^0;1^K:$L(X)>240!($L(X)<3)!'(X'?1P.E) X
"^DD",176.801,176.801,.01,.1)
NLM VALUE SET
"^DD",176.801,176.801,.01,1,0)
^.1^^0
"^DD",176.801,176.801,.01,3)
Answer must be 3-240 characters in length.
"^DD",176.801,176.801,.01,"DT")
3130322
"^DD",176.801,176.801,.02,0)
ID^F^^1;1^K:$L(X)>240!($L(X)<3) X
"^DD",176.801,176.801,.02,.1)
VALUE SET ID
"^DD",176.801,176.801,.02,3)
Answer must be 3-240 characters in length.
"^DD",176.801,176.801,.02,"DT")
3130322
"^DD",176.801,176.801,.03,0)
SHORT ID^F^^5;1^K:$L(X)>30!($L(X)<1) X
"^DD",176.801,176.801,.03,.1)
SHORT IDENTIFIER BASED ON THE NAME AND THE END OF THE OID
"^DD",176.801,176.801,.03,3)
Answer must be 1-30 characters in length.
"^DD",176.801,176.801,.03,"DT")
3130412
"^DD",176.801,176.801,.05,0)
DATE UPDATED^D^^3;1^S %DT="ET" D ^%DT S X=Y K:X<1 X
"^DD",176.801,176.801,.05,.1)
DATE OF LAST UPDATE
"^DD",176.801,176.801,.05,3)
(No range limit on date)
"^DD",176.801,176.801,.05,"DT")
3130322
"^DD",176.801,176.801,1,0)
CODE^176.8011^^2;0
"^DD",176.801,176.801,2,0)
MEASURE^176.8012P^^4;0
"^DD",176.801,176.8011,0)
CODE SUB-FIELD^^.03^3
"^DD",176.801,176.8011,0,"DT")
3130322
"^DD",176.801,176.8011,0,"IX","B",176.8011,.01)

"^DD",176.801,176.8011,0,"NM","CODE")

"^DD",176.801,176.8011,0,"UP")
176.801
"^DD",176.801,176.8011,.01,0)
CODE^MF^^0;1^K:$L(X)>60!($L(X)<1) X
"^DD",176.801,176.8011,.01,.1)
VALUE SET CODE
"^DD",176.801,176.8011,.01,1,0)
^.1
"^DD",176.801,176.8011,.01,1,1,0)
176.8011^B
"^DD",176.801,176.8011,.01,1,1,1)
S ^C0QVS(176.801,DA(1),2,"B",$E(X,1,30),DA)=""
"^DD",176.801,176.8011,.01,1,1,2)
K ^C0QVS(176.801,DA(1),2,"B",$E(X,1,30),DA)
"^DD",176.801,176.8011,.01,3)
Answer must be 1-60 characters in length.
"^DD",176.801,176.8011,.01,"DT")
3130322
"^DD",176.801,176.8011,.02,0)
DISPLAY NAME^F^^1;1^K:$L(X)>240!($L(X)<1) X
"^DD",176.801,176.8011,.02,.1)
CODE DISPLAY NAME
"^DD",176.801,176.8011,.02,3)
Answer must be 1-240 characters in length.
"^DD",176.801,176.8011,.02,"DT")
3130322
"^DD",176.801,176.8011,.03,0)
CODE SYSTEM^P176.803^C0QVS(176.803,^1;2^Q
"^DD",176.801,176.8011,.03,.1)
CODING SYSTEM
"^DD",176.801,176.8011,.03,"DT")
3130322
"^DD",176.801,176.8012,0)
MEASURE SUB-FIELD^^.03^3
"^DD",176.801,176.8012,0,"DT")
3130329
"^DD",176.801,176.8012,0,"IX","B",176.8012,.01)

"^DD",176.801,176.8012,0,"NM","MEASURE")

"^DD",176.801,176.8012,0,"UP")
176.801
"^DD",176.801,176.8012,.01,0)
MEASURE^MP176.802^C0QVS(176.802,^0;1^Q
"^DD",176.801,176.8012,.01,.1)
USED IN MEASURE GROUP
"^DD",176.801,176.8012,.01,1,0)
^.1
"^DD",176.801,176.8012,.01,1,1,0)
176.8012^B
"^DD",176.801,176.8012,.01,1,1,1)
S ^C0QVS(176.801,DA(1),4,"B",$E(X,1,30),DA)=""
"^DD",176.801,176.8012,.01,1,1,2)
K ^C0QVS(176.801,DA(1),4,"B",$E(X,1,30),DA)
"^DD",176.801,176.8012,.01,"DT")
3130322
"^DD",176.801,176.8012,.02,0)
EP/EH^CJ^^ ; ^X ^DD(176.8012,.02,9.3) S Y(176.8012,.02,101)=$S($D(^C0QVS(176.802,D0,14)):^(14),1:"") S X=$P($P(Y(176.8012,.02,102),$C(59)_$P(Y(176.8012,.02,101),U,2)_":",2),$C(59)) S D0=Y(176.8012,.02,80) S D1=Y(176.8012,.02,81)
"^DD",176.801,176.8012,.02,.1)
COPY OF EP/EH FIELD IN THE MEASURE FILE
"^DD",176.801,176.8012,.02,9.01)
176.802^5;176.8012^.01
"^DD",176.801,176.8012,.02,9.1)
MEASURE:EP/EH
"^DD",176.801,176.8012,.02,9.2)
S Y(176.8012,.02,81)=$G(D1),Y(176.8012,.02,80)=$G(D0),Y(176.8012,.02,1)=$S($D(^C0QVS(176.801,D0,4,D1,0)):^(0),1:"")
"^DD",176.801,176.8012,.02,9.3)
X ^DD(176.8012,.02,9.2) S D0=$P(Y(176.8012,.02,1),U,1) S:'D0!'$D(^C0QVS(176.802,+D0,0)) D0=-1 S Y(176.8012,.02,102)=$C(59)_$P($G(^DD(176.802,5,0)),U,3)
"^DD",176.801,176.8012,.02,"DT")
3130329
"^DD",176.801,176.8012,.03,0)
NQF^CJ^^ ; ^X ^DD(176.8012,.03,9.3) S X=$P(Y(176.8012,.03,101),U,2) S D0=Y(176.8012,.03,80) S D1=Y(176.8012,.03,81)
"^DD",176.801,176.8012,.03,.1)
COPY OF THE NQF FIELD IN THE MEASURE FILE
"^DD",176.801,176.8012,.03,9.01)
176.802^.03;176.8012^.01
"^DD",176.801,176.8012,.03,9.1)
MEASURE:NQF
"^DD",176.801,176.8012,.03,9.2)
S Y(176.8012,.03,81)=$G(D1),Y(176.8012,.03,80)=$G(D0),Y(176.8012,.03,1)=$S($D(^C0QVS(176.801,D0,4,D1,0)):^(0),1:"")
"^DD",176.801,176.8012,.03,9.3)
X ^DD(176.8012,.03,9.2) S D0=$P(Y(176.8012,.03,1),U,1) S:'D0!'$D(^C0QVS(176.802,+D0,0)) D0=-1 S Y(176.8012,.03,101)=$S($D(^C0QVS(176.802,D0,1)):^(1),1:"")
"^DD",176.801,176.8012,.03,"DT")
3130329
"^DD",176.802,176.802,0)
FIELD^^5.2^23
"^DD",176.802,176.802,0,"DDA")
N
"^DD",176.802,176.802,0,"DT")
3130412
"^DD",176.802,176.802,0,"ID",.03)
W:$D(^(1)) "   ",$P(^(1),U,2)
"^DD",176.802,176.802,0,"ID",.05)
W:$D(^(15)) "   ",$P(^(15),U,1)
"^DD",176.802,176.802,0,"ID",2.2)
W:$D(^(4)) "   ",$P(^(4),U,1)
"^DD",176.802,176.802,0,"ID",5)
W:$D(^(14)) "   ",@("$P($P($C(59)_$S($D(^DD(176.802,5,0)):$P(^(0),U,3),1:0)_$E("_DIC_"Y,0),0),$C(59)_$P(^(14),U,2)_"":"",2),$C(59),1)")
"^DD",176.802,176.802,0,"ID",5.1)
S %I=Y,Y=$S('$D(^(15)):"",$D(^C0QVS(176.804,+$P(^(15),U,2),0))#2:$P(^(0),U,1),1:""),C=$P(^DD(176.804,.01,0),U,2) D Y^DIQ:Y]"" W "   ",Y,@("$E("_DIC_"%I,0),0)") S Y=%I K %I
"^DD",176.802,176.802,0,"IX","KWIC",176.802,.011)

"^DD",176.802,176.802,0,"NM","C0Q NLM QUALITY MEASURE GROUPS")

"^DD",176.802,176.802,0,"PT",176.8012,.01)

"^DD",176.802,176.802,.01,0)
TITLE^RF^^0;1^K:$L(X)>240!($L(X)<3)!'(X'?1P.E) X
"^DD",176.802,176.802,.01,.1)
EMEASURE TITLE
"^DD",176.802,176.802,.01,1,0)
^.1^^-1
"^DD",176.802,176.802,.01,1,2,0)
^^TRIGGER^176.802^.011
"^DD",176.802,176.802,.01,1,2,1)
K DIV S DIV=X,D0=DA,DIV(0)=D0 S Y(1)=$S($D(^C0QVS(176.802,D0,14)):^(14),1:"") S X=$P(Y(1),U,1),X=X S DIU=X K Y X ^DD(176.802,.01,1,2,1.1) X ^DD(176.802,.01,1,2,1.4)
"^DD",176.802,176.802,.01,1,2,1.1)
S X=DIV S X=DIV X "F %=1:1:$L(X) S:$E(X,%)?1L X=$E(X,0,%-1)_$C($A(X,%)-32)_$E(X,%+1,999)"
"^DD",176.802,176.802,.01,1,2,1.4)
S DIH=$G(^C0QVS(176.802,DIV(0),14)),DIV=X S $P(^(14),U,1)=DIV,DIH=176.802,DIG=.011 D ^DICR
"^DD",176.802,176.802,.01,1,2,2)
Q
"^DD",176.802,176.802,.01,1,2,3)
AUTOMATIC UPPERCASE OF TITLE FIELD
"^DD",176.802,176.802,.01,1,2,"CREATE VALUE")
UPPERCASE(TITLE)
"^DD",176.802,176.802,.01,1,2,"DELETE VALUE")
NO EFFECT
"^DD",176.802,176.802,.01,1,2,"DT")
3130323
"^DD",176.802,176.802,.01,1,2,"FIELD")
UPPERCASE TITLE
"^DD",176.802,176.802,.01,3)
Answer must be 3-240 characters in length.
"^DD",176.802,176.802,.01,"DT")
3130329
"^DD",176.802,176.802,.011,0)
UPPERCASE TITLE^F^^14;1^K:$L(X)>240!($L(X)<1) X
"^DD",176.802,176.802,.011,.1)
AUTOMATIC UPPERCASE TITLE
"^DD",176.802,176.802,.011,1,0)
^.1
"^DD",176.802,176.802,.011,1,1,0)
176.802^KWIC^KWIC
"^DD",176.802,176.802,.011,1,1,1)
S %1=1 F %=1:1:$L(X)+1 S I=$E(X,%) I "(,.?! '-/&:;)"[I S I=$E($E(X,%1,%-1),1,30),%1=%+1 I $L(I)>2,^DD("KWIC")'[I S ^C0QVS(176.802,"KWIC",I,DA)=""
"^DD",176.802,176.802,.011,1,1,2)
S %1=1 F %=1:1:$L(X)+1 S I=$E(X,%) I "(,.?! '-/&:;)"[I S I=$E($E(X,%1,%-1),1,30),%1=%+1 I $L(I)>2 K ^C0QVS(176.802,"KWIC",I,DA)
"^DD",176.802,176.802,.011,1,1,"DT")
3130323
"^DD",176.802,176.802,.011,3)
Answer must be 1-240 characters in length.
"^DD",176.802,176.802,.011,5,1,0)
176.802^.01^2
"^DD",176.802,176.802,.011,9)
^
"^DD",176.802,176.802,.011,"DT")
3130323
"^DD",176.802,176.802,.02,0)
GUID^F^^1;1^K:$L(X)>120!($L(X)<3) X
"^DD",176.802,176.802,.02,.1)
MEASURE GUID
"^DD",176.802,176.802,.02,3)
Answer must be 3-120 characters in length.
"^DD",176.802,176.802,.02,"DT")
3130322
"^DD",176.802,176.802,.03,0)
NQF NUMBER^F^^1;2^K:$L(X)>60!($L(X)<1) X
"^DD",176.802,176.802,.03,.1)
MEASURE NQF NUMBER
"^DD",176.802,176.802,.03,3)
Answer must be 1-60 characters in length.
"^DD",176.802,176.802,.03,"DT")
3130322
"^DD",176.802,176.802,.04,0)
VERSION^F^^11;1^K:$L(X)>120!($L(X)<1) X
"^DD",176.802,176.802,.04,.1)
EMEASURE VERSION NUMBER
"^DD",176.802,176.802,.04,3)
Answer must be 1-120 characters in length.
"^DD",176.802,176.802,.04,"DT")
3130322
"^DD",176.802,176.802,.05,0)
ADDITIONAL IDENTIFIER^F^^15;1^K:$L(X)>120!($L(X)<1) X
"^DD",176.802,176.802,.05,.1)
Additional Measure Identifier - some measures have no NQF number
"^DD",176.802,176.802,.05,3)
Answer must be 1-120 characters in length.
"^DD",176.802,176.802,.05,"DT")
3130323
"^DD",176.802,176.802,1,0)
DESCRIPTION^176.8021^^2;0
"^DD",176.802,176.802,1.1,0)
SHORT DESCRIPTION^F^^13;1^K:$L(X)>240!($L(X)<1) X
"^DD",176.802,176.802,1.1,.1)
FIRST PART OF DESCRIPTION FIELD
"^DD",176.802,176.802,1.1,3)
Answer must be 1-240 characters in length.
"^DD",176.802,176.802,1.1,"DT")
3130322
"^DD",176.802,176.802,2.1,0)
CATEGORY^F^^3;1^K:$L(X)>40!($L(X)<3) X
"^DD",176.802,176.802,2.1,.1)
MEASURE CATEGORY
"^DD",176.802,176.802,2.1,3)
Answer must be 3-40 characters in length.
"^DD",176.802,176.802,2.1,"DT")
3130322
"^DD",176.802,176.802,2.2,0)
CMS eMEASURE ID^F^^4;1^K:$L(X)>240!($L(X)<1) X
"^DD",176.802,176.802,2.2,.1)
CMS E MEASURE ID
"^DD",176.802,176.802,2.2,3)
Answer must be 1-240 characters in length.
"^DD",176.802,176.802,2.2,"DT")
3130322
"^DD",176.802,176.802,2.3,0)
ENDORSED BY^F^^5;1^K:$L(X)>120!($L(X)<1) X
"^DD",176.802,176.802,2.3,.1)
MEASURE ENDORSED BY
"^DD",176.802,176.802,2.3,3)
Answer must be 1-120 characters in length.
"^DD",176.802,176.802,2.3,"DT")
3130322
"^DD",176.802,176.802,2.4,0)
MEANINGFUL USE MEASURES^F^^5;2^K:$L(X)>120!($L(X)<1) X
"^DD",176.802,176.802,2.4,.1)
MEANINGFUL USE MEASURE IDENTIFIER
"^DD",176.802,176.802,2.4,3)
Answer must be 1-120 characters in length.
"^DD",176.802,176.802,2.4,"DT")
3130322
"^DD",176.802,176.802,2.5,0)
MEASURE DEVELOPER^F^^6;1^K:$L(X)>120!($L(X)<3) X
"^DD",176.802,176.802,2.5,.1)
MEASURE DEVELOPER ORGANIZATION
"^DD",176.802,176.802,2.5,3)
Answer must be 3-120 characters in length.
"^DD",176.802,176.802,2.5,"DT")
3130322
"^DD",176.802,176.802,2.6,0)
MEASURE STEWARD^F^^6;2^K:$L(X)>120!($L(X)<1) X
"^DD",176.802,176.802,2.6,.1)
MEASURE STEWARD ORGANIZATION
"^DD",176.802,176.802,2.6,3)
Answer must be 1-120 characters in length.
"^DD",176.802,176.802,2.6,"DT")
3130322
"^DD",176.802,176.802,2.7,0)
MEASURE TYPE^F^^7;1^K:$L(X)>120!($L(X)<1) X
"^DD",176.802,176.802,2.7,.1)
MEASURE TYPE TEXT
"^DD",176.802,176.802,2.7,3)
Answer must be 1-120 characters in length.
"^DD",176.802,176.802,2.7,"DT")
3130322
"^DD",176.802,176.802,2.8,0)
SHEETNAME^F^^8;1^K:$L(X)>240!($L(X)<1) X
"^DD",176.802,176.802,2.8,.1)
EXCEL SPREADSHEET SHEET NAME
"^DD",176.802,176.802,2.8,3)
Answer must be 1-240 characters in length.
"^DD",176.802,176.802,2.8,"DT")
3130322
"^DD",176.802,176.802,2.9,0)
COPYRIGHT^F^^9;1^K:$L(X)>240!($L(X)<1) X
"^DD",176.802,176.802,2.9,.1)
EMEASURE COPYRIGHT
"^DD",176.802,176.802,2.9,3)
Answer must be 1-240 characters in length.
"^DD",176.802,176.802,2.9,"DT")
3130322
"^DD",176.802,176.802,3,0)
IDENTIFIER^F^^10;1^K:$L(X)>120!($L(X)<1) X
"^DD",176.802,176.802,3,.1)
EMEASURE IDENTIFIER
"^DD",176.802,176.802,3,3)
Answer must be 1-120 characters in length.
"^DD",176.802,176.802,3,"DT")
3130322
"^DD",176.802,176.802,3.1,0)
STATUS^F^^10;2^K:$L(X)>120!($L(X)<1) X
"^DD",176.802,176.802,3.1,.1)
EMEASURE STATUS
"^DD",176.802,176.802,3.1,3)
Answer must be 1-120 characters in length.
"^DD",176.802,176.802,3.1,"DT")
3130322
"^DD",176.802,176.802,4,0)
VALUE SET^176.8024P^^12;0
"^DD",176.802,176.802,5,0)
EP/EH^S^EP:CQMEP;EH:CQMEH;^14;2^Q
"^DD",176.802,176.802,5,.1)
Eligible Provider or Eligible Hospital Applicability
"^DD",176.802,176.802,5,"DT")
3130329
"^DD",176.802,176.802,5.1,0)
CLINICAL CATEGORY^P176.804^C0QVS(176.804,^15;2^Q
"^DD",176.802,176.802,5.1,.1)
MEASURE CLINICAL CATEGORY
"^DD",176.802,176.802,5.1,"DT")
3130329
"^DD",176.802,176.802,5.2,0)
CLINICAL CATEGORY ABBREVIATION^CJ^^ ; ^X ^DD(176.802,5.2,9.2) S Y(176.802,5.2,101)=$S($D(^C0QVS(176.804,D0,0)):^(0),1:"") S X=$P(Y(176.802,5.2,101),U,2) S D0=Y(176.802,5.2,80)
"^DD",176.802,176.802,5.2,.1)
ABBREVIATION OF CLINICAL CATEGORY
"^DD",176.802,176.802,5.2,9.01)
176.804^.02;176.802^5.1
"^DD",176.802,176.802,5.2,9.1)
5.1:ABBREVIATION
"^DD",176.802,176.802,5.2,9.2)
S Y(176.802,5.2,80)=$G(D0),Y(176.802,5.2,1)=$S($D(^C0QVS(176.802,D0,15)):^(15),1:""),D0=$P(Y(176.802,5.2,1),U,2) S:'D0!'$D(^C0QVS(176.804,+D0,0)) D0=-1
"^DD",176.802,176.802,5.2,"DT")
3130324
"^DD",176.802,176.8021,0)
DESCRIPTION SUB-FIELD^^.01^1
"^DD",176.802,176.8021,0,"DT")
3130322
"^DD",176.802,176.8021,0,"NM","DESCRIPTION")

"^DD",176.802,176.8021,0,"UP")
176.802
"^DD",176.802,176.8021,.01,0)
DESCRIPTION^Wx^^0;1
"^DD",176.802,176.8021,.01,.1)
MEASURE DESCRIPTION
"^DD",176.802,176.8021,.01,"DT")
3130322
"^DD",176.802,176.8024,0)
VALUE SET SUB-FIELD^^.03^4
"^DD",176.802,176.8024,0,"DT")
3130412
"^DD",176.802,176.8024,0,"IX","B",176.8024,.01)

"^DD",176.802,176.8024,0,"NM","VALUE SET")

"^DD",176.802,176.8024,0,"UP")
176.802
"^DD",176.802,176.8024,.01,0)
VALUE SET^MP176.801^C0QVS(176.801,^0;1^Q
"^DD",176.802,176.8024,.01,.1)
VALUE SETS USED IN THE MEASURE
"^DD",176.802,176.8024,.01,1,0)
^.1
"^DD",176.802,176.8024,.01,1,1,0)
176.8024^B
"^DD",176.802,176.8024,.01,1,1,1)
S ^C0QVS(176.802,DA(1),12,"B",$E(X,1,30),DA)=""
"^DD",176.802,176.8024,.01,1,1,2)
K ^C0QVS(176.802,DA(1),12,"B",$E(X,1,30),DA)
"^DD",176.802,176.8024,.01,"DT")
3130329
"^DD",176.802,176.8024,.03,0)
SHORT ID^F^^1;1^K:$L(X)>30!($L(X)<1) X
"^DD",176.802,176.8024,.03,.1)
SHORT IDENTIFIER OF THE VALUE SET
"^DD",176.802,176.8024,.03,3)
Answer must be 1-30 characters in length.
"^DD",176.802,176.8024,.03,"DT")
3130412
"^DD",176.802,176.8024,1,0)
COMMENT^F^^0;2^K:$L(X)>240!($L(X)<1) X
"^DD",176.802,176.8024,1,.1)
VALUE SET USAGE COMMENT
"^DD",176.802,176.8024,1,3)
Answer must be 1-240 characters in length.
"^DD",176.802,176.8024,1,"DT")
3130322
"^DD",176.802,176.8024,10,0)
SHORT ID^CJ30^^ ; ^X ^DD(176.8024,10,9.3) S X=$P(Y(176.8024,10,101),U,1) S D0=Y(176.8024,10,80) S D1=Y(176.8024,10,81)
"^DD",176.802,176.8024,10,9)
^
"^DD",176.802,176.8024,10,9.01)
176.801^.03;176.8024^.01
"^DD",176.802,176.8024,10,9.1)
VALUE SET:SHORT ID
"^DD",176.802,176.8024,10,9.2)
S Y(176.8024,10,81)=$G(D1),Y(176.8024,10,80)=$G(D0),Y(176.8024,10,1)=$S($D(^C0QVS(176.802,D0,12,D1,0)):^(0),1:"")
"^DD",176.802,176.8024,10,9.3)
X ^DD(176.8024,10,9.2) S D0=$P(Y(176.8024,10,1),U,1) S:'D0!'$D(^C0QVS(176.801,+D0,0)) D0=-1 S Y(176.8024,10,101)=$S($D(^C0QVS(176.801,D0,5)):^(5),1:"")
"^DD",176.802,176.8024,10,"DT")
3130412
"^DD",176.803,176.803,0)
FIELD^^.03^3
"^DD",176.803,176.803,0,"DDA")
N
"^DD",176.803,176.803,0,"DT")
3130322
"^DD",176.803,176.803,0,"NM","C0Q CODE SYSTEMS")

"^DD",176.803,176.803,0,"PT",176.8011,.03)

"^DD",176.803,176.803,.01,0)
NAME^RF^^0;1^K:$L(X)>30!(X?.N)!($L(X)<3)!'(X'?1P.E) X
"^DD",176.803,176.803,.01,.1)
CODE SYSTEM NAME
"^DD",176.803,176.803,.01,1,0)
^.1^^0
"^DD",176.803,176.803,.01,3)
NAME MUST BE 3-30 CHARACTERS, NOT NUMERIC OR STARTING WITH PUNCTUATION
"^DD",176.803,176.803,.01,"DT")
3130322
"^DD",176.803,176.803,.02,0)
CODE SYSTEM OID^F^^1;1^K:$L(X)>240!($L(X)<3) X
"^DD",176.803,176.803,.02,.1)
CODE SYSTEM OBJECT ID
"^DD",176.803,176.803,.02,3)
Answer must be 3-240 characters in length.
"^DD",176.803,176.803,.02,"DT")
3130322
"^DD",176.803,176.803,.03,0)
CODE SYSTEM VERSION^F^^2;1^K:$L(X)>120!($L(X)<1) X
"^DD",176.803,176.803,.03,.1)
CODE SYSTEM VERSION TEXT
"^DD",176.803,176.803,.03,3)
Answer must be 1-120 characters in length.
"^DD",176.803,176.803,.03,"DT")
3130322
"^DD",176.804,176.804,0)
FIELD^^.02^2
"^DD",176.804,176.804,0,"DDA")
N
"^DD",176.804,176.804,0,"DT")
3130324
"^DD",176.804,176.804,0,"ID",.02)
W "   ",$P(^(0),U,2)
"^DD",176.804,176.804,0,"IX","B",176.804,.01)

"^DD",176.804,176.804,0,"NM","C0Q CYPRESS CLINICAL CATETORIES")

"^DD",176.804,176.804,0,"PT",176.802,5.1)

"^DD",176.804,176.804,.01,0)
NAME^RFO^^0;1^K:$L(X)>160!($L(X)<3)!'(X'?1P.E) X
"^DD",176.804,176.804,.01,.1)
CLINICAL CATEGORY
"^DD",176.804,176.804,.01,1,0)
^.1
"^DD",176.804,176.804,.01,1,1,0)
176.804^B
"^DD",176.804,176.804,.01,1,1,1)
S ^C0QVS(176.804,"B",$E(X,1,30),DA)=""
"^DD",176.804,176.804,.01,1,1,2)
K ^C0QVS(176.804,"B",$E(X,1,30),DA)
"^DD",176.804,176.804,.01,2)
S Y(0)=Y S Y=$$GET1^DIQ(176.804,$O(^C0QVS(176.804,"B",Y,""))_",",.02)
"^DD",176.804,176.804,.01,2.1)
S Y=$$GET1^DIQ(176.804,$O(^C0QVS(176.804,"B",Y,""))_",",.02)
"^DD",176.804,176.804,.01,3)
Answer must be 3-160 characters in length.
"^DD",176.804,176.804,.01,"DT")
3130329
"^DD",176.804,176.804,.02,0)
ABBREVIATION^F^^0;2^K:$L(X)>20!($L(X)<1) X
"^DD",176.804,176.804,.02,.1)
CATEGORY ABBREVIATION
"^DD",176.804,176.804,.02,3)
Answer must be 1-20 characters in length.
"^DD",176.804,176.804,.02,"DT")
3130324
"^DIC",176.801,176.801,0)
C0Q VALUE SET CODES^176.801
"^DIC",176.801,176.801,0,"GL")
^C0QVS(176.801,
"^DIC",176.801,176.801,"%D",0)
^^2^2^3130322^
"^DIC",176.801,176.801,"%D",1,0)
This file lists the value sets from the National Library of Medicine for 
"^DIC",176.801,176.801,"%D",2,0)
Meaningful Use e-Measures, and links them to codes and measures.
"^DIC",176.801,"B","C0Q VALUE SET CODES",176.801)

"^DIC",176.802,176.802,0)
C0Q NLM QUALITY MEASURE GROUPS^176.802
"^DIC",176.802,176.802,0,"GL")
^C0QVS(176.802,
"^DIC",176.802,176.802,"%D",0)
^^2^2^3130322^
"^DIC",176.802,176.802,"%D",1,0)
This file stores quality measures from the National Library of Medicine 
"^DIC",176.802,176.802,"%D",2,0)
for Meaningful Use eMeasures.
"^DIC",176.802,"B","C0Q NLM QUALITY MEASURE GROUPS",176.802)

"^DIC",176.803,176.803,0)
C0Q CODE SYSTEMS^176.803
"^DIC",176.803,176.803,0,"GL")
^C0QVS(176.803,
"^DIC",176.803,"B","C0Q CODE SYSTEMS",176.803)

"^DIC",176.804,176.804,0)
C0Q CYPRESS CLINICAL CATETORIES^176.804
"^DIC",176.804,176.804,0,"GL")
^C0QVS(176.804,
"^DIC",176.804,"B","C0Q CYPRESS CLINICAL CATETORIES",176.804)

**END**
**END**
